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Abstract	
Aberrations	of	EGFR	signalling	drive	cancer	development.	In	squamous	cell	lung	
cancer,	EGFR	is	overexpressed.	LRIG1	is	a	negative	regulator	of	EGFR	and	patient	
pre-invasive	squamous	cell	lung	cancer	samples	show	LRIG1	loss,	suggesting	
involvement	in	early	disease	pathogenesis.	In	skin	and	gut	homeostasis,	LRIG1	
regulates	stem	cells.	In	the	upper	airway,	basal	cells	act	as	stem	cells	and	are	the	
putative	origin	of	squamous	cell	lung	cancer.	I	hypothesise	LRIG1	has	a	key	role	in	
the	airway	homeostasis	and	its	loss	tilts	this	towards	pre-invasive	squamous	cell	lung	
cancer	development.	
Lrig1	EGFP-ires-CreERT2	mice	delineated	airway	LRIG1	expression.	Flow	sorted	
LRIG1-positive	and	-negative	murine	basal	cells	were	used	in	2D	and	3D	colony-
forming,	spheroid	and	proliferation	assays.	A	murine	squamous	cell	lung	cancer	
model	was	set	up	through	application	of	N-Nitrosotris-(2-chloroethyl)urea	(NTCU).	
Pre-invasive	lesions	and	tumour	development	were	compared	between	wild-type	
(WT),	LRIG1-heterozygous	and	LRIG1-null	animals.	Human	basal	cells	obtained	from	
bronchoscopy	were	sorted	according	to	LRIG1	expression	and	used	directly	in	
colony-forming	assays	or	maintained	in	primary	culture	to	assess	the	effect	of	shRNA	
knockdown	of	LRIG1.	
LRIG1	is	expressed	by	50%	of	airway	basal	cells.	LRIG1-expressing	murine	basal	cells	
exhibit	increased	colony-forming	capacity	(p=0.0133),	spheroid	formation	(p=0.0020)	
and	proliferation	(p=0.0011)	compared	to	LRIG1-negative	cells.	Similarly,	LRIG1-
expressing	human	airway	basal	cells	isolated	from	endobronchial	brush	biopsy	
samples	exhibit	increased	colony-forming	capacity	(p=0.0067)	and	proliferation	
(p=0.0153).	Topical	application	of	NTCU	to	mice	recapitulates	the	development	of	
human	pre-invasive	and	squamous	cell	lung	cancer	lesions	after	23	weeks.	Results	
show	lesions	in	LRIG1-null	mice	to	be	larger	than	those	of	WT	animals.	shRNA	
knockdown	of	LRIG1	in	cultured	human	airway	basal	cells	alters	cell	phenotype,	
leading	to	increased	colony-forming	efficiency	and	greater	proliferation	at	cell	
confluence.	
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LRIG1	has	an	important	role	in	stem	cell	homeostasis	of	the	human	and	murine	
airway	epithelium.	Loss	of	LRIG1	promotes	lesion	development	in	a	murine	
squamous	cell	lung	cancer	mouse	model	and	alters	behaviour	of	human	epithelial	
cells	in	culture,	indicating	a	potential	target	for	the	treatment	of	squamous	cell	lung	
cancer	in	humans.	
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1.		 Introduction	
	
1.1	 Lung	cancer	
	
Lung	cancer	is	responsible	for	22%	of	all	UK	cancer	deaths,	amounting	to	46,000	
deaths	a	year.		It	is	the	commonest	cause	of	UK	cancer	death,	and	in	contrast	to	
other	malignancies,	little	improvement	in	lung	cancer	survival	has	been	seen	over	
the	past	four	decades.		In	1972,	the	lung	cancer	5-year	survival	was	4.6%,	increasing	
to	9.5%	by	2011,	but	in	contrast,	leukaemia	survival	has	gone	from	12.9	to	51.6%	
over	the	same	time	period	(1).		These	figures	highlight	the	need	for	improved	lung	
cancer	diagnostics	and	treatment	strategies.	
	
There	are	two	main	subtypes	of	lung	cancer,	which	are	distinguished	by	their	
histological	appearances.		Small	cell	lung	cancer	(SCLC)	is	responsible	for	15%	of	lung	
cancer	cases,	and	is	termed	due	to	the	histological	appearance	of	tightly	packed	
small	cells	with	a	large	nucleus,	whilst	non-small	cell	lung	cancer	(NSCLC)	constitutes	
around	85%	of	cases	(2).		NSCLCs	can	be	further	divided	into	adenocarcinomas,	
squamous	cell	carcinomas	and	large	cell	carcinomas	(2).		Squamous	cell	lung	cancer	
is	the	commonest	form	of	lung	cancer	in	the	UK	(1).	
		
The	association	of	smoking	with	lung	cancer	has	been	known	since	the	1950s	(3)	and	
smoking	remains	the	predominant	lung	cancer	risk	factor,	particularly	in	relation	to	
SCLC	and	squamous	cell	carcinoma.		Other	risk	factors	include	exposure	to	radon	gas	
(where	risk	is	increased	in	smokers)	(4),	passive	smoking	(5,	6),	air	pollution,	
occupational	asbestos	exposure	and	a	genetic	predisposition	(2).	
	
1.1.1	 Staging	of	lung	cancers	
	
The	extent	to	which	the	lung	cancer	has	affected	the	body	is	classified	according	to	
two	staging	systems,	the	first	is	the	TNM	(tumour,	node,	metastases)	staging	system;	
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T	considers	the	tumour	size,	N	the	presence	of	any	associated	lymph	nodes	and	M,	
whether	the	disease	has	metastasised	beyond	the	lungs	(7).		The	second	
classification	system	divides	the	disease	into	4	groups;	stage	1	is	localised	to	the	
lungs,	stage	2	and	3	are	where	the	tumour	has	grown	larger	and	may	have	spread	to	
the	lymph	nodes,	and	stage	4	is	when	the	cancer	has	spread	to	other	areas	of	the	
body	(8).		The	stage	of	lung	cancer	influences	the	available	treatments.		In	early	
stage	lung	cancer,	the	goal	is	to	eradicate	disease	and	surgical	management	is	the	
treatment	of	choice	(9).		With	more	advanced	disease	and	spread	to	the	lymph	
nodes	or	other	organs	chemotherapy	or	radiotherapy	becomes	appropriate.		48%	of	
patients	present	with	late	stage	lung	cancer	(stage	4)	(8)	and	palliative	
chemotherapy	or	radiotherapy	treatments,	where	the	aim	is	to	prolong	life	and	treat	
symptoms,	are	the	only	options.		
	
1.1.2	 Targeted	treatments	for	lung	cancer	
	
Until	the	1990s	treatment	of	lung	cancer	consisted	of	platinum-based	
chemotherapies;	these	were	later	followed	by	the	introduction	of	third-generation	
cytotoxic	agents	such	as	gemcitabine	that	improved	lung	cancer	survival	to	around	8	
months	and	at	this	point	the	lung	cancer	survival	was	seen	to	plateau	(10).		In	recent	
years	the	molecular	pathogenesis	of	adenocarcinoma	has	been	investigated.		The	
development	of	lung	adenocarcinoma	is	frequently	associated	with	a	single	
molecular	abnormality,	including	the	presence	of	activating	mutations	in	Kirsten	rat	
sarcoma	viral	oncogene	homolog	(KRas)	and	the	epidermal	growth	factor	receptor	
(EGFR)	(11).		Targeting	lung	cancer	treatments	to	the	abnormality	within	the	tumour	
has	been	shown	to	improve	survival	in	appropriately	selected	patients.		These	
targeted	treatments	include	EGFR	inhibitors	and	inhibitors	of	the	echinoderm	
microtubule-associated	protein-like	4	(EML4)	and	anaplastic	lymphoma	kinase	(ALK)	
	(ELM4-ALK)	fusion	transcript	(10).			
	
EGFR	inhibitors	
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Activation	of	the	EGFR	signalling	pathway	leads	to	a	number	of	downstream	
consequences	including	proliferation	and	inhibition	of	apoptosis,	which	are	
important	in	lung	cancer	development	(12).		Activating	mutations	in	the	tyrosine	
kinase	domain	of	the	EGF	receptor	leads	to	constitutively	active	signalling.		EGFR	
mutations	act	as	driver	mutations	in	10%	of	UK	adenocarcinomas,	but	account	for	as	
many	as	30-50%	of	driver	mutations	in	tumours	from	South-East	Asia	(13).		These	
mutations	occur	most	frequently	in	women	and	non-smokers	(2).		The	
administration	of	tyrosine	kinase	inhibitors	such	as	gefitinib,	have	been	found	to	
improve	survival	beyond	that	of	platinum-based	chemotherapy	agents	(14,	15).		
However,	despite	the	initial	response	rate,	resistance	to	tyrosine	kinase	inhibitors	
occurs	after	9-11	months.		This	is	due	to	the	development	of	a	second	mutation	in	
the	catalytic	cleft	of	the	EGFR	tyrosine	kinase	domain,	which	prevents	access	of	the	
tyrosine	kinase	inhibitor	(16).		The	most	common	mutation	is	the	T790M	mutation	
that	prevents	binding	of	the	inhibitor	molecule	(17).	
	
ELM4-ALK	inhibition	
	
The	EML4-ALK	fusion	transcript	is	seen	in	6.7%	of	patients	with	non-small	cell	lung	
cancer,	predominantly	in	adenocarcinomas	(18).		This	is	an	oncogenic	rearrangement	
in	chromosome	2	that	leads	to	ligand-independent	dimerisation	of	the	ALK	domain	
and	consequent	constitutive	cellular	proliferation	and	inhibition	of	apoptosis	
through	the	downstream	activation	of	mitogen-activated	protein	(MAP)	kinases	and	
the	phosphatidylinositol	3-kinase	(PI3K)	signalling	pathways.		Crizotinib,	a	drug	that	
targets	the	ALK	rearrangement,	has	been	shown	to	improve	progression-free	
survival	from	3.0	months	with	conventional	chemotherapy	to	7.7	months	(19).		
	
Cetuximab	
	
Cetuximab	is	a	chimeric	human	IgG1	antibody	that	competitively	binds	to	the	EGF	
receptor	and	prevents	ligand	binding,	receptor	phosphorylation	and	activation	of	
downstream	signalling	(20).		Antibody-receptor	complexes	are	internalised,	resulting	
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in	the	removal	of	the	EGF	receptor	from	the	cell	membrane	and	preventing	further	
activation	(21).	
	
1.1.3	 Molecular	pathogenesis	of	squamous	cell	lung	cancer	and	potential	
treatment	targets	
	
The	molecular	pathogenesis	of	squamous	cell	lung	cancer	is	more	complex	than	that	
of	adenocarcinoma,	and	the	development	of	targeted	treatments	for	squamous	cell	
lung	cancer	is	lagging	behind	that	for	adenocarcinoma.		Common	pathways	that	are	
affected	in	the	development	of	squamous	cell	lung	cancer	include	those	regulating	
the	response	to	cellular	stress	(Nuclear	factor	erythroid	2-related	factor	1	
(NFE2LL)/	Kelch-like	ECH-associated	protein	1	(KEAP1)/	Cullin-3	
(CUL3)),	squamous	differentiation	(sex	determining	region	Y-box	2	
(SOX2)/	NOTCH/tumour	protein	p63	(TP63)),	intracellular	signalling	(PI3K/protein	
kinase	B	(AKT))	and	cell	cycle	regulation	(cyclin-dependent	kinase	inhibitor	2A	
(CDKN2A)/	retinoblastoma	1	(RB1))	(22,	23).	
	
Potential	squamous	cell	lung	cancer	therapeutic	targets	are	the	PIK3	mutation	(4%	of	
squamous	lesions)	and	amplification	(33%	of	lesions),	or	the	overexpression	of	the	
fibroblast	growth	factor	receptor	1	(FGFR1)	that	is	seen	in	20%	of	cases	(22,	24).		The	
use	of	FGF	inhibitors	in	xenograft	tumour	models	has	led	to	lesion	regression	(25)	
and	there	are	currently	early	clinical	trials	of	PIK3	inhibitors	such	as	buparlisib	and	
FGFR1	inhibitors,	the	results	for	which	are	awaited	(24).		
	
In	contrast	to	adenocarcinoma,	EGFR-activating	mutations	are	seen	in	only	1-2%	of	
squamous	cell	lung	cancers	(22),	however	as	many	as	88%	of	squamous	cell	lung	
cancers	show	overexpression	of	EGFR	in	the	absence	of	a	mutation	(26,	27).			This	
EGFR	overexpression	has	been	targeted	by	the	administration	of	cetuximab	to	
patients	with	squamous	cell	cancers.		In	the	SQUIRE	trial,	stage	4	squamous	cell	lung	
cancers	were	randomly	assigned	to	chemotherapy	+/-	necitumumab	(an	IgG1	
monoclonal	antibody	to	the	EGF	receptor	agent	that	is	related	to	cetuximab),	with	
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the	necitumumab	treatment	shown	to	improve	survival	from	9.9	to	11.5	months	
(28).		Further	results	obtained	from	the	FLEX	trial,	which	added	cetuximab	to	
standard	chemotherapy	for	NSCLC,	found	a	survival	benefit	that	was	greatest	in	
patients	with	squamous	cell	lung	cancer	arm	compared	to	those	with	other	
histological	subtypes	(28,	29).			
	
1.1.4	 Impact	of	smoking	and	genetic	changes	within	the	airway	epithelium	
	
Smokers	are	predisposed	to	a	number	of	respiratory	conditions	including	
emphysema,	bronchitis	and	lung	cancer.		The	majority	of	squamous	cell	lung	cancers	
are	caused	by	smoking	(8),	with	exposure	to	cigarette	smoke	associated	with	effects	
on	airway	epithelial	gene	expression	(30).		A	recent	study	has	revealed	that	for	every	
year	a	smoker	smokes	one	packet	of	cigarettes	per	day,	there	is	the	accumulation	of	
an	extra	150	mutations	per	lung	cell	(31).		A	comparison	of	samples	obtained	at	
bronchoscopy	from	smokers	and	never	smokers	found	97	differentially	expressed	
genes	within	airway	epithelial	cells.		Upregulated	genes	in	smokers	included	those	
for	xenobiotic	function	(e.g.	cytochrome	P450	family	1	subfamily	B	member	1	
(CYP1B1)),	antioxidants	(e.g.	aldehyde	dehydrogenase	3	family	member	A1	
(ALDH3A1))	and	electron	transport	system	(e.g.	nicotinamide	adenine	dinucleotide	
phosphate	(NADPH))	(32).		On	smoking	cessation,	many	of	these	changes	were	fully	
reversed,	but	a	few	persisted	(33).		Work	by	Boelens	et	al	(30)	confirmed	these	
findings	and,	in	addition,	showed	that	genes	associated	with	the	oxidative	stress	
response,	adhesion,	cell	proliferation	and	apoptosis	were	upregulated	in	the	
epithelium	of	current	smokers	compared	with	ex-smokers,	and	that	these	changes	
were	magnified	further	on	the	development	of	squamous	cell	lung	cancers.	
	
1.1.5	 Preinvasive	squamous	cell	lung	cancer		
	
One	of	the	reasons	lung	cancer	survival	is	so	poor	is	its	late	detection	(34,	35).		
However,	squamous	cell	lung	cancer	has	an	early,	premalignant	phase,	where	lesions	
develop	from	abnormal	areas	of	bronchial	epithelium.		Histologically,	these	become	
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increasingly	dysplastic	before	the	development	of	carcinoma-in-situ	(CIS)	and	the	
eventual	breach	of	the	basement	membrane	that	leads	to	the	development	of	an	
invasive	tumour.		The	World	Health	Organisation	has	classified	lesions	into	nine	
categories	ranging	from	normal	through	to	inflammation,	basal	cell	hyperplasia,	
squamous	metaplasia,	mild	dysplasia,	moderate	dysplasia,	severe	dysplasia,	CIS	and	
invasive	disease	(36,	37)	(Figure	1.1).		The	morphology	of	these	lesions	changes	with	
increasing	severity:	initially	the	nuclei	change,	with	an	increase	in	nuclear	to	
cytoplasmic	ratio,	the	presence	of	nucleoli	and	a	lack	of	nuclear	orientation,	and	this	
is	accompanied	by	an	increase	in	cell	crowding	and	a	lack	of	orientation	in	the	tissue.		
The	initial	abnormalities	only	affect	the	basal	layer,	but	subsequently	increase	to	
involve	the	full	thickness	of	the	epithelium	(38).		These	changes	are	accompanied	by	
an	increased	mutational	burden.	 	
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Figure	1.1:		Histological	changes	associated	with	preinvasive	lung	cancer	
	
The	development	of	preinvasive	lung	cancer	lesions	is	associated	with	progressively	more	
disorganisation	within	the	airway	epithelium.		A)	Normal	airway		B)		Squamous	metaplasia		C)		Mild	
dysplasia		D)	Moderate	dysplasia		E)		Severe	dysplasia		F)		Carcinoma-in-situ.		Changes	according	to	
the	WHO	classification	of	preinvasive	lung	cancer	lesions	(39).	
	
	
Reproduced	with	permission	of	the	European	Respiratory	Society	©.		European	Respiratory	Journal	
Jun	2002,	19	(6)	1151-1158;	DOI:	10.1183/09031936.02.00294102	
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The	natural	history	of	preinvasive	lung	cancer	is	uncertain,	with	Auerbach	et	al	
reporting	from	post-mortem	studies	in	the	1960s	that	most	CIS	lesions	do	not	
progress	into	invasive	cancers	(40).		Monitoring	of	preinvasive	lesions	has	previously	
proved	challenging,	but	with	the	introduction	of	autofluorescence	bronchoscopy,	a	
technique	by	which	subtle	changes	in	the	bronchial	mucosa	are	detected	following	
blue	light	(490–700	nm)	excitation,	preinvasive	lesions	are	identifiable	from	normal	
epithelium	(41,	42).		It	is	difficult	to	study	the	natural	history	of	lesions	as	they	are	
often	detected	by	chance,	repeated	biopsies	are	needed	at	the	same	site	and	there	
is	often	a	high	intra-observer	variability	on	the	lesion	grade	(43).		Despite	these	
limitations,	it	has	been	shown	that	lesions	are	often	dynamic;	some	lesions	progress	
to	invasive	cancer,	while	others	regress.		Work	by	George	et	al	showed	that	7	out	of	
36	high-grade	lesions	were	observed	to	regress	over	long-term	follow	up,	6	out	of	36	
progressed	to	cancer	whilst	the	remainder	were	static	(44).		Interestingly	the	
presence	of	high-grade	dysplasia	is	a	risk	factor	for	the	development	of	invasive	
lesions	elsewhere	in	the	bronchial	tree	(45).		The	‘field	of	cancerisation’	hypothesis	
may	explain	these	findings:	due	to	the	entire	bronchial	tree	being	exposed	to	the	
same	precipitating	stimulus,	a	preinvasive	lesion	in	one	area	is	an	indicator	of	the	
susceptibility	of	the	entire	epithelium	to	disease	development	(46).		This	theory	is	
also	consistent	with	the	widespread	epithelial	changes	that	are	seen	in	smokers.		
However,	recent	longitudinal,	molecular	mapping	of	both	CIS	lesions	and	
surrounding	normal	tissue	by	gene	sequencing	and	loss-of-heterozygosity	analysis	
has	revealed	that	spatially	segregated	clonal	lesions	develop	(47).		The	finding	of	
normal	epithelium	between	lesions,	raises	the	possibility	of	the	field	cancerisation	
occurring	through	a	process	of	cell	migration	rather	than	contiguous	spread.			
	
There	is	currently	no	consensus	on	when	to	treat	preinvasive	lesions	or	the	stage	of	
the	disease	when	treatment	becomes	necessary.		There	are,	as	yet,	no	clear	
biomarkers	to	suggest	whether	a	lesion	will	progress,	remain	static	or	regress.	
However,	it	is	interesting	to	note	that	when	10	high-grade	lesions	were	examined	all	
were	found	to	have	chromosome	3q	amplifications.		This	3q	amplification	
progressively	increased	during	the	evolution	of	the	squamous	cell	carcinoma	and	
was	associated,	in	three	of	the	patients,	with	an	incremental	increase	in	SOX2	
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expression	(48).			Treatment	decisions	need	to	consider	the	likelihood	of	lesion	
progression	in	addition	to	the	fitness	of	the	patient	to	undergo	the	treatment	
modality.		The	finding	that	cells	from	preinvasive	lesions	may	migrate,	supports	the	
more	aggressive	treatment	of	lesions,	before	abnormal	cells	are	able	to	migrate	from	
the	site	of	the	lesion	to	affect	other	areas	within	the	bronchial	tree	(47).		Current	
therapeutic	strategies	include	cryotherapy,	photo-dynamic	therapy,	argon	plasma	
coagulation	and	brachytherapy	(43).	
	
Challenges	for	the	chemoprevention	of	preinvasive	lesions	include	the	
heterogeneous	nature	of	the	lesions	and	their	complex	mutational	burden	(49).		If,	
following	a	biopsy,	there	is	no	targetable	mutation,	the	most	appropriate	agents	are	
those	that	target	general	processes	such	as	inflammation	and	the	augmentation	of	
apoptosis	(49).		Lesions	are	associated	with	an	inflammatory	infiltrate,	therefore	
trials	of	inhaled	corticosteroids	have	been	administered	(43).		However,	in	smokers	
with	at	least	one	preinvasive	lesion,	administration	of	the	inhaled	corticosteroid	
budesonide	for	6	months	did	not	increase	lesion	regression	compared	with	placebo	
treatment	(50).		Other	strategies	have	included	the	administration	of	myo-inositol,	
an	inhibitor	of	PIK3,	with	a	phase	1	trial	(of	10	patients)	showing	an	increase	in	the	
regression	of	dysplastic	lesions	from	48%	to	91%	over	a	3-month	period	(51).		These	
results	do	need	to	be	treated	with	caution,	due	to	the	inclusion	of	only	10	patients.		
In	a	larger	study	of	152	patients,	Iloprost,	a	prostacyclin	analogue	(prostacyclin	levels	
are	reduced	in	lung	cancer),	was	administered	and	led	to	a	significant	improvement	
in	endobronchial	histology,	with	lesions	assigned	a	pre-	and	post-treatment	score	
after	6	months.		Of	note,	these	effects	were	only	seen	in	patients	who	were	former	
smokers,	and	no	differences	were	detected	in	those	currently	smoking	(52).	
	
1.2	 The	EGF	receptor	and	regulation	of	signalling	
	
The	EGF	receptor	belongs	to	the	avian	erythroblastosis	oncogene	B	(ERBB)	family	of	
four	receptors	proteins	comprising	ERBB1/	EGFR	(hereafter	referred	to	as	EGFR),	
ERBB2,	ERBB3	and	ERBB4.		Each	receptor	consists	of	a	cysteine-rich,	extracellular	
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binding	domain,	a	single	pass	alpha	helix	transmembrane	domain,	a	C-terminal	
signalling	domain	and,	with	the	exception	of	ERBB3,	a	cytoplasmic	tyrosine	kinase.		
There	are	13	known	ligands	of	ERBB	signalling:	these	include	EGF,	transforming	
growth	factor	α	(TGFα)	and	amphiregulin	(12).		The	activating	ligands	are	shed	from	
the	surface	of	the	cell,	through	the	action	of	a	disintegrin	and	metalloproteinase	
(ADAM)	family	of	proteases	in	response	to	both	pharmacological	and	physiological	
stimuli	(53).		The	ligands	are	capable	of	inducing	receptor	activity	through	autocrine	
(self	activation),	paracrine	(activation	of	adjacent	cells),	juxtacrine	(where	the	
tethered	ligand	on	one	cell	is	capable	of	activating	a	receptor	on	another)	and	
extracrine	(where	ERBB	activation	occurs	within	exosomes)	mechanisms	(54).		On	
ligand	binding,	the	receptors	dimerise	and	undergo	receptor	autophosphorylation,	
whereby	the	tyrosine	residues	in	the	intrinsic	tyrosine	kinase	domain	of	one	receptor	
cross-phosphorylates	specific	residues	on	its	partnering	receptor.		The	ERBB2	
receptor	is	unable	to	directly	bind	ligand,	therefore	heterodimerisation	is	necessary	
for	its	activation	(55).		Specific	ligands	trigger	different	heterodimerisations,	for	
example,	EGF	will	induce	the	heterodimerisation	of	EGFR	with	ERBB2,	ERBB3	and	
ERBB4	(55).	
	
Receptor	autophosphorylation	activates	a	number	of	downstream	pathways	
including	the	MEK/ERK	(MAPK	kinase/extracellular	signal-regulated	kinase),	
PI3K/AKT,	STAT	(signal	transducer	and	activator	of	transcription)	and	mTOR	
(mammalian	target	of	rapamycin)	signalling	cascades	(12,	56).			
	
The	ERBB	signalling	pathways	are	crucial	for	normal	cell	proliferation,	angiogenesis,	
differentiation	and	cell	survival	(57),	they	also	play	a	key	role	in	lung	development.		
Mice	lacking	EGFR	have	impaired	lung	development	which	leads	to	death	in	utero	
(58).		Whilst	ERBB	signalling	provides	an	important	role	in	the	maintenance	of	airway	
homeostasis,	aberrations	have	been	linked	to	lung	cancer,	lung	fibrosis	and	
hypersecretory	diseases	including	cystic	fibrosis,	chronic	obstructive	pulmonary	
disease	(COPD)	and	asthma	(59-63).	
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1.2.1	 The	regulation	of	ERBB	signalling	
	
Given	the	complexity	of	the	ERBB	signalling	pathway,	due	to	the	variety	of	activating	
ligands,	the	strength	of	ligand	binding,	the	dimerisation	of	receptors	and	the	number	
of	downstream	pathways	that	are	activated,	it	is	vital	the	amplitude	of	signalling	is	
tightly	regulated.		In	the	airway,	a	physical	barrier	exists	between	the	ERBB	receptor	
that	is	located	on	the	basolateral	surface	of	the	cell	and	the	ligands	that	are	released	
apically	(12).		This	means	that	unless	a	breach	of	the	epithelium	occurs,	the	ligand	
and	receptor	do	not	come	into	contact.		On	breach	of	the	epithelial	membrane	the	
ERBB	receptor	becomes	activated,	and	triggers	a	signalling	cascade	that	rapidly	
restores	epithelial	integrity	(61).			
	
Once	activated,	the	phosphorylated	receptors	are	immediately	targeted	by	protein	
tyrosine	phosphatases	such	as	density-enhanced	phosphatase	(DEP1),	that	
deactivate	the	receptor	(55).		The	activated	ERBB	receptors	are	then	internalised,	
separating	the	receptor	from	the	apical	source	of	ligands	and	preventing	continued	
activation	(64).		The	internalised	receptors	are	either	recycled	back	to	the	cell	
surface	or	there	is	recruitment	of	adaptor	proteins	such	as	growth	factor	receptor	
bound	protein	2	(GRB2).		These	adaptor	proteins	facilitate	both	the	clathrin-
mediated	endocytosis	of	the	activated	ERBB	receptor	and	the	subsequent	
recruitment	of	the	E3	ubiquitin	ligase,	CBL	(Casitas	B-lineage	Lymphoma).		The	CBL	
molecule	ubiquitinates	the	ERBB	receptor	and	targets	it	to	the	lysosomes	for	
degradation	(65).		At	this	point,	de-ubiquitinating	enzymes	may	intervene	to	remove	
the	ubiquitin	tag	and	allow	the	receptor	to	recycle	back	to	the	cell	membrane	(64).			
	
The	ligand	responsible	for	receptor	activation	has	been	shown	to	influence	receptor	
fate.		EGF	remains	tightly	bound	(allowing	continued	signalling	whilst	within	the	
vesicle)	and	triggers	the	lysosomal	degradation	pathway,	whilst	TGFα	rapidly	
dissociates	from	the	receptor,	favouring	receptor	recycling	(66).		Additional	
regulation	is	exerted	through	timing	of	ligand	expression	and	tissue	specific	ligand	
availability	(67),	allowing	a	tight	control	of	receptor-mediated	effects.			
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The	synthesis	of	de	novo	inhibitors	that	are	turned	on	once	the	ERBB	has	been	
activated	provide	a	further	level	of	ERBB	signalling	control	(68).		These	include	the	
proteins	suppressor	of	cytokine	signalling	4	and	5	(SOCS4	and	SOCS5),	mitogen	
inducible	gene	6	(MIG6)	and	leucine	rich	repeats	and	immunoglobulin	like	domains	1	
(LRIG1).		These	proteins	are	induced	within	30	minutes	(SOCS4	and	SOCS5)	to	4	
hours	(LRIG1	and	MIG6)	post	receptor	activation	and	are	capable	of	binding	to	all	
four	of	the	ERBB	receptors,	inhibiting	their	activity	(69).		SOCS4	and	SOCS5	belong	to	
a	family	of	intracellular	proteins	that	negatively	regulate	cytokine	receptor	signalling.		
It	is	suggested	these	molecules	act	by	binding	to	the	tyrosine	residue	1068	of	the	
EGFR	(that	becomes	phosphorylated	on	receptor	activation)	and	then	targeting	the	
receptor	for	ubiquitination	(68).		MIG6	is	a	cytosolic	protein	that	is	recruited	to	the	
ERBB	receptor	on	ligand	activation.		It	can	bind	to,	and	lock	the	receptor	into	an	
inactive	configuration,	preventing	the	activation	of	downstream	signalling	(70).		
MIG6	can	also	target	the	receptor	for	endocytosis,	with	its	subsequent	breakdown	
via	the	ubiquitination	pathway	(68).		
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Figure	1.2:		Regulation	of	ERBB	Signalling	
	
The	ERBB	pathway	is	regulated	through	a	number	of	mechanisms.		1)		The	choice	of	receptor,	
and	the	strength	of	ligand	binding,	2)	whether	the	ERBB	receptor	form	hetero-	or	homodimers,	
3)	the	release	of	extracellular	ligands	and	segregation	of	ligands	and	receptor	4)	
	
During homeostasis several endogenous mechanisms exist to modulate EGFR pathway activity. 
These include 1) ligand–receptor choice and binding affinity, 2) EGFR homo- and 
heterodimerisation, 3) extracellular ligand release and receptor–ligand segregation, 4) cytoplasmic 
and cell surface antagonist abundance, 5) rate of intracellular receptor recycling, and 6) 
downstream pathway choice causing differential gene expression. MEK/ERK: MAPK 
kinase/extracellular signal-regulated kinase; PI3K: phosphatidylinositol-3-kinase; JAK/STAT: 
Janus kinase/signal transducer and activator of transcription. 
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1.2.2	 LRIG1	structure	
	
	
LRIG1	belongs	to	a	group	of	three	proteins,	called	the	leucine	rich	repeat	and	
immunoglobulin	like	domain	proteins.		These	are	transmembrane	proteins,	each	
with	an	extracellular	portion	consisting	of	15	leucine	rich	repeats	followed	by	three	
immunoglobulin-like	domains,	a	transmembrane	region	and	a	cytoplasmic	tail.		
There	is	57-67%	amino	acid	identity	between	the	3	proteins,	with	LRIG1	the	most	
extensively	studied	(71).		The	gene	is	expressed	on	chromosome	band	3p14,	a	region	
of	the	genome	that	is	frequently	mutated	in	human	cancers	(72).		The	LRIG1	
nucleotide	sequence	encodes	1093	amino	acids,	and	83%	sequence	conservation	
exists	between	the	human	and	murine	amino	acid	sequences	(72).		Two	different	
isoforms	of	LRIG1	have	been	identified,	with	molecular	weights	of	143	kDa	and	134	
kDa.		Both	forms	are	larger	than	the	calculated	polypeptide	molecular	mass	of	120	
kDa,	indicating	the	presence	of	post	translational	modifications	such	as	glycosylation	
(73).		32	kDa	and	111	kDa	LRIG1	fragments	are	also	detected	on	the	use	of	
antibodies	to	the	internal	and	external	membrane	components	respectively.		This	
suggests	that	LRIG1	is	cleaved	and	there	is	a	shedding	of	LRIG1’s	extracellular	
domain	(the	111	kDa	portion)	(73).	
	
LRIG1	has	been	identified	in	all	studied	tissues	of	the	body	(72),	the	highest	protein	
expression	levels	are	seen	in	the	brain,	followed	by	the	kidney,	then	lung.		The	
protein	is	found	in	a	perinuclear	location	and	along	the	basolateral	membrane	of	
cells.		These	sites	correspond	to	those	where	the	ERBB	receptors	are	located	(61,	
74).			
	
1.2.3	 LRIG1	in	the	negative	regulation	of	EGFR	
	
LRIG1	negatively	inhibits	all	members	of	the	ERBB	receptor	family,	and	has	also	been	
found	to	down-regulate	the	action	of	other	tyrosine	kinases.		These	include	the	
hepatocyte	growth	factor	receptor	(MET)	(75),	proto-oncogene	tyrosine-protein	
kinase	receptor	Ret	(RET)	(76),	and	platelet-derived	growth	factor	receptor	alpha	
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(PDGFRα)	receptors	(77).		Additionally,	LRIG1	exerts	a	negative	inhibitory	action	on	
the	constitutively	active	mutant	form	of	EGFR,	EGFRvIII	(78).		Once	activation	of	the	
ERBB	receptor	occurs,	there	is	an	increase	in	LRIG1	mRNA	expression,	with	a	2-4	fold	
induction	seen	in	HeLa	cells	over	the	course	of	a	few	hours	(69).		Both	LRIG1	and	
MIG6	are	labile	and	undergo	proteasomal	degradation;	the	half-	life	of	LRIG1	is	4	
hours	but	further	activation	of	the	EGF	receptor	leads	to	LRIG1	instability	and	a	
shorter	duration	of	action	(69).	
	
The	mechanism	by	which	LRIG1	regulates	ERBB	signalling	is	controversial.		All	4	ERBB	
receptors	co-immunoprecipitate	with	LRIG1,	indicating	that	there	is	a	direct	
interaction	between	LRIG1	and	the	ERBB	family	member.		The	deletion	of	the	entire	
cytoplasmic	portion	of	EGFR	does	not	prevent	LRIG1	binding,	which	shows	that	
ERBB/LRIG1	interaction	occurs	through	the	ectodomain	of	the	ERBB	(69,	74).		
Conversely,	LRIG1	mutants	lacking	the	leucine	rich	repeats	or	the	immunoglobulin	
like	domain	components	can	still	interact	with	EGFR.		It	is	only	following	the	deletion	
of	both	of	these	sections	that	the	interaction	is	inhibited	(69).		
	
LRIG1	knock	down	increases	the	cell	surface	expression	of	EGFR	(79),	whilst	LRIG1	
overexpression	enhances	the	EGF-stimulated	cellular	uptake	of	EGFR,	suggesting	
that	LRIG1	is	involved	in	receptor	endocytosis	(80,	81).		It	was	initially	proposed	that	
LRIG1	triggered	EGFR	degradation	through	the	ubiquitination	of	the	receptor’s	
cytoplasmic	portion.		The	presence	of	EGF	ligand	stimulates	EGFR	ubiquitination	and	
this	stimulation	was	found	to	be	enhanced	by	LRIG1	expression	(74).		Tagged	
ubiquitin	was	further	found	to	co-immunoprecipitate	with	both	LRIG1	and	EGFR,	
indicating	the	formation	of	a	ternary	complex	between	the	three	(74).		To	support	
this	finding,	there	were	similar	rates	of	EGFR	ubiquitination	in	the	presence	of	LRIG1	
as	there	was	when	CBL	was	ectopically	expressed,	indicating	a	similar	mechanism	of	
action	(69).		A	role	for	ubiquitination	and	the	CBL	protein	has	been	shown	following	
induced	expression	of	a	dominant	negative	form	of	CBL,	70Z-CBL.		70Z-CBL	is	able	to	
bind	to	EGFR	in	preference	to	CBL	but	it	cannot	induce	receptor	ubiquitination.		
When	70Z-CBL	was	coexpressed	with	LRIG1,	EGFR	was	stabilised	and	not	degraded.		
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This	suggests	that	LRIG1-mediated	ubiquitination	of	EGFR	is	dependent	on	a	
functional	CBL	(69).			
	
Interestingly,	the	binding	of	CBL	to	EGFR	and	interaction	with	LRIG1,	in	addition	to	
reducing	EGFR	levels,	was	shown	to	reduce	levels	of	LRIG1.		A	series	of	LRIG1	
truncation	mutants	showed	that	CBL	binds	to	LRIG1’s	cytoplasmic	portion.		
Therefore,	to	establish	whether	the	binding	of	LRIG1	to	EGFR	and	CBL	led	to	the	
degradation	of	LRIG1,	HEK293T	cells	transfected	with	LRIG1	mutants	were	treated	
with	a	proteasome	inhibitor	(to	prevent	LRIG1	degradation	through	the	alternative	
proteasomal	degradation	pathway).		These	LRIG1	mutants	could	not	bind	either	CBL	
or	EGFR	and	showed	very	limited	degradation	suggesting	that	binding	of	CBL	to	the	
LRIG1/EGFR	complex	also	targets	LRIG1	depletion	(69).	
	
However	the	work	by	Stutz	et	al,	who	analysed	the	effects	of	LRIG1	on	the	mutant	
EGFRVIII	receptor	contradicted	the	above	findings	(78).		The	EGFRVIII	receptor	is	a	
mutated	form	of	EGFR	that	lacks	a	portion	of	the	extracellular	domain	and	is	
therefore	unable	to	bind	any	ligand.		Despite	this,	the	receptor	is	constitutively	
active	and	its	activity	enhanced	by	its	decreased	internalisation	rate	and	altered	
intracellular	trafficking.		LRIG1	and	EGFRVIII	were	shown	to	co-immunoprecipitate,	
as	with	the	other	ERBB	receptors,	so	there	is	a	direct	interaction	between	the	two	
proteins.		When	the	EGFRVIII	and	LRIG1	were	expressed	in	HEK293T	cells,	LRIG1	led	
to	a	reduction	in	EGFRVIII	levels,	with	recovery	curves	showing	that	EGFRVIII	was	
more	sensitive	to	LRIG1	regulation	than	wild-type	EGFR.		However,	the	investigators	
showed	that	the	70Z-CBL	protein	had	no	effect	on	receptor	stability,	and	did	not	
affect	the	rate	of	receptor	degradation.		This	is	despite	EGFRVIII	having	an	entirely	
functional	cytoplasmic	domain.		Subsequent	studies	using	the	wild-type	EGFR	
receptor	and	70Z-CBL,	failed	to	show	any	engagement	of	LRIG1	with	CBL	to	mediate	
the	degradation	of	EGFR	(78).		Further	support	of	these	findings	is	provided	by	
experiments	determining	the	effects	of	LRIG1	on	the	degradation	of	the	MET	
receptor.		Until	recently,	MET	receptor	degradation	was	considered	to	be	
ubiquitination-dependent.		There	is	a	binding	motif	in	the	juxtamembrane	domain	of	
MET	that	binds	CBL,	with	an	uncoupling	of	this	MET/CBL	binding	leading	to	cellular	
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transformation	(82).		However,	when	70Z-CBL	was	coexpressed	with	LRIG1,	there	
was	no	effect	of	70Z-CBL	on	LRIG1’s	ability	to	destabilise	the	MET	receptor.		This	
effect	was	seen	both	in	the	presence	and	absence	of	the	MET	ligand	hepatocyte	
growth	factor	(HGF)	and	subsequent	CBL	RNAi	experiments	found	CBL	to	have	no	
influence	over	LRIG1-mediated	MET	receptor	degradation	(75).		This	indicates	LRIG1	
triggers	MET	receptor	degradation	by	an	alternative	mechanism	to	that	of	CBL,	and	
suggests	that	the	LRIG1	mediated	degradation	of	EGFR	may	also	be	independent	of	
CBL.	
	
The	extracellular	portion	of	LRIG1,	containing	the	leucine	rich	repeats,	has	been	
demonstrated	to	regulate	EGFR	signalling	independently	of	either	receptor	
internalisation	or	receptor	degradation	(83).		The	action	of	the	protein	ADAM17	
causes	shedding	of	the	LRIG1	ectodomain	(84)	and	this	shed	portion	is	thought	to	act	
in	a	paracrine	fashion	as	a	‘competitive	inhibitor’,	of	ERBB	ligand	binding.		A	down	
regulation	of	EGFR	signalling	was	seen	in	A431,	HeLa	and	MDA-468	cancer	cell	lines	
in	response	to	administration	of	the	LRIG1	ectodomain,	whilst	cells	that	do	not	
express	EGFR	did	not	respond	to	the	LRIG1	ectodomain	(83).		Increasing	
concentrations	of	EGF	reduced	the	negative	inhibition	exerted	by	exogenous	LRIG1	
on	the	EGFR	receptor,	through	the	displacement	of	LRIG1	by	the	EGF	ligand.		The	
LRIG1	ectodomains	do	not	cause	a	physical	down	regulation	of	EGFR,	instead	it	is	
speculated	that	LRIG1’s	soluble	ectodomain	binds	to	the	EGFR,	preventing	the	
binding	of	ligands	and	keeping	EGFR	in	an	inactive	conformation.		This	is	analogous	
to	the	ERBB	monoclonal	antibody	cetuximab	that	inhibits	EGFR	signalling	(85).		The	
extracellular	portion	of	LRIG1	has	also	been	shown	to	inhibit	tumour	growth	of	
patient	derived	glioblastoma	xenografts	in	mice	(86).		These	soluble	LRIG1	
ectodomains	were	continually	administered	via	a	bead	delivery	system	and	
demonstrate	the	inhibitory	role	of	the	cleaved	portion	of	the	LRIG1	protein	and	its	
potential	therapeutic	effects.	
	
Whilst	LRIG1	is	subject	to	proteasomal	degradation	and	its	breakdown	is	accelerated	
by	the	presence	of	CBL,	further	complexity	to	LRIG1’s	control	of	ERBB	signalling	
arises	with	the	finding	that	LRIG1	can	interact	with	LRIG3.		The	two	proteins	co-
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immunoprecipitate,	even	in	the	absence	of	an	ERBB	receptor,	implying	potential	
cross-regulation	(80).		Rafidi	et	al	(80)	showed	that	LRIG3	overexpression	leads	to	
increased	numbers	of	both	EGFR	and	ERBB2	receptors	at	the	cell	surface	of	HEK293T	
cells,	directly	opposing	the	actions	of	LRIG1.		Conversely,	when	LRIG1	was	
overexpressed,	this	acted	to	destabilise	LRIG3	and	reduced	LRIG3	detection	at	the	
cell	surface.			
	
In	summary,	whilst	LRIG1	clearly	regulates	cell	surface	EGFR	levels	(79),	the	
mechanism	of	action	remains	to	be	determined.		
	
1.2.4	 LRIG1	as	a	stem	cell	regulator	
	
Stem	cells	are	defined	by	their	ability	to	self-renew	and	their	capacity	to	produce	
daughter	cells	with	more	restricted	potential	(87).		Early	research	into	the	role	of	
LRIG1	has	identified	a	role	for	the	protein	in	the	regulation	of	tissue	stem	cell	
compartments.	
	
1.2.4.1	LRIG1	in	the	skin	
	
Our	initial	understanding	of	the	function	of	LRIG1	has	come	from	loss-of-function	
studies	in	mouse.		Suzuki	et	al	first	detected	the	LRIG1	gene	following	a	screen	for	
genes	that	were	upregulated	during	the	neural	differentiation	of	the	mouse	cancer	
cell	line	P19	(88).		Following	Northern	blot	analysis,	LRIG1	was	found	to	be	highly	
expressed	in	the	brain,	and	in	the	anticipation	of	a	neurological	phenotype,	an	Lrig1	
knockout	mouse	was	developed	(89).		Although	there	were	no	neurological	sequelae	
caused	by	loss	of	Lrig1,	by	3-	4	weeks	of	age	the	Lrig1	knockout	mice	were	noted	to	
have	skin	abnormalities,	with	thickening	of	the	tail	skin	and	alopecia	around	the	
facial	area.		Histological	examination	revealed	marked	epidermal	hyperplasia	and	an	
increased	epidermal	proliferation	on	Ki67	staining	(89).		A	comparison	of	these	skin	
changes	was	made	to	those	of	psoriatic	epidermal	hyperplasia	in	humans,	with	both	
showing	similar	histological	appearances.			It	was	found	that	LRIG1	protein	
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expression	was	absent	in	the	psoriatic	lesions,	but	was	detectable	at	normal	levels	in	
the	surrounding,	unaffected	tissue	(89).	
	
A	further	insight	into	the	role	of	LRIG1	was	obtained	through	experiments	designed	
to	elucidate	markers	of	the	keratinocyte	stem	cell	population.		Single-cell	expression	
profiling	was	performed	in	both	stem	cells	and	the	more	differentiated,	transit-	
amplifying	cell	population	of	human	epidermal	keratinocytes.		LRIG1	transcripts	
were	found	to	be	enriched	in	the	stem	cell	fraction	(79).		Subsequent	LRIG1	
knockdown	using	siRNA	was	noted	to	increase	both	cell	proliferation	and	clonogenic	
capacity,	with	increased	EGFR	levels	and	downstream	signalling	activation	(79).		
These	findings	suggested	that	LRIG1’s	role	may	be	to	regulate	stem	cell	activity	and	
maintain	the	epidermal	stem	cells	in	a	quiescent,	non-proliferative	state	that	is	
mediated	through	LRIG1’s	regulation	of	EGFR	signalling.	
	
Further	studies	have	shown	that	LRIG1	regulates	the	proliferative	capacity	of	
epidermal	cells	(90).		5-bromo-2'-deoxyuridine	(BrdU)	pulse-chase	studies	have	
shown	that	in	LRIG1-null	animals,	a	decrease	in	the	number	of	epidermal	DNA	label-
retaining	cells	is	seen	after	a	70	day	chase	period,	compared	to	wild-type	animals	
indicating	that	the	population	is	dividing	more	rapidly	and	diluting	out	the	BrdU	
label,	suggesting	that	LRIG1	is	necessary	for	stem	cell	quiescence.			Interestingly,	in	
skin	reconstitution	assays,	where	GFP	labelled	LRIG1	positive	cells	are	isolated	and	
mixed	with	unlabelled	cells,	the	LRIG1	positive	cells	were	able	to	contribute	to	all	
epidermal	lineages,	highlighting	their	potential	stem	cell	phenotype	(90).			
	
Recent	increases	in	the	understanding	of	the	skin	stem	cell	compartment	have	
shown	LRIG1	to	mark	a	population	of	cells	in	the	upper	isthmus	of	the	hair	follicle.		
This	compartment	maintains	the	upper	pilosebaceous	unit	that	contains	the	
infundibulum	and	sebaceous	gland	(91).		Lineage-tracing	analysis	using	tamoxifen	
inducible	Cre	under	the	control	of	the	Lrig1	promoter	have	shown	that	during	
homeostasis	this	LRIG1-positive	subpopulation	is	responsible	for	the	maintenance	of	
the	pilosebaceous	unit	and	is	not	detectable	outside	these	margins.		It	is	interesting	
to	note	that	a	single	LRIG1-expressing	cell	either	maintains	the	infundibulum	or	
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sebaceous	gland,	but	an	individual	cell	is	incapable	of	contributing	to	both.		This	
restriction	changes	on	skin	wounding,	where	the	LRIG1-expressing	cells	are	able	to	
replace	cells	lost	from	other	areas,	including	the	hair	follicle	and	interfollicular	
epidermis	(91).		Furthermore,	this	study	showed	the	highly	proliferative	nature	of	
LRIG1	positive	cells,	as	following	a	short	BrdU	pulse,	where	the	LRIG1-expressing	
cells	showed	increased	labelling	compared	to	both	the	CD34+	hair	follicle	stem	cells	
and	the	interfollicular	epidermal	skin	cells.		This	is	seemingly	in	contradiction	to	
LRIG1’s	role	as	a	negative	regulator	of	proliferation	and	may	best	be	explained	by	
LRIG1	controlling	the	amplitude	of	ERBB	signalling.	
	
1.2.4.2	LRIG1	in	the	gut	
	
Intestinal	stem	cells	reside	at	the	crypt	base,	where	they	divide	to	self-renew	and	to	
maintain	the	continuously	renewing	epithelial	surface.		As	cells	move	away	from	the	
crypt	base,	they	become	progressively	more	differentiated	(92).		LRIG1	shows	a	
gradient	of	expression	that	is	highest	at	the	crypt	base,	but	is	diluted	as	the	cells	
move	out	along	the	walls.		These	levels	of	LRIG1	expression	correlate	to	those	of	the	
intestinal	stem	cell	marker	leucine	rich	repeat	containing	G	protein	coupled	receptor	
5	(LGR5)	(93).		Other	intestinal	stem	cell	markers	including	Achaete-Scute	Family	
BHLH	Transcription	Factor	2	(ASCL2)	and	Musashi	RNA	Binding	Protein	1	(MSI1)	are	
also	enriched	in	this	area.		To	investigate	the	proliferative	nature	of	gut	LRIG1	
positive	cells	BrdU	pulse	chase	labelling	was	used.		After	a	3	day	pulse,	60%	of	LRIG1	
expressing	cells	were	BrdU-labelled,	indicating	that,	as	shown	in	the	skin,	LRIG1	
marks	a	highly	proliferative	cell	population	(93).			
	
Lrig1	loss	in	the	inbred	mouse	strain	FVB/N	resulted	in	a	marked	increase	in	crypt	
size	along	the	length	of	the	intestine,	and	produced	a	phenotype	so	severe	that	the	
mice	needed	to	be	sacrificed	around	postnatal	day	10.		This	model	was	interesting	
for	two	reasons;	the	effects	of	loss	of	Lrig1	in	a	knockout	model	are	dependent	on	
mouse	background	(with	these	changes	not	seen	in	the	initial	Lrig1	knock	out,	used	
by	Suzuki	et	al,	on	an	outbred	background	(89))	and	that	the	phenotypic	change	
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corresponded	directly	with	an	expansion	of	the	stem	cell	compartment.		Rescue	of	
the	phenotype	was	achieved	either	pharmacologically	through	the	administration	of	
gefitinib,	an	EGFR	receptor	blocker,	or	genetically	by	the	crossing	of	the	Lrig1	
knockout	animals	to	hypomorphic	EGFR	w-2	mice.		This	directly	demonstrates	that	
LRIG1	is	exerting	its	action	on	the	intestinal	stem	cell	compartments	through	an	
effect	on	EGFR	signalling	(93).		
	
Lineage	tracing	using	tamoxifen	inducible	Cre	under	the	control	of	the	LRIG1	
promoter	confirmed	that	LRIG1	marks	a	population	in	the	gut	with	stem	cell	
properties	(94).		Activation	of	the	lineage	marker	in	LRIG1+	cells	showed	that	labelled	
cells	first	appeared	in	the	crypt	bases,	before	spreading	over	a	14-day	period	to	
repopulate	the	entire	crypt.		All	cell	types	within	the	crypt	were	labelled	and	
labelling	was	still	evident	after	3	months,	indicating	the	effective	labelling	of	a	stem	
cell	(94).		
	
A	recent	controversy	in	the	field	is	that	the	rapidly	proliferative	LRIG1	positive	gut	
population	identified	by	Wong	et	al	(93),	contrasts	to	the	findings	of	Powell	et	al,	
where	their	Ki67	and	BrdU	analyses	determined	LRIG1	positive	cells	to	be	
infrequently	cycling	(94).		However,	a	recently	published	paper	has	drawn	light	on	
the	confusion;	Wong	et	al	used	a	commercially	available	LRIG1	antibody	against	
LRIG1’s	entire	ectodomain,	whilst	the	Powell	group	developed	their	own	antibody	
against	a	12	amino	acid	motif	within	the	ectodomain,	a	site	that	is	possibly	affected	
by	glycosylation,	and	that	may	affect	antibody	binding	(95).		It	is	likely	that	the	work	
of	Wong	et	al	gives	a	better	indication	of	the	activity	of	all	LRIG1	expressing	cells,	
rather	than	a	potentially	more	quiescent	LRIG1-expressing	subpopulation.	
	
1.2.5.3	LRIG1	in	the	eye	
	
In	addition	to	the	findings	in	the	skin	and	gut,	the	importance	of	LRIG1’s	regulation	
of	the	stem	cell	compartment	has	been	shown	in	the	cornea	(96).		Gene	expression	
analysis	has	shown	increased	LRIG1	expression	in	the	corneal	epithelial	cells	that	
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exhibit	a	stem	cell	phenotype	compared	to	the	corneal	cells	that	are	more	
differentiated.		LRIG1	appears	to	regulate	cell	fate	decisions,	with	its	loss	changing	
cell	fate	from	corneal	to	keratinised	epithelium,	and	leading	to	corneal	opacification	
in	an	Lrig1	knockout	mouse	model.		These	effects	are	exerted	through	the	action	of	
LRIG1	on	the	STAT3	inflammatory	pathway,	as	corneal	wounding	in	Lrig1	knockout	
animals	led	to	an	increased	expression	of	phospho-STAT3.		The	pharmacological	
inhibition	of	STAT3	blockade	prevented	these	changes	occurring.		Interestingly,	K5	
Stat3	transgenic	mice	that	exhibit	constitutively	active	STAT3	signalling,	show	a	
similar	phenotype	to	the	Lrig1	knockout	animals	after	corneal	injury	(96).		This	is	the	
first	research	that	links	LRIG1	with	the	STAT3	pathway	and	it	remains	uncertain	as	to	
whether	this	restricted	to	the	cornea	or	may	be	a	more	widespread	action	of	LRIG1.		
	
1.2.5	 LRIG1	in	cancer	
	
	
The	first	indication	of	LRIG1	as	a	potential	tumour	suppressor	arose	through	the	
development	of	adenomas	in	Lrig1-null	mice.		At	five	months	of	age,	80%	of	the	
Lrig1-null	mice	had	developed	duodenal	adenomas	and	by	14	months,	these	had	
progressed	to	adenocarcinomas	with	invasion	of	the	bowel	wall	(94).		The	tumours	
were	associated	with	increased	EGFR	expression	and	indicated	a	direct	effect	of	
LRIG1	absence.		Powell	et	al	further	showed	that	by	inducing	the	loss	of	one	
adenomatous	polyposis	coli	(APC)	allele,	a	tumour	suppressor	protein	in	which	
mutations	lead	to	colonic	cancer,	in	an	LRIG1	expressing	cell	that	the	stochastic	loss	
of	the	second	APC	allele	led	to	multiple	colonic	tumours.		These	findings	add	further	
weight	to	LRIG1	marking	a	gut	stem	cell,	as	the	lifespan	of	an	LRIG1	expressing	cell	
needs	to	be	sufficiently	long	in	order	to	acquire	the	stochastic	loss	of	the	second	APC	
allele	(94).	
	
In	humans,	LRIG1	is	localised	to	the	chromosome	band	3p14.3,	a	location	frequently	
deleted	in	various	human	cancers	(97).		Rouam	et	al	undertook	a	large	
bioinformatics	study	where	8	datasets	were	combined	to	assess	prognostic	factors	in	
various	solid	tumours.		Remarkably,	they	found	that	LRIG1	was	one	of	4	key	genes	(in	
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addition	to	ESPL1,	KIF4A	and	HJURP)	whose	decreased	expression	led	to	reduced	
survival	outcomes	across	five	tumour	types	including	breast,	bladder,	glioma,	
melanoma	and	lung	cancer	(98).			
	
A	reduction	in	LRIG1	protein	expression	and	a	worsening	of	outcome	has	been	
shown	in	cervical	cancer	(99),	astrocytomas	(100),	nasopharyngeal	(101)	and	
oropharyngeal	malignancies.		LRIG1	is	seen	in	higher	concentrations	in	the	well-	
differentiated	squamous	cell	carcinomas	of	the	skin	(102)	and	loss	of	LRIG1	is	
associated	with	the	invasion	of	ocular	surface	neoplasia	in	the	eye	(103).		
	
1.2.5.1	LRIG1	in	lung	cancer	
	
Analysis	of	the	gene	expression	within	the	airway	epithelium	shows	that	LRIG1	is	
downregulated	in	current	smokers	compared	to	ex-smokers,	and	this	drop	in	
expression	falls	further	on	the	development	of	squamous	cell	carcinoma	(30).			Loss	
of	LRIG1	protein	expression	is	seen	in	preinvasive	lung	cancer	lesions,	a	loss	that	is	
associated	with	increased	EGFR	expression	(104).		This	may,	in	part,	explain	the	
finding	of	increased	EGFR	expression	in	squamous	cell	lung	tumours	(26,	27).			
	
The	isolation	of	mRNA	and	protein	expression	in	paired	samples	of	preinvasive	and	
normal	epithelium	from	the	same	patient	have	shown	both	decreased	gene	
expression	and	a	reduced	immunoreactivity	of	LRIG1	in	each	of	the	10	cases	
examined.		In	four	out	of	the	10	cases	there	was	loss	of	heterozygosity	(LOH)	at	the	
LRIG1	locus,	but	unfortunately,	due	to	the	small	amount	of	frozen	tissue	available	for	
assessment,	promoter	methylation	or	mutation	in	the	other	allele	was	not	
identifiable	(104).		LOH	analysis	for	LRIG1	was	subsequently	analysed	in	138	lung	
cancer	cell	lines	as	part	of	the	Sanger	Cancer	Genome	Project,	with	LOH	reported	at	
the	LRIG1	locus	in	75%	of	cases	(104).			
	
Loss	of	LRIG1	was	shown	to	reduce	contact	inhibition	in	human	airway	epithelial	
cells	grown	at	air-liquid-interface.		It	was	observed	in	LRIG1	expressing	cells	that	
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LRIG1	expression	co-localised	with	that	of	EGFR	and	E-cadherin	at	cell	confluence,	
with	co-immunoprecipitation	experiments	showing	the	formation	of	a	tripartite	
complex	between	LRIG1,	E-cadherin	and	EGFR	(104).		This	may	provide	a	further	
mechanism	by	which	LRIG1	regulates	the	effects	of	EGFR	and	may	explain	the	
development	of	tumours	in	the	gut	with	loss	of	LRIG1,	as	there	is	a	removal	of	the	
contact	inhibition	provided	by	the	EGFR/E-cadherin/LRIG1	complex	(104).		Whether	
this	complex	exists	in	tissues	other	than	the	lung	and	the	downstream	consequences	
of	EGFR/E-cadherin/LRIG1	complex	formation	remain	to	be	determined.	
	
The	possibility	of	LRIG1	as	a	prognostic	biomarker	in	NSCLC	has	been	raised	by	
Kvarnbrink	et	al	(105).		In	their	analysis	of	LRIG1	protein	expression	in	347	NSCLC	
tumours,	they	detected	that	high	LRIG1	expression	was	related	to	a	dramatically	
improved	survival	of	2.8	years.		Initial	analysis	showed	the	survival	advantage	to	be	
most	marked	in	adenocarcinoma,	however	only	the	presence	of	LRIG1	in	the	tumour	
cells	was	considered.		The	group’s	subsequent	analysis	of	the	Oncomine	database,	
where	LRIG1	mRNA	was	strongly	correlated	to	an	improved	squamous	cell	lung	
cancer	prognosis,	prompted	their	re-examination	of	the	tumour	and	showed	LRIG1	
protein	expression	in	the	surrounding	cell	types	(stromal	and	immune	cells)	was	
highly	correlated	to	the	improved	outcome	(105).	
	
1.2.5.2	LRIG1	in	breast	and	prostate	cancer	
	
In	breast	and	prostate	cancer	LRIG1	expression	is	induced	by	oestrogen	and	
androgens	respectively.	A	recent	study	has	shown	in	971,	stage	1/2,	breast	tumours	
(of	all	subtypes)	that	the	loss	of	LRIG1	is	associated	with	an	increased	risk	of	both	
breast	cancer	relapse,	relapse	of	breast	cancer	after	5	years,	and	death	(106).			
However,	LRIG1	expression	in	breast	cancer	is	variable	according	to	both	tumour	
type	and	the	sensitivity	of	the	tumour	cells	to	oestrogen.	LRIG1	expression	is	seen	in	
higher	levels	in	oestrogen	receptor	positive	(ERα+)	breast	cancer	than	ERα-	disease.		
Krieg	et	al	showed	that	LRIG1	is	a	target	of	ERα,	so	in	the	presence	of	oestrogen	
LRIG1	levels	are	increased,	with	LRIG1	acting	as	an	oestrogen-regulated	growth	
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inhibitor	(107).		Intermediate	to	high	levels	of	LRIG1	transcripts	in	ERα+	disease	were	
shown,	through	the	analysis	of	the	Oncomine	database,	to	be	associated	with	an	
improved	relapse	free	survival	time.				
	
The	ERBB2	receptor	is	over	expressed	in	20-30%	of	breast	cancers	and	this	up	
regulation	is	associated	with	a	reduction	in	both	protein	and	transcript	levels	of	
LRIG1	(108).		The	reduction	in	LRIG1	protein	in	turn	contributes	to	further	ERBB2	
over	expression	(108).		Kreig	et	al	further	showed	ERBB2	over	expression	to	reduce	
ERα+	induced	LRIG1	expression,	indicating	mechanistically,	how	LRIG1	expression	
may	be	reduced	in	ERBB2	over	expressing	tumours	(107).		
	
The	role	of	LRIG1	in	prostate	cancer	is	interesting.		LRIG1	expression	is	increased	by	
androgen	administration	and	the	transduction	of	the	PC3	prostate	cancer	cell	line	
with	LRIG1	lentivirus	causes	a	slower	growth	rate.		In	a	cohort	of	patients	that	had	
not	undergone	treatment,	high	LRIG1	expression	levels	were	associated	with	a	poor	
prognosis,	however	in	a	cohort	that	had	undergone	prostatectomy	high	LRIG1	
expression	levels	were	related	to	improved	outcomes	(109).	The	authors	describe	a	
possible	explanation	for	this	paradox,	whereby	in	a	high	androgen	environment	the	
inhibitory	effects	of	LRIG1	are	not	sufficient	to	counteract	the	tumour	burden,	whilst	
in	patients	who	have	undergone	treatment	the	tumour	burden	is	less	and	LRIG1	is	
better	able	to	exert	its	inhibitory	role	(109).	
	
1.2.6	 The	role	of	LRIG1	in	epithelial-to-mesenchymal	transition	(EMT)		
	
Two	recent	studies	have	indicated	a	possible	role	for	LRIG1	in	the	modulation	of	
epithelial-to-mesenchymal	transition	(EMT)	(110,	111).	EMT	is	the	process	by	which	
an	epithelial	cell	phenotype	changes	to	become	mesenchymal	(112).		It	is	associated	
with	a	loss	of	cellular	polarity	and	the	reorganization	of	the	cytoskeleton.		There	is	a	
downregulation	of	epithelial	markers	including	E-cadherin,	Zinc	finger	protein	SNAI1	
	(SNAI1)	and	zonula-ocludens	(ZO-1),	whilst	there	is	upregulation	of	markers	
including	Twist	Family	BHLH	Transcription	Factor	1	(TWIST),	fibronectin	and	matrix	
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metalloproteinases	(MMPs).		These	changes	in	expression	contribute	to	cancer	
progression	(112).			
	
Assessment	of	the	effects	of	LRIG1	within	head	and	neck	squamous	cell	cancers,	
have	shown	that	the	reintroduction	of	LRIG1	to	a	nasopharyngeal	cell	line	lacking	
LRIG1	resulted	in	a	morphology	change	from	spindle-like	to	cuboidal,	with	activation	
of	integrins	and	a	downregulation	of	SNAI1	expression.		Conversely,	when	LRIG1	was	
knocked	down	in	an	LRIG1-expressing	cancer	cell	line,	cell	migration,	invasion	and	
proliferation	were	enhanced.	This	was	associated	with	extracellular	matrix	
remodelling	activity	and	an	increase	in	MMP	expression,	all	changes	that	are	
associated	with	the	onset	of	EMT	(110).	
	
As	discussed	above,	LRIG1	is	associated	with	poor	prognosis	from	breast	cancer,	and	
studies	with	breast	cancer-derived	cell	lines	have	implicated	LRIG1	as	a	possible	EMT	
regulator.		During	EMT	of	breast	cancer	cells	LRIG1	is	downregulated,	whilst	the	re-
expression	in	an	LRIG1	negative	invasive	cell	line	induces	a	mesenchymal-to-
epithelial	transition	(reversal	of	EMT).		This	is	associated	with	a	reduction	of	
tumoursphere	formation	and	an	inhibition	of	invasive	growth	(111).	
	
1.2.7	 The	other	LRIG	proteins	
	
LRIG2	and	LRIG3	have	been	less	extensively	studied	than	LRIG1,	and	their	functions	
have	not	been	fully	defined.			Genetic	inactivation	of	Lrig2	in	a	mouse	leads	to	no	
phenotype	other	than	reduced	weight	at	5	days,	and	an	increased	likelihood	of	
malnutrition	and	premature	death	(77).		In	humans,	LRIG2	mutations	are	associated	
with	congenital	urofacial	syndrome	(113),	where	the	clinical	features	of	
hydronephrosis	and	facial	grimace,	are	indistinguishable	from	those	of	Heparanase-2	
(HPSE2)	linked	urofacial	syndrome.		This	suggests	that	there	is	a	functional	overlap	
between	LRIG1	and	HPSE2,	with	loss	of	either	protein	leading	to	aberrant	growth	
factor	signalling	(81,	114).			
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Following	the	finding	that	LRIG2	expression	is	associated	with	poor	survival	
outcomes	in	patients	with	oligodendroglioma	(115),	the	effects	of	the	lack	of	LRIG2	
on	tumour	growth	were	investigated	in	a	murine	glioma	model.		It	was	found	that	
LRIG2	deficient	animals	were	protected	against	platelet	derived	growth	factor	B	
(PDGFB)	induced	tumours,	suggesting	a	potential	role	of	LRIG2	in	regulating	PDGFB	
signalling	(77).		The	expression	of	LRIG2	in	cancer	has	been	associated	with	a	
worsening	of	the	prognosis	from	a	number	of	other	malignancies.		These	include	an	
association	of	LRIG2	expression	with	the	increased	invasion	of	pituitary	adenomas	
(116),	poor	survival	in	early	stage	cervical	cancer	(117)	and	a	worsening	of	outcome	
from	non-small	cell	lung	cancer	(118).	
	
Lrig3	knockout	mutant	mice	show	impaired	morphogenesis	of	the	inner	ear,	where	
LRIG3	is	necessary	for	lateral	canal	development,	a	process	independent	of	ERRB	
signalling	(119).		The	protein	also	plays	a	role	in	the	neural	crest	formation	of	
Xenopus	through	the	modulation	of	Fgf	and	Wnt	signalling	(120).		Similarly	to	LRIG1	
and	2,	LRIG3	expression	has	been	associated	with	malignancies.		A	high	number	of	
LRIG3	positive	cells	in	cervical	adenocarcinoma	specimens	are	associated	with	an	
improved	outcome	(121),	whereas	the	perinuclear	staining	of	LRIG3	is	inversely	
correlated	to	the	grade	of	astrocytic	tumour	and	patient	survival	(100).		Two	studies	
looking	at	the	effects	of	LRIG3	in	glioblastoma	cell	lines	have	shown	that	LRIG3	
overexpression	causes	a	reduction	of	glioblastoma	cell	proliferation	(122),	whilst	
LRIG3	shRNA	mediated	knockdown	leads	to	increased	EGFR	expression	and	cellular	
proliferation	(123).		Interestingly,	these	findings	oppose	those	of	Rafidi	et	al	who	
suggest	that	LRIG3	directly	antagonises	the	action	of	LRIG1	(80)	and	it	is	possible	that	
these	contradictions	may	be	explained	by	a	tissue-to-tissue	variability	in	the	function	
of	LRIG3.	
	
1.3	 Stem	cells	of	the	lung	and	lung	cancer	cell	of	origin	
	
1.3.1	 Structure	of	the	lung	and	respiratory	epithelium	
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The	lungs	are	directly	exposed	to	the	external	environment,	with	the	respiratory	
epithelium	subject	to	a	number	of	chemicals,	viruses,	bacteria	and	other	insults	over	
the	lifetime	of	an	individual.		The	presence	of	an	intact	epithelium	is	essential	for	
warming	inspired	air,	performing	gaseous	exchange	in	the	distal	airway,	and	in	the	
production	of	mucus	that	defends	against	inhaled	pathogens	(124).		In	humans,	the	
airways,	down	to	a	diameter	of	1-	1.5	mm,	are	lined	by	a	pseudostratified	columnar	
epithelium	consisting	of	ciliated	cells,	mucous	secreting	goblet	cells,	club	cells	and	
basal	cells.		Mucous	cells	predominate	in	the	larger	airways	and	club	cells	increase	
distally.		Neuroendocrine	cells	are	scattered	throughout	the	airway,	but	also	form	
collections	around	the	airway	branch	points	that	are	termed	the	neuroepithelial	
bodies	(NEBs).		The	simple	cuboidal	epithelium	that	leads	to	the	alveoli	is	poorly	
characterised,	but	the	alveolar	epithelium	consists	of	cuboidal	alveolar	type	2	cells	
(AT2)	and	squamous	alveolar	type	1	cells	(AT1)	(125).		Differences	exist	between	the	
human	and	murine	airway.		In	the	mouse,	the	pseudostratified	airway	epithelium	is	
seen	only	in	the	trachea	and	the	mainstem	bronchi,	with	the	basal	cells	limited	to	
these	areas.		The	smaller	airways	of	the	mouse	are	lined	by	a	simple	cuboidal	
epithelium	consisting	of	ciliated	and	club	cells,	and	there	are	fewer	neuroendocrine	
cells	compared	to	the	human	(125).	
	
1.3.2	 Lung	stem	cells	and	the	stem	cell	niche		
	
Stem	cells	are	vital	in	maintenance	of	an	intact	respiratory	epithelium.		They	are	
defined	by	their	ability	to	self-renew	and	their	capacity	to	produce	multiple,	more	
differentiated	daughter	cells	of	varying	types	(87).		Our	understanding	of	stem	cell	
behaviour	has	been	derived	from	studies	in	the	haematopoietic	system.		In	the	
haematopoietic	system	there	is	a	quiescent	stem	cell	at	the	apex	of	the	hierarchy,	
which	divides	asymmetrically	to	produce	new	stem	cells,	which,	in	turn,	divide	to	
produce	progressively	more	rapidly	dividing	progenitor	cells.		As	cells	move	through	
this	system	they	become	increasingly	differentiated	and	the	full	complement	of	
blood	cell	types	is	produced	(126).			
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In	contrast	to	the	haematopoietic	system,	where	the	stem	cell	hierarchies	are	well	
defined,	the	stem	cell	populations	maintaining	solid	organs	and	in	particular	the	
airway	epithelium	is	more	complex.		Studies	in	the	airway	have	been	hampered	by	
the	slow	turnover	of	the	respiratory	epithelium,	making	lineage-tracing	studies	
during	homeostasis	challenging.		Murine	lung	injury	models	have	been	crucial	in	
defining	the	putative	stem	cell	populations	of	the	airway	and	through	the	damaging	
of	a	discrete	cell	population,	combined	with	lineage	tracing	(124),	three	possible	
stem	cell	niches	have	been	identified	within	the	murine	lung	(Figure	1.2).			
	
A	stem	cell	niche	is	a	particular	area	within	a	tissue	where	the	stem	cells	reside.		The	
stem	cells	interact	with	the	cells	of	the	niche	where	they	are	kept	in	a	quiescent	and	
dormant	state.		The	role	of	the	niche	is	to	protect	the	stem	cells	from	exhaustion	or	
death,	and	on	activation	of	the	stem	cell	population,	promote	cellular	differentiation	
and	influence	the	fate	of	daughter	cells	(127).		Within	the	mouse	lung,	stem	cell	
niches	are	reported	in	the	submucosal	glands	of	the	trachea	where	there	is	an	
increased	density	of	basal	cells,	the	neuroepithelial	bodies	(NEBs)	that	are	located	at	
airway	branch	points,	and	the	bronchoalveolar	duct	junctions	(BADJs)	that	are	
positioned	where	the	bronchioles	transition	into	the	gas	exchanging	alveoli	(128,	
129).	
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Figure	1.2:			Schematic	showing	the	different	epithelial	cell	types	within	the	murine	
bronchial	tree	
	
Image	shows	the	different	cells	types	moving	from	the	trachea,	with	a	high	density	of	basal	cells	seen	
in	the	upper	airways,	to	the	alveoli.		The	position	of	the	three	stem	cell	niches	are	indicated.		These	
are	the	upper	airway	submucosal	gland,	the	neuroepithelial	body	positioned	at	airway	branch	points	
and	the	bronchoalveolar	duct	junction	situated	at	the	point	where	the	small	airways	become	alveoli.		
Figure	adapted	from	reference	(124).	
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1.3.3	 Stem	cells	of	the	upper	airway	
	
Basal	cells	constitute	30%	of	the	upper	airway	epithelium	and	are	identified	by	the	
expression	of	the	markers	p63,	nerve	growth	factor	receptor	(NGFR)	and	keratins	5	
and	14	(KRT5	and	KRT14)	(130).		The	basal	cells	are	considered	the	upper	airway	
stem	cell,	as	shown	through	lineage-tracing	experiments	using	KRT5-
CreERT2;Rosa26R-LacZ	mice.		Exposure	of	these	mice	to	sulphur	dioxide	(SO2)	leads	to	
the	loss	of	both	secretory	and	ciliated	cell	populations,	whilst	leaving	the	basal	cells	
intact.		Over	the	course	of	a	7	day	period,	the	basal	cells	proliferate	and	repair	the	
damaged	epithelium	including	the	replacement	of	lost	secretory	and	ciliated	cells	
(130).		Notch	signalling	promotes	the	luminal	differentiation	of	basal	cells,	as	shown	
through	the	pharmacological	inhibition	of	Notch	in	a	tracheosphere	assay.		The	
Notch-inhibited	tracheospheres	fail	to	form	a	lumen	and	remained	as	clumps	of	p63+	
basal	cells,	whereas	the	controls	hollowed	and	formed	p63-KRT8+	progenitors.		This	
is	also	seen	in	vivo,	where	mindbomb	E3	ubiquitin	protein	ligase	1	(Mib1)	deficient	
mice	(that	are	unable	to	activate	Notch	signalling)	were	less	able	to	repopulate	the	
airway	epithelium	following	SO2-mediated	airway	damage	(131).		The	levels	of	Notch	
signalling	regulate	the	differentiation	of	p63+	basal	cells	into	either	secretory	or	
ciliated	lineages.		The	p63+	basal	cell	may	either	show	intracellular	Notch	2	
activation,	and	ultimately	develop	into	a	secretory	cell,	or	exhibit	c-myb	expression	
and	differentiate	into	a	ciliated	cell	(132).			
	
Whilst	basal	cells	have	been	shown	to	replace	ciliated	and	secretory	cells	
populations,	recent	research	has	shown	that	following	the	complete	ablation	of	
basal	cells	(using	doxycycline-dependent	diphtheria	toxin	expression	targeted	to	
KRT5+	cells)	there	is	a	dedifferentiation	of	luminal	secretory	cells	to	a	basal	cell	
phenotype.		These	dedifferentiated	cells	persist	and	act	as	functional	stem	cells,	
capable	of	producing	new	ciliated,	secretory	and	basal	cells	(133).		This	suggests	that	
airway	epithelial	cells	exhibit	more	plasticity	than	previously	considered.	
	
The	stem	cell	phenotype	of	basal	cells	has	also	been	shown	in	the	human	airway.		
When	integrin	α6+,	NGFR+	basal	epithelial	cells	are	isolated	from	the	human	airway	
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and	grown	in	tracheosphere	culture	there	is	evidence	of	ciliated	differentiation	after	
25	days,	findings	that	are	absent	in	the	integrin	α6-,	NGFR-	population	(130).		
Additionally,	when	human	basal	cells	are	isolated	and	grown	at	air-liquid	interface,	
using	a	rat	trachea	as	a	scaffold,	the	basal	cells	are	capable	of	forming	a	fully	
differentiated	mucociliary	epithelium	(134).		
	
Further	insight	into	the	maintenance	of	the	human	airway	has	been	obtained	from	
Teixeira	et	al	(135),	who	have	shown	that	in	the	large	airways	homeostasis	is	
maintained	by	the	stochastic	division	of	basal	cells,	spread	throughout	the	airways	
that	self	renew	and	differentiate.		The	experiments	used	clonal	lineage	analysis,	
where	the	airway	epithelium	was	stained	for	the	presence	of	cytochrome	C	oxidase	
(CCO),	a	gene	that	becomes	stochastically	mutated	in	mitochondrial	DNA	and	passed	
to	daughter	cells.		Clones	of	CCO	negative	cells	were	visible	within	the	airway	
epithelium	and	mathematical	modelling	showed	that	these	clones	were	associated	
with	airway	basal	cells.		The	basal	cells	did	not	appear	to	be	pre-programmed	stem	
cells,	but	were	equipotent	in	their	ability	to	maintain	epithelial	integrity.		However,	it	
remains	uncertain	as	to	whether	these	cells	are	responsible	for	the	repair	of	airway	
damage,	or	whether	a	more	defined	stem	cell	pool	is	activated	(125).	
	
1.3.4	 Stem	cells	of	the	small	airways	and	alveoli	
	
The	small	airways	contain	two	stem	cell	niches,	one	situated	within	the	NEB	and	the	
other	at	the	BADJ.		Again	our	knowledge	of	the	small	airway	stem	cell	populations	
has	been	derived	predominantly	from	murine	injury	models,	and	it	remains	
uncertain	as	to	how	closely	correlated	these	findings	are	to	the	human	airway.		
	
The	small	airways	are	predominantly	lined	by	Clara	cell	10	KDa	(CC10)	expressing	
club	cells	and	Forkhead	Box	J1	(FOXJ1)	expressing	ciliated	cells.		Naphthalene	
administration	to	a	mouse	leads	to	acute	club	cell	toxicity.		On	club	cell	death,	the	
ciliated	cells	are	seen	to	spread	across	the	respiratory	epithelium	but	they	fail	to	
divide	to	replace	the	lost	club	cell	population	(136).		72	hours	post-injury	there	is	an	
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expansion	of	cells	at	the	NEB,	including	both	the	calcitonin	gene	related	peptide	
(CGRP)	expressing	neuroendocrine	cells	and	a	variant	CC10-expressing	club	cell	
population	(137).		The	variant	club	cells	lack	the	cytochrome	P450	2F2-
immunoreactive	protein	that	metabolises	naphthalene,	leading	to	naphthalene	
resistance	and	their	survival.		To	determine	whether	the	neuroendocrine	cells,	or	the	
variant	club	cells	re-epithelialise	the	airway	following	damage,	complete	club	cell	
obliteration	was	achieved	through	the	administration	of	ganciclovir	to	transgenic	
mice	expressing	herpes	simplex	kinase	under	the	regulatory	control	of	the	mouse	
CC10	promoter	(this	depletes	all	club	cells,	including	the	variant	club	cells).		The	
CGRP-expressing	neuroendocrine	cells	were	unable	to	replace	the	lost	cells,	
indicating	that	the	CC10	variant	club	cell	population	is	vital	to	the	regeneration	of	
the	airway	epithelium	(138).	
	
Moving	distally,	the	most	terminal	bronchioles	lack	a	NEB	and	following	naphthalene	
exposure,	it	is	the	variant	club	cells	that	are	situated	at	the	BADJ	which	proliferate,	
indicating	a	possible	further	stem	cell	niche	at	this	location	(139).		Subsequently,	Kim	
et	al	have	reported	the	finding	of	a	unique	cell	population	at	the	BADJ,	cells	that	
they	have	termed	bronchioalveolar	stem	cells	(BASCs)	(129).		These	cells	express	
both	surfactant	protein	C	(SPC),	that	is	associated	with	alveolar	type	2	cells	(AT2),	
and	CC10.		On	either	naphthalene-induced	airway	damage	or	the	alveolar	injury-
inducing	bleomycin,	the	BASCs	proliferate,	implying	they	have	a	role	in	both	distal	
airway	regeneration,	and	the	replacement	of	both	club	cells	and	alveolar	epithelium.			
It	was	further	shown	that	when	BASCs	were	isolated	and	grown	in	vitro	in	Matrigel,	
they	were	able	to	generate	club	cells,	AT2	cells	and	AT1	cells	(129).			
	
Whilst	the	above	experiments	suggest	the	BASC	to	be	a	distal	airway	stem	cell,	
subsequent	lineage-tracing	of	the	club	cell	population	at	the	BADJ	(including	the	
marking	of	the	previously	identified	BASCs)	using	a	transgenic	mouse	line	expressing	
tamoxifen	inducible	Cre	from	the	CC10	locus,	has	contradicted	these	findings.		
Following	naphthalene	damage,	CC10	expressing	cells	are	able	to	regenerate	the	
bronchiolar	epithelium,	but	following	hyperoxia	(that	causes	alveolar	cell	damage),	
alveolar	cell	replacement	does	not	arise	from	the	BADJ,	but	it	is	the	AT2	cells	that	
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divide	and	replace	the	lost	AT1	cells	(136).		Influenza	infection	causes	more	severe	
alveolar	damage	than	oxygen,	and	following	influenza	exposure	it	has	been	
suggested	that	replacement	of	lost	AT2	cells	can	occur	from	the	CC10	expressing	
club	cells	(140).		Another	group	used	the	same	CC10	lineage-tracing	mice	and	
exposed	the	animals	to	bleomycin	injury.		In	this	case,	both	AT1	and	AT2	cells	were	
lineage-traced	from	the	CC10	population	(141).		Therefore	the	mode	of	airway	
regeneration	may	be	dependent	on	both	the	degree	and	mechanism	of	injury.		To	
confirm	the	significance	of	the	BASC	population	direct	labelling	and	lineage-tracing	
from	the	BASC	would	be	necessary.		However,	to	date,	no	unique	markers	of	the	
BASC	population	have	been	identified.					
	
To	further	complicate	our	understanding	of	distal	airway	repair,	p63+	cells	have	been	
shown	to	arise	in	the	distal	airway	following	influenza	infection.		These	p63	cells	
organise	into	KRT5+	pods	that	subsequently	enlarge	and	contribute	to	the	repair	of	
the	alveolar	epithelium	(142).		Isolation	of	these	p63+	cells	from	the	mouse,	rat	and	
human	distal	lung	shows	the	capacity	of	these	cells	to	generate	alveolar	structures	in	
vitro	(142).		
	
Whilst	activation	of	the	stem	cell	populations	occurs	on	airway	damage,	during	
airway	homeostasis,	it	has	been	suggested	that	a	group	of	‘committed’	airway	
progenitors	maintains	the	integrity	of	the	epithelium	(143).		Experiments	using	GFP	
chimeric	mice,	shows	that	the	severity	of	airway	injury	influences	the	cell	population	
that	is	activated	and	contributes	to	airway	regeneration.		Mice	were	exposed	to	
naphthalene,	and	the	degree	of	airway	injury	assessed	by	the	animals	weight	loss.		
When	mice	were	severely	injured,	with	a	greater	than	10%	weight	loss,	large	GFP	
patches	were	seen	centred	around	the	airway	branch	points	(at	sites	of	NEBs)	and	at	
the	BADJ.		When	the	mice	were	less	severely	injured	(less	than	10%	weight	loss)	
there	was	no	association	of	the	GFP	patches	to	either	of	the	stem	cell	niches.		This	
suggests	that	the	airway	stem	cells	only	become	activated	following	severe	airway	
damage	and	less	severe	injury	triggers	the	proliferation	of	a	more	widespread,	
differentiated	population	(143).		The	findings	are	supported	by	the	observation	that	
club	cells	are	able	to	regenerate	the	ciliated	population	within	the	main	airways	
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without	activating	the	basal	stem	cells	(136)	and	that	AT2	cells	are	able	to	divide	and	
replenish	lost	AT1	cells	in	the	alveoli	(144).	
	
It	currently	remains	uncertain	as	to	how	these	findings	relate	to	the	stem	cell	
populations	of	the	human.		Kajstura	et	al	identified	a	population	of	c-kit	expressing	
cells	from	the	human	airway	that	exhibited	the	stem	cell	features	of	self-renewal,	
clonogenicity	and	multipotency	both	in	vitro	and	in	vivo	(145).		Flow	cytometry-
isolated	human	airway	c-kit	positive	cells	were	administered	to	mice	that	had	
undergone	cryogenic	damage	to	their	lung	tissue.	The	cells	were	seen	to	engraft	and	
replace	not	only	the	airway	epithelium,	but	also	the	pulmonary	vasculature	and	
pulmonary	interstitium	(145).		However	the	validity	of	these	findings	has	been	
thrown	in	doubt	by	the	observation	that	c-kit	positive	cells	also	express	the	
leucocyte	marker	CD45	(135)	and	that	lineage	tracing	from	the	c-kit	positive	cells	
shows	they	do	not	contribute	to	the	lung	epithelium	during	either	homeostasis	or	
repair,	but	that	they	maintain	a	vascular	endothelial	cell	fate	(146).		Neither	BASCs	
nor	variant	club	cells	have	been	identified	in	the	human	lung	and	this	is	a	focus	of	
ongoing	research	(147).	
		
1.3.5	 The	lung	cancer	cell	of	origin		
	
A	key	characteristic	of	lung	stem	cells	is	their	longevity.		This	means	that	over	the	
course	of	their	lifetime,	these	cells	are	long-lived	enough	to	accumulate	the	
necessary	mutations	needed	to	drive	the	development	of	lung	cancer	(148).		More	
differentiated	cell	have	a	shorter	lifespan	and	have	less	likelihood	of	acquiring	the	
necessary	mutational	burden.			
	
In	humans	there	is	a	proximal	to	distal	tumour	pattern	of	tumour	development,	with	
squamous	cell	carcinomas	found	in	the	trachea	and	upper	airway,	small	cell	lung	
cancers	in	the	intermediate	airways	and	adenocarcinomas	more	distally.		This	
suggests	that	the	tumour	cell	of	origin	may	be	a	cell	type	found	at	each	location,	
with	the	tumour	subtypes	sharing	characteristics	to	each	of	the	stem	cell	
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populations	involved	in	the	repair	of	each	of	the	areas	of	the	bronchial	tree	(128).		
The	use	of	murine	models,	with	the	overexpression	of	an	oncogene	or	the	removal	
of	a	tumour	suppressor,	has	provided	insight	into	the	cell	of	origin	of	lung	cancer.			
	
Squamous	cell	carcinomas	originate	in	the	large	airways	and	are	characterised	by	a	
high	number	of	basal	cells	and	the	stepwise	morphological	changes	through	basal	
cell	hyperplasia,	metaplasia,	dysplasia	and	carcinoma	in	situ	during	the	development	
of	malignancy	(44).		Both	preinvasive	and	squamous	cell	carcinomas	maintain	a	basal	
cell	phenotype	with	persistent	KRT5	expression	(149),	whilst	squamous	cell	
carcinomas	are	also	situated	at	submucosal	duct	gland	junctions	or	intracartilaginous	
boundaries.		These	are	areas	of	high	basal	cell	concentration,	suggesting	basal	cells	
are	the	likely	cell	of	origin	of	squamous	cell	lesions	(128).			
	
Small	cell	lung	cancers	arise	in	the	bronchioles	and	express	markers,	including	CGRP,	
that	are	seen	in	the	neuroendocrine	population.		Rb1	loss	of	function	negatively	
regulates	neuroendocrine	cell	differentiation	and	in	common	with	Trp53	loss,	is	
frequently	found	in	SCLCs	(150).		Targeting	the	sequential	loss	of	both	Rb1	and	Trp53	
in	a	murine	model	to	club	cells,	neuroendocrine	cells	and	AT2	cells	demonstrated	
that	tumours	arose	most	consistently,	and	with	the	shortest	time-lag,	from	the	
neuroendocrine	cells.		These	tumours	exhibited	SCLC	features	on	histology,	
expressed	SCLC	cell	markers	and	readily	metastasised	(151).		SCLCs	did	not	arise	
when	disruption	of	Rb1	and	Trp53	was	targeted	to	club	cells	and	only	infrequently	
caused	lesions	when	targeted	to	the	AT2	cell	population.		Collectively,	these	results	
indicate	that	the	neuroendocrine	population	is	the	likely	SCLC	cell	of	origin.	
	
Lung	adenocarcinomas	are	associated	with	the	expression	of	the	markers	CC10	and	
SPC,	with	25-50%	of	lesions	associated	with	an	activating	mutation	in	KRAS	(152).		
BASCs	were	initially	proposed	as	the	adenocarcinoma	cell	of	origin,	due	to	their	co-
expression	of	CC10	and	SPC,	and	the	observation	that	naphthalene	increases	tumour	
formation	in	a	murine	KRasG12D	model	(where	KRas	is	constitutively	active)	(129).		
However	following	the	activation	of	KRasG12D	in	both	CC10+	and	SPC+	epithelial	cells	
of	murine	lungs,	
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bronchiole	club	cells,	whilst	adenocarcinomas	only	developed	from	the	AT2	cells	
(153),	suggesting	that	this	population	is	the	likely	adenocarcinoma	cell	of	origin.			
	
1.3.6	 Lung	cancer	stem	cells	
	
The	cancer	stem	cell	(CSC)	hypothesis	is	a	concept	that	describes	cells	within	a	
tumour	that	drive	the	tumour’s	growth	and	metastatic	potential.	To	be	defined	as	a	
CSC,	the	cells	need	to	be	capable	of	self-renewal,	the	generation	of	differentiated	
progeny	and	the	production	of	tumours	in	xenotransplantation	models	(124,	154).		
CSCs	may	originate	either	from	a	stem	cell,	or	a	more	differentiated	long-lived	
progenitor	cell	that	has	accumulated	sufficient	mutations	over	the	course	of	its	
lifespan	to	become	tumorigenic.	CSCs	have	been	identified	in	a	number	of	
malignancies	including	brain,	haematopoietic	cancers,	breast	and	lung	tumours	
(154).	
	
Due	to	their	longevity	and	their	role	in	replacing	lost	cells,	stem	cells	utilise	several	
protective	mechanisms.		These	include	high	levels	of	anti-apoptotic	proteins	and	ABC	
transporter	proteins	that	are	involved	in	toxin	efflux.		It	has	been	suggested	that	
CSCs	also	express	high	levels	of	ABC	transporter	proteins	that	remove	
chemotherapeutic	agents	from	the	cells,	making	the	CSCs	resistant	to	therapy.		
Therefore,	following	chemotherapy	the	tumour	bulk	is	reduced,	but	the	resistant	
CSCs	remain	and	on	treatment	cessation,	repopulate	the	tumour,	resulting	in	disease	
relapse	(124).		Cells	with	CSC	characteristics	may	also	explain	the	finding	that	tumour	
cells	are	often	found	in	the	peripheral	circulation,	but	are	not	always	associated	with	
metastatic	deposits.		The	circulating	tumour	cells	may	need	to	have	CSC	
characteristics	to	be	able	to	seed	metastases	elsewhere	(155).	
	
Several	markers	have	been	used	to	identify	cells	within	a	lung	cancer	that	have	CSC	
characteristics,	these	include	CD133,	CD44,	CD166,	aldehyde	dehydrogenase	(ALDH)	
and	being	of	a	‘side	population’	(SP)	phenotype	(154).		SP	cells	are	recognised	by	
their	ability	to	efflux	Hoescht	33342	through	their	ABC	transporters	and	are	
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identifiable	using	flow	cytometry	techniques.		Isolation	of	the	SP	from	cultured	lung	
cancer	cells	has	revealed	these	cells	to	have	increased	tumorigenicity	in	a	xenograft	
model,	increased	invasion	capacity,	and	an	ability	to	form	both	SP	and	non-SP	cells	
on	culture	(whilst	non-SP	cells	only	produced	non-SP	cells	on	culture)	(156).		SP	cells	
isolated	from	squamous	cell	lung	cancers	have	also	been	shown	to	be	resistant	to	
chemotherapy,	but	become	sensitised	following	the	administration	of	the	ABC	
transporter	activity	blocker	verapamil	(157).		CD133	has	an	unknown	function	(154),	
but	is	detected	on	the	surface	of	many	tumours.		Isolation	of	CD133+	cells	from	
primary	non-small	cell	lung	cancer	shows	these	cells	to	have	both	a	greater	
tumorigenic	potential	in	SCID	mice	and	have	an	upregulation	of	genes	involved	in	
stemness,	adhesion	and	cell	motility	compared	to	their	CD133-	counterparts	(158).		
The	CD133+	cells	also	exhibit	a	higher	number	of	ABC	transporters.		When	cisplatin	(a	
chemotherapeutic	agent	removed	through	ABC	transporter	activity)	was	
administered	to	CD133+	xenotransplanted	mice	the	tumours	were	shown	to	reduce	
in	size,	but	the	remaining	cisplatin-resistant	cells	were	entirely	CD133+.		Of	note,	
following	the	examination	of	CD133+	cells	in	tumours	from	NSCLC	patients,	it	was	
revealed	that	those	with	a	higher	proportion	of	CD133+	cells	had	a	tendency	towards	
a	shorter	progression-free	survival	(158).				
	
The	cancer	stem	cell	hypothesis	is	an	important	consideration	for	the	development	
of	successful	cancer	therapies.		Conventional	treatments	target	the	rapidly	
proliferating	cell	population	and	are	unlikely	to	eradicate	the	more	quiescent,	often	
ABC	transporter-expressing,	CSC	population.	
	
1.3.7	 Genetic	heterogeneity	and	clonal	evolution	in	lung	cancer	
	
A	further	consideration	in	the	administration	of	successful	cancer	therapy	is	the	
genetic	heterogeneity	that	exists	within	a	tumour.		Tumours,	due	to	their	rapid	
proliferation,	will	develop	several	mutations	(159),	a	number	of	these	will	be	
passenger,	with	no	impact	on	the	behaviour	of	the	tumour	mass,	but	a	few	will	be	
cancer	driver	events	that	have	a	selective	advantage	over	the	other	tumour	cells,	
and	lead	to	‘clones’	with	variability	across	the	tumour	(159-161).		When	sequencing	
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several	areas	from	resected	renal	cell	carcinomas	wide-ranging	intratumour	
heterogeneity	was	revealed	across	the	tumour	bulk,	with	63-69%	of	these	mutations	
heterogeneous	and	not	seen	in	every	sample	(162).		This	study	gave	rise	to	the	
terminology	‘branched	evolution’,	and	the	concept	of	a	phylogenetic	tree	in	cancer,	
where	a	few,	key	mutations	are	common	across	all	cells,	but	where	the	branches	of	
the	tree	are	representative	of	clones	that	have	arisen	later	in	the	tumours	natural	
history	and	are	not	shared	by	the	entire	tumour	mass	(162).		For	a	cancer	treatment	
to	be	successful,	focus	should	be	on	therapies	that	target	mutations	found	in	the	
lesion	trunk	rather	than	those	detected	in	the	branches,	where	the	cancer	cell	
subsets	are	seen.	
	
1.4	 Summary	
	
Lung	cancer	has	a	poor	prognosis,	with	new	treatments	desperately	needed.		
Squamous	cell	lung	cancer	has	a	preinvasive	period,	and	if	the	disease	is	detected	
and	treated	at	this	stage,	lesions	may	be	prevented	from	progressing.		Preinvasive	
squamous	cell	lesions	and	squamous	cell	lung	cancers	are	associated	with	an	
overexpression	of	EGF	receptors.		LRIG1	negatively	regulates	EGFR	signalling	and	has	
been	shown	to	be	important	in	the	regulation	of	the	stem	cell	compartments	of	the	
skin	and	gut,	and	is	also	associated	with	both	the	development	and	outcome	of	a	
number	of	malignancies.		It	has	been	shown	that	LRIG1	is	lost	in	the	development	of	
preinvasive	lung	cancer	and	that	LRIG1	loss	is	associated	with	a	worsening	of	NSCLC	
prognosis.	
	
It	is	possible	that	LRIG1	regulates	the	stem	cell	compartment	of	the	human	airway.		
A	loss	of	the	protein	may	lead	to	dysregulation	of	the	lung	stem	cell	compartment.		
This	may	influence	the	behaviour	of	the	putative	cancer	stem	cells	and	lead	to	the	
development	of	malignancy.		By	understanding	the	role	of	LRIG1	within	airway	
homeostasis	and	how	its	loss	leads	to	preinvasive	disease,	new	therapeutic	avenues	
may	be	opened.	
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1.5	 Hypothesis	
	
I	hypothesise	that	LRIG1	expression	controls	airway	cell	homeostasis	and	its	loss	
contributes	to	the	initiation	of	pre-invasive	lung	cancer.	
	
1.6	 Aims	
	
1. To	delineate	LRIG1	expression	in	normal	and	cancerous	airways	
2. To	determine	the	role	of	LRIG1	in	homeostasis	and	cancer	initiation		
3. To	identify	the	mechanism	by	which	LRIG1	regulates	airway	epithelial	growth	
and	cancer	initiation	
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2.	 Materials	and	methods	
	 	
	 52	
2.	 Materials	and	methods	
2.1	 Chemicals,	solvents	and	plastic	ware	
	
All	chemicals	used	were	of	analytical	grade	or	above	and	obtained	from	Sigma	
Aldrich	(unless	otherwise	stated).		Water	was	distilled	and	deionised	using	a	
Millipore	water	purification	system	(Millipore	LTD,	US).		Laboratory	plastic	ware	was	
from	BD	Biosciences.	
	
2.2	 Tissue	collection	
2.2.1	 Animal	breeding	strategy	
	
Two,	eight	week	old	male	mice	containing	an	EGFP–ires-CreERT2	‘knock	in’	cassette	
at	the	translational	start	site	of	exon	1	of	the	Lrig1	locus	(91)	(Figure	3.1.A.		Gene	
construct)	on	an	FVB/N	C57BL/6	background	were	a	kind	gift	from	Dr	Kim	Jensen,	
BRIC,	Copenhagen.		These	mice	were	crossed	with	FVB/N	females	(Harlan,	UK)	
producing	heterozygous,	experimental	animals.		These	heterozygous	mice	were	then	
crossed	to	produce	homozygous	animals	(Figure	3.1.B).						
	
For	lineage	tracing	experiments,	a	homozygous	breeding	pair	of	Rosa-26td	tomato	
mice	was	purchased	(Stock	number	07909,	Jackson	laboratories,	USA).		Homozygous	
LRIG1	EGFP-ires-CreERT2	animals	were	then	crossed	with	homozygous	Rosa-26td	
tomato	animals,	creating	offspring	heterozygous	for	Rosa	26	tdtomato	reporter	and	
the	EGFP-ires-CreERT2	cassette.	
	
Animals	were	kept	in	individually	ventilated	cages	at	the	central	biological	services	
facility	at	University	College	London.		Animals	were	kept	on	a	12-hour	light/dark	
cycle	at	25°C	and	were	provided	with	food	and	water	ad	libitum.		All	animal	studies	
were	performed	in	accordance	with	British	Home	Office	procedural	and	ethical	
guidelines.	
	
2.2.2	 Human	tissue	collection	
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Ethical	approval	was	obtained	through	the	National	Research	Ethics	Committee	(REC	
references	06/Q0505/12).		Samples	of	human	bronchial	cells	were	taken	from	areas	
of	normal	bronchial	epithelium,	and	either	used	directly	for	analysis	(bronchial	brush	
experiments)	or	expanded	and	then	frozen	to	create	a	tissue	bank.		Cells	were	taken	
from	this	cell	bank	for	cell	culture	experiments.	
	
2.3	 Genotyping	Animals	
	
2.3.1	 Ear	snip	digest	and	PCR	
	
Mouse	ear	snip	samples	were	placed	into	50	μl	of	ear	snip	buffer	(1M	Tris	pH	8.0,	5M	
NaCl,	10%	SDS	and	proteinase	K	at	20	mg/ml)	and	were	incubated	at	55°C	for	1	hour.		
After	1	hour	the	samples	were	vortexed	and	incubated	for	a	further	2	hours.		150	μl	
of	DNase/RNase	free	water	(Life	Technologies,	UK)	was	added	and	samples	and	
heated	for	20	minutes	at	95°C	to	inactivate	the	proteinase	K	(P6556,	Sigma,	UK).		The	
samples	were	then	freeze-thawed,	and	centrifuged	at	300	x	g	for	5	minutes	to	
remove	any	undigested	fragments.		1	μl	of	extracted	DNA	was	used	for	each	PCR	
reaction.		
	
Primers	were	used	at	a	concentration	of	20	ng/μl	and	added	to	12.5	μl	OneTaq	PCR	
2x	mastermix	(M0270L,	New	England	Biolabs,	UK),	or	OneTaq	PCR	2x	master	mix	
with	GC	buffer	(M0483S,	New	England	Biolabs,	UK),	9.5	μl	ddH2O	to	make	up	to	25.		
1	μl	of	extracted	DNA	was	used	for	genotyping	from	the	Cre	insert	and	20	ng	of	DNA	
was	used	for	the	other	reactions.	
	
Gene	 	 Reference	 Sequence	 Bases	
Cre	insert	 5	 Professor	Kim	Jensen	 GCC	TGC	ATT	ACC	GGT	CGA	TGC	AAC	
GA	
700	
Cre	insert	 3	 Professor	Kim	Jensen	 GTG	GCA	GAT	GGC	GCG	GCA	ACA	
CCA	TT	
	
LRIG1	wild-type	 5	 Designed	using		
Primer	3	
CGG	CGC	GTT	CCA	GAC	AAG	 355	
LRIG1	wild-type	 3	 Designed	using		 CAC	CCA	CAA	GTC	TCC	CAG	 	
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Primer	3	
Rosa	26	tdtomato	
mutant	
5	 The	Jackson	
Laboratory		
GGC	ATT	AAA	GCA	GCG	TAT	CC	 196	
Rosa	26	tdtomato	
mutant	
3	 The	Jackson	
Laboratory	
CTG	TTC	CTG	TAC	GGC	ATG	G	 	
Rosa	26	tdtomato	wild-
type	
5	 The	Jackson	
Laboratory	
AAG	GGA	GCT	GCA	GTG	GAG	TA	 297	
Rosa	26	tdtomato	wild-
type	
3	 The	Jackson	
Laboratory	
CCG	AAA	ATC	TGT	GGG	AAG	TC	 	
	 	
PCR	reaction	protocols	
	
	 Cre	reaction	 	 LRIG1	WT	 	 Rosa	WT/	
Mutant	
	
Step	 Temperature	
	(°C)	
Time	(s)	 Temperature	
(°C)	
Time	(s)	 Temperature	
(°C)	
Time	(s)	
1	 94	 30	 94	 30	 94	 30	
2	 94	 30	 94	 30	 94	 30	
3	 67	 30	 62	 30	 61	 30	
4	 68	 60	 68	 30	 68	 30	
	 	 repeat	2-4	
30	cycles	
	 repeat	2-4	
30	cycles	
	 repeat	2-4	
30	cycles	
5	 68	 300	 68	 300	 68	 	
	
Primers	were	designed	around	the	native	copy	of	Lrig1	using	the	first	ATG	start	
codon	of	exon	1	of	LRIG1.		The	Primer	3	package	was	used	for	primer	design	(163,	
164)	and	three	potential	primers	selected	for	subsequent	optimisation;	primer	A,	B	
and	C.	
	
Primer	 Bases	 Direction	 Sequence	
A	 353	 5’	 GAG	TCG	GGC	GTC	CAT	GTC	
	 	 3’	 CAA	AGG	CGA	TAC	TCA	CAG	GC	
B	 355	 5’	 CGG	CGC	GTT	CCA	GAC	AAG	
	 	 3’	 CAC	CCA	CAA	GTC	TCC	CAG	
C	 393	 5’	 CTG	GAG	TCG	GGC	GTC	CAT	
	 	 3’	 AGC	AGC	CCC	GTC	TTA	ATG	
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2.3.2	 Agarose	gel	electrophoresis	
	
Gel	separation	electrophoresis	was	used	to	confirm	the	PCR	products	were	of	the	
expected	size.		A	1%	gel	was	made	by	dissolving	1.5	g	of	agarose	in	150	mls	1x	TBE.		
The	solution	was	heated	in	the	microwave	to	dissolve	the	agarose	and	4.5	μl	10,000	
x	gel	red	added	(Biotium,	California,	USA).		The	solidified	gel	was	placed	in	a	tank	
filled	with	1	x	TBE	running	buffer	and	10	μl	PCR	product	loaded,	in	DNA	loading	
buffer	(BIO-37045,	Bioline	UK).		A	DNA	marker	(BIO-33053,	Bioline,	UK)	was	included	
and	the	gel	run	for	45	minutes	at	140	volts.		The	DNA	bands	were	visualised	using	
the	Gene	Genius	UV	source	and	camera	(Syngene,	UK).	
	
2.3.3	 Ethanol	purification	of	ear	snip	DNA	
	
Taking	the	supernatant	from	the	initial	DNA	digest,	50	μl	3	M	sodium	acetate	and	
500	μl	ice	cold	100%	ethanol	were	added	and	the	samples	incubated	at	–	20°C	for	30	
minutes.		The	samples	were	then	centrifuged	at	14,800	rpm	for	15	minutes	and	the	
supernatant	removed.		The	DNA	was	washed	by	re-suspension	in	70%	ethanol	and	
centrifuged	at	14,800	rpm	for	a	further	5	minutes.			The	supernatant	was	again	
removed	and	the	pellet	left	to	air-dry	overnight.		The	following	day	the	pellet	was	
rehydrated	in	50	μl	of	ddH20	and	DNA	quantity	and	purity	assessed	using	the	
Nanodrop.		20	ng	of	purified	DNA	was	used	for	subsequent	PCRs.			
	
2.3.4	 Sequencing	primer	B	
	
The	entire	25	μl	PCR	product	from	the	primer	B	reaction	was	loaded	into	a	1%	
agarose	gel.		The	gel	was	run	at	140	volts	for	45	minutes	and	the	DNA	band	
visualised	by	examination	under	UV	light.		The	band	that	corresponded	to	the	
predicted	bases	(350	bp)	was	carefully	cut	from	the	membrane	and	the	sample	
weighed.		The	DNA	was	isolated	from	the	sample	following	the	QIAquick	Gel	
Extraction	Kit	protocol	(28704,	Qiagen,	UK).		The	sample	was	sequenced	at	Life	
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Biosciences	with	results	compared	to	the	anticipated	product	using	the	software	
Chromas	(South	Brisbane,	Australia).		
	
2.3.5	 Immunofluorescent	imaging	of	earnsips	
	
Earsnips	were	placed	onto	a	glass	slide	and	mounted	in	ddH20	and	coverslipped.		
Microscopy	was	performed	using	a	Carl	Zeiss	Axioskop	2	fluorescent	microscope.		
Images	were	obtained	using	a	QImaging	camera	and	QCapture	Pro	6.0	and	analysed	
using	Adobe	Photoshop	CS6.		
	
2.4	 Isolation	of	murine	tissues	
	
All	mice	were	used	at	6-8	weeks	old	and	sacrificed	using	a	200	μl	intraperitoneal	
injection	of	200	mg/ml	pentobarbital	(Euthatal,	Merial,	UK)	followed	by	laparotomy	
and	exsanguination.			
	
2.4.1	 Isolation	of	the	trachea		
	
The	trachea	was	identified	and	cuts	made	above	at	the	larynx	and	below	at	the	main	
carina,	and	the	oesophagus	and	associated	soft	tissues	were	removed.		For	culture	
or	flow	cytometry	analysis	the	tracheas	were	harvested	into	DMEM	(41966,	Gibco)	
supplemented	with	100	U/ml	penicillin	and	100	μg/ml	streptomycin	(15070,	Gibco)	
or	for	histology,	was	placed	directly	into	4%	paraformaldehyde	(PFA).		
	
2.4.2	 Isolation	of	murine	lungs	following	insufflation	
	
Lung	insufflation	followed	the	methods	described	by	Giangreco	et	al	(165).		In	brief,	
the	murine	trachea	and	lungs	were	exposed,	whilst	taking	care	not	to	damage	the	
lung	tissue.		The	trachea	was	cannulated	and	4%	PFA	infiltrated	from	a	height	of	10	
cm.		Once	the	lungs	were	seen	to	expand,	insufflation	continued	for	3	minutes	
before	the	trachea	was	tied	off	and	the	cannula	removed.		The	lungs	and	heart	were	
removed	from	the	point	of	tracheal	intubation	and	placed	into	4%	PFA.			
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2.4.3	 Isolation	of	bone	marrow	cells		
	
Both	femurs	were	isolated	from	the	mouse,	and	the	soft	tissues	cleaned	away.		The	
ends	of	the	bone	were	cut	off.		Using	a	syringe	and	a	25	G	needle,	F12	media	was	
flushed	through	the	bone	causing	the	bone	to	become	translucent	and	the	bone	
marrow	cells	to	be	released.		Fetal	Bovine	Serum	(FBS,	10270,	Gibco)	was	added	to	
the	media,	to	a	final	concentration	of	10%	and	the	solution	pipetted	vigorously	to	
create	a	single	cell	suspension.			
	
2.4.4	 Isolation	of	skin	samples	for	histological	processing		
	
The	dorsal	skin	was	shaved	to	remove	fur	and	using	forceps	the	skin	‘tented’.		A	
patch	of	skin	of	approximately	5	cm	in	diameter	was	removed.		The	skin	was	
stretched	flat	onto	stiffened	paper	and	placed	into	4%	PFA	for	processing.	
	
2.4.5	 Isolation	of	skin	cells	for	flow	cytometry	
	
The	collected	skin	sample	was	washed	first	in	iodine	surgical	solution	and	then	twice	
with	distilled	water,	followed	by	immersion	in	70%	ethanol	for	2	minutes	and	two	
further	washes	in	distilled	water.		Using	a	petri	dish,	the	subcutaneous	fat	was	
scraped	off	with	a	scalpel	until	the	remaining	tissue	became	translucent.		The	skin	
was	floated,	hair	side	up	on	0.25%	trypsin	(T4049,	Sigma,	UK)	and	incubated	
overnight	at	4°C.		The	following	day	the	skin	samples	were	washed	in	F12	media	
(21765,	Gibco)	supplemented	with	10%	FBS,	100	U/ml	penicillin	and	100	μg/ml	
streptomycin,	inactivating	the	trypsin.		The	hairy	side	of	the	skin	was	scraped	to	lift	
off	the	epithelial	cells	and	the	fragments	cut	into	small	pieces	using	two	scalpels.		
The	samples	were	collected	in	media	and	residual	hairs/solid	pieces	removed	
through	passing	through	a	70	μm	cell	strainer.		The	cells	were	centrifuged	at	300	x	g	
for	10	minutes	at	4°C,	followed	by	removal	of	the	supernatant	and	resuspension	in	
supplemented	F12	media.			
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2.5	 Isolation	of	murine	airway	basal	cells		
	
2.5.1	 Pronase	digest	
	
The	isolated	tracheas	were	cleaned	under	a	dissecting	microscope	(Leica	MZ6)	to	
remove	any	remaining	soft	tissues	and	cut	along	the	long	axis.		The	tracheas	were	
placed	in	0.15%	pronase	(10165921001,	Roche,	UK)	in	serum	free,	supplemented	
DMEM	and	incubated	at	4°C	for	16	hours.		FBS	was	then	added	to	the	pronase	
solution,	to	a	final	concentration	of	10%	and	the	tube	vortexed	to	detach	remaining	
epithelial	cells.		The	residual	trachea	was	then	transferred	to	a	further	falcon	
containing	DMEM/FBS	and	vortexed	again.		This	process	was	repeated	four	times	
and	the	samples	combined.		The	remaining	tracheal	soft	tissues	were	disposed	of.		
The	cell	suspension	was	centrifuged	at	300	x	g,	for	10	minutes	at	4°C	following	which	
the	media	was	removed	and	the	cells	resuspended	in	DNase	solution	(stock:		10	mg	
crude	pancreatic	DNase	I	(Sigma,	UK),	2	mls	1%	BSA	and	18	mls	FAD)	at	200	μl	per	
trachea.		After	5	minutes	the	sample	were	centrifuged	at	300	x	g	for	5	minutes	and	
the	cells	resuspended	in	DMEM/FBS.		The	sample	was	filtered	through	a	40	μm	filter,	
and	cells	counted.		The	presence	of	epithelial	cells	was	confirmed	by	checking	for	
ciliated	cells	on	light	microscopy.		The	isolated	cells	were	either	used	for	flow	
cytometry	analysis	or	cell	culture.	
	
2.5.2	 Dispase/DNase/trypsin/collagenase	digest	
	
Method	was	adapted	from	those	previously	reported	(166-168).		The	tracheas	were	
isolated	as	previously	described	and	cut	along	the	long	axis,	and	then	incubated	in	
dispase	16	units/ml	(Corning,	UK),	made	up	in	serum	free	DMEM	for	30	minutes.		
The	tracheas	were	then	transferred	to	DNase	solution	(as	above)	for	20	minutes.		
The	samples	were	checked	under	the	dissecting	microscope,	and	once	the	
epithelium	had	become	‘ruffled’	it	was	gently	removed	from	the	underlying	tissues	
with	fine	forceps	using	the	dissecting	microscope.		The	epithelial	sheets	were	
collected	using	a	pipette	into	a	0.1%	trypsin/	EDTA	(Sigma,	UK)	solution,	in	serum	
free	DMEM,	and	placed	in	a	37°C	water	bath	for	30	minutes.		The	remainder	of	the	
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trachea	was	minced	and	placed	into	a	0.25%	collagenase	solution	(Roche,	UK),	in	
serum	free	DMEM	and	was	placed	in	the	water	bath	for	30	minutes	(solution	was	
made	at	30	mg/ml	in	PBS,	use	917	μl	of	media	and	83	μl	of	collagenase	solution).		
Samples	were	vortexed	every	15	minutes	to	ensure	tissue	breakdown.	
	
Once	the	digestion	steps	were	complete,	the	samples	were	either	combined	or	
analysed	separately	(in	experiments	to	establish	the	maximal	basal	cell	yield	from	a	
trachea).		The	samples	were	then	filtered	through	40	μm	cell	strainers	and	the	
enzymes	neutralised	by	the	addition	of	FBS,	to	a	final	concentration	of	10%.		The	
cells	were	centrifuged	at	300	x	g	for	10	minutes	and	resuspended	in	media	according	
to	the	volume	required	for	flow	cytometry.		
	
2.5.3	 Isolation	of	tracheal	cells	via	collagenase	digest	
	
Tracheas	were	cleaned	and	minced	into	small	pieces	with	a	scalpel	(168).		The	
samples	were	incubated	in	a	0.25%	collagenase	solution	(as	above)	at	37°C	for	90	
minutes.		Every	15	minutes	the	samples	were	vortexed.		The	samples	were	then	
filtered	and	the	enzymes	neutralised	by	the	addition	of	FBS,	for	use	of	the	cells	in	
flow	cytometry.	
	
2.6	 Lineage	tracing	
	
During	optimisation,	4-Hydroxytamoxifen	(4OH-tamoxifen)	was	made	up	in	corn	oil	
to	concentrations	of	1mg,	0.1	mg,	and	0.01	mg.		200	μl	of	tamoxifen	solution	was	
injected	intraperitoneally	to	6-8	week	animals	heterozygous	for	both	the	eGFP–ires-
CreERT2	cassette	and	the	Rosa	26	tdtomato	reporter.		The	animals	were	observed	
for	2	weeks	before	sacrifice.		The	skin	was	isolated	for	flow	cytometry	analysis	and	
the	trachea,	bowel	and	skin	isolated	for	histological	examination.	
	
Following	the	selection	of	the	1	mg	dosage	for	use	in	the	airway,	mice	were	treated	
with	1	mg	4OH-tamoxifen	and	culled	2	days	later.		Their	tracheas	were	isolated	for	
histological	examination.	
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2.7	 Isolation	of	human	brush	biopsied	epithelial	cells	
	
Two	bronchial	brushings	were	collected	from	a	normal	area	of	bronchial	mucosa	into	
collection	media	(αMEM	supplemented	with	penicillin/streptomycin	and	
amphotericin	B)	on	ice.		Brushes	were	vortexed	vigorously	to	release	the	cells,	with	
the	brushes	remaining	in	situ	in	the	collection	falcon	and	then	centrifuged	at	300	x	g	
for	5	minutes.		The	cells	were	resuspended	in	red	cell	lysis	buffer	(Sigma,	R7757)	and	
incubated	at	room	temperature	for	three	minutes.		Cells	were	resuspended	in	10%	
FBS	diluted	in	1%	BSA	in	PBS	for	blocking	in	preparation	for	flow	cytometry	staining.	
	
2.8	 Analysis	of	cells	by	flow	cytometry		
2.8.1	 Flow	cytometry	staining	
Mouse	
	
Isolated	epithelial	cells	were	blocked	for	10	minutes	in	complete	DMEM.		Primary	
antibodies	were	applied	at	room	temperature	for	20	minutes,	followed	by	washing	3	
times	in	complete	DMEM.		Secondary	antibodies	were	subsequently	applied	for	20	
minutes.		After	staining	the	cells	were	washed	3	further	times	in	DMEM.		Secondary-
only	stains	were	used	when	non-conjugated	antibodies	were	included.		DAPI	at	a	
concentration	of	1:1000	was	added	to	the	sample	immediately	prior	to	running	the	
experiment.			
	
Human	
	
Cells	were	blocked	for	10	minutes	in	10%	FBS	diluted	in	1%	BSA	in	PBS.		All	
antibodies	used	were	conjugated	and	applied	for	20	minutes	in	1%	BSA	in	PBS	at	4°C.		
After	staining,	samples	were	washed	3	times	in	1%	BSA	in	PBS.		DAPI	at	a	
concentration	of	1:1000	was	added	immediately	prior	to	running	the	experiment.	
	
2.8.2	 Flow	cytometry	analysis	
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Samples	were	analysed	using	the	LSR	FACS	machine	(BD	LSR	Flow	cytometer,	UK)	
and	were	gated	according	to	forward	and	side	scatter	characteristics	to	exclude	cell	
debris	and	doublets.		Where	possible,	a	minimum	of	1,000	events	in	the	population	
of	interest	was	collected	for	each	sample	analysed.		All	gates	were	set	using	
fluorescence	minus	one	controls.		Sample	analysis	was	performed	using	FlowJo	
Software	(Tree	Star	Inc.,	Oregon,	USA).	
	
2.8.3	 Flow	cytometry	antibodies	
	
Antigen	 Colour	 Antibody	 Reactivity	 Concentration	
CD31	 PE	 102407,	Biolegend,	UK	 mouse	 1:100	
CD31	 PE	 303106,	Biolegend,	UK	
	
human	 1:100	
CD31	 BV421	 303124,	Biolegend,	UK	 human	 1:100	
CD31	 PE-Cy7	 102417,	Biolegend,	UK	 mouse	 1:100	
CD45	 PE	 103105,	Biolegend	UK	 mouse	 1:100	
CD45	 PE	 368510,	Biolegend	UK	 human	 1:100	
CD45	 BV421	 304032,	Biolegend	UK	 human	 1:100	
CD49f	 APC	 17-0495-80,	EBioscience	 mouse/	
human	
1:100	
EpCAM	 BV711	 BD	Biosciences,	UK	 mouse	 1:100	
Isolectin	
GS-IB4	
Biotin	 I21414,	Invitrogen,	UK	 mouse	 1:100	
GS-IB4	
secondary		
Streptavidin	 Q10101MP,	Invitrogen,	UK	
	
	 1:100	
CD24	 PeCy7	 101821,	Biolegend,	UK	 mouse	 1:100	
SSEA1		
	
PerCP	
efluor700	
46-8813-41,	eBioscience,	UK	 mouse	 1:50	
LRIG1	 PE	 FAB7498P,	R	and	D	Systems	 human	 1:100	
NGFR	 PE-Cy7	 345110,	Biolegend,	UK	 human	 1:100	
	
	
2.8.4	 Flow	cytometry	cell	sorting	
	
Cells	were	processed	as	previously	and	sorting	took	place	using	a	BD	FACS	Aria	II	
Flow	Cytometer.	
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Mouse	
	
After	the	final	wash	the	cells	were	resuspended	in	flow	cytometry	sorting	buffer	(45	
mls	media,	5	mls	25	mM	HEPES,	40	μl	2	mM	EDTA).		When	cells	were	used	for	
tracheosphere	assays	they	were	sorted	into	media	with	20%	FBS,	for	colony	forming	
assays	were	sorted	directly	into	96	well	plates	and	for	sc-RNA	seq	into	media	
containing	5%	FBS.	
	
Human	
	
After	the	final	wash,	cells	were	resuspended	in	flow	cytometry	sorting	buffer	(45	mls	
1%	BSA	in	PBS,	5	mls	25	mM	HEPES,	40	μl	2	mM	EDTA).		Cells	were	sorted	directly	
into	96	well	plates	for	colony	forming	assays.	
	
2.8.5	 Hoescht	33342	cell	cycle	analysis	
	
Mouse	
	
Cell	samples	were	blocked	for	10	minutes	in	supplemented	DMEM	and	Hoechst	
33342	added	to	a	final	concentration	of	10	μg/ml.		The	samples	were	incubated	at	
37	°C	for	45	minutes.		After	Hoescht	33342	incubation,	the	samples	were	transferred	
to	ice	with	application	of	antibodies	as	described	previously.		PI,	at	a	final	
concentration	of	1	μg/ml	was	used	as	a	viability	marker	and	added	immediately	prior	
to	running	the	sample.		The	Hoechst	33342	data	was	acquired	in	linear.		
	
Human	
	
After	the	blocking	step,	samples	were	incubated	with	Hoescht	33342	added	to	a	final	
concentration	of	10	μg/ml	at	37°C	for	30	minutes.		After	incubation,	the	samples	
were	transferred	to	ice	and	antibodies	applied	as	described	previously.		Sytox	red	
(S34859,	ThermoFisher,	UK)	was	used	1:100	as	a	viability	marker,	it	was	added	
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immediately	prior	to	running	the	sample.		The	Hoescht	33342	data	was	acquired	in	
linear.	
	
2.8.6	 EdU	cell	proliferation	analysis	
	
Cells	were	plated	in	triplicate	in	a	6-well	plate	and	grown	in	BEGM.		Once	confluence	
was	reached,	the	media	was	changed	and	24	hours	later	EdU	(Life	Technologies	
Click-iT	EdU	Alexa	Fluor	647;	C10424)	added	to	a	final	concentration	of	10	μM.	The	
cells	were	incubated	for	2	hrs	and	then	trypsinised	and	stained	according	to	the	
manufacturers	instructions.			
	
2.9	 Analysis	of	epithelial	cells	in	situ	
	
2.9.1	 Tissue	processing	and	haematoxylin	and	eosin	staining	
	
The	isolated	tissue	samples	were	left	in	4%	PFA	at	4°C	for	24	hours.		The	formalin	
was	subsequently	replaced	with	70%	ethanol	and	the	samples	processed	in	paraffin	
wax,	using	an	automated	system	(Leica	TP	1050).		4	μm	sections	were	cut	from	the	
embedded	sections	and	mounted	on	polylysine	slides	for	staining.		Haematoxylin	
and	eosin	(H&E)	staining	was	performed	using	an	automated	staining	system	
(TissueTek).			
	
2.9.2	 Immunofluorescent	staining		
	
Cytospun	cells	
	
Isolated	airway	epithelial	cells	were	pelleted	and	resuspended	in	media	at	a	
concentration	of	500,000	cells/ml.		100	μl	of	this	solution	was	applied	to	each	funnel,	
and	the	cytospin	set	at	400	rpm	for	5	minutes.		Cells	were	fixed	in	4%	PFA	for	15	
minutes,	and	washed	three	times	in	PBS.		The	slides	were	incubated	in	blocking	
solution	(36	mls	PBS,	4	mls	FBS,	80	μl	fish	skin	solution,	80	μl	Triton	X)	and	stained	
overnight	with	primary	antibodies,	made	up	in	blocking	solution.	
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The	following	morning,	the	slides	were	washed	three	times	in	PBS	and	secondary	
antibody	applied	in	block	solution	at	a	concentration	of	1:300	for	3	hours.		The	cells	
were	washed	twice	more	in	PBS.		DAPI	at	a	concentration	of	1:10,000	was	applied	to	
the	slide	for	10	minutes.		The	cells	were	washed	in	PBS	once	more	and	mounted	with	
immunomount	(Thermo	Scientific,	UK).	
	
Paraffin	embedded	sections	
	
4	μm	sections	were	dewaxed	and	rehydrated	by	immersion	in	xylene	followed	by	
decreasing	concentrations	of	ethanol	through	to	water,	performed	by	an	automated	
staining	system	(TissueTek).	
	
Antigen	retrieval	was	performed	using	either	citrate	buffer	(10	mM	sodium	citrate,	
adjusted	to	pH	6),	or	EDTA	(1	mM	EDTA	adjusted	to	pH	8)	and	samples	heated	in	the	
microwave	on	high	power	for	2	periods	of	10	minutes.		The	samples	were	left	to	cool	
for	15	minutes	and	the	samples	blocked	(36	mls	PBS,	4	mls	FBS,	80	μl	fish	skin	gelatin	
solution)	at	room	temperature	for	1	hour.		Primary	antibody	was	applied	overnight	
and	the	following	morning	samples	were	washed	3	times,	with	application	of	
secondary	antibodies	and	cover	slipping	as	above.	
	
When	staining	for	GFP,	antigen	retrieval	was	performed	via	incubation	in	0.2%	Triton	
X	in	PBS	and	for	10	minutes	at	room	temperature.		After	blocking,	anti	eGFP	primary	
antibody	(ab13970,	Abcam,	1:1000)	was	applied	in	blocking	solution	overnight.		Due	
to	difficulties	with	antigen	retrieval	when	using	eGFP,	the	concentration	of	KRT5	
antibody	for	dual	staining	needed	to	be	increased	to	1:500.		MUC5AC	was	effective	
at	previous	concentrations	and	no	antigen	retrieval	was	performed	when	staining	for	
eGFP	and	FOXJ1	expression.	
	
Frozen	sections	
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Frozen	sections	were	left	to	dry,	fixed	for	10	minutes	in	4%	PFA	and	washed	3	times	
in	PBS.		Slides	were	then	blocked	in	blocking	solution	(36	mls	PBS,	4	mls	FBS,	80	μl	
fish	skin	solution,	80	μl	Triton	X)	for	1	hour	and	then	primary	antibodies	applied.	
	
Imaging	
	
All	images	were	captured	using	a	Leica	TCS	SP8	confocal	microscope	(Department	of	
Cell	and	Developmental	Biology,	UCL)	or	Carl	Zeiss	Axiovert	A1	microscope	and	
Axiocam	503	camera	(Carl	Zeiss,	UK).		Images	were	analysed	using	ZEN	lite	Imaging	
Software	(Carl	Zeiss,	UK)	or	Adobe	Photoshop	CS6.	
	
2.9.3	 Antibodies	used		
	
Antigen	 Antibody	 Species	 Concentration	 Antigen	Retrieval		
eGFP	 Abcam	ab13970	 Chicken	 1:1000	 0.2%	Triton	X	
FOXJ1	 EBioscience		14-9965-80	 Mouse	IgG1	 1:50	 Nil	
LRIG1	 R	and	D	Systems	AF3688	 Goat	 1:200	 0.2%	Triton	X/	
citrate	
Tdtomato	 Rockland	600-401-379	 Rabbit	 1:1000	 0.2%	Triton	X	
Ki67	 Abcam	ab15580	 Rabbit	 1:100	 Citrate	
Ki67	 Biolegend	151202	 Rat	IgG2b	 1:200	 Citrate	
GS-IB4	 L2895	Sigma,	488	conjugate	 	 1:75	 Citrate	
KRT5	 Abcam	ab24647	 Rabbit	 1:1000	 Citrate/	0.2%	
Triton	X	
KRT5	 Biolegend	905501	 Rabbit	 1:1000	 Citrate/	0.2%	
Triton	X	
ACT	 T6793	Sigma	 Mouse	
IgG2b	
1:800	 Citrate/	0.2%	
Triton	X	
p63	 Abcam	ab53039		 Rabbit	 1:50	 Citrate	
EGFR	 LS	Bio	LS-B2914	
	
Sheep	 1:400	 Citrate/	0.2%	
Triton	X	
Phospho-EGFR	 Invitrogen	36-9700	 Rabbit	 1:500	 Citrate	
SPC	 Santa	Cruz	SC-7706	 Goat	 1:50	 Citrate	
TTF1	 Novocastra	NCL-L-TTF-1	 Mouse	IgG1	 1:200	 Citrate	
CC10	 Santa	Cruz	SC-9772	 Goat	 1:400	 Citrate	
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CC10	 Santa	Cruz	SC-365992	 Mouse	IgG1	 1:400	 Citrate	
Annexin	5	 Abcam	ab14196	 Rabbit	 1	μg/ml	 Citrate	
BrdU	 Bio-Rad	BU1/75	(ICR1)	 Sheep	 1:200	 Citrate	
	
All	secondary	antibodies	for	immunofluorescence	were	AlexaFluor	conjugates.	
	
2.9.4	 Immunohistochemistry	staining	
	
4	μm	tissue	sections	were	dewaxed	and	antigens	retrieved	via	sodium	citrate	
retrieval.		Slides	were	washed	once	with	PBS	and	endogenous	peroxidases	blocked	
for	10	minutes	in	1%	hydrogen	peroxide.		The	samples	were	washed	again	in	PBS	and	
then	were	blocked	for	30	minutes	in	blocking	solution	(1%	casein	(VectorLabs),	1%	
BSA,	2%	goat	serum	(VectorLabs)	in	PBS).		The	primary	antibody	was	applied	
overnight	in	blocking	solution	at	4°C.		The	following	morning	slides	were	washed	3	
times	with	PBS,	and	a	streptavidin	conjugated	secondary	antibody	applied	at	a	1:200	
dilution	in	block	solution	(BA-1000	VectorLabs)	for	45	minutes.		After	washing	a	
further	3	times	in	PBS,	avidin/biotin	blocking	was	performed	according	to	kit	
instructions	(SP-2001,	VectorLabs).		Cells	were	washed	3	x	in	PBS	and	stained	with	3,	
3'-diaminobenzidine	(DAB)	(SK-4100,	VectorLabs),	according	to	kit	instructions.		
Slides	were	counterstained	using	the	automated	staining	system	(TissueTek).	
	
2.9.5	 Assessing	the	proliferation	of	adult	airway	epithelial	cells	
	
6-8	week	old	mice	were	injected	with	10	ul/gram	of	BrdU	(Invitrogen,	UK)	and	
observed	for	5	hours.		After	5	hours,	the	tracheas	were	isolated	and	placed	in	4%	
PFA	for	embedding.		A	bowel	sample	was	taken	as	a	positive	control	for	the	BrdU	
staining.	
	
2.9.6	 Assessment	of	epithelial	thickness,	proliferation	and	number	of	basal	cells	
	
Sections	were	stained	for	H&E	or	appropriate	stains	(Ki67	or	KRT5).		Epithelial	
thickness	was	measured	using	NDP	Viewing	Software	(Hamamatsu,	UK).		Depth	was	
measured	from	the	basement	membrane	to	the	lumen,	perpendicular	to	the	
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tracheal	length.		Measurements	were	taken	in	6	locations	and	an	average	obtained	
for	each	trachea.	
	
For	BrdU,	Ki67	and	KRT5	staining,	6	images	of	the	epithelium	were	taken	across	the	
length	of	the	trachea,	and	images	overlaid.		The	numbers	of	epithelial	cells	seen	
above	the	basement	membrane	were	counted	(based	on	DAPI	staining)	and	the	
numbers	of	either	BrdU,	Ki67	or	KRT5	positive	cells	above	the	basement	membrane	
were	counted.		These	cell	counts	were	expressed	as	a	percentage	of	the	total	
epithelial	cell	number	in	that	section,	and	an	average	of	the	6	images	was	recorded.		
	
2.10	 Mouse	airway	epithelial	cell	culture		
	
All	tissue	culture	plastics,	tissue	culture	grade	trypsin,	tissue	culture	antibiotics	and	
FBS	were	purchased	from	Invitrogen,	unless	otherwise	stated.		Sterile	tissue	culture	
flasks	and	plates	were	purchased	from	Nunc	(ThermoFisher).		All	tissue	culture	
plates	were	coated	with	rat	tail	collagen	type	1	(354263,	BD)	prior	to	seeding	of	cells.	
	
3T3-J2	feeder	layers	were	prepared	as	below.		Flow	cytometry	sorted	murine	basal	
cells	or	murine	airway	epithelial	cells	obtained	following	pronase	digest,	were	plated	
on	feeder	layers	in	mouse	tracheal	epithelial	cell	culture	media	(MTEC)	(169,	170).		
MTEC	consisted	of	DMEM	(41966,	Gibco)	and	F12	(21765,	Gibco)	in	a	1:1	ratio	with	
penicillin/streptomycin	(15070,	Gibco),	supplemented	with	15	mM	HEPES,	3.6	mM	
sodium	bicarbonate,10	μg/ml	insulin	(I6634,	Sigma),	5	μg/ml	transferrin	(T1147,	
Sigma),	0.1	μg/ml	cholera	toxin	(C3012,	Sigma),	25	ng/ml	epidermal	growth	factor	
(354001	Becton-Dickinson),	30	μg/ml	bovine	pituitary	extract	(13028014,	
ThermoFisher),	5%	FBS	(10270,	Gibco),	and	freshly	added	0.01	μM	retinoic	acid	
(R2625,	Sigma).	Media	was	changed	every	3	days.	At	confluence,	cells	were	
expanded	and	then	passaged	at	a	1:5	ratio	onto	fresh	3T3-J2	feeder	layers.		
	
2.10.1	 Tracheosphere	assay	
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Flow	cytometry-sorted	murine	basal	epithelial	cells	were	plated	at	1,250	cells/	well	
in	matrigel	(#354230,	BD	Biosciences)	and	cultured	in	MTEC,	for	7	days.		After	7	days	
the	media	was	changed	to	MTEC	differentiation	media,	consisting	of	DMEM	(41966,	
Gibco)	and	F12	(21765,	Gibco)	in	a	1:1	ratio	with	penicillin/streptomycin	(15070,	
Gibco),	supplemented	with	15	mM	HEPES,	3.6	mM	sodium	bicarbonate,5	μg/ml	
insulin	(I6634,	Sigma),	5	μg/ml	transferrin	(T1147,	Sigma),	0.025	μg/ml	cholera	toxin	
(C3012,	Sigma),	5	ng/ml	epidermal	growth	factor	(354001	Becton-Dickinson),	30	
μg/ml	bovine	pituitary	extract	(13028014,	ThermoFisher),	1mg/ml	BSA	and	freshly	
added	0.01	μM	retinoic	acid	(R2625,	Sigma).		At	day	14	tracheospheres	were	
counted,	photographed,	washed	in	ice	cold	PBS	and	fixed	in	4%	PFA.		Spheres	were	
processed	in	Histogel	(HG-4000-012,	Fisher	Scientific)	prior	to	paraffin	embedding.	
	
2.10.2	 Colony	forming	assay	
	
Epithelial	cells	were	sorted	directly	into	each	well	of	a	96-well	plate	containing	
mitotically	inactivated	3T3-J2	fibroblasts	and	MTEC	media.		MTEC	was	replaced	2-3	
times	a	week.		At	day	10	the	colonies	were	fixed	in	4%	PFA	for	15	minutes	and	then	
stained	with	crystal	violet	(HT90132,	Sigma,	UK)	at	room	temperature	for	10	
minutes.		The	plates	were	washed	in	tap	water	until	it	ran	clear	and	then	left	to	air-
dry.		The	numbers	of	colonies,	which	consisted	of	more	than	10	cells	were	counted.	
	
2.11	 Human	airway	epithelial	cell	culture	
	
2.11.1	 3T3-J2	feeder	cell	culture	
	
3T3-J2	feeder	cells	were	cultured	in	DMEM	(41966,	Gibco)	supplemented	with	100	
U/ml	penicillin,	100	μg/ml	streptomycin	(15070,	Gibco)	and	9%	bovine	serum	
(26170,	Gibco).		The	cells	were	cultured	at	37°C,	in	5%	CO2.		The	media	changed	3	
times	a	week	and	cells	were	used	up	to	passage	12.		To	generate	feeder	layers,	
confluent	cells	were	mitotically	inactivated	by	treatment	for	2	hours	with	4	μg/ml	
mitomycin	(M4278,	Sigma).		Following	inactivation,	the	cells	were	trypsinised	and	
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plated	at	a	density	of	20,000	cells/cm2,	in	DMEM	growth	media.		The	epithelial	cells	
were	added	to	the	feeder	layers	the	following	day.	
	
2.11.2	 Human	airway	epithelial	cell	culture	in	3T3-J2	co-culture	with	ROCK	
	 inhibition	(3T3	+	Y)	
	
3T3-J2	feeder	layers	were	prepared	as	above.		Cells	were	cultured	at	37	°C	in	5%	CO2	
in	epithelial	culture	medium	consisting	of	DMEM	(41966,	Gibco)	and	F12	(21765,	
Gibco)	in	a	3:1	ratio	with	penicillin/streptomycin	(15070,	Gibco)	and	7.5%	FBS	
(10270,	Gibco)	with	the	supplementation	of	5	μM	Y-27632	(ROCK	inhibitor,	Y1000,	
Cambridge	Bioscience),	25	ng/ml	hydrocortisone	(HO888,	Sigma),	0.125	ng/ml	
epidermal	growth	factor	(10605,	Sino	Biological),	5	μg/ml	insulin	(I6634,	Sigma),	0.1	
nM	cholera	toxin	(C8052,	Sigma),	250	ng/ml	amphotericin	B	(10746254,	Fisher	
Scientific)	and	10	μg/ml	gentamycin	(15710,	Gibco).		Media	was	changed	three	times	
a	week.	
	
When	experiments	necessitated	a	pure	epithelial	cell	population,	the	3T3-J2	feeder	
layers	were	removed	by	differential	trypsinisation	(171).		In	brief,	cells	were	washed	
with	PBS	and	0.05%	Trypsin/EDTA	added.		The	cells	were	incubated	at	37	°C	and	the	
feeder	cells	seen	to	detach.		The	trypsin	was	removed	and	cell	layers	washed	with	
PBS	and	further	trypsin	added,	after	a	further	5	minutes	the	epithelial	cells	were	
seen	to	detach.	
	
All	epithelial	culture	using	the	generated	LRIG1	shRNA	cell	lines,	was	performed	with	
the	parent	cells,	the	LRIG1	shRNA	knockdown	cells	and	the	LRIG1	expressing	non-
silencing	controls	at	the	same	passage	number.	
	
2.11.3	 Colony	forming	assay	directly	from	flow-sorted	cells	(96-well	plates)	
	
Epithelial	cells	were	sorted	directly	into	each	well	of	a	96-well	plate	containing	
mitotically	inactivated	3T3-J2	fibroblasts	and	50:50	conditioned	media	(from	a	
confluent	layer	of	human	epithelial	cells	filtered	through	a	40	μm	filter)	and	3T3	+	Y	
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media,	and	supplemented	with	additional	ROCK	inhibitor	at	a	concentration	of	5	μM.		
After	7	days	the	media	was	replaced	with	3T3	+	Y	media.		Throughout	the	
experiment	media	was	replaced	2-3	times	a	week.		At	day	14	the	colonies	were	fixed	
and	stained	with	crystal	violet,	and	colonies	counted	as	above.		
	
2.11.4	 Colony	forming	assay	in	cultured	HBECs	(6-well	plates)		
	
6-well	plates	were	coated	with	collagen	and	seeded	with	mitotically	inactivated	3T3-
J2	cells	in	10	%	DMEM.		Human	epithelial	cells	were	seeded	at	1,000	cells/well	in	
FMED.		The	media	was	changed	on	days	3,	5,	7	and	9.		On	day	10	the	plates	were	
fixed	in	4	%	PFA	and	then	stained	with	crystal	violet.		After	washing	in	tap	water	and	
air-drying	the	number	of	colonies	per	well	were	counted.		Colonies	greater	than	10	
cells	were	included.	
	
2.11.5	 XTT	assay	
	
7,500	cells	were	plated	in	BEGM	(CC-2540B,	Lonza,	with	all	the	aliquots	added	to	the	
BEBM),	in	triplicate,	per	well	of	a	collagen-coated	96-well	plate.		Cells	were	left	
overnight	to	adhere,	and	then	the	media	changed	and	XTT	(A8088,	Applichem)	
added	according	to	the	manufacturers	instructions.		Three	control	wells	containing	
BEGM	media	were	included	as	blanks.		After	a	4	hour	incubation,	the	absorbance	of	
samples	were	measured	using	a	Titertec	Multiscan	MCC/340	plate	reader	
(Labsystems,	Turku,	Finland)	at	wavelengths	of	490	and	630	nm.		The	630	nm	
measurement	was	subtracted	from	the	490	nm	to	obtain	the	absorbance	reading.		
Percentage	change	was	expressed	as	a	proportion	of	the	initial	reading.		Readings	
were	taken	at	1,	2,	3,	4,	7,	9,	11	and	14	days.	
	
2.11.6	 Invasion	assay	through	Matrigel	
	
Matrigel	(#354234,	BD	Biosciences),	was	mixed	1:1	with	serum	free	media	
(containing	3:1	DMEM	to	F12	with	penicillin/streptomycin)	on	ice,	with	200	μl	added	
to	the	upper	chamber	of	a	transwell	plate.		The	matrigel	solution	was	left	to	set	for	
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30	minutes	at	37°C.		Epithelial	cells	were	seeded	at	50,000	and	100,000	cells	above	
the	Matrigel	in	serum	free	media.		The	wells	were	filled	with	500	μl	of	complete	
epithelial	media	containing	ROCK	inhibitor.		After	96	hours	the	Matrigel	was	carefully	
removed	using	a	cotton	bud,	and	the	media	replaced	with	4%	PFA.		The	membranes	
were	left	at	room	temperature	for	20	minutes	and	then	stained	with	crystal	violet	
and	washed	gently	in	tap	water	until	the	water	ran	clear.		The	membranes	were	left	
to	air-dry	overnight.		The	following	morning	the	membranes	were	treated	with	350	
μl	of	10%	glacial	acetic	acid.		100	ul	of	this	solution	was	added,	in	triplicate	to	a	96	
well	plate	and	the	absorbance	read	at	550	nm.	
	
2.11.7	 Organotypic	assay	
	
A	solution	containing	rat	tail	collagen	type	1	(354263,	BD),	Matrigel	(#354234,	BD	
Biosciences),	10	x	DMEM,	10%	FBS	complete	DMEM,	and	human	fibroblasts	at	a	
concentration	of	5	x	106	cells/ml	was	prepared	on	ice,	in	a	volume	ratio	of	
3.5:3.5:1:1:1.		1M	NaOH	was	added	to	the	solution	in	100	μl	aliquots	until	the	
mixture	became	a	pink	colour.		1ml	of	the	gel	mix	was	added	per	well	of	a	24-well	
plate	and	plates	were	incubated	at	37°C	for	1	hour	to	allow	the	gels	to	solidify.		1ml	
of	10%	FBS	complete	DMEM	was	then	added	to	each	well	and	the	plates	returned	to	
the	incubator	overnight.	
	
The	following	day,	2	cm	squares	of	nylon	were	sterilised	by	autoclaving.		A	collagen	
mix	was	prepared	consisting	of	collagen/10x	DMEM/FCS/10%	FBS	complete	DMEM,	
in	a	ratio	of	7:1:1:1.		250	μl	of	the	collagen	solution	was	added	per	nylon	sheet	and	
left	at	37°C	for	30	minutes.		1%	glutaraldehyde	solution	(G5882,	Sigma,	UK)	was	used	
to	wash	the	sheets,	with	incubation	in	the	1%	glutaraldehyde	solution	at	4°C	for	1	
hour.		The	sheets	were	washed	in	PBS	to	remove	any	excess	glutaraldehyde	and	
stored	in	serum	free	DMEM	until	required.	
	
The	DMEM	overlying	the	gels	was	removed	and	750,000	epithelial	cells	in	FMED	+	Y	
media	were	added	to	each	gel,	in	triplicate.			After	48	hours	the	media	was	changed.		
At	96	hours,	the	gels	were	detached	from	the	wells	and	raised	onto	a	metal	grid	
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within	a	6-well	plate.		A	collagen-coated	square	was	added	to	each	of	the	grids	and	
then	the	gel	added	on	top.		Tracheosphere	media	(172)	was	added	to	each	well	of	
the	6-well	plate,	so	that	the	collagen	membrane	was	covered,	but	the	upper	surface	
of	the	gel,	with	the	over-lying	epithelial	cells	was	exposed	to	air.	Tracheosphere	
medium	consisted	of	50%	BEBM	(CC-2540B,	Lonza)	and	50%	DMEM	(41966,	Gibco)	
supplemented	with	BEGM	supplements	(minus	triiodothyronine,	gentamycin,	
amphotericin	and	retinoic	acid).	100	nM	retinoic	acid	(R2625,	Sigma)	was	added	
immediately	before	each	use.		
		
The	media	was	replaced	every	2-3	days.		After	24	days,	the	media	and	metal	grids	
were	removed	from	the	gels.		The	membranes	were	fixed	in	4%	PFA	for	6	hours	and	
then	paraffin	embedded.		
	
2.12	 Other	tissue	culture	
	
2.12.1	 HEK293T	cell	culture	
	
HEK293T	cells	were	grown	in	DMEM	(41966,	Gibco)	supplemented	with	
penicillin/streptomycin	(15070,	Gibco)	and	10%	FBS.		On	cell	confluence,	cells	were	
trypsinised	and	passaged	at	a	1:10	ratio.	
	
2.12.2	 Human	lung	fibroblast	culture	
	
Primary	human	lung	fibroblasts	derived	from	healthy	donor	lungs	were	a	kind	gift	
from	Professor	Robin	McAnulty	(University	College	London,	UK).		The	fibroblasts	
were	cultured	in	DMEM	with	100	U/ml	penicillin	and	100	µg/ml	streptomycin	(Gibco;	
#15070)	and	10%	FBS.	
	
2.12.3	 Mycoplasma	testing	
	
Cells	in	culture	were	routinely	tested	for	mycoplasma	contamination.		This	was	
performed	through	either	the	MycoAlert	Mycoplasma	Detection	Kit	(LT07-318,	
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Lonza),	according	to	manufacturers	instructions,	or	using	published	PCR	techniques	
(173).	
	
2.13	 shRNA	knock	down	of	LRIG1	
	
2.13.1	 Preparation	of	plasmid	DNA	
	
Three	LRIG1	plasmids,	V2LHS_229246,	V3LHS_332387	and	V3LHS_404471,	
purchased	as	bacterial	stabs,	were	used.		These	were	arbitrarily	labelled	1,	2	and	3	
for	the	purposes	of	assessment.		Initially	an	LB	broth,	containing	25	g	of	LB	broth	
(Sigma,	UK)	dissolved	in	1	litre	of	water	and	adjusted	to	pH	7	was	produced.		This	
solution	was	autoclaved	and	left	to	cool.		1	ml	of	100	mcg/ml	ampicillin	
(concentration	1:10000)	was	added	to	the	solution.		3	mls	of	the	broth	was	aliquoted	
into	3	falcons	and	a	sample	of	the	bacterial	stab	added	to	each.		The	solution	was	
incubated	at	37°C,	in	an	orbital	incubator	at	230	rpm	for	5	hours.			200	mls	of	fresh	
broth	was	added	to	autoclaved	500	ml	glass	bottles.		25	µl	of	the	resulting	bacterial	
solution	was	added	to	each	of	these	bottles	and	incubated	overnight	at	37°C,	230	
rpm.		The	following	day,	the	DNA	was	extracted	using	the	Qiagen	HiSpeed	Plasmid	
Maxi	Kit	12663	(Qiagen,	UK),	according	to	the	manufacturers	instructions.		The	DNA	
concentration	was	quantified	via	Nanodrop.	
	
2.13.2	 Production	of	virus	
	
HEK293T	cells	were	seeded	into	4	T175	flasks,	containing	DMEM	(41966,	Gibco)	
supplemented	with	penicillin/streptomycin	(15070,	Gibco)	and	10%	FBS.		The	flasks	
were	left	to	reach	80-	90%	confluence.		For	each	T175	flask,	20	μg	of	plasmid	DNA	
(UCLH	shRNA	library),	7	μg	pmD.G	and	13	μg	of	PCMV_dR8_74	packaging	plasmids	
(Plasmid	Factory,	Germany)	were	added	to	1	ml	of	150	mM	NaCl,	vortexed	for	10	
seconds	and	passed	through	a	0.22	μm	filter.		80	µl	of	jet	PEI	was	added	to	1	ml	of	
150	mM	NaCl	solution.		The	jet	PEI	solution	was	added	to	the	plasmid	DNA/NaCl	
solution,	vortexed	for	10	seconds	and	incubated	for	20	minutes	at	room	
temperature.		The	NaCl/DNA/jet	PEI	solution	(2	mls)	was	added	to	13	mls	DMEM	and	
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replaced	the	media	in	each	T175	flask.		The	flasks	were	incubated	for	4	hours	at	
37°C,	and	after	this	period	the	media	replaced	with	20	ml	fresh	DMEM.		After	24	
hours	the	media	was	replaced	with	12mls	of	fresh	media,	and	following	another	24	
hours	the	media	was	collected	for	virus	isolation.	In	total,	two	12	ml	aliquots	of	
media	were	collected	from	each	flask	at	48	and	72	hours	post	initial	virus	incubation.	
	
The	ultracentrifuge	was	set	to	4°C	and	Beckman	centrifuge	tubes	were	washed	in	
70%	IMS	and	left	to	dry	in	a	hood.		The	collected	media	was	centrifuged	at	300	x	g	
for	10	minutes	at	4°C.	The	supernatant	was	removed	and	filtered	through	0.45	μm	
filters,	and	then	transferred	to	the	dry	centrifuge	tubes	and	centrifuged	at	17,000	
rpm	for	2	hours	at	4°C	(SW28	rotor,	Optima	LE80K	Ultracentrifuge,	Beckman).		After	
centrifuging,	virus	was	resuspended	and	stored	in	aliquots	at	-80°C	for	further	use.	
	
2.13.3	 Titration	of	virus	
	
50,000	HEK293T	cells	were	seeded	per	well	of	a	12-well	plate.		The	following	day	the	
media	was	replaced	with	virus-	containing	media,	with	2,	1,	0.5,	0.25,	0.125	μl	of	
virus	and	4	μg/ml	of	polybrene.		After	48	hours,	the	cells	were	trypsinised	and	
prepared	for	flow	cytometry.		A	GFP	reporter	is	contained	within	the	plasmid,	so	the	
percentage	of	GFP	expressing	cells	was	elucidated	by	flow	cytometry.		The	viral	titre	
in	particles/ml	was	calculated	using	the	formula:	-	
	
Viral	titre	 =	 %	of	positive	cells		x		number	of	cells	plated	
	 	 	 	 volume	of	virus	added	(in	ml)	
	
2.13.4	 Viral	transduction		
	
50,000	epithelial	cells	were	seeded	onto	mitotically	inactivated	3T3-J2	feeder	layers	
in	6-well	plates.		The	following	day,	virus	was	added	at	a	multiplicity	of	infection	
(MOI)	of	3.		The	J2	feeder	layers	were	included	in	the	assessment	of	MOI.		The	virus	
was	added	with	4	μg/ml	polybrene.	The	media	was	exchanged	with	fresh	FMED	after	
4	hours.	Transduction	success	was	confirmed	through	both	the	expression	of	GFP	
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protein	that	was	seen	detectable	immunofluorescence	and	through	immunoblotting	
for	LRIG1.	
	
2.14		 Western	Blotting	
	
2.14.1	 Sample	preparation	
	
Cerebella	
	
6-	8	week	old	adult	mice	were	euthanised	and	their	brains	removed	and	placed	in	
ice-cold	PBS.		Cerebella	were	dissected	and	lysed	in	P40	extraction	buffer	consisting	
of	50	mM	Tris-HCl	pH	8.0,	150	mM	NaCl,	1%	IGEPAL,	1	mM	Na2VO3,	25	mM	NaF	with	
the	addition	of	protease	and	phosphatase	inhibitor	cocktail	(#1861281,	
ThermoFisher).	The	samples	were	frozen	at	-80°C,	defrosted	on	ice,	macerated	and	
centrifuged	at	13000	×	g	for	3	min.		The	cleared	supernatants	were	collected	for	
Western	blotting.	
	
Cells	used	in	the	assessing	the	success	of	shRNA	knock	down		
	
HBECs	were	grown	in	3T3	+	Y	conditions.		When	confluent,	the	3T3	cells	were	
removed	by	differential	trypsinisation	and	the	media	replaced.		The	following	
morning	the	HBECs	were	washed	twice	in	ice	cold	PBS	and	cell	lysis	performed	using	
RIPA	buffer	(R0278,	Sigma)	containing	a	protease	and	phosphatase	inhibitor	cocktail	
(ThermoFisher).		The	cells	were	left	at	–	80°C	for	1	hour	prior	to	cell	scraping.		After	
cell	scraping,	the	lysates	were	transferred	to	microfuge	tubes	and	stored	at	–	20°C	
for	future	use.		When	needed,	the	samples	were	defrosted	on	ice	and	centrifuged	at	
14,000	x	g	for	10	minutes	at	4	degrees.		The	cleared	lysates	were	transferred	to	a	
clean	microfuge	tube.			
	
Samples	used	in	the	assessment	of	the	effects	of	EGF	
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HBECs	were	grown	in	3T3	+	Y	conditions.		When	confluent,	the	3T3	cells	were	
removed	by	differential	trypsinisation,	the	cells	washed	with	complete	media	to	
neutralise	the	trypsin	and	then	starved	for	16	hours	in	DMEM	(41966,	Gibco)	with	
penicillin/streptomycin	(15070,	Gibco).		Cells	were	stimulated	with	10	ng/ml	EGF	for	
30	minutes.		After	30	minutes,	the	cells	were	washed	twice	in	ice	cold	PBS	and	
underwent	cell	lysis	as	above.	
	
2.14.2	 Immunoblotting	
	
The	protein	concentration	of	samples	was	determined	by	BCA	assay	and	samples	
diluted	in	dH20	to	equivalent	concentrations.		The	samples	were	mixed	with	5	x	
laemmlli	buffer	(3.125	mM	Tris-	base	pH	6.8,	10%	(w/v)	SDS,	20%	(v/v)	glycerol,	50	
mM	Dithiothreitol	(DTT),	in	dH20)	and	heated	to	80°C	for	10	minutes.		The	proteins	
were	separated	on	4-12%	Bis-	Tris	gels	(Invitrogen)	and	transferred	onto	a	
nitrocellulose	membrane	using	the	iBlot	transfer	system	(Invitrogen),	or	the	XCell	II	
blot	module	according	to	manufacturers	instructions	(EI9051,	ThermoFisher).	
	
The	blots	were	blocked	for	1	hour	at	room	temperature	in	blocking	buffer,	tris-
buffered	saline	(Cell	Signalling	Technologies)	containing	0.1%	Tween	20	(TBST)	and	
5%	non-fat	dry	milk	in	TBST.		Antibodies	were	added	in	5%	BSA	in	TBST	overnight	at	
4	degrees.		The	membranes	were	washed	3	times	in	TBST	and	then	incubated	for	1	
hour	at	room	temperature	with	an	HRP	conjugated	secondary	antibody	in	5%	milk.		
The	membranes	were	then	washed	3	further	times	in	TBST	and	the	developed	using	
Luminata	Western	HRP	Chemiluminescence	Reagent	(Millipore).		Protein	bands	were	
detected	using	an	ImageQuant	LAS	4000	system	(GE	Healthcare).		When	blots	were	
re-probed,	they	were	stripped	in	stripping	buffer	for	10	minutes	at	room	
temperature	(21059,	ThermoFisher),	reblocked,	and	a	further	antibody	applied	as	
above.	
	
2.14.3	 Antibodies	used	
	
Antibody	 Species	 Supplier	 Code	 Concentration	
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LRIG1		
(anti	mouse)	
Rabbit	 Abcam	 Ab36707	 1	μg/ml	
LRIG1	
(anti	human)	
Rabbit	 Cell	Signalling	Technologies	 #12752	 1:1000	
α-tubulin	 Rabbit	 Cell	Signalling	Technologies	 #9099	 1:1000	
EGFR	 Rabbit	 Cell	Signalling	Technologies	 #4267	 1:1000	
phospho-EGFR	 Rabbit	 Cell	Signalling	Technologies	 #2234	 1:1000	
ERK	½	 Rabbit	 Cell	Signalling	Technologies	 #9102	 1:1000	
phospho-	ERK	1/2	 Rabbit	 Cell	Signalling	Technologies	 #9101	 1:1000	
	
	
2.15	 Single	cell	RNA	sequencing	
	
Flow	cytometry	sorted	epithelial	cells	were	transported	in	collection	media	to	either	
the	Genome	Centre,	University	of	London	(UK),	or	to	The	Mill	Hill	Laboratory,	Francis	
Crick	Institute	(UK).		In	both	institutions	the	experiments	were	run	by	a	technician.		
The	cells	were	inserted	into	a	C1	Fluidigm	according	to	the	manufacturers	
instructions.		Medium	sized	C1	Fluidigm	plates	were	used	(Fluidigm,	UK)	and	an	ERCC	
control	added	to	samples	(Invitrogen,	UK).		The	cDNA	library	was	prepared	using	the	
Nextera	XT	DNA	Library	Preparation	Kit.		Prior	to	sequencing,	the	cDNA	quality	was	
assessed	using	a	bioanalyser.		cDNA	sequencing	was	performed	on	an	a	HiSeq2500	
(Illumina,	UK).		Data	was	received	in	the	form	of	FASTQ	files.		These	were	given	to	
bioinformaticians	at	the	Bill	Lyons	Informatics	Centre	UCL	for	data	analysis.	
	
2.16	 N-Nitrosotris-(2-chloroethyl)urea	(NTCU)	in	a	squamous	
	 carcinogenesis	model	
	
2.16.1	 NTCU	treatment	
	
6	week	old	female,	LRIG1-null,	LRIG1-heterozygous	and	wild-type	FVB/N	C57BL/6	
mice	were	treated.		24	hours	prior	to	the	first	dose,	murine	dorsal	skin	was	shaved.		
NTCU	(sc-212265	Santa	Cruz)	was	diluted	in	acetone	to	a	concentration	of	0.013	M,	
with	aliquots	stored	at	-20°C	in	Nunc	Cryovials	(ThermoFisher)	for	future	use.		75	μl	
of	NTCU	was	applied	twice	weekly,	between	the	shoulder	blades	of	the	mouse	
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(within	a	class	II	microbiological	safety	cabinet).		The	NTCU	solutions	were	kept	on	
ice	at	all	times.		Skin	was	allowed	to	dry	before	the	animal	placed	back	into	its	cage.		
Acetone	was	used	as	a	control.		Prior	to	application,	the	animals	were	weighed	and	
skin	checked	to	ensure	no	irritation.		Skin	was	shaved	once	a	week,	24	hours	before	
dosing	and	bedding	changed	every	2	weeks.		Animals	underwent	12	weeks	of	
treatment	(24	doses),	followed	by	an	11	week	monitoring	period,	where	twice-
weekly	weights	were	continued.		After	23	weeks	animals	were	culled	via	
pentobarbital	injection.		4	hours	prior	to	sacrifice,	BrdU	(000103,	ThermoFisher)	was	
administered	intraperitoneally.			
	
2.16.2	 Assessment	of	disease	extent	
	
Lung	blocks	were	sectioned	until	the	trachea	and	main	bronchi	were	visible	(Figure	
2.1.A).		To	assess	disease	extent,	two	continuous	4	μm	sections	were	taken	followed	
by	a	further	2	sections	200	μm	from	the	first.		The	first	of	each	of	these	were	stained	
with	H&E,	and	the	second	stained	for	KRT5	by	immunohistochemistry.	
	
Abnormal	airways	were	determined	by	the	presence	of	KRT5	staining	distal	to	the	
cartilage	containing	trachea	and	the	left	and	right	main	bronchi.		Slides	were	
scanned	using	a	NanoZoomer	(Hamamatsu,	UK),	and	NDP	Viewing	Software	
(Hamamatsu,	UK)	was	used	to	draw	around	the	KRT5	stained	bronchial	tree.		The	
entire	bronchial	tree	(beyond	the	cartilage	containing	areas)	was	then	measured.		
The	percentage	of	abnormal	airway	defined	by	the	length	of	the	KRT5	stained	airway	
was	then	divided	by	the	total	length	of	the	bronchial	tree	(Figure	2.1.Bi	and	2.1.Bii).		
An	average	of	the	percentage	of	KRT5	stained	airway	was	then	obtained	from	the	
two	sections	that	were	200	μm	apart.	
	
The	KRT5	stained	areas	were	then	compared	to	the	corresponding	H&E	image.		
Staining	was	divided	into	flat	atypia,	low-grade	and	high-grade	dysplasia.		The	
percentage	of	each	type	of	lesion	was	then	divided	by	the	total	length	of	abnormal	
bronchial	tree,	to	obtain	the	proportion	affected	by	each	lesion	type.		Flat	atypia	was	
defined	as	any	KRT5	staining	of	the	airway	beyond	the	cartilage	containing	bronchial	
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tree	that	was	one	cell	layer	in	thickness.		Low-grade	dysplasia,	encompassed	
metaplasia,	mild	and	moderate	dysplasia	and	consisted	of	KRT5	staining	of	more	
than	one	cell	in	thickness,	but	with	clear	differentiation/organisation	of	cells	from	
the	basal	layer	to	those	adjacent	to	the	lumen.		High-grade	dysplasia	was	severe	
dysplasia	or	carcinoma	in	situ,	with	KRT5	staining	of	more	than	one	cell	thickness,	
with	disorganization;	the	nuclei	were	large	and	there	was	no	evidence	of	
organisation	of	cells	between	those	along	the	basal	layer	and	the	lumen	(Figure	
2.1.C).	
	
When	the	abnormal	areas	of	KRT5	staining	eroded	through	the	basement	membrane	
these	were	defined	as	cancers.		Using	the	NDP	Viewing	Software,	the	total	surface	
area	of	the	lung	and	lesion	areas	were	calculated.	Cancers	were	counted	as	
individual	lesions	if	they	were	greater	than	200	μm	apart.		The	number	of	tumours	
were	counted	across	two	sections	of	lung	that	were	separated	by	200	μm.		An	
average	size	number	of	tumours	for	each	mouse	(from	the	average	of	the	two	
sections	was	determined.			
	
The	size	of	each	tumour	was	considered	as	a	single	entity	and	analysed	according	to	
the	genotype	of	the	mouse.		Therefore	the	tumours	were	divided	into	three	groups,	
dependent	on	the	genotype	of	the	parent.		This	is	similar	to	the	method	reported	by	
Alcolea	et	al	in	their	analysis	of	clonal	patches	in	the	oesophagus	(174).	The	
percentage	of	lung	affected	by	cancer	was	determined	by	averaging	the	percentage	
of	surface	area	covered	be	invasive	cancers	in	two	sections,	200	μm	apart	(Figure	
2.1.B	iv).	
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Figure	2.1:		Assessment	of	NTCU	induced	disease	
	
A)		Transverse	sections	of	lungs	were	cut	until	a	section	containing	the	cross	section	of	the	trachea	and	
the	right	and	left	main	bronchi	were	reached.		B)	i)	Keratin	5	stained	lung	was	drawn	around	using	NDP	
image	software,	this	was	then	compared	to	the	length	of	the	entire	bronchial	tree	that	was	visible	in	ii).		
iii)	shows	the	assessment	of	the	surface	area	of	lung	cancers,	with	the	perimeter	of	the	lesion	drawn	
around	by	using	NDP	image	software,	whilst	iv)	shows	how	the	entire	lung	was	drawn	around	to	work	
out	the	total	surface	area	of	the	lungs.		Scale	bars	=	0.5	cm.		C)		Examples,	from	left	to	right	of	flat	atypia	
lesions,	low	grade	dysplasia	and	high	grade	dysplasia,	scale	bars	=	100	μm	
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2.16.3	 Assessment	of	tumour	proliferation	
	
Sections,	from	LRIG1-null,	LRIG1-heterozygous	and	wild-type	mice	were	stained	for	
immunofluorescence	with	Ki67,	Annexin	V,	KRT5	and	DAPI.		The	number	of	DAPI	
stained	cells	within	a	KRT5	stained	tumour	were	counted,	along	with	the	number	of	
Ki67	and	Annexin	V	positive	cells.		These	were	expressed	as	a	percentage	of	the	DAPI	
positive	cells	making	up	the	tumour.	
	
2.17	 Statistics		
	
Statistical	analysis	was	performed	using	GraphPad	Prism	(GraphPad	Software,	CA,	
USA)	and	Microsoft	Excel.		Mouse	and	human	tissue	culture	data	were	analysed	
using	t-test	and	one-way	ANOVA.		NTCU	data	was	assessed	for	normality	using	the	
D'Agostino	&	Pearson	test,	followed	by	the	Kruskal-Wallis	or	one-way	ANOVA	as	
appropriate.		Percentages	underwent	arcsine	transformation	to	enable	assessment.	
Results	were	considered	statistically	significant	when	p	≤	0.05.		All	data	points	are	
represented	as	mean	±	standard	error	of	mean.			
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3.	 Expression	of	LRIG1	in	the	
murine	airway		 	
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3.	 Expression	of	LRIG1	within	the	murine	airway		
	
3.1	 Background	
	
The	role	of	leucine-rich	repeats	and	immunoglobulin-like	domains	protein	1	(LRIG1)	
in	the	skin	and	the	gut	has	been	defined	through	the	use	of	mouse	models.	In	situ	
hybridisation	has	shown	expression	of	LRIG1	in	the	stem	cell	niche	of	the	small	
intestine	and	colon	(93).		Whilst	LRIG1	is	expressed	throughout	the	skin,	it	is	seen	in	
the	highest	concentrations	in	the	melanoma-associated	chondroitin	sulfate	
proteoglycan	(MCSP)-positive	keratinocyte	stem	cell	population	(90).		Lrig1	knockout	
mouse	models	have	shown	the	role	of	LRIG1	in	the	regulation	of	the	stem	cell	
compartments,	where	loss	of	LRIG1	leads	to	the	hyperproliferation	of	both	skin	(89)	
and	gut	epithelia	(93).		To	assess	how	LRIG1	could	lead	to	preinvasive	lung	cancer,	
LRIG1’s	expression	in	the	normal	airway	and	its	association	with	the	stem	cell	
compartments	of	the	airways	needs	to	be	delineated.		Then,	through	the	use	of	an	
LRIG1-null	mouse	model,	the	effect	of	loss	of	LRIG1	in	the	airway,	and	how	loss	of	
LRIG1	leads	to	preinvasive	cancer,	can	be	established.	
	
The	external	domain	of	LRIG1	is	susceptible	to	cleavage	by	trypsin	and	there	are	few	
reports	of	the	successful	use	of	antibodies	against	LRIG1	in	immunohistochemistry,	
flow	cytometry	analysis	or	western	blotting.			To	make	detection	easier,	LRIG1	has	
previously	been	tagged	with	the	FLAG	protein	(104)	and	research	groups	have	
generated	their	own	LRIG1	antibody	(94),	although	with	limited	success	(175).		Due	
to	these	difficulties,	this	project	makes	use	of	the	Lrig1	EGFP-ires-CreERT2	mouse,	
where	an	EGFP-ires-CreERT2	cassette	is	placed	behind	the	start	codon	of	Lrig1	(91).		
This	means	that	when	the	Lrig1	promoter	is	activated,	the	reporter	protein	eGFP	is	
expressed	instead	of	LRIG1,	labelling	the	cell.		The	CreERT2	component	of	the	
cassette	allows	lineage	tracing	of	LRIG1-expressing	daughter	cells,	should	the	animal	
to	be	crossed	with	a	reporter	strain.			As	an	Lrig1	EGFP-ires-CreERT2	heterozygous	
mouse	only	has	a	single	copy	of	the	cassette,	functional	LRIG1	is	still	produced.		By	
using	the	expression	of	eGFP,	these	Lrig1	EGFP-ires-CreERT2	mice	have	been	used	to	
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identify	the	presence	of	LRIG1-expressing	cells	in	the	epidermis	through	both	
immunohistochemistry	and	flow	cytometry	(91).		Previous	work	has	found	there	to	
be	no	effect	of	Lrig1	haploinsufficiency,	with	no	detectable	differences	between	
Lrig1	wild-type	and	Lrig1-heterozygous	animals	(104).		When	both	copies	of	the	Lrig1	
gene	are	replaced	by	the	Lrig1	EGFP-ires-CreERT2	cassette	no	functional	LRIG1	
protein	is	produced;	this	means	an	animal	homozygous	for	the	Lrig1	EGFP-ires-
CreERT2	cassette	is	the	equivalent	of	an	LRIG1-null	mouse.		
	
Basal	cells	are	the	stem	cells	of	the	upper	airway	(176)	so	by	extrapolating	from	
studies	in	the	skin	and	gut,	where	the	highest	LRIG1	expression	is	seen	in	the	stem	
cell	compartments,	the	airway	basal	cells	would	be	expected	to	have	the	greatest	
LRIG1	expression.		Airway	basal	cells	are	further	considered	to	be	the	cell	of	origin	of	
squamous	cell	lung	cancer	(177,	178).		Therefore,	the	loss	of	LRIG1	seen	in	
preinvasive	cancer	could	affect	the	airway	basal	cells,	leading	to	their	dysregulation	
and	the	development	of	preinvasive	disease.	To	understand	the	effects	of	LRIG1	in	
the	murine	airway,	the	expression	of	LRIG1	in	the	airway	epithelium	needs	to	be	
determined	and	airway	basal	cells	need	to	be	isolated	to	analyse	this	in	more	detail.		
By	comparing	LRIG1-expressing	basal	cells	(from	heterozygous	animals)	to	LRIG1-null	
basal	cells	(from	mice	homozygous	for	the	Lrig1	EGFP-ires-CreERT2	cassette),	the	
effect	of	loss	of	LRIG1	on	the	behaviour	of	the	airway	stem	cell	compartment	and	
how	its	loss	may	lead	to	preinvasive	lung	cancer	can	be	determined.		
	
To	fully	establish	the	role	of	LRIG1	in	the	airway,	I	intended	to	perform	lineage	
tracing	using	the	CreERT2	component	of	the	gene	cassette.		This	would	characterise	
the	stem	cell	potential	of	an	LRIG1-expressing	cell,	as	when	Lrig1	EGFP-ires-CreERT2	
mice	are	crossed	with	reporter	animals	the	progeny	of	an	LRIG1-expressing	cell	will	
be	permanently	labelled.		When	lineage	tracing	in	animals	heterozygous	for	Lrig1	
EGFP-ires-CreERT2	cassette,	the	potential	of	an	LRIG1-positive	cell	to	maintain	the	
epithelium	during	homeostasis,	during	repair	and	on	cancer	induction	can	be	
assessed.		Subsequent	lineage-tracing	experiments	using	animals	homozygous	for	
the	Lrig1	EGFP-ires-CreERT2	cassette	could	then	be	used	to	determine	how	the	
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lineage	tracing	changes	when	LRIG1	is	deleted	and	the	effect	of	the	loss	of	LRIG1	in	
homeostasis,	repair	and	cancer	induction.	
	
3.2	 Aims	
	
• To	establish	and	characterise	Lrig1	EGFP-ires-CreERT2	mice	
• To	assess	the	expression	of	LRIG1	within	the	murine	trachea	and	lung,	
particularly	in	the	airway	stem	cell	compartments	
• To	isolate	LRIG1-expressing	basal	cells	from	the	trachea	to	enable	a	more	
detailed	assessment	of	the	properties	of	LRIG1-expressing	cells	
• To	assess	the	behaviour	of	LRIG1-expressing	cells	in	a	lineage-tracing	model		
	
3.3	 Results	
3.3.1	 Establishment	of	the	Lrig1	EGFP-ires-CreERT2	colony	
	
To	study	LRIG1	in	the	airway	epithelium,	reporter	mice,	where	one	copy	of	native	
Lrig1	is	replaced	with	an	Lrig1	EGFP-ires-CreERT2	cassette	(Figure	3.1.A)	were	used.		
These	Lrig1	EGFP-ires-CreERT2	heterozygous	animals,	a	gift	from	Professor	K.	Jensen,	
The	University	of	Copenhagen,	were	on	an	FVB/N	C57BL/6	background	and	were	
crossed	with	commercially	available	FVB/N	animals.		The	viability	of	the	Lrig1-
knockout	offspring	is	dependent	on	background:	animals	inbred	on	a	pure	FVB/N	
background	have	a	severe	phenotype,	with	the	development	of	a	grossly	distended	
bowel	and	malabsorption	that	necessitates	culling	at	around	P10	(93),	whereas	
outbred	Lrig1	knockout	animals	survive	into	adulthood	(89,	90).		FVB/N	mice	were	
selected	due	to	their	susceptibility	to	the	development	of	chemically	induced	
squamous	cell	carcinomas	(179,	180),	which	would	become	of	relevance	in	later	
carcinogenesis	experiments.	
	
Following	the	cross	of	the	Lrig1	EGFP-ires-CreERT2	cassette	animals	with	the	FVB/N	
animals,	heterozygous	progeny	were	produced.		These	were	crossed	again	creating	
wild-type,	LRIG1-heterozygous	and	LRIG1-null	animals	(Figure	3.1.B).	The	LRIG1-null	
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animals	had	no	phenotypic	characteristics	other	than	a	reduced	weight	at	weaning	
(Figure	3.1.C),	there	was	no	evidence	of	the	previously	described	skin	thickening,	
dermatitis	or	bowel	abnormalities	(89,	93).		There	were,	however,	fewer	LRIG1-null	
animals	produced	than	anticipated	by	Mendelian	genetics	(Figure	3.1.D).		To	
increase	the	number	of	LRIG1-null	animals,	breeding	pairs	were	set	up	between	
LRIG1-null	and	LRIG1-heterozygous	animals.		Between	30-50%	of	these	litters	were	
lost	prior	to	weaning,	which	contravened	Home	Office	Guidelines.		The	breeding	
strategy	was	initially	abandoned,	but	subsequently	returned	to	and,	with	improved	
animal	husbandry,	was	a	greater	success.			
	
3.3.2	 The	effect	of	Lrig1	haploinsufficiency	
	
The	loss	of	LRIG1	initiates	hyperproliferation	of	the	skin	and	gut	(89,	93),	however,	it	
has	previously	been	reported	that	there	is	no	effect	of	Lrig1	haploinsufficiency	(104).		
To	confirm	this	finding,	airway	cell	proliferation	in	wild-type	and	LRIG1-heterozygous	
animals	was	compared	(Figure	3.1.E	and	3.1.F).		Assessment	of	the	rate	of	
proliferation	followed	a	6-hour	pulse	of	BrdU.		BrdU	uptake	was	noted	in	
approximately	0.8%	of	airway	epithelial	cells.		There	was	no	difference	in	epithelial	
cell	proliferation	between	LRIG1-heterozygous	and	wild-type	mice	and	no	
differences	between	male	and	female	animals.		
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Figure	continued	over	page.	
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Figure	3.1:	Characterisation	of	the	Lrig1	EGFP-ires-CreERT2	colony	
		
A)	The	EGFP-ires-CreERT2	cassette	situated	at	the	start	of	exon	1	of	Lrig1,	placed	behind	the	first	ATG	start	
codon.		Image	reproduced,	with	permission	from	reference	(91).		B)		The	breeding	strategy	used	to	produce	
LRIG1-null,	LRIG1-heterozygous	and	LRIG1-wild-type	mice.		The	initial	cross	involved	breeding	mice	heterozygous	
for	the	EGFP-ires-CreERT2	cassette	with	wild-type	FVB/N	animals.		The	litters	produced	were	50%	heterozygous	
for	the	EGFP-ires-CreERT2	cassette	and	50%	wild-type.		The	mice	heterozygous	for	the	EGFP-ires-CreERT2	
cassette	were	bred	with	other	heterozygous	animals.		This	cross	would	lead	to,	according	to	Mendelian	ratios:	
25%	LRIG1-null	mice	(with	two	copies	of	the	EGFP-ires-CreERT2	cassette,	but	no	LRIG1	expression),	50%	LRIG1-
heterozygous	mice	(with	one	copy	of	the	EGFP-ires-CreERT2	cassette	and	a	functional	LRIG1	allele)	and	25%	
LRIG1-wild-type	mice	(without	a	copy	of	the	EGFP-ires-CreERT2	cassette).			C)	Weight	at	weaning	(at	3	weeks)	of	
mice	in	the	Lrig1	EGFP-ires-CreERT2	colony.		The	weight	of	LRIG1-null	animals	was	significantly	lower	than	the	
LRIG1-heterozygous	or	wild-type	mice.		Statistical	analysis	was	performed	using	a	Kruskal-Wallis	test,	following	
assessment	of	normality	using	the	D'Agostino	&	Pearson	normality	test	with	Dunn’s	post-	test;	n=	25	–	119	mice;	
mean	+/-	SEM;	***	indicates	p<	0.0001.		D)	Proportion	of	animals	of	each	genotype,	n=	194.		E)	Assessment	of	
the	proliferation	of	epithelial	cells,	showing	the	percentage	of	BrdU-positive	epithelial	cells	after	a	6-hour	chase,	
divided	into	gender	and	Lrig1-wild-type	or	-heterozygous	genotype.		Statistical	analysis	was	performed	using	a	
Kruskal-Wallis	test,	with	Dunn’s	post-test;	n=	3	mice;	mean	+/-	SEM.		F)	A	single	BrdU-positive	proliferating	
epithelial	cell	(BrdU;red),	DAPI	(blue)	used	as	a	counterstain.		Scale	bar	=	50	μm.			
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3.3.3	 The	establishment	of	a	genotyping	strategy	for	the	Lrig1	EGFP-ires-CreERT2	
colony	
	
The	presence	of	the	EGFP-ires-CreERT2	cassette	was	identifiable	using	primers	to	the	
Cre	recombinase	component.		This	allowed	wild-type	and	LRIG1-heterozygous	
animals	to	be	discriminated	(Figure	3.2.A).		To	discriminate	LRIG1-heterozygous	from	
LRIG-null	animals,	a	second	round	of	genotyping	was	necessary	and	new	primers	
were	designed.		The	EGFP-ires-CreERT2	cassette	is	situated	at	the	ATG	start	codon	of	
the	first	exon	of	Lrig1,	so	using	the	Primer3	design	tool,	primers	were	designed	
around	the	native	Lrig1	gene.		LRIG1-heterozygous	animals	have	one	normal	Lrig1	
allele	and	therefore	a	PCR	product	would	be	detectable	on	a	gel,	whereas	the	LRIG1-
null	animals,	without	a	normal	Lrig1	allele,	would	be	negative	for	this	PCR	product.		
The	final	genotyping	strategy	therefore	required	two	steps:	the	first	to	identify	wild-
type	mice	and	the	second	to	distinguish	LRIG1-heterozygous	from	LRIG1-null	mice	
(Figure	3.2.B).			
	
Initially,	three	sets	of	forward	and	reverse	primers	were	designed.		These	all	
encompassed	the	native	Lrig1	allele.		The	sequences	were	designed	to	overlap	at	the	
point	where	the	EGFP-ires-CreERT2	cassette	was	inserted	in	the	native	allele,	
meaning	a	product	would	only	be	detectable	if	the	native	allele	was	present.		Each	
primer	was	trialled	on	the	extracted	DNA	of	two	LRIG1-heterozygous	mice	and	the	
PCR	products	were	run	on	an	agarose	gel.		However,	each	of	the	product	bands	were	
poorly	defined	(Figure	3.2.C).		In	the	first	Cre	PCR	reaction,	the	extracted	ear	snip	
DNA	was	used	directly,	and	a	clear,	well-defined	band	was	seen	in	the	agarose	gel	
(Figure	3.2.A).		However,	when	the	ill-defined	bands	were	seen	in	the	second	
reaction,	the	DNA	purity	was	assessed	using	a	Nanodrop.		This	measurement	implied	
the	DNA	contained	impurities,	therefore	any	contaminating	salts	were	removed	
using	the	ethanol	precipitation	method.		The	initial	Cre	PCR	reaction	may	have	been	
successful	due	to	the	strength	of	primer	binding	to	the	DNA,	however,	the	second	
PCR	reaction	involved	amplifying	a	region	of	DNA	that	was	‘GC	rich’	(made	up	of	75%	
G	or	C	bases).		A	GC-rich	area	affects	the	ability	of	the	primers	to	anneal,	so	in	
combination	with	impurities	in	the	DNA,	may	have	led	to	the	ill-defined	bands.		By	
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removing	the	impurities	through	ethanol	precipitation	and	adjusting	the	PCR	
mastermix	to	one	suitable	for	GC-rich	areas,	the	PCR	product	became	cleaner	(Figure	
3.2.D).			
	
Primer	B	produced	the	cleanest	product,	but	two	bands	were	present	in	the	lane.		
The	lowest	band	corresponded	to	the	predicted	size	of	355	bp.		To	ensure	the	primer	
was	annealing	to	the	correct	section	of	DNA,	sequencing	of	the	PCR	product	was	
performed	at	Source	Biosciences.			This	revealed	that	primer	B	was	annealing	to	the	
correct	DNA	target	(Figure	3.2.E).		Different	annealing	temperatures	were	assessed	
to	see	if	the	band	could	become	clearer	and	eliminate	the	contaminant	band;	62°C	
was	found	to	be	most	effective	(Figure	3.2.F).		The	optimisation	of	the	PCR	reaction	
led	to	clear	PCR	product	bands	and	allowed	successful	genotyping	(Figure	3.2.G).			
	
The	accuracy	of	genotyping	was	essential	to	ensure	the	appropriate	animals	were	
used	in	downstream	experiments.		Therefore,	visual	genotyping	was	used	as	an	
additional	step.		eGFP,	and	the	presence	of	the	EGFP-ires-CreERT2	cassette,	was	
confirmed	by	analysing	the	ear	snips	by	immunofluorescence	(Figure	3.2.H).		The	low	
weaning	weights	of	the	LRIG1-null	mice	supported	the	PCR	confirmation	of	
genotype.		
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Figure	3.2:		Genotyping	the	Lrig1	EGFP-ires-CreERT2	colony	
	
A)	Agarose	gel	demonstrating	the	presence	of	the	Cre	protein	in	Lrig1	EGFP-ires-CreERT2	heterozygous	
animals.		The	PCR	product	is	visible	at	700	bp	in	animals	containing	the	Lrig1	EGFP-ires-CreERT2	cassette.		B)	
Genotyping	strategy	to	distinguish	wild-type,	LRIG1-heterozygous	and	LRIG1-null	animals.		If	the	Cre	insert	is	
present,	a	second	PCR	reaction	is	necessary	to	distinguish	LRIG1-heterozygous	from	LRIG1-null	mice.		C)	Initial	
genotyping	using	the	designed	primers	A,	B	and	C.		DNA	from	two	mice	was	used	for	analysis.			Negative	
controls	were	used	for	each	of	the	three	primers.		Note	multiple	bands	in	each	of	the	lanes.		D)	Optimisation	of	
primers	using	the	improved	quality	DNA.		Clearer	bands	were	seen	when	using	primers	B	and	primer	C.		The	
Cre	primers	were	used	as	a	positive	control	to	ensure	the	DNA	was	of	high	quality.		E)	Sequencing	results	from	
Source	Biosciences.		Top	graph	shows	transcript	obtained.		The	bottom	diagram	indicates	correspondence	of	
the	sequence	with	the	expected	DNA	transcript.		Green	highlighting	indicates	primer	B	forward	and	reverse.		
The	[ATG]	start	codon	of	Lrig1	exon	1	is	indicated.		The	blue	highlights	areas	of	matching	of	the	sequenced	
product	to	the	expected	transcript.		This	shows	the	LRIG1	primers	anneal	to	the	anticipated	part	of	the	
transcript.		F)	Trial	of	annealing	temperatures	using	primer	B.		The	clearest	PCR	product	band	is	seen	at	62°C.		
G)	Final,	optimised	PCR	reaction	showing	samples	positive	for	the	native	Lrig1,	including	a	positive	control.		H)	
Immunofluorescence	of	ear	snip	samples,	showing	endogenous	eGFP	expression	in	Lrig1	EGFP-ires-CreERT2	
animals	located	around	the	hair	follicle.		There	is	no	eGFP	expression	in	wild-type	animals.		
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3.3.4	 Confirmation	that	homozygosity	for	the	Lrig1	EGFP-ires-CreERT2	cassette	
correlates	with	loss	of	protein	production	
	
The	use	of	mice	with	a	double	EGFP-ires-CreERT2	cassette	(LRIG1-null	animals)	has	
not	previously	been	reported,	with	heterozygous	animals	used	for	all	experiments	in	
the	skin	(91).		It	was	essential	to	ensure	that	the	LRIG1-null	animals	did	not	express	
LRIG1	protein.		The	insert	is	a	knock-in	behind	the	start	codon	of	Lrig1,	where	the	
Lrig1	DNA	beyond	the	EGFP-ires-CreERT2	cassette	remains	in	place.		Whilst	it	is	
unlikely	that	functional	LRIG1	is	produced,	given	both	a	probable	frame-shift	
following	the	insertion	and	that	the	LRIG1-null	animals	have	a	subtle	phenotype	
(lower	weaning	weight),	confirmation	of	loss	of	LRIG1	protein	production	through	
Western	blotting	was	necessary.			
	
The	highest	LRIG1	protein	expression	in	humans	is	seen	in	the	cerebellum	(181)	and	
in	the	mouse	significant	LRIG1	mRNA	levels	are	seen	in	the	brain	(182).		Therefore,	
cerebella	were	collected	from	6	animals;	2	wild-type,	2	LRIG1-heterozygous	and	2	
LRIG1-null	mice	and	protein	extracted.		Western	blotting	demonstrated	LRIG1	
protein	expression	in	the	wild-type	mice,	a	reduction	in	the	heterozygous	mice	and	a	
complete	absence	in	the	LRIG1-null	mice	(Figure	3.3.A).			
	
3.3.5	 Correlation	of	eGFP	with	LRIG1	expression	
	
The	Lrig1	EGFP-ires-CreERT2	mice	express	eGFP	following	activation	of	the	Lrig1	
promoter,	therefore,	in	heterozygous	animals,	eGFP	expression	should	co-localise	to	
that	of	native	LRIG1	expression.		This	has	previously	been	shown	in	the	skin	of	Lrig1	
EGFP-ires-CreERT2	animals	(91),	but	to	confirm	this	finding	in	the	airway,	tracheas	
from	LRIG1-heterozygous	animals	were	stained	for	both	LRIG1	and	eGFP.	
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Figure	3.3:		Confirmation	of	absence	of	LRIG1	protein	in	the	LRIG1-null	animals	and	
correlation	of	eGFP	with	LRIG1	expression	
	
A)	Detection	of	LRIG1	in	lysates	of	murine	cerebella	from	wild-type,	LRIG1-heterozygous	and	LRIG1-null	mice.		
The	greatest	LRIG1	protein	expression	is	seen	in	the	wild-type	animals	(142	kDa);	there	is	slightly	less	
expression	in	the	LRIG-heterozygous	mice	and	a	complete	absence	in	LRIG1-null	animals.		α-tubulin	used	as	a	
loading	control	(50	kDa).		n=	2.		B)	Immunofluorescence	staining	of	the	hair	follicles,	which	is	consistent	with	
that	previously	reported.		Dual	staining	for	LRIG1	(red)	and	eGFP	(green),	indicating	a	complete	overlap	
between	the	staining	of	these	proteins,	scale	bar	=	50	μm,	image	representative	of	n	=	3.		C)	
Immunofluorescence	staining	of	the	trachea	with	dual	staining	for	LRIG1	(red)	and	eGFP	(green),	showing	
correlation	of	LRIG1	expression	to	eGFP,	scale	bar	=	50	μm,	image	representative	of	n	=	3.			
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The	expression	of	eGFP	in	the	skin	co-localised	with	that	of	LRIG1	(Figure	3.3.B),	
consistent	with	the	previously	reported	study	(91).		When	the	tracheas	were	
examined	(Figure	3.3.C),	there	was	a	similar	overlap	between	eGFP	and	LRIG1	
expression,	indicating	eGFP	is	an	appropriate	reporter	of	LRIG1	in	the	airway.		Of	
note,	LRIG1	is	expressed	on	the	cell	and	nuclear	membranes,	whilst	eGFP	is	
cytoplasmic.		When	the	staining	is	closely	examined,	the	different	cellular	locations	
of	the	two	proteins	can	be	determined.	
	
3.3.6	 Expression	of	LRIG1	in	the	airway	epithelium	
	
In	humans,	loss	of	LRIG1	is	an	early	event	in	the	development	of	preinvasive	lung	
cancer	(104).		These	preinvasive	lesions	occur	in	the	trachea	and	upper	airways,	
where	the	airway	basal	cells	are	situated.		In	the	mouse,	airway	basal	cells	are	
restricted	to	the	trachea	and	first	division	of	right	and	left	main	bronchi.		To	
understand	the	expression	of	LRIG1	in	the	mouse	airways	and	to	be	able	to	relate	
this	to	the	human	airway,	tracheas	were	isolated	from	LRIG1-heterozygous	mice	and	
were	stained	for	eGFP	in	combination	with	keratin	5	(KRT5)	to	identify	basal	cells,	
forkhead	box	J1	(FOXJ1)	to	identify	ciliated	cells,	and	mucin	5AC	(MUC5AC)	to	mark	
goblet	cells.				
	
LRIG1	expression	was	confirmed	across	all	epithelial	cell	populations	(Figure	3.4.A-
D).		This	contrasts	to	the	findings	in	the	skin	and	the	gut	where	there	is	a	clear	
association	with	the	stem	cell	compartments	(91,	93).		Beneath	the	basement	
membrane	eGFP	staining	is	seen	both	in	the	cartilage	rings	and	some	stromal	cells	
(Figure	3.4.C,	arrowed).		LRIG1	expression	in	the	skin	is	concentrated	within	the	
sebaceous	glands	of	the	epidermis	(91),	however,	within	the	tracheal	submucosal	
glands	(where	the	basal	cells	are	concentrated)	an	increased	eGFP	expression	is	not	
visualised	compared	to	the	rest	of	the	epithelium	(Figure	3.4.B).	
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Figure	3.4:		Coexpression	of	LRIG1	with	other	airway	epithelial	markers	and	LRIG1	in	the	distal	
airway	
	
A)	Immunofluorescence	staining	of	the	tracheal	epithelium	for	eGFP	(green)	and	KRT5	(red).		DAPI	used	as	a	
counterstain.		Scale	bar	=	50	μm,	image	representative	of	n	=	3.		B)	Immunofluorescence	staining	for	eGFP	(green)	and	
keratin	5	(KRT5;	red)	within	the	submucosal	glands.		DAPI	used	as	counterstain.		Scale	bar	=	50	μm,	image	
representative	of	n	=	3.		C)	Immunofluorescence	staining	showing	coexpression	of	eGFP	(green)	with forkhead	box	J1	
(FOXJ1;	red),	a	marker	of	ciliated	epithelial	cells.		Arrows	indicate	eGFP-stained	stromal	cells.		DAPI	used	as	a	
counterstain.		Scale	bar	=	50	μm,	image	representative	of	n	=	3.		D)		Immunofluorescence	staining	of	the	tracheal	
epithelium	for	eGFP	(green)	and	mucin	5AC	(MUC5AC;	red).		DAPI	used	as	a	counterstain.		Scale	bar	=	50	μm,	image	
representative	of	n	=	3.		E)	Immunofluorescence	staining	of	eGFP	(green)	in	the	distal	airway	showing	(in	i	and	ii),eGFP	
expression	in	the	distal	bronchioles,	indicating	the	expression	of	LRIG1	in	the	distal	airway,	but	no	eGFP	is	in	the	distal	
lung	parenchyma.		Staining	performed	in	LRIG1-heterozygous	mice	(iii).		Scale	bar	=	50	μm,	image	representative	of	n	
=3.	
	 96	
To	establish	the	expression	of	LRIG1	in	the	distal	airways,	sections	including	both	the	
bronchioles	and	alveolar	epithelium,	were	stained	for	eGFP.		LRIG1	was	seen	
throughout	the	distal	airway,	located	within	the	bronchiolar	epithelium	(Figure	
3.4.Ei).		The	staining	appeared	homogeneous	and	was	not	increased	at	the	
bronchoalveolar	duct	junctions,	which	would	suggest	a	concentration	of	expression	
within	this	stem	cell	compartment.		There	was	no	LRIG1	staining	within	the	lung	
parenchyma	(Figure	3.4.Eii).	
	
3.3.7	 Effect	of	loss	of	LRIG1	on	the	airway	epithelium	
	
To	examine	the	effects	of	loss	of	LRIG1	on	the	airway	epithelium,	tracheas	from	
LRIG1-null	and	LRIG1-heterozygous	animals	were	compared.		The	loss	of	LRIG1	has	
been	shown	to	cause	the	hyperproliferation	phenotype	through	an	increase	in	EGFR	
signalling.		This	has	been	previously	shown	in	the	airway	epithelium	where	Lrig1-
knockout	mice	have	increased	epithelial	staining	for	phosho-EGFR,	compared	to	
wild-type	controls	(104).		On	repeat	of	the	phospho-EGFR	staining,	the	staining	was	
variable	across	the	length	of	the	epithelium,	but	collectively	there	was	no	difference	
seen	between	the	phospho-EGFR	staining	of	LRIG1-heterozygous	and	LRIG1-null	
animals	(Figure	3.5.A).		The	intensity	of	EGFR	staining	was	greater	in	the	LRIG1-null	
animals,	indicating	that	absence	of	LRIG1	may	lead	to	an	upregulation	in	the	density	
of	EGF	receptors.						
	
LRIG1-null	mice	have	been	shown	to	have	increased	airway	epithelial	thickness	
compared	to	LRIG1-heterozygous	controls,	with	an	increased	proliferation	seen	on	
Ki67	staining	(104).		An	increase	in	epithelial	depth	was	confirmed	in	the	Lrig1	EGFP-
ires-CreERT2	mice	where	heterozygous	animals	had	a	mean	epithelial	depth	of	21.71	
μm	compared	to	27.86	μm	in	the	LRIG1-null	animals	(Figure	3.5.B).			
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Figure	3.5:		Comparison	of	tracheal	epithelium	between	LRIG-heterozygous	and	
LRIG1-null	mice	
	
A)		Immunofluorescence	staining	of	murine	tracheal	epithelium	for	phospho-EGFR	(green)	and	EGFR	
(red).		DAPI	used	as	a	counterstain,	i)	shows	images	from	two	LRIG1-heterozygous	tracheas	and	ii)	shows	
images	from	two	LRIG1-null.		Scale	bar	=	50	μm,	images	representative	of	n	=	3.			B)	The	comparison	of	
epithelial	thickness	between	LRIG1-heterozygous	and	LRIG1-null	mice.		Statistical	analysis	performed	
using	the	unpaired	t-test;	n=	4-5;	*	indicates	p<0.05;	mean	±	SEM.		C)	The	percentage	of	the	epithelium	
consisting	of	KRT5+	basal	cells	in	LRIG1-heterozygous	and	LRIG1-null	animals.		Statistical	analysis	
performed	using	the	unpaired	t-test;	n=	4-5;	mean	±	SEM.		D)	The	percentage	of	Ki67+,	proliferating	cells	
within	the	tracheal	epithelium	of	LRIG1-heterozygous	and	LRIG1-null	mice.		Statistical	analysis	
performed	using	the	unpaired	t-test;	n=	4-5;	mean	±	SEM.				
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The	increase	in	epithelial	depth	in	the	previous	study	was	attributed	to	increased	
proliferation	(104),	but	here	there	was	no	difference	in	the	number	of	Ki67-positive	
cells	in	the	airways	of	LRIG1-heterozygous	and	LRIG1-null	animals	(Figure	3.5.C).		
There	was,	however,	a	large	spread	of	proliferation	rates	within	the	heterozygous	
animals	that	ranged	from	2.2%	to	8.0%,	which	may	indicate	a	number	of	outliers.	
	
An	increase	in	the	size	of	the	stem	cell	compartment	has	been	detected	in	the	gut	of	
Lrig-knockout	mice.	To	assess	whether	there	was	an	effect	of	LRIG1	loss	on	the	stem	
cell	compartment	of	the	murine	trachea,	the	proportion	of	KRT5-positive	basal	cells	
was	counted	in	LRIG1-heterozygous	and	LRIG1-null	mice	(Figure	3.5.D).		Although	no	
statistically	significant	differences	were	seen,	there	was	a	trend	towards	an	
increased	proportion	of	KRT5-positive	basal	cells	in	the	tracheas	of	LRIG1-null	
animals	(with	p=0.0576)	compared	to	the	LRIG1-heterozygous	mice.			
	
3.3.8	 Isolation	of	airway	epithelial	cells	
	
As	LRIG1	is	expressed	across	the	tracheal	epithelium,	to	understand	how	loss	of	
LRIG1	influences	the	development	of	preinvasive	lung	cancer,	I	needed	to	compare	
LRIG1-expressing	epithelial	cells	(from	heterozygous	mice)	to	cells	where	LRIG1	is	
absent	(in	LRIG1-null	mice).			The	murine	epithelium	contains	a	heterogeneous	cell	
population,	including	basal,	ciliated	and	secretory	cells.		To	allow	a	direct	cell	
comparison,	and	to	avoid	confounding	from	multiple	cell	populations,	I	needed	to	
compare	cells	of	the	same	type.		Basal	cells	are	the	putative	cell	of	origin	of	
squamous	cell	lung	cancer	(128)	and	the	earliest	indication	of	preinvasive	disease	is	
basal	cell	hyperplasia	(36).		Therefore,	any	changes	associated	with	development	of	
preinvasive	squamous	cell	lesions	are	likely	to	occur	in	the	basal	cells,	so	a	flow	
cytometry	strategy	was	devised	to	identify	and	isolate	this	population.		This	would	
allow	a	defined	population	of	eGFP+	LRIG1-expressing	basal	cells	from	LRIG1-
heterozygous	mice	to	be	compared	to	eGFP+,	but	LRIG1-negative,	basal	cells	from	
LRIG1-null	mice	(cells	that	should	have	expressed	LRIG1,	but	where	the	active	gene	
has	been	disrupted,	and	that	are	eGFP+	due	to	the	activation	of	the	Lrig1	promoter).		
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To	allow	their	use	in	in	vitro	cell	culture	comparison	studies,	it	was	important	that	
the	airway	basal	cells	remained	viable,	so	a	strategy	using	extracellular	markers	was	
employed.		A	staining	strategy	was	devised	that	involved	the	negative	selection	of	
CD31+CD45+	cells,	eliminating	the	endothelial	and	haematopoietic	populations,	
respectively,	and	then	positively	selecting	for	either	EpCAM+	or	integrin	α6+	and	then	
using	Griffonia	Simplicifolia	isolectin	(GS-IB4)+	to	identify	basal	cells	(Figure	3.6.A).		
The	expression	of	eGFP	could	later	be	used	to	collect	LRIG1+	and	LRIG1-	basal	cell	
populations.		Lectins	are	specific	carbohydrate-binding	proteins	found	on	the	cell	
surface	and,	although	identification	occurs	through	protein	binding	rather	than	
epitope/antibody	interactions,	GS-IB4	can	be	used	to	identify	airway	basal	cells	(133,	
183-185).		The	specificity	of	GS-IB4	for	airway	basal	cells	was	confirmed	by	assessing	
its	binding	in	association	with	KRT5+	cells	in	the	tracheal	epithelium	(Figure	3.6.B).		
This	showed	that	all	KRT5+	basal	cells	were	stained	with	GS-IB4	and	that	it	was	a	
suitable	marker	to	use.		A	few	cells	beneath	the	basement	membrane	were	positive	
for	GS-IB4,	but	these	would	be	excluded	by	positive	selection	for	the	EpCAM+	or	
integrin	α6+	epithelial	populations	(which	would	not	be	found	on	these	cells).	
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Figure	3.6:		Isolation	of	basal	cells	from	the	tracheal	epithelium	
	
A)	Sorting	strategy	to	obtain	a	pure,	viable	population	of	airway	basal	cells.		B)	Immunofluorescence	staining	of	
murine	trachea	for	Griffonia	Simplicifolia	isolectin	B4	(GS-IB4;	green)	and	keratin	5	(KRT5;	red),	showing	staining	
of	the	same	epithelial	populations	and	the	suitability	of	GS-IB4	as	a	basal	cell	marker.		Scale	bar	=	100	μm.	C)	Flow	
cytometric	analysis	of	the	cell	populations	obtained	following	pronase	digestion	of	the	murine	airway.	Red	boxes	
indicate	the	populations	of	interest,	while	red	arrows	show	the	population	taken	forward.		Antibodies	were	used	
in	the	following	colours:	CD31-PECy7,	CD45-PE,	GS-IB4-qdot	605,	and	Integrin α6-APC.		D)	Immunofluorescence	
staining	for	KRT5	in	murine	airway	epithelial	cells	following	pronase	digestion,	in	a	cytospun	sample.	Scale	bar	=	
50	μm.				
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3.3.9	 Pronase	digestion	of	the	tracheal	epithelium	
	
The	enzyme	pronase	has	been	traditionally	used	for	creating	a	single	cell	suspension	
of	tracheal	epithelial	cells	for	use	in	cell	culture	or	downstream	applications	(170,	
186-188).		When	using	pronase,	a	single	trachea	is	expected	to	yield	around	2.5	x	105	
tracheal	epithelial	cells	(189)	and	basal	cells	constitute	30%	of	airway	epithelial	cells	
(130).		However,	when	using	flow	cytometry	to	identify	the	basal	cell	population	
from	pronase-digested	tracheas,	the	basal	cell	fraction	was	extremely	low.		After	
excluding	the	immune	and	endothelial	cells,	the	proportion	of	basal	cells	was	only	
0.77%	(Figure	3.6.C).		To	confirm	how	many	basal	cells	would	be	expected	in	a	
pronase-digested	cell	suspension,	a	fresh	pronase-isolated,	epithelial	cell	sample	was	
cytospun,	fixed	and	stained	for	the	intracellular	basal	cell	marker	KRT5	(Figure	3.6.D).	
KRT5+	cells	were	then	counted	and	found	to	constitute	40%	of	the	cell	suspension,	in	
line	with	the	expected	yields	(130).		It	became	apparent	pronase	may	be	cleaving	the	
epitopes	required	for	flow	cytometry	analysis,	meaning	a	reduction	in	overall	cell	
yield.	
	
3.3.10	 Analysis	of	epitope	expression	following	pronase	digestion	
	
To	explore	the	effect	of	pronase	on	epitopes	of	interest,	a	cell	source	that	did	not	
require	enzymatic	digestion	was	necessary.		Isolation	of	bone	marrow	cell	
populations	can	be	obtained	through	simply	flushing	the	extracted	long	bones	of	a	
mouse	with	saline	(190,	191).		CD31,	CD45	and	integrin	α6	(192)	are	all	expressed	by	
bone	marrow	populations,	whilst	GS-IB4	binds	to	antigens	on	bone	marrow	
endothelial	cells	(193)	and	macrophages	(194).		EpCAM	is	an	epithelial	cell	marker	
and	is	not	detectable	in	any	bone	marrow	cell	population.		For	this	reason,	the	
effects	of	pronase	on	the	EpCAM	epitope	were	not	assessed.		
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Figure	3.7:		Investigation	of	epitope	cleavage	in	bone	marrow	cells	
	
A)	Flow	cytometry	plots	showing	a	reduction	in	cells	following	pronase	digestion	of	bone	marrow	cells.	
Antibodies	were	used	in	the	following	colours:	CD31-PECy7,	CD45-PE,	GS-IB4-qdot	605,	and	Integrin α6-
APC.		B)	Quantification	of	the	proportion	of	bone	marrow	cells	expressing	epitopes	of	interest	with	or	
without	pronase	digestion	in	flow	cytometry	experiments	(n	=	6	for	CD45,	integrin	α6	and	GS-IB4,	and	n	=	3	
for	CD31).		Statistical	analysis	performed	using	the	unpaired	t-test;	**	p	<	0.01,	****	p	<	0.0001;	mean	±	
SEM.		
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Bone	marrow	cells	were	isolated,	treated	overnight	in	0.15%	pronase	(as	per	the	
tracheal	samples),	or	were	left	in	serum-free	medium	as	a	control	and	then	stained	
the	following	morning	for	flow	cytometry.		These	results	showed	CD45	was	resistant	
to	the	effects	of	pronase;	however,	following	pronase	incubation,	CD31,	integrin	α6	
and	GS-IB4	expression	were	significantly	reduced	compared	to	the	undigested	
controls	(Figures	3.7.A	and	3.7.B).	These	results	imply	that	pronase	cleaves	either	the	
epitopes	or	protein-binding	sites	(of	GS-IB4)	and	may	explain	the	lower	than	
expected	population	of	basal	cells	detected	by	flow	cytometry	(Figure	3.6.C).	
	
3.3.11	 Alternative	methods	of	epithelial	digestion	
	
As	pronase	digestion	was	unsuitable	to	identify	a	basal	cell	population	by	flow	
cytometry,	alternative	strategies	were	explored.		A	simple	collagenase	digestion,	
where	entire	rat	tracheas	were	minced	prior	to	collagenase	incubation	(195),	and	a	
more	complex	dispase/DNase/trypsin	method	(166,	167)	used	in	mice	and	human	
airways	were	identified	from	the	literature.		The	dispase/DNase/trypsin	method	
involved	using	dispase	and	DNase	to	detach	sheets	of	epithelium	from	the	
underlying	stroma	and	then	incubating	these	sheets	with	trypsin	to	create	a	single	
cell	suspension.		However,	when	trialling	the	dispase/DNase/trypsin	method,	the	
epithelium	failed	to	detach	in	complete	sheets	and	I	became	concerned	there	were	
still	basal	cells	attached	to	the	underlying	stroma.		I	was	further	concerned	that	the	
basal	cells	buried	deep	within	the	crypts	of	the	trachea	may	also	not	be	removed	
with	the	epithelial	sheets.		To	ensure	all	basal	cells	were	being	collected,	after	the	
removal	of	the	epithelial	sheets	the	remaining	tracheal	pieces	were	incubated	in	
collagenase.		It	was	intended	that	the	collagenase	would	break	down	the	stroma	and	
release	any	basal	cells	within	the	crypts	together	with	any	remaining	cells	that	failed	
to	detach	when	the	epithelial	sheets	were	removed.		
	
In	total,	3	methods	were	compared.		These	were	the	collagenase	method,	the	
reported	dispase/DNase/trypsin	method,	and	the	dispase/DNase/trypsin	method	
followed	by	collagenase	digestion	of	the	remaining	tracheal	pieces.		Each	of	these	
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methods	was	compared	to	the	initial	pronase	digestion.		The	amount	of	cell	death,	
the	total	number	of	cells	and	the	total	number	of	basal	cells	obtained	per	trachea	
was	considered.	
	
The	greatest	cell	death	occurred	following	the	collagenase	digestion	(Figure	3.8.B).		
This	was	possibly	related	to	the	incubation	time	needed	to	ensure	that	the	tissue	
had	sufficiently	broken	down	into	a	single	cell	suspension	(195).		Using	pronase	or	
the	dispase/DNase/trypsin/collagenase	method	led	to	the	greatest	number	of	viable	
cells,	however,	pronase	digestion	yielded	the	lowest	number	of	basal	cells	(Figure	
3.8.A	and	3.8.B).		The	low	yield	of	basal	cells	following	pronase	digestion	is	likely	to	
be	caused	by	epitope	cleavage,	meaning	that	although	present,	the	basal	cells	
cannot	be	identified.		The	highest	number	of	basal	cells	was	obtained	using	the	
dipase/DNase/trypsin/collagenase	method	(Figure	3.8.B).		This	method	produced	an	
average	of	19,021	cells	per	trachea,	compared	to	442	cells	following	pronase	
digestion.		Adding	collagenase	to	digest	the	remaining	tracheal	pieces	was	of	benefit	
(Figure	3.8.C),	with	a	clear	basal	cell	population	identifiable	by	flow	cytometry	and	
the	basal	cell	yield	increasing	by	as	much	as	3	fold	(an	increase	in	the	average	
number	of	basal	cells	from	6,274	to	19,021	cells	per	trachea).	
	
Method	 Number	of	cells	
Pronase	 442	
Collagenase	 7,495	
Dispase/DNase/Trypsin	 6,274	
Dispase/	DNase/	Trypsin/	Collagenase	 19,021	
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Figure	3.8:	Comparison	of	digestion	methods	to	obtain	basal	cells	from	the	murine	
tracheal	epithelium	
	
A)	Flow	cytometric	comparison	of	digestion	strategies	(pronase,	collagenase,	dispase/DNase/trypsin	
and	dispase/DNase/trypsin/collagenase)	for	murine	airway	basal	cell	isolation.	Living	cells	were	
analysed	by	selection	of	the	DAPI-	population	(upper	panel),	non-endothelial	and	non-haematopoietic	
cells	were	selected	by	their	lack	of	expression	of	CD31	and	CD45,	respectively	(middle	panel),	and	
basal	epithelial	cells	were	analysed	by	their	expression	of	both	integrin	α6	and	GS-IB4	(bottom	panel).	
Antibodies	were	used	in	the	following	colours:	CD31-PECy7,	CD45-PE,	GS-IB4-qdot	605,	and	integrin-
α6-APC.		B)	Quantification	of	cell	death,	the	total	number	of	living	cells	and	the	total	number	of	basal	
epithelial	cells	obtained	per	trachea,	using	each	digestion	strategy	(n=6).		Each	digestion	strategy	was	
compared	to	pronase	digestion.		Statistical	analysis	was	performed	by	ordinary	one-way	ANOVA,	with	
Dunnett’s	multiple	comparison	test;	*	p<0.05,	**	p<0.01,	****p<0.0001;	mean	+/-	SEM.		C)		Flow	
cytometry	plots	to	identify	the	additional	basal	cell	population	obtained	by	digestion	of	the	remaining	
tracheal	pieces.		n	=	6.	
	
	
Figure	continued	over	page.		
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3.3.11	 Assessment	of	growth	and	differentiation	potential	of	isolated	murine	basal	
cells	
	
To	ensure	that	the	FACS-sorted	basal	cells	retained	their	growth	and	differentiation	
potential	(after	the	digestion	and	sorting	steps),	the	cells	were	used	in	2D	and	3D	cell	
culture	assays.		Basal	cells	were	directly	used	in	a	tracheosphere	assay	where	the	
tracheospheres	hollowed	and	then	differentiated	over	a	3-week	period	(Figure	
3.9.A).		Differentiation	was	confirmed	by	immunofluorescence	staining	for	MUC5B	
(secretory	cells)	and	acetylated	tubulin	(ACT,	ciliated	cells)	(Figure	3.9.B).	
	
There	are	limited	reports	of	2D	murine	airway	basal	cell	culture	(196-198).		Most	
methods	relate	to	the	use	of	the	air-liquid	interface	model	in	which	basal	cells	are	
obtained	directly	from	a	mouse,	without	cell	sorting	or	in	vitro	expansion.			There	are	
few	reports	of	cultured	basal	cells	being	passaged	successfully,	with	those	that	are	
grown	in	2D	culture	losing	the	ability	to	differentiate	(196).		To	assess	whether	the	
isolated	basal	cells	could	be	grown	in	vitro	and	used	in	subsequent	colony-forming	
assays	(Chapter	4),	the	basal	cells	were	co-cultured	on	mitomycin	C-inactivated	3T3-
J2	feeder	layers	in	mouse	tracheal	epithelial	cell	(MTEC)	medium	(170).		Colonies	
were	noted	to	appear	after	7-10	days	(Figure	3.9.C).		
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Figure	3.9:		Expansion	of	murine	basal	epithelial	cells	in	culture	following	
dispase/DNase/trypsin/collagenase	digestion	and	fluorescence-activated	cell	sorting	
	
A)		Haematoxylin	and	eosin	(H&E)	staining	of	fluorescence-activated	cell-sorted	murine	basal	cells	grown	in	a	3D	
tracheosphere	assay,	showing	evidence	of	differentiation	and	cilia	formation	(arrows).		Scale	bars	=	100	μm	and	20	
μm.		B)	Immunofluorescence	staining	of	mucosecretory	(MUC5B;	red;	left)	and	ciliated	(ACT;	green;	right)	cells	in	3D	
tracheospheres.		Scale	bars	=	100	μm.		C)	Brightfield	microscopy	shows	a	colony	of	murine	epithelial	cells	expanded	
on	a	3T3-J2	feeder	layer.	Scale	bar	=	100	μm.		D)	Immunofluorescence	staining	of	cytospun	cultured	murine	epithelial	
cells	following	differential	trypsinisation	to	remove	3T3-J2	cells,	cultured	epithelial	cells	are	keratin	5-positive	(KRT5;	
red)	basal	cells.	Scale	bar	=	100	μm.	E)		H&E	staining	of	passaged	murine	basal	cells	grown	in	a	3D	tracheosphere	
assay.	Scale	bar	=	100	μm.	F)	Immunofluorescence	staining	of	mucosecretory	(MUC5B;	red;	left)	and	ciliated	(ACT;	
green;	right)	cells	in	3D	tracheospheres	generated	from	passage	5	cultured	murine	basal	cells.	DAPI	used	as	
counterstain.		Scale	bars	=	100	μm.		
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As	the	sorted	epithelial	cells	readily	formed	colonies,	I	assessed	whether	murine	
epithelial	cells	could	be	serially	passaged	and	whether	they	could	retain	their	
differentiation	capacity	following	culture	on	mitomycin	C-inactivated	3T3-J2	feeder	
layers.		I	performed	initial	experiments	using	FACS-sorted	epithelial	cells	and,	
although	I	found	that	these	formed	small	colonies	(as	in	the	colony-forming	assays),	
they	then	failed	to	develop	into	confluent	monolayers.		As	the	cell	number	following	
FACS	sorting	was	low,	to	assess	whether	it	was	possible	to	culture	mouse	basal	cells	
in	vivo,	I	increased	the	seeding	density	by	using	pronase-digested	epithelial	cells	and	
plated	these	directly,	without	cell	sorting,	onto	3T3-J2	feeder	layers.	Colonies	
appeared	after	a	few	days	and	differential	trypsinisation	(171)	allowed	the	epithelial	
cells	to	be	separated	from	the	supporting	3T3-J2	feeder	cells.		The	basal	cell	
phenotype	of	the	growing	colonies	was	confirmed	by	the	expression	of	KRT5	on	cell	
cytospin	(Figure	3.9.D).		Cells	were	passaged	at	a	1:5	ratio	and,	at	passage	5,	were	
used	in	tracheosphere	assays.		Mucociliary	differentiation	of	these	tracheospheres	
was	confirmed	through	the	expression	of	MUC5B	and	ACT	(Figures	3.9.E	and	3.9.F).		
	
3.3.12	 Assessment	of	LRIG1	expression	in	airway	epithelial	cells	
	
Having	optimised	a	strategy	for	the	isolation	of	airway	basal	cells,	the	expression	of	
eGFP	as	a	reporter	for	LRIG1	in	this	population	could	also	be	established.		eGFP-	
positive	epithelial	cells	were	seen	on	a	cytospin	following	pronase	digestion	(Figure	
3.10.A)	and	flow	cytometry	confirmed	that	LRIG1	(through	the	constitutive	presence	
of	eGFP)	could	be	identified	in	the	basal	cell	population	(Figure	3.10.B).		Of	note,	as	
eGFP	is	not	an	extracellular	marker,	and	is	resistant	to	trypsin	and	pronase	(199),	
there	was	no	effect	of	enzymatic	digestion	on	its	expression.		The	proportion	of	
eGFP+	cells	seen	by	flow	cytometry	mirrored	that	seen	by	immunofluorescence	
(Figure	3.5).			
	
Although	eGFP+	basal	cells	were	detectable	in	LRIG1-heterozygous	mice	using	flow	
cytometry,	a	significant	percentage	of	these	were	eGFP-,	and	hence	LRIG1-negative,	
with	LRIG1-expressing	basal	cells	making	up	only	50%	of	the	total	basal	cell	
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population	(Figure	3.10.C).		This	was	also	the	case	in	LRIG1-null	animals,	where	
eGFP+	(cells	where	the	Lrig1	promoter	is	active,	although	with	no	active	LRIG1	
expression)	and	eGFP-	populations	were	detectable.	
	
Using	immunofluorescence,	LRIG1	was	identified	in	other	epithelial	cell	populations:	
in	both	secretory	and	ciliated	cells.		To	confirm	this	finding	by	flow	cytometry,	the	
eGFP+	epithelial	population	was	identified	and	the	component	cell	types	analysed.		
Of	the	eGFP+	cells,	basal	cells	constitute	20%,	CD24-positive	(ciliated	cells)	make	up	
50%	and	there	is	a	smaller,	SSEA1-positive	(secretory	cell)	population	(Figures	3.10.D	
and	3.10.E).	
	
The	highest	expression	of	LRIG1	may	be	expected	in	the	cells	that	are	the	most	‘stem	
like’.		In	the	skin,	LRIG1	is	expressed	across	all	epithelial	cell	populations,	but	is	at	the	
highest	concentration	in	the	cells	that	express	other	stem	cell	markers	(90).		To	
identify	whether	LRIG1	expression	was	highest	in	basal	cells,	only	the	most	eGFP+	
cells	were	analysed	(Figure	3.10.F).		If	LRIG1	was	most	concentrated	in	the	basal	
cells,	when	taking	the	top	25%	of	eGFP+	cells	there	would	be	an	enrichment	of	basal	
cells.		However,	the	proportion	of	eGFP+	cell	types	did	not	change	across	any	of	the	
groups,	including	in	the	basal	cells.		This	indicates	that	the	level	of	eGFP	expression	
(and	by	inference	the	LRIG1	expression)	is	similar	across	all	epithelial	populations.	
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Figure	3.10:		Identification	of	LRIG1	expression	in	epithelial	populations	by	flow	cytometry	
	
A)	Immunofluorescence	for	eGFP	(green)	in	a	cytospun	sample	following	pronase	digestion	of	the	tracheal	
epithelium.		DAPI	used	as	counterstain.		Scale	bar	=	50	μm.		B)	Flow	cytometry	plots	showing	the	identification	of	a	
CD31-CD45-DAPI-	population	(shown	in	red;	left	plot),	an	EpCAM+GS-IB4+	population	(shown	in	red;	middle	plot)	and	
an	eGFP-positive	and	-negative	population	(left	plot).		The	red	boxes	indicate	the	population	taken	forwards	for	
analysis.	n=	5.		C)	The	proportion	of	LRIG1-positive	and	-negative	basal	cells	obtained	from	the	tracheal	epithelium.		
D)	Flow	cytometry	plots	showing	the	identification	of	a	CD31-CD45-DAPI-	population,	followed	by	selection	of	an	
EpCAM+eGFP+	population	and	the	identification	of	the	proportion	of	GS-IB4	basal	cells.		Then,	in	the	GS-IB4-	
population,	the	proportion	of	GFP-positive	ciliated	cells	(CD24-positive)	and	secretory	cells	(SSEA1-positive),	n	=	5.		
Antibodies	were	used	in	the	following	colours:	CD31-	and	CD45-	PE,	GS-IB4-	qdot	605,	EpCAM-APC,	SSEA1-PerCP	
efluor700	and	CD24-PECy7.		E)	Percentage	of	each	type	of	epithelial	cell	in	the	tracheal	epithelium	that	is	eGFP-
positive.		Mean	±	SEM.		F)	When	the	most	eGFP	positive	epithelial	cells	are	selected,	there	is	no	enrichment	in	the	
proportion	of	either	basal,	ciliated	or	secretory	cells.		
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3.3.13	 Lineage	tracing	from	LRIG1-expressing	basal	cells	
	
To	assess	whether	LRIG1	labels	a	stem	cell	population	in	the	respiratory	epithelium,	
a	lineage-tracing	model	was	also	used.		Lineage	tracing	allows	cell	fate	determination	
and	was	performed	by	crossing	Lrig1	EGFP-ires-CreERT2	mice	with	Rosa26	tdtomato	
reporter	mice	(Figure	3.11.A).		In	brief,	when	4-hydroxytamoxifen	(4OH-tamoxifen)	is	
given	it	activates	a	Cre-lox	system	causing	release	of	a	Cre	recombinase	protein	from	
the	CreERT2	4OH-tamoxifen-responsive	element.		The	Cre	recombinase	then	
catalyses	the	removal	of	a	stop	codon	placed	between	the	Rosa26	gene	and	an	
inserted	transgene,	in	this	case,	the	red	fluorescent	protein,	tdtomato.		Rosa26	is	
ubiquitously	expressed	(200)	meaning	activation	of	tdtomato	is	possible	in	all	cells	
where	Cre	is	present.		When	the	Lrig1	promoter	is	active	the	cell	will	express	eGFP	
and	following	the	administration	of	4OH-tamoxifen	the	cell	will	also	express	
tdtomato.		The	removal	of	the	stop	codon	is	a	permanent	change,	so	all	daughter	
cells,	arising	from	the	LRIG1-expressing	parent	cell,	will	express	tdtomato,	
irrespective	of	whether	the	Lrig1	promoter	is	active	or	whether	eGFP	is	being	
expressed.			
	
To	set	up	in	vivo	lineage	tracing,	I	first	established	the	appropriate	4OH-tamoxifen	
dose	to	use.		In	the	skin,	Cre-lox	activation	occurs	following	the	administration	of	0.1	
mg	4OH-tamoxifen	(91).		However,	the	tracheal	epithelial	turnover	is	lower	
compared	to	the	skin,	so	doses	of	1,	0.1	and	0.01	mg	4OH-tamoxifen	were	trialled.		1	
mg	of	4OH-tamoxifen	successfully	activated	the	transgene	and,	after	two	weeks,	
there	was	clear	expression	of	tdtomato	in	tracheal	cells	adjacent	to	the	basement	
membrane	(Figure	3.11.B).		Gut	samples	were	taken	as	a	positive	control	and	here,	
due	to	the	higher	epithelial	turnover,	clear	crypt	labelling	was	identified	(Figure	
3.11.B).			
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Figure	3.11:		In	vivo	lineage	tracing			
	
A)		The	action	of	the	tdtomato	reporter	gene.		When	the	Lrig1	promoter	is	active	eGFP	is	expressed	from	the	
cell.		On	administration	of	4OH	tamoxifen	the	stop	codon	is	removed	from	the	reporter	gene.		If	the	cell	has	an	
active	Lrig1	promoter	and	the	stop	codon	is	removed	the	cell	will	express	eGFP	and	tdtomato.		The	removal	of	
the	stop	codon	is	permanent,	so	all	daughter	cells	will	express	the	tdtomato	protein,	irrespective	of	the	
expression	of	the	Lrig1	gene.	B)		Clear	activation	of	the	tdtomato	protein	in	the	airway	i)	and	gut	ii),	(without	
antibody	staining).		DAPI	used	as	a	counterstain.			Scale	bar	=	50	µm.		Samples	shown	are	representative	
images,	n=	3.		C)		Flow	cytometry	analysis	of	tdtomato	activation	in	the	skin,	following	increasing	
concentrations	of	4OH	tamoxifen	administration,	n=	3.		Note,	following	1	mg	of	4OH	tamoxifen	an	
eGFP+/tdtomato+	cell	population	is	seen,	in	addition	to	a	singly	labelled	tdtomato+	population,	implying	these	
are	the	daughter	cells	of	LRIG1-expressing	cells	that	are	no	longer	expressing	LRIG1	(as	not	eGFP+).		
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To	confirm	the	activation	of	tdtomato	in	association	with	eGFP,	skin	epithelial	cells	
were	analysed	by	flow	cytometry.		There	was	no	expression	of	tdtomato	(indicating	
reporter	gene	activation)	in	the	corn	oil	or	0.01	mg	4OH-tamoxifen	dosing	regimens	
after	2	weeks	and	minimal	dual	labelling	in	mice	treated	with	0.1	mg	4OH-tamoxifen	
(2%	of	cells).		However,	using	a	1	mg	dose	of	4OH-tamoxifen,	dual	labelling	with	
eGFP	and	tdtomato	was	detectable	in	13%	of	the	population	and,	notably,	12%	of	
cells	were	singly	stained	for	tdtomato.		This	suggests	the	singly	tdtomato-expressing	
cells	were	the	progeny	of	the	initially	labelled	parents	(Figure	3.11.C).	
	
Extrapolating	from	studies	in	the	skin	and	gut,	LRIG1	was	anticipated	to	be	expressed	
in	the	airway	stem	cells.		However,	I	have	shown	here	that	LRIG1	expression	is	seen	
throughout	the	respiratory	epithelium.		If	LRIG1	were	expressed	across	the	
epithelium,	lineage	tracing	may	be	futile	as	tdtomato	would	be	expressed	in	several	
populations.		This	means	the	cell	of	origin	of	the	lineage	trace	could	not	be	
determined	and	the	resultant	patches	of	lineage-traced	cells	would	be	meaningless.	
	
To	assess	the	cell	type	where	the	tdtomato	reporter	is	being	activated,	animals	were	
administered	1	mg	of	tamoxifen	and	observed	for	2	days.		At	this	point	they	were	
culled	and	their	tracheas	extracted,	paraffin-embedded	and	sectioned.		Sections	
were	stained	for	tdtomato	(to	assess	for	activation	of	the	transgene),	together	with	
KRT5	(basal	cells)	and	FOXJ1	(ciliated	cells).		Only	singly	labelled	cells	were	
detectable.		The	majority	of	tdtomato	stained	cells	were	KRT5-positive	(Figure	
3.12.A),	however,	there	were	occasional	cells	that	were	KRT5-negative	(Figure	
3.12.B,	arrowed).	When	dual	staining	was	performed	with	tdtomato	and	FOXJ1,	an	
occasional	cell	was	both	tdtomato-	and	FOXJ1-positive	(Figure	3.12.C),	suggesting	
activation	of	the	transgene	in	the	ciliated	cell	population.	This	indicates	that	the	
transgene	is	activated	in	cells	other	than	basal	cells	and	that	any	lineage-traced	
progeny	would	have	an	uncertain	origin.		
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Figure	3.12:		Activation	of	tdtomato	in	cells	other	than	the	basal	cells	
	
	A)		Immunofluorescence	staining	of	tracheal	epithelium	showing	tdtomato	(red)	and	keratin	5	expression	
(KRT5;	green).		Arrows	indicate	cells	dual	stained	for	tdtomato	and	KRT5.		B)		Not	all	tdtomato	(red)	stained	
cells	are	KRT5-positive	(green).	Single,	KRT5-negative	(green),	tdtomato-positive	(red)	epithelial	cell	are	
seen.		The	arrow	indicates	a	tdtomato	stained	cell	that	is	not	positive	for	KRT5.		C)		Immunofluorescence	
staining	of	the	tracheal	epithelium	for	forkhead	box	J1	(FOXJ1)	to	identify	ciliated	cells	(green)	and	for	
tdtomato	(red).		Tdtomato-positive,	FOXJ1-positive	epithelial	cells	are	seen	after	48	hours	of	tamoxifen	
exposure,	indicated	by	arrows,	suggesting	activation	of	the	transgene	in	cells	other	than	the	basal	cells.		
DAPI	used	as	counterstain	in	all	images.		Scale	bars	=	50	µm,	images	representative	of	n=	3.		
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3.4	 Discussion	
	
I	have	successfully	set	up	a	colony	of	Lrig1	EGFP-ires-CreERT2	mice	on	a	mixed	
FVB/N	and	C57BL/6	background,	with	the	generation	of	wild-type,	LRIG1-
heterozygous	and	LRIG1-null	animals.		The	phenotype	of	the	LRIG1-null	mice	is	mild,	
with	the	only	change	being	a	reduced	weight	at	weaning;	this	equilibrates	by	6-8	
weeks.		The	previously	seen	gut	hyperplasia	in	Lrig1	knockout	mice	(93)	is	not	seen	
in	these	C57BL/6	FVB/N	animals,	possibly	due	to	their	mixed	background.		My	results	
confirm	there	is	nil	effect	of	haploinsufficiency	of	Lrig1.	
	
The	eGFP	reporter	successfully	identifies	the	expression	of	LRIG1	and,	although	eGFP	
has	been	shown	to	degrade	over	a	period	of	24	hours	(201),	immunofluorescence	
staining	shows	a	clear	correlation	between	LRIG1	and	eGFP	expression.	As	the	
airway	epithelial	turnover	is	so	low,	and	studies	were	carried	out	in	the	absence	of	
damage	or	other	airway	insult,	any	subtle	differences	in	the	breakdown	time	of	eGFP	
and	LRIG1	are	unlikely	to	have	a	significant	impact	at	homeostasis.			
	
Based	on	the	findings	in	other	organs,	LRIG1	was	only	anticipated	to	be	expressed	by	
the	airway	basal	cells,	however,	it	is	detectable	across	all	epithelial	cell	types	in	the	
upper	airway	epithelium	by	both	immunofluorescence	and	flow	cytometry.		LRIG1	is	
further	seen	throughout	the	epithelium	of	the	distal	airway.		The	protein	does	not	
appear	concentrated	in	the	areas	of	known	stem	cell	compartments	in	either	the	
tracheal	submucosal	glands,	the	airway	branch	points	or	at	the	bronchoalveolar	duct	
junctions.		This	is	in	contrast	to	the	skin	and	gut	findings,	where	there	is	clear	
association	of	LRIG1	with	the	stem	cell	compartments	(90,	93).		As	the	break	down	of	
eGFP	is	over	a	24-hour	period	and	varies	according	to	cell	type,	it	is	possible	that	the	
slow	breakdown	of	eGFP	may	lead	to	the	persistent	marking	of	differentiated	cells	
that	no	longer	express	LRIG1,	if	they	originated	from	an	LRIG1-expressing,	eGFP+	
basal	cell.	However,	if	this	were	the	case,	the	differentiated	cell	types	would	
probably	be	less	eGFP	bright,	but	when	flow	cytometry	was	used	to	select	the	25%	
most	eGFP+	cells,	there	was	no	enrichment	of	the	basal	cell	population	and	the	
relative	proportions	of	all	cell	types	remained	static.		This	indicates	that	there	is	
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LRIG1	expression	across	epithelial	cell	types.		In	further	support	of	this,	when	an	
LRIG1	antibody	was	used	to	assess	LRIG1	expression	in	the	epithelium	there	was	
homogeneous	staining	across	all	epithelial	cells.		
	
It	is	notable	that	although	LRIG1	is	expressed	across	the	airway,	when	basal	cells	are	
considered	independently,	there	are	two	populations:	50	%	of	the	total	basal	cells	
are	LRIG1-positive,	while	50%	are	LRIG1-negative.		With	LRIG1	shown	to	mark	a	
more	‘stem	cell’-like	population	of	the	skin	and	gut,	this	poses	the	question	as	to	
whether	the	expression	of	LRIG1	in	this	basal	cell	population	confers	a	phenotype.		
Whilst	basal	cells	were	previously	considered	a	homogeneous	population,	the	
possibility	of	basal	cell	heterogeneity	has	been	raised.		One	study	used	clonal	
dynamics	to	show	that	basal	stem	cells	give	rise	to	a	‘basal	luminal	precursor’	prior	
to	their	differentiation	into	other	cell	types	(202).		This	basal	luminal	precursor,	
although	expressing	basal	cell	markers,	can	be	differentiated	from	the	basal	stem	
cell	through	expression	of	keratin	8	(202).		A	further	study	looking	at	basal	cell	
heterogeneity	has	identified	keratin	14	as	marking	a	subpopulation	of	basal	cells.		
This	population	makes	up	20%	of	the	basal	cells,	and	is	associated	with	a	unipotent	
basal	cell	population	at	homeostasis;	but	this	population	becomes	multipotent	and	
can	regenerate	the	tracheal	epithelium	on	airway	damage	(203).		Therefore,	it	is	
possible	that	the	50%	of	basal	cells	that	express	LRIG1	may	exhibit	different	
properties	to	the	LRIG1-negative	population.		As	loss	of	LRIG1	may	lead	to	
preinvasive	cancer,	the	cell	type	of	origin	needs	to	originally	express	LRIG1,	meaning	
that	there	might	be	a	change	in	phenotype	when	LRIG1	is	lost.		Therefore	the	LRIG1-	
expressing	basal	cells	are	likely	to	be	more	significant	than	LRIG1-negative	basal	cells	
in	preinvasive	lung	cancer	development.				
	
Loss	of	LRIG1	leads	to	skin	hyperproliferation	(89)	and	gut	abnormalities	(93).		It	has	
previously	been	shown	that	the	tracheal	epithelium	in	an	LRIG1-null	mouse	is	thicker	
than	that	in	an	LRIG1-heterozygous	animal	(104).		I	have	confirmed	this	finding	in	the	
Lrig1	EGFP-ires-CreERT2	animals.		However,	in	contrast	to	this	data,	there	was	not	a	
noticeable	increase	in	the	number	of	proliferative	cells,	suggesting	that	the	rate	of	
epithelial	turnover	did	not	explain	this	difference.		I	did,	however,	notice	an	
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increased	number	of	KRT5-positive	basal	cells	in	the	LRIG1-null	mice	and,	although	
not	significant,	it	suggests	that	there	may	be	an	increase	in	the	airway’s	basal	stem	
cell	pool.		This	may	indicate	that	LRIG1	is	behaving	in	the	airway	in	a	similar	manner	
to	its	role	in	the	skin	and	gut,	where	it	has	a	regulatory	role	in	these	stem	cell	
compartments.		An	expansion	of	the	KRT5-positive	cells	in	the	LRIG1-null	mice	may	
suggest	that	LRIG1	loss	leads	to	increased	basal	cell	numbers	in	the	airway.		To	
confirm	these	findings,	increased	numbers	of	animals	would	need	to	be	examined.		
To	confirm	whether	LRIG1	regulates	the	basal	cell	compartment	of	the	airway,	in	
addition	to	the	number	of	proliferative	epithelial	cells,	the	proliferation	of	the	basal	
cells	could	be	specifically	determined.		Whilst	the	number	of	mice	used	here	were	
similar	to	the	numbers	used	by	Lu	et	al	(104),	there	may	be	some	strain-to-strain	
variability	in	the	effects	of	LRIG1	loss	and	an	increase	in	the	sample	size	would	
increase	the	power	of	these	preliminary	findings.	Strain-to-strain	variability	may	also	
explain	the	differences	in	the	phospho-EGFR	staining	shown	here	to	that	of	Lu	et	al.		
In	contrast	to	their	findings,	I	detected	no	differences	in	the	staining	between	the	
LRIG1-heterozygous	and	LRIG1-null	animals,	there	was	however,	an	increased	
intensity	of	staining	for	EGFR	in	the	LRIG1-null	tracheas.		To	conclusively	show	that	
loss	of	LRIG1	exerts	its	effects	through	loss	of	its	inhibitory	action	on	EGFR	signalling	
in	the	airway	epithelium,	a	larger	number	of	animals	could	be	examined	and	stained	
for	other	downstream	protein	such	as	extracellular	signal–regulated	kinases	
(ERK)	and	phospho-ERK,	which	I	have	shown	is	upregulated	in	the	human	epithelium	
upon	LRIG1	shRNA	knockdown	(Chapter	5).		Using	the	murine	epithelial	cell	culture	
techniques	documented	above	I	may	also	be	able	to	culture	sufficient	cells	from	
LRIG1-null	and	LRIG1-heterozygous	animals	to	allow	Western	blotting	for	both	EGFR	
and	ERK.			
	
A	key	advantage	in	the	use	of	Lrig1	EGFP-ires-CreERT2	mice	is	the	ability	to	perform	
lineage	tracing	and	to	establish	the	role	of	LRIG1	in	marking	the	stem	cell	
compartment.		I	intended	to	use	lineage	tracing	in	a	squamous	lung	carcinogenesis	
model	to	identify	whether	preinvasive	and	invasive	squamous	cell	lung	cancer	
lesions	originate	from	an	LRIG1-expressing	basal	cell.		Thus,	the	role	of	LRIG1	in	
regulating	a	potential	cancer	stem	cell	of	origin	could	be	considered	in	wild-type,	
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LRIG1-heterozygous	and	LRIG1-null	mice.		Initially,	the	basal	cells	were	the	only	
airway	cell	population	that	I	expected	to	be	marked,	however,	as	I	have	identified	by	
both	immunofluorescence	and	flow	cytometry,	LRIG1	is	expressed	throughout	the	
airway	epithelium	and	does	not	appear	to	be	concentrated	in	the	basal	cell	
population.		Therefore	the	origin	of	a	clone	would	not	be	clear	and	the	information	
obtained	by	lineage	tracing	would	be	of	limited	use	in	the	assessment	of	a	cancer	
cell	of	origin.		Whilst	it	is	possible	that	the	48-	hour	post	4OH-tamoxifen	time	point	is	
not	short	enough	to	exclude	the	differentiation	of	an	LRIG1-expressing	basal	cell	to	a	
labelled	ciliated	cell,	this	is	unlikely	as	only	single	cells	were	seen	and	the	tracheal	
epithelial	turnover	at	homeostasis	is	extremely	low.		In	further	support	of	this	
finding,	when	KRT5-expressing	basal	cells	are	labelled	with	an	eGFP	reporter,	
labelled	secretory	cells	and	ciliated	cells	were	not	seen	until	3-6	weeks	and	then	they	
were	rare	(202).			
	
Although	lineage	tracing	may	not	clearly	delineate	the	fate	of	an	LRIG1-expressing	
cell,	by	comparing	the	clone	sizes	derived	from	LRIG1-heterozygous	and	LRIG1-null	
mice,	an	indication	of	the	role	of	LRIG1	in	airway	epithelial	regulation	may	be	
obtained.		As	LRIG1	is	anticipated	to	regulate	the	stem	cell	compartments,	clones	
from	cells	lacking	LRIG1	may	be	larger	than	those	from	LRIG1-heterozygous	animals.		
The	growth	dynamics	of	a	clone	from	an	LRIG1-null	mouse	compared	to	a	
heterozygous	mouse	may	differ	similarly	to	when	larger	clonal	patches	are	seen	in	
human	smokers	compared	to	non-smokers	in	airway	dynamic	studies	(135)	and	
when	loss	of	Notch	leads	to	a	clonal	advantage	within	the	oesophageal	epithelium	
(204).		The	activation	of	the	reporter	gene	in	cells	other	than	basal	cells	would	have	
less	of	an	impact	in	these	experiments.		The	lineage	tracing	experiments	were	
initially	abandoned,	as	they	were	unable	to	answer	whether	preinvasive	lung	cancers	
developed	from	LRIG1-expressing	basal	cells.		However,	it	may	be	useful	to	revisit	
these	experiments	compare	the	size	of	epithelial	clones	from	LRIG1-heterozygous	
and	LRIG1-null	mice,	both	at	homeostasis	and	following	injury	to	determine	the	
effect	of	LRIG1	loss	on	clonal	behaviour.	
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The	difficulties	encountered	with	pronase	digestion	of	the	trachea	have	been	
addressed	through	the	optimisation	of	a	method	involving	
dispase/DNase/trypsin/collagenase	digestion	steps.		The	problems	encountered	with	
pronase	digestion	highlight	wider	issues	when	analysing	cell	populations	obtained	
through	tissue	digestion.		The	choice	of	enzyme	affects	the	cell	population	that	is	
collected	and	should	influence	the	choice	of	markers	used	to	obtain	this	population.		
For	digestion	of	the	airway,	the	choice	of	enzyme	used	has	previously	been	shown	to	
affect	the	population	of	epithelial	cells	obtained	when	TROP2-positive	epithelial	cells	
were	isolated	from	the	mouse	trachea.		TROP2	(found	in	the	highest	concentrations	
in	the	upper	murine	airway)	is	extremely	sensitive	to	trypsin,	but	much	more	
resistant	to	pronase	digestion.		To	account	for	this,	when	these	cells	are	isolated	the	
upper	third	of	the	trachea	is	separated	from	the	lower	part	and	each	section	
digested	differently	(167).			
	
The	addition	of	the	collagenase	step	to	the	reported	dispase/DNase/trypsin	strategy	
is	of	importance	and	greatly	increased	the	basal	cell	yield.		The	basal	cells	located	
within	the	submucosal	glands	may	have	different	characteristics	to	those	lining	the	
tracheal	surface	(205)	and	LRIG1	expression	has	clearly	been	seen	in	these	areas.		It	
is	vital	that	these	remaining	basal	cells	are	considered	in	any	subsequent	
comparisons.		
	
To	fully	assess	the	characteristics	of	isolated	basal	epithelial	cells	it	is	necessary	to	
use	them	in	downstream	assays	and	to	be	able	to	grow	them	in	cell	culture.		I	have	
shown	that	this	is	possible	through	the	use	of	3T3-J2	mouse	embryonic	fibroblast	co-
culture.		The	isolated	basal	cells	can	then	be	used	in	tracheosphere	assays	where	
they	show	evidence	of	mucociliary	differentiation.		Until	recently,	the	differentiation	
capacity	of	cultured	murine	epithelial	cells	had	not	been	reported.		A	recent	method	
(206)	describes	replacing	the	growth	of	murine	epithelial	cells	on	mitotically	
inactivated	J2-3T3	feeder	layers,	as	used	here,	with	pharmacological	inhibition	of	the	
SMAD	and	Rho-associated	protein	kinase	(ROCK)	signalling	pathways	and	the	growth	
of	cells	on	a	laminin	matrix.				Growing	cells	on	either	J2-3T3	feeder	layers	or	the	
pharmacological	inhibition	of	the	SMAD	and	ROCK	pathways	using	a	laminin	matrix	
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will	enable	the	number	of	basal	cells	obtained	from	a	single	mouse	to	be	increased	
through	in	vitro	expansion.		This	may	ultimately	reduce	the	number	of	animals	
required	for	experiments	and	improve	animal	welfare	issues,	in	accordance	with	the	
‘3	R’s’	(207).		The	successful	culture	of	mouse	basal	cells	allows	the	properties	of	
LRIG1-expressing	cells	to	be	explored	further.		The	identification	of	a	method	to	
isolate	and	culture	these	basal	cells	in	both	2D	and	3D	assays	will	allow	comparison	
of	the	effect	of	LRIG1	on	murine	basal	cell	behaviour.	
	
3.5	 Summary	
	
• LRIG1-wild-type,	-heterozygous	and	-null	mice	can	be	generated	from	the	
Lrig1	EGFP-ires-CreERT2	colony.	
• The	eGFP	reporter	co-localises	with	LRIG1	expression.	
• LRIG1	expression	is	seen	throughout	the	tracheal	epithelial	populations.		It	is	
also	seen	within	the	distal	bronchioles.	
• Only	50%	of	airway	basal	cells	express	LRIG1.			
• Due	to	the	expression	of	LRIG1	across	the	epithelial	populations,	lineage	
tracing	cannot	be	used	to	assess	the	stem	cell	potential	of	LRIG1-expressing	
basal	cells.	
• A	viable,	pure	population	of	basal	cells	can	be	isolated	from	the	tracheal	
epithelium.		These	cells	can	be	used	in	2D	and	3D	assays.	
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4.	 Analysing	the	effects	of	LRIG1	
expression	on	the	properties	of	
murine	basal	cells		
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4.	 Analysing	the	effects	of	LRIG1	expression	on	the	
	 properties	of	murine	basal	cells	
	
4.1	 Background	
	
Despite	expression	patterns	in	the	skin	and	gut	suggesting	that	LRIG1	localises	in	the	
highest	concentrations	to	the	stem	cell	compartments	(90,	91,	93),	I	have	shown	that	
in	the	airway	LRIG1	expression	is	seen	across	the	ciliated,	secretory	and	basal	
epithelial	cells.		However,	following	analysis	of	the	airway	basal	cell	population,	
LRIG1	is	detectable	in	only	half	of	these	cells.		Until	recently	the	airway	basal	cell	
population	was	considered	as	a	homogeneous	group.		However,	Ghosh	et	al	have	
shown	that	20%	of	the	keratin	5	(KRT5)	basal	cell	population	co-express	KRT14	(203);	
these	KRT5/KRT14	expressing	cells	unipotent	in	the	steady	state,	but	that	become	
multipotent	after	injury.		In	addition,	Watson	et	al	(202)	have	identified	keratin	8	
(KRT8)	as	marking	50%	of	basal	cells,	with	these	cells	exhibiting	a	more	differentiated	
phenotype.	It	is	therefore	possible	that	the	LRIG1-expressing	basal	epithelial	cells	
have	distinct	properties	compared	to	LRIG1-negative	basal	cells.	To	understand	the	
role	of	LRIG1	in	airway	epithelial	cell	homeostasis,	the	differences	between	LRIG1+	
and	LRIG1-	basal	cells	need	to	be	explored,	and	this	necessitates	airway	basal	cell	
isolation	(Figure	4.1).		
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The	airway	basal	cells	are	the	putative	origin	of	squamous	cell	lung	cancer	and	LRIG1	
is	lost	in	the	development	of	preinvasive	lesions	(104).		Therefore,	to	understand	
how	the	loss	of	LRIG1	influences	basal	cell	behaviour	and	how	this	loss	may	lead	to	
preinvasive	lung	cancer,	LRIG1+	cells	from	LRIG1-heterozygous	mice	were	isolated	
and	compared	to	the	eGFP+	basal	cells	isolated	from	LRIG1-null	mice	(Figure	4.2).	
	
Figure	4.1.		LRIG1+	epithelial	cells	were	compared	to	LRIG1-	from	an	LRIG1-	
heterozygous	mouse	
Figure	4.2.		LRIG1+	epithelial	cells	from	an	LRIG1-heterozygous	mouse	were	
compared	to	eGFP+	epithelial	cells	(in	which	LRIG1	expression	has	been	lost)	from	
an	LRIG1-null	mouse.		
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Initially	the	behaviour	of	these	basal	cell	populations	was	investigated	using	cell	
culture	techniques.		Then,	to	understand	how	the	loss	of	LRIG1	leads	to	preinvasive	
disease,	the	gene	expression	profiles	of	each	population	was	determined.		The	aim	
of	these	experiments	was	to	create	a	list	of	candidate	targets	that	could	be	explored	
in	more	detail,	potentially	identifying	therapeutic	candidates	and	leading	to	the	
identification	of	molecules	and	inhibitors	that	are	able	to	reverse	the	effects	of	
LRIG1	loss.		
	
4.2	 Aims	
	
• To	assess	whether	LRIG1+	basal	cells	behave	differently	to	LRIG1-	(both	cell	
types	from	an	LRIG1-heterozygous	mouse)	and	whether	LRIG1	expression	
confers	a	more	stem	cell-like	phenotype		
• To	assess	whether	the	absence	of	LRIG1	(in	eGFP+	basal	cells	from	an	LRIG1-
null	mouse)	alters	cell	behaviour	
• To	assess	the	difference	in	gene	expression	between	LRIG1+	and	LRIG1-	basal	
cells	(from	a	heterozygous	mouse)	
• To	assess	the	difference	in	gene	expression	between	LRIG1+	cells	(from	an	
LRIG1-heterozygous	mouse)	and	eGFP+	cells	(from	an	LRIG1-null	mouse),	to	
understand	the	changes	that	occur	in	preinvasive	lung	cancer	
	
4.3	 Results	
	
4.3.1	 The	effect	of	LRIG1	expression	on	the	proliferation	of	airway	basal	cells	
	
Cells	expressing	LRIG1	within	the	murine	gut	and	skin	are	more	proliferative	than	
LRIG1-negative	cells	(91,	93).		This	appears	counterintuitive,	due	to	LRIG1	being	a	
negative	inhibitor	of	EGFR	signalling,	but	it	is	possible	that	LRIG1	moderates	the	
amplitude	of	EGFR	signalling,	therefore	is	seen	at	higher	levels	in	more	proliferative	
cells.		
	
	 126	
To	assess	whether	LRIG1	marks	more	proliferative	basal	cells	in	the	airway,	cells	
were	isolated	from	murine	tracheas.		Initially	basal	cells	were	isolated	from	LRIG1-	
heterozygous	mice	and	the	cell	cycle	distribution	of	LRIG1+	and	LRIG1-	cells	(based	on	
eGFP	expression)	compared	using	Hoescht	33342	uptake	(Figure	4.3.A).		LRIG1+	basal	
cells	were	found	to	be	significantly	more	proliferative	than	LRIG1-	basal	cells,	with	a	
greater	proportion	of	cells	in	the	G2/M	phase	of	the	cell	cycle	(p=0.0011)	(Figure	
4.3.B).			
	
To	assess	whether	LRIG1	loss	influences	cell	proliferation,	eGFP+	cells	from	LRIG1-
null	mice	(with	no	LRIG1	expression,	but	an	active	LRIG1	promoter)	were	compared	
to	the	LRIG1+	basal	cells	from	an	LRIG1-heterozygous	mouse.		This	comparison	
revealed	no	differences	in	proliferation	(Figure	4.3.C).			
	
The	eGFP+	LRIG1-null	basal	cells	were	then	compared	to	the	eGFP-	LRIG1-null	basal	
cells	from	the	LRIG1-null	mouse	and	were	found	to	be	significantly	more	
proliferative	(Figure	4.3.D).		
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Figure	4.3:		Proliferation	of	airway	basal	cells			
	
A)		Example	of	Hoescht	33342	staining	in	airway	basal	cells	from	LRIG1-heterozygous	mice.		CD31/CD45/Dead	
cells	were	negatively	selected	for,	followed	by	the	plotting	of	Hoescht	33342	area	against	width	which	was	
used	to	exclude	doublets	and	then	the	plotting	of	FSC	against	SSC	to	eliminate	cell	debris.		GS-IB4+	and	EpCAM+	
indicate	the	basal	cell	population,	whilst	eGFP	is	used	as	a	marker	of	LRIG1	expression.		eGFP-positive	and	-
negative	populations	are	gated	and	cell	proliferation	determined	by	analysis	of	the	peaks	Hoescht	33342	
uptake.		Cells	in	the	G2/M	phase	are	indicated	in	the	second	peak	of	the	Hoescht	33342/cell	count	flow	
cytometry	plot.		The	red	gates	indicate	the	population	taken	forward	for	analysis.		Antibodies	were	used	in	the	
following	colours;	CD31	and	CD45-	APC,	Live/Dead-PI,	GS-IB4+-qdot605	and	EpCAM-BV711.		B)		Proliferation	of	
LRIG1+	compared	to	LRIG1-	basal	cells	from	LRIG1-heterozygous	mice,	showing	the	proportion	of	cells	in	the	
G2/M	phase	of	the	cell	cycle.		Mean	±	SEM.		Statistical	analysis	performed	using	the	paired	t	test,	**	indicates	p	
<	0.005,	n	=	6.		C)		Proliferation	of	LRIG1+	basal	cells	(from	LRIG1-heterozygous	mice)	compared	to	eGFP+	basal	
cells	from	LRIG1-null	mice.		Mean	±		SEM.		Statistical	analysis	was	performed	by	the	unpaired	t	test,	p	=	0.3685,	
n	=	6.		D)		Proliferation	of	eGFP+	basal	cells	compared	to	eGFP-	basal	cells	from	LRIG1-null	mice.		Mean	±	SEM.		
Statistical	analysis	performed	by	the	paired	t-test,	*	indicates	p	<	0.05,	n	=	6.		
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4.3.2	 The	effect	of	LRIG1	on	the	stem	cell	behaviour	of	airway	basal	cells	
	
4.3.2.1	Spheroid-forming	assays	
	
To	compare	the	stem	cell	potential	of	the	LRIG1+	and	LRIG1-	basal	cells	from	LRIG1-
heterozygous	mice,	fluorescent	activated	cell	sorted	(FACS)	basal	cells	were	seeded	
into	a	spheroid-forming	assays	(Figure	4.4.A).		LRIG1+	basal	cells	were	seen	to	form	
significantly	more	spheroids	than	LRIG1-	basal	cells	(with	p	=	0.0020)	(Figure	4.4.B).				
	
To	assess	the	effect	of	LRIG1	loss	on	spheroid-forming	ability,	eGFP+	LRIG1-null	basal	
cells	were	also	seeded	into	spheroid-forming	assays	and	compared	to	LRIG1+	basal	
cells	from	LRIG1-heterozygous	mice.		No	significant	difference	in	the	spheroid-
forming	efficiency	was	detectable	between	the	two	populations	(Figure	4.4.C).	
	
Although	comparable	spheroid-forming	efficiencies	were	seen	in	LRIG1+	cells	from	
LRIG1-heterozygous	mice	and	the	eGFP+,	LRIG1-null	basal	cells	to	those	reported	in	
the	literature	(208,	209),	at	high	seeding	densities	spheroids	form	from	epithelial	
cells	that	pool	together,	rather	than	from	a	single	cell	of	origin	(210).		Due	to	the	
potential	of	spheroids	to	form	from	pooled	epithelial	cells,	colony-forming	assays	
were	performed	to	further	investigate	the	‘stem	cell’	potential	of	these	populations	
of	cells.			
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Figure	4.4:		Formation	of	spheroids	from	airway	basal	cells	
	
A)		Example	of	growth	of	spheroids	from	airway	basal	cells	in	Matrigel	following	flow	cytometry	
sorting	into	LRIG1+	and	LRIG1-		populations	from	LRIG1-heterozygous	mice.		Note	the	increased	
spheroid	numbers	from	LRIG1+	cells.		B)		Comparison	of	spheroid-forming	efficiency	between	LRIG1+	
and	LRIG1-	basal	cells	from	LRIG1-heterozygous	mice.		Mean	±	SEM.		Statistical	analysis	performed	by	
the	paired	t-test,	**	indicates	p	<	0.005,	n	=	10.		C)		Comparison	of	spheroid-forming	efficiency	
between	LRIG1+	and	eGFP+	cells	from	LRIG1-null	mice.		Mean	±	SEM.		Statistical	analysis	performed	by	
the	unpaired	t-test,	p	=	0.3176,	n	=	10	in	the	LRIG1+	group	and	n	=	6	in	the	LRIG1-null	cells.	
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	4.3.2.2	 Colony-forming	assays	
	
Colony	forming	assays	assess	a	cell’s	stem	cell	potential	as	they	determine	the	ability	
of	a	population	to	self	renew	(211)	.		Sorted	epithelial	cells	were	initially	seeded	into	
6	well	plates,	where	they	were	grown	on	3T3-J2	feeder	layers	(as	optimised	in	
Chapter	3).		However,	due	to	the	low	numbers	of	LRIG1+	and	LRIG1-	basal	cells	
obtained	from	each	murine	trachea,	the	numbers	of	mice	needed	to	ensure	
replicates	could	be	performed	was	prohibitive.		To	overcome	this	problem,	I	chose	to	
use	a	single	cell	colony	forming	assay	instead.		Individual	basal	cells	were	sorted	
directly	into	each	well	of	a	96-well	plate	containing	mitotically	inactivated	3T3-J2	
feeder	cells	and	mouse	tracheal	epithelial	cell	(MTEC)	media	(169).		LRIG1+	and	
LRIG1-	basal	cells	from	LRIG1-heterozygous	animals	were	collected	as	well	as	eGFP+	
basal	cells	from	LRIG1-null	mice	(Figure	4.5.A).	
	
After	two	weeks	of	culture,	colonies	that	were	greater	than	10	cells	were	counted.		
Significantly	more	colonies	grew	from	LRIG1+	basal	cells	compared	to	the	LRIG1-	
population	in	LRIG1-heterozygous	mice	(Figure	4.5.B).		There	was	no	difference	in	
the	number	of	colonies	forming	in	LRIG1+	basal	cells	(from	LRIG1-heterozygous	
animals)	compared	to	the	eGFP+	basal	cells	from	LRIG1-null	mice	(Figure	4.5.C).		
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Figure	4.5:			Colony-forming	efficiency	in	airway	basal	cells	
	
A)		Example	of	colony-forming	assay.		Colonies	that	were	greater	than	10	cells	were	counted.		B)		
Comparison	of	colony-forming	efficiency	in	LRIG1+	and	LRIG1-	epithelial	cells	from	LRIG1-
heterozygous	animals.		Mean	±	SEM.		Statistical	analysis	performed	by	paired	t-test,	*	indicates	p	<	
0.05,	n	=	4.		C)		Comparison	of	colony-forming	efficiency	between	LRIG1+	from	LRIG1-heterozygous	
and	eGFP+	basal	cells	from	LRIG1-null	mice.		Mean	±	SEM.		Statistical	analysis	performed	by	the	
unpaired	t-test,	p	=	0.1946,	n=	4.		
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4.3.3	 Single	cell	RNA	Sequencing:		Cell	preparation	
	
To	address	my	initial	hypothesis	that	the	loss	of	LRIG1	leads	to	preinvasive	lung	
cancer,	I	first	intended	to	look	at	differential	gene	expression	between	airway	basal	
epithelial	cells	that	expressed	LRIG1	and	cells	in	which	LRIG1	had	been	lost	(in	the	
LRIG1-null	animals).		However,	after	demonstrating	that	LRIG1+	basal	cells	have	
distinct	properties	to	LRIG1-	basal	cells	from	LRIG1-heterozygous	mice	I	further	
compared	the	gene	expression	profiles	of	these	two	populations	to	gain	further	
insights	into	the	biological	differences	between	these	cell	populations.		
	
In	total	the	gene	expression	of	3	groups	was	compared	(Figure	4.6.A).		To	assess	for	
the	effects	of	loss	of	LRIG1,	group	1	(eGFP+	basal	cells	from	LRIG1-null	mice)	was	
compared	with	group	2	(LRIG1+	basal	cells	from	LRIG1-heterozygous	mice)	basal	
cells.		This	would	determine	the	gene	expression	changes	likely	to	be	occurring	in	
preinvasive	lung	cancer	and	could	lead	to	the	identification	of	potential	therapeutic	
candidates.		To	understand	the	differences	in	behaviour	that	I	found	between	LRIG1+	
and	LRIG1-	basal	cells,	group	2	(LRIG1+	basal	cells	from	LRIG1-heterozygous	mice)	
was	compared	to	group	3	(LRIG1-	basal	cells	from	LRIG1-heterozygous	mice).		
	
Initially,	I	had	planned	to	analyse	pooled	populations	of	murine	basal	cells	and	to	use	
the	extracted	RNA	for	microarray	analysis.		However,	the	recommended	total	
amount	of	RNA	for	a	microarray	is	in	the	range	of	micrograms	(212)	and,	as	a	limited	
number	of	basal	cells	could	be	obtained	from	one	trachea	(Chapter	3),	of	which	only	
50%	would	express	LRIG1,	a	large	number	of	mice	would	be	needed.		The	
experiment	would	also	need	to	be	performed	in	triplicate,	increasing	further	the	
number	of	animals	required.		Alternative	strategies	to	a	microarray	were	considered	
and	single	cell	RNA	sequencing	(sc-RNA	seq)	appeared	the	best	option.		The	
advantages	to	sc-RNA	seq	were	two	fold:	firstly,	the	technique	allows	gene	
expression	analysis	in	cell	numbers	too	low	for	conventional	microarray	purposes	(as	
the	results	from	individual	cells	can	be	pooled	to	understand	the	population	
characteristics);	secondly,	any	heterogeneity	within	the	three	groups	of	basal	cells	
could	be	determined	(213).	
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Figure	4.6:		Preparation	of	cells	for	single	cell	RNA	sequencing	
	
A)		The	division	of	cells	into	3	groups	for	single	cell	RNA	seq.		Group	1:	eGFP+,	LRIG1-null	basal	cells.		Group	2:	
LRIG1+	cells	from	LRIG1-heterozygous	mice.		Group	3:		LRIG1-	cells	from	LRIG1-heterozygous	mice.		B)		Process	
of	sample	preparation	for	single	cell	RNA	seq.		C)		Collection	of	single	cells,	cell	clumps	and	debris	within	the	
wells	of	the	C1	Fluidigm.		D)		Initial	flow	cytometry	sorting	strategy	for	single	cell	RNA	Seq.		Live,	CD31-,CD45-	
cells	are	gated,	and	FSC	against	SSC-width	selected	to	ensure	the	removal	of	cell	doublets.		Next,	FSC	against	
SSC	removes	cell	debris	and	EpCAM+	and	GS-IB4+	cells	identifies	the	basal	cell	population.		LRIG1+	and	LRIG1-	
populations	are	sorted	on	the	expression	of	eGFP.		The	red	gates	indicate	the	population	taken	forward	for	
analysis.		Antibodies	were	used	in	the	following	colours;	CD31	and	CD45-PE,	Live/dead-DAPI,	EpCAM-APC,	GS-
IB4-qdot605.		E)		Adjustments	to	the	sorting	strategy	to	ensure	a	reduced	amount	of	debris	is	collected.		The	
doublets	gate	was	tightened,	as	was	the	FSC/SSC	gate.		The	red	gates	indicate	the	population	taken	forward	for	
analysis.		Once	an	eGFP	positive	population	had	been	selected,	this	was	then	re-analysed	against	the	DAPI,	
ensuring	the	removal	of	any	dead	cells.		
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The	strategy	for	sc-RNA	seq	followed	the	flow	diagram	displayed	in	Figure	4.6.B.		To	
obtain	single	cells	for	analysis,	eGFP+	and	eGFP-	basal	cells	from	digested	murine	
tracheas	were	sorted	by	FACS,	and	the	isolated	cells	loaded	into	a	C1	Fluidigm,	a	
microfluidic	device	where	a	cDNA	library	is	prepared.		Advantages	to	the	use	of	a	C1	
Fluidigm	over	other	methods	includes	a	high	level	of	inter-sample	reproducibility	and	
a	low	volume	of	sample	preparation,	which	lowers	false	positives	and	bias	(213).		
	
Initial	attempts	revealed	a	very	low	single	cell	capture	rate	on	the	C1	Fluidigm.		
When	the	wells	were	examined	there	were	empty	wells,	cell	clumps	and	debris	
(Figure	4.6.C).		Optimisation	of	the	initial	FACS	strategy	(Figure	4.6.D)	was	performed	
and	sample	quality	improved	by	adjustment	of	the	sorting	buffer	(through	reducing	
the	serum	concentration)	and	a	tightening	of	the	flow	cytometry	gates	(Figure	4.6.E).		
This	included	the	addition	of	a	final	gate	where	the	eGFP+	population	was	examined	
against	the	live-versus-dead	stain.		This	step	dramatically	reduced	the	amount	of	
debris	in	the	sample.		The	C1	Fluidigm	steps	were	performed	in	two	different	
institutions	(due	to	the	possibility	of	technician	error).		cDNA	libraries	were	prepared	
within	the	C1	Fluidigm	plates	and	libraries	sequenced	on	the	HiSeq	2500.		The	data	
for	the	single	cell	sequencing	were	obtained	in	FASTQ	format	and	passed	to	a	
bioinformatician	for	analysis.	
	
4.3.4	 Single	cell	sequencing:	cell	quality	and	gene	checks	
	
After	the	exclusion	of	any	doublets	or	debris,	225	cells	were	considered	suitable	for	
analysis.		These	cells	were	screened	further	by	the	assessment	of	the	number	of	
genes	detected	in	each	cell	sample	(Figure	4.7.A).	The	median	number	of	genes	
detected	per	sample	was	around	4,000,	which	is	consistent	with	that	previously	
reported	for	sc-RNA	seq	experiments	(214).		Any	cell	that	expressed	less	than	2,000	
genes	was	of	poor	quality	(where	a	poor	quality	reaction	occurred	or	where	there	
was	low	RNA	sampling)	and	removed.		After	exclusion	of	27	cells	for	low	gene	
expression	levels,	199	cells	remained	(Figure	4.7.A).		
	
	 135	
An	External	RNA	Controls	Consortium	(ERCC)	spike-in	was	added	to	the	C1	Fluidigm	
reaction.		These	spike-ins	assess	the	quality	of	transcript	detection	following	
sequencing.			The	spike-ins	contain	92	transcripts,	so	any	cell	expressing	less	than	25	
transcripts	was	excluded	as	the	quality	of	the	reaction	and	sample	labelling	was	
likely	to	be	poor.		This	removed	a	further	37	samples,	leaving	154.		Of	these	154	
cells,	28	were	not	suitable	for	analysis,	as	were	dead	or	contained	debris	on	visual	
inspection	of	the	cells	in	the	C1	Fluidigm,	and	126	cells	remained	(Figure	4.7.A).	
	
Genes	that	were	detected	in	less	than	10	of	the	126	cells	were	removed	from	the	
overall	data	set	(Figure	4.7.B).		Therefore,	after	quality	assessment	checks	126	cells	
remained	and	13090	genes	were	included.		The	number	of	cells	in	each	population	is	
shown	in	Figure	4.7.C.	
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Figure	4.7:		Selection	of	cell	population	suitable	for	sc-RNA	seq	analysis	
	
A)		225	collected	single	cells	across	five	C1	Fluidigm	plates	were	reduced	to	126	cells	that	were	
suitable	for	further	analysis.		Initially,	cells	were	excluded	where	less	than	2,000	cells	were	detectable	
in	the	sample,	followed	by	the	exclusion	of	cells	where	less	than	25	ERCC	RNA	spike-ins	were	
detected.		Cells	unsuitable	following	visual	inspection	on	the	C1	Fuildigm	were	also	excluded.		B)		
Graph	showing	the	number	of	genes	detected	in	each	sample.		When	genes	were	detected	in	fewer	
than	10	cells,	these	genes	were	excluded	from	the	analysis.	The	data	analysis	was	performed	and	
graphs	drawn	by	Dr	Stephen	Henderson,	Bill	Lyons	Informatics	Centre,	UCL.			C)		Table	to	show	the	
number	of	cells	in	each	of	the	3	groups.	
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4.3.5	 Single	cell	sequencing:	Assessment	of	cell	populations	
	
In	addition	to	the	above	quality	controls,	I	wanted	to	confirm	that	the	cells	being	
analysed	were,	as	anticipated,	epithelial.		This	would	show	that	the	FACS	strategy	
was	adequate	and	confirm	that	the	correct	populations	were	being	analysed.			
Therefore,	cells	were	assessed	for	the	expression	of	the	epithelial	genes,	Krt5,	Krt8,	
Krt14,	Trp63,	Epcam,	Itgα6,	Cd151,	Tacstd2,	Egfr,	Met	and	Aqp3.		Of	the	154	cells	
suitable	for	analysis,	only	one	cell	did	not	express	any	epithelial	genes	(and	was	
excluded)	(Figure	4.8.A),	indicating	the	analysed	cells	were	epithelial.		
	
The	expression	of	the	different	epithelial	markers	was	then	determined	in	each	of	
the	three	groups.		No	significant	differences	in	expression	were	detectable	across	
any	of	the	epithelial	genes.		It	is	notable	that	levels	of	both	Krt8	and	Krt14,	each	
shown	to	mark	a	subpopulation	of	basal	cells	(202,	203),	were	comparable	between	
the	three	groups,	indicating	that	LRIG1	does	not	co-localise	with	known	markers	of	
basal	cell	heterogeneity	(Figure	4.8.B).	
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Figure	4.6:		Expression	of	specific	genes	within	the	single	cell	RNA	sequencing	population	
	
A)		Assessment	of	the	expression	of	genes	associated	with	the	airway	epithelium	in	the	154	isolated	cells	to	be	used	
in	the	sc-RNA	seq	experiments.		The	proportion	of	the	number	of	epithelial	genes	out	of	Krt5,	Krt8,	Krt14,	Trp63,	
Epcam,	Itgα6,	Cd151,	Tacstd2,	Egfr,	Met	and	Aqp3	that	each	cell	expressed.		B)		The	median	and	90th	percentile	
range	for	the	above	genes	split	between	the	three	groups.		Note	there	are	no	significant	differences	in	the	gene	
expression	of	the	groups.		In	particular,	the	expression	of	Krt8	and	Krt14	is	similar	in	all	three	groups.		C)		The	
number	of	Cre	transcripts	detectable	in	the	cell	populations	of	groups	1,	2	and	3	and	combined.		There	are	more	
Cre	transcripts	in	group	2,	although	the	majority	have	no	Cre	transcripts.		D)		Lrig1	detection	within	each	of	the	
three	populations.		The	graph	on	the	left	shows	the	proportion	of	cells	expressing	at	least	one	transcript	of	Lrig1,	
whilst	the	graph	on	the	right	shows	the	proportion	of	cells	that	are	expressing	more	than	5	transcripts	of	Lrig1.		E)		
Random	forest	plot	of	PC4	plotted	against	PC5,	showing	some	separation	of	group	3	from	groups	1	and	2.		F)		Gene	
expression	that	is	most	associated	with	group	3.		Level	of	gene	expression,	mean	±	90th	percentiles	in	each	of	the	
three	groups.		The	genes	most	associated	with	group	3	are	Col1a1,	Col1a3,	Mgp	andTpm2.				The	data	analysis	was	
performed	and	graphs	drawn	by	Dr	Stephen	Henderson,	Bill	Lyons	Informatics	Centre,	UCL.		
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Next,	to	confirm	that	flow	cytometry	was	able	to	adequately	discriminate	between	
eGFP+	and	eGFP-	cells,	the	cells	were	examined	for	the	expression	of	eGFP	
transcripts.		However,	the	eGFP	sequence	failed	to	align	to	any	transcripts,	and	eGFP	
was	undetectable	in	the	samples.		To	ensure	this	was	not	the	result	of	an	eGFP	
sequence	anomaly,	the	transcripts	were	aligned	to	the	Cre	component	of	the	LRIG1	
cassette.		Although	some	transcripts	were	seen,	these	were	detected	at	very	low	
levels,	and	most	cells	did	not	express	any	Cre	transcripts.		There	was	a	slightly	higher	
proportion	of	Cre	transcripts	in	group	2	(LRIG1+	basal	cells	from	LRIG1-heterozygous	
mice),	but	this	was	not	high	enough	to	differentiate	this	population	(Figure	4.8.C).		
As	these	results	were	unclear,	the	expression	of	Lrig1	transcripts	was	analysed	
across	the	three	groups.		Lrig1	transcripts	should	only	be	detected	in	group	2	(LRIG1+	
cells	from	LRIG1-heterozygous	mice),	but	would	still	give	an	indication	as	to	how	
successful	the	sorting	had	been	and	how	well	defined	the	populations	were.		
Unfortunately	Lrig1	transcripts	were	seen	in	all	populations	(Figure	4.8.D)	and	were	
detectable	in	as	many	as	a	third	of	cells	from	group	1	(eGFP+,	LRIG1-null	basal	cells).		
In	group	2	(LRIG1+	basal	cells	from	LRIG1-heterozygous	mice),	where	cells	should	be	
producing	Lrig1	transcripts,	only	a	third	showed	evidence	of	Lrig1	transcript	
expression,	and	in	group	3	(LRIG1-	basal	cells	from	LRIG1-heterozygous	mice),	
transcripts	were	detectable.	To	assess	if	this	was	non-specific,	the	number	of	
transcripts	of	Lrig1	required	to	confirm	positive	detection	was	increased	from	1	read	
to	greater	than	5.		Whilst	this	slightly	increased	the	number	of	cells	that	expressed	
the	transcript	in	group	2	(LRIG1+	basal	cells	from	LRIG1-heterozygous	mice),	the	
relative	proportions	of	cells	expressing	Lrig1	transcripts	did	not	change	significantly	
(Figure	4.8.D).	
	
To	assess	for	differences	in	the	groups,	principal	component	analysis	(PCA)	was	used	
to	look	for	clustering.		PCA	showed	that	group	3	(LRIG1-	basal	cells	from	LRIG1-
heterozygous	mice)	was	separated	from	the	other	two	groups	(Figure	4.8.E).		These	
were	the	cells	with	the	most	distinctive	phenotype	in	the	in	vitro	experiments	and	
showed	a	reduced	colony-	and	spheroid-forming	ability	and	a	reduced	proliferation.		
There	were	4	genes;	collagen	alpha	1	chain	(Col1a1),	collagen	alpha	3	chain	(Col3a1),	
matrix	gla	protein	(Mgp)	and	β-tropomyosin	(Tpm2)	(Figure	4.8.F)	were	found	to	be	
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most	associated	with	group	3	(LRIG1-	basal	cells	from	LRIG1-heterozygous	mice).		
Both	Col1a1	and	Col1a3	are	genes	for	secreted	proteins	for	collagen	production	and	
the	formation	of	the	extracellular	matrix	(215),	whilst	the	Mgp	gene	encodes	a	
secreted	protein	that	regulates	the	organisation	of	bone	tissue	(216),	and	Tpm2	has	
a	role	in	the	cell	cytoskeleton	and	is	involved	in	muscle	contraction	(217).		None	of	
the	genes	were	able	to	distinguish	the	population	with	certainty	on	their	own,	but	
collectively	could	identify	the	group	with	65%	accuracy,	compared	to	a	33%	accuracy	
expected	should	the	cells	have	been	completely	random.			
	
4.4	 Discussion	
	
LRIG1	marks	a	population	of	airway	basal	cells	from	LRIG1-heterozygous	mice	that	is	
more	proliferative	and	shows	an	increased	stem	cell-like	phenotype	with	increased	
spheroid-	and	colony-forming	ability.		The	increased	proliferative	capacity	of	LRIG1+	
basal	cells	is	consistent	with	that	reported	in	the	skin	and	the	gut	(91,	93).			
	
Assessment	of	the	effect	of	loss	of	LRIG1	on	basal	cell	behaviour	analysed	through	
the	use	of	eGFP+	basal	cells	from	LRIG1-null	mice	showed	there	is	no	effect	of	the	
loss	of	LRIG1	on	either	the	proliferation	or	spheroid-	or	colony-forming	capacity	of	
airway	basal	cells.		This	contrasts	with	the	findings	of	Jensen	et	al,	who	show	that,	in	
the	skin,	when	keratinocytes	are	isolated	from	an	Lrig1-knockout	mouse,	there	is	an	
increase	in	colony-forming	capacity	(90).		
	
The	lack	of	effect	of	LRIG1	loss	on	airway	basal	cells	(when	LRIG1+	and	eGFP+	cells	
from	LRIG1-null	mice	are	compared)	may	be	due	to	LRIG1	simply	marking	an	airway	
basal	cell	population,	without	having	a	regulatory	function.		Although	LRIG1	does	
have	a	clear	role	in	other	tissues,	the	effects	may	be	organ-specific.		If	the	LRIG1	
protein	were	redundant	in	the	airway,	its	loss	would	have	no	biological	impact.		The	
proliferation	of	eGFP+	LRIG1-null	basal	cells	and	eGFP-	LRIG1-null	basal	cells	(Figure	
4.3.D)	is	very	similar	to	that	of	the	proliferation	of	the	LRIG1+	and	LRIG1-	basal	cells	
from	LRIG1-heterozygous	animals	(Figure	4.3.B).		If	LRIG1	were	simply	marking	a	
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basal	cell	population,	these	findings	would	be	expected,	as	the	loss	of	the	‘marker’	
would	have	no	biological	effect,	and	a	redundancy	of	LRIG1	exists.		The	lack	of	
phenotype	in	the	LRIG1-null	eGFP+	basal	cells	may	further	be	explained	by	the	loss	of	
LRIG1	in	the	Lrig1	EGFP-ires-CreERT2	mouse	being	constitutive,	rather	than	
conditional.		In	this	mouse,	any	LRIG1	protein	expression	would	have	been	absent	
throughout	the	animal’s	life,	so	compensatory	upregulation	of	other	cellular	proteins	
may	have	occurred	(for	example	the	negative	inhibitor	of	EGFR	signalling,	MIG6	
(218)).		To	clearly	assess	the	change	in	LRIG1	expression,	an	alternative	mouse	model	
with	conditional	loss	of	LRIG1	should	be	used.		This	would	also	more	closely	mirror	
the	changes	that	are	seen	in	the	human	airway	on	the	loss	of	LRIG1	during	the	
development	of	preinvasive	disease.			
	
However,	eGFP	expression	in	LRIG1-null	animals	goes	against	LRIG1	being	redundant	
in	the	airway.			eGFP	is	expressed	on	activation	of	the	LRIG1	promoter,	therefore	if	
the	cell	was	not	trying	to	express	LRIG1,	the	promoter	would	not	be	active	
(indicative	of	a	possible	ongoing	biological	need	for	LRIG1).		It	is	also	interesting	to	
note	that	the	tracheal	epithelium	is	thicker	in	LRIG1-null	mice	compared	to	LRIG1-
heterozygous	animals	(Chapter	3),	which	is	in	line	with	the	findings	of	Lu	et	al	(104).		
As	there	is	increased	epithelial	thickness,	there	is	an	in	vivo	airway	phenotype	
caused	by	the	loss	of	LRIG1.		It	is	possible	that	this	phenotype	is	reflective	of	the	loss	
of	LRIG1	in	the	multiple	cell	types	that	constitute	the	respiratory	epithelium,	rather	
than	just	the	basal	cells	that	are	analysed	here.		
	
Although	there	are	a	number	of	limitations	to	the	sc-RNA	seq	data	(discussed	later),	
the	above	factors	may	explain	why	no	differential	gene	expression	is	seen	between	
groups	1	(eGFP+	cells	from	LRIG1-null	mice)	and	2	(LRIG1+	basal	cells	from	LRIG1-
heterozygous	mice).		If	LRIG1	is	simply	marking	the	cell	it	is	not	influencing	the	
transcripts	that	are	produced	and	no	differences	would	be	seen	between	the	two	
groups.		Alternatively,	if	there	was	an	upregulation	of	other	factors	that	compensate	
for	the	constitutive	loss	of	LRIG1	then	these	may	have	been	apparent	in	the	sc-RNA	
seq	data,	and	this	was	not	seen	in	the	data,	suggesting	that	compensation	is	not	
occurring.	
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In	general,	the	single	cell	RNA	seq	results	are	disappointing.		I	was	initially	concerned	
the	quality	of	the	data	would	be	poor	due	to	the	prolonged	sample	preparation	time	
and	the	need	to	perform	different	components	of	the	experiment	across	3	different	
institutions.		Surprisingly,	the	Bioanalyser	measurements	of	RNA	integrity	were	good	
and	the	samples	did	not	appear	to	be	unduly	affected	by	the	length	of	time	between	
the	cell	harvest	and	their	insertion	into	the	C1	Fluidigm.		
	
The	FACS	strategy	initially	appeared	successful	and	the	single	cells	appear	to	be	an	
almost	pure	epithelial	cell	population,	however,	there	was	no	alignment	of	the	eGFP	
transcript	to	cellular	gene	expression.		Possible	explanations	for	this	include	the	
stability	of	the	eGFP	mRNA,	with	degradation	possibly	occurring	prior	to	the	cDNA	
synthesis	step.		Around	7	hours	elapsed	between	the	harvesting	of	the	airway	basal	
cells	and	their	insertion	into	the	C1	Fluidigm.		The	half-life	of	eGFP	mRNA	has	been	
demonstrated	to	be	around	5	hours	(219),	therefore	detection	of	at	least	a	small	
number	eGFP	transcripts	would	still	be	expected.		The	eGFP	protein	was	also	
detectable	by	flow	cytometry	and	allowed	sorting	of	eGFP+	and	eGFP-	populations	
(using	a	fluorescence	minus	one	control	to	set	the	gates),	so	eGFP	mRNA	was	clearly	
being	produced	at	least	prior	to	cell	harvest.		I	have	previously	shown	a	clear	
correlation	between	eGFP	protein	and	LRIG1	protein	expression,	so	eGFP	should	be	
reflective	of	LRIG1	protein	production	(Chapter	3).		As	the	cells	contained	the	large	
cassette	at	the	Lrig1	locus,	instead	of	aligning	to	the	eGFP	sequence,	I	attempted	to	
align	to	the	Cre	component	of	the	cassette.			Although	some	Cre	transcripts	were	
expressed,	the	majority	(>	90%	of	cells)	in	groups	1	and	2	(where	the	insert	is	
present)	were	negative	for	Cre	transcripts,	making	this	alignment	unsuitable	too.		
This	suggests	that	either	the	Cre	transcript	is	expressed	at	very	low	levels	or	is	
unstable.	
	
It	is	concerning	that	the	level	of	Lrig1	transcript	did	not	distinguish	between	the	
three	populations.		Group	2	(LRIG1+	basal	cells	from	LRIG1-heterozygous	mice)		
should	show	the	presence	of	Lrig1	transcript	in	all	of	the	cells,	but	was	seen	in	only	a	
third,	and	group	1	(eGFP+	cells	from	LRIG1-null	mice)	showed	similar	Lrig1	transcript	
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levels	to	group	2	(LRIG1+	basal	cells	from	LRIG1-heterozygous	mice),	despite	these	
cells	not	producing	Lrig1.		Lrig1	transcripts	were	also	seen	in	group	3	(LRIG1-	basal	
cells	from	LRIG1-heterozygous	mice).		The	FACS	strategy	is	unlikely	to	be	at	fault,	as	
the	eGFP	gate	was	set	based	on	the	fluorescence	minus	one	controls	and	there	was	
a	clear	separation	of	eGFP+	and	eGFP-	cell	populations	(Figure	4.5.D).		If	the	eGFP	
were	to	degrade	during	the	prolonged	experimental	time	course,	it	would	mean	that	
there	are	LRIG1	false-negative	cells	in	group	3	(LRIG1-	basal	cells	from	LRIG1-
heterozygous	mice)	and	may	explain	the	small	number	of	cells	with	LRIG1	expression	
seen	in	this	population.		The	possibility	that	LRIG1	was	still	being	expressed	in	the	
LRIG1-null	animals	was	considered	as	a	cause	for	the	presence	of	Lrig1	transcript,	
but	immunoblotting	clearly	confirmed	no	LRIG1	protein	production	in	LRIG1-null	
mice	(Chapter	3).			The	detection	of	Lrig1	transcript	in	group	1	(eGFP+,	LRIG1-null	
basal	cells)	is	probably	due	to	the	position	of	the	EGFP-ires-CreERT2	cassette:	the	
Lrig1	EGFP-ires-CreERT2	cassette	is	situated	behind	the	start	codon	of	Lrig1,	so	
despite	there	being	no	LRIG1	protein	produced,	a	simple	frame-	shift	mutation	
would	mean	the	mRNA	is	still	present	(but	not	transcribed	due	to	the	mutation)	and	
the	transcript	is	detectable	on	sequencing.		This	would	account	for	there	being	a	
similar	number	of	transcripts	seen	in	groups	1	(eGFP+,	LRIG1-null	basal	cells)	and	2	
(LRIG1+	basal	cells	from	LRIG1-heterozygous	mice).		In	group	1	(eGFP+,	LRIG1-null	
basal	cells)	the	frame-shifted	transcript	aligns,	whilst	in	group	2	(LRIG1+	basal	cells	
from	LRIG1-heterozygous	mice)	the	‘real’	Lrig1	mRNA	aligns.		LRIG1	belongs	to	a	
family	of	three	proteins	designated	LRIG1-3	and	these	proteins	share	a	degree	of	
mRNA	transcript	similarity.		The	percentage	identity	between	Lrig1	and	Lrig2	is	
57.26%	and	between	Lrig1	and	Lrig3	is	59.72%	(220).	This	means	it	is	unlikely	that	
these	transcripts	are	being	detected	in	place	of	Lrig1.		Additionally,	Lrig2	and	Lrig3	
are	likely	to	be	expressed	at	similar	levels	across	the	three	populations,	therefore	
any	confounding	is	likely	to	be	comparable	between	the	groups.			
	
The	low	detection	of	Lrig1	transcript	(along	with	other	genes	in	the	gene	expression	
analysis)	within	group	2	(LRIG1+	basal	cells	from	LRIG1-heterozygous	mice)		may	be	
explained	by	the	stability	of	the	Lrig1	transcript	or	that	a	low	number	of	transcripts	
are	present	per	cell.		Lrig1	transcripts	are	detectable	by	sc-RNA	seq	(221),	this	has	
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been	shown	in	the	sequencing	of	gut	epithelial	cells	where	Lrig1	transcript	
expression	levels	correlate	to	those	of	Lgr5	and	Hopx,	implying	Lrig1	transcript	
stability	should	not	pose	a	problem.		A	further	consideration	is	the	length	of	the	
Lrig1	transcript.		There	are	different	methods	by	which	sc-RNA	seq	is	performed	and	
the	cDNA	is	amplified.		My	samples	underwent	the	SMART-seq	method	of	RNA	
amplification,	where	there	is	the	attachment	of	a	universal	primer	sequence	to	
either	end	of	the	transcripts	prior	to	cDNA	amplification.		This	gives	a	wide	coverage	
of	the	transcriptome,	but	is	subject	to	a	transcript	length	bias,	where	there	are	low	
read	counts	for	long	RNAs	(222).		The	Lrig1	transcript	is	4966	base	pairs	and	the	
average	mammalian	mRNA	size	is	1400	base	pairs	(223);	the	length	of	Lrig1	
transcript	may	therefore	result	in	lower	than	anticipated	Lrig1	reads.			
	
Unfortunately,	sc-RNA	seq	does	not	give	a	fully	comprehensive	view	of	the	
transcriptome.		Whilst	sc-RNA	seq	is	reflective	of	highly	expressed	genes,	during	the	
sequencing	process	the	loss	of	RNA	transcripts	may	be	as	high	as	50-60%.		These	
losses	have	been	shown	to	be	greatest	for	low	abundant	transcripts	(at	a	
concentration	of	less	than	5-10	copies/cell)	(224).		In	addition,	when	transcripts	are	
expressed	at	low	levels	(with	less	than	10	copies	per	cell)	the	sensitivity	of	sc-RNA	
seq	is	limited,	and	it	becomes	challenging	to	distinguish	between	the	‘technical	
noise’	of	the	experiment	and	any	biological	variability,	for	example,	when	cells	of	the	
same	type	are	at	different	phases	of	the	cell	cycle	leading	to	variations	in	gene	
expression	that	are	detected	in	the	sequencing.		It	then	becomes	challenging	to	
determine	a	differentially	expressed	gene	from	those	with	background	variability	
(224).			
	
4	different	genes	were	reported	as	differentially	expressed	between	groups	2	
(LRIG1+	basal	cells	from	LRIG1-heterozygous	mice)	and	3	(LRIG1-	basal	cells	from	
LRIG1-heterozygous	mice).		It	is	remarkable	that	there	are	so	few,	given	that	these	
two	populations	have	different	phenotypes.		I	was	expecting	to	see	changes	in	either	
the	proliferation	or	stem	cell	signatures,	but	three	of	the	genes	(Col1a1,	Col1a3	and	
Mgp)	encode	secretory	proteins	that	are	involved	in	the	extracellular	matrix	
formation	or	bone	production	and	the	fourth	(Tpm2)	is	found	in	the	cytoskeleton	
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(215-217).		The	significance	of	these	genes	is	uncertain,	and	due	to	the	difficulties	
that	I	have	encountered	in	the	sc-RNA	seq	process	may	not	be	of	biological	
relevance	in	distinguishing	the	three	groups.		
	
On	consideration,	sc-RNA	seq	may	not	have	been	the	most	appropriate	choice	of	
assay	when	attempting	to	distinguish	the	subtleties	between	very	similar	cell	
populations.		Single	cell	RNA	sequencing	was	used	successfully	by	Treutlein	et	al	to	
analyse	the	populations	of	the	distal	airway	(214).		The	different	cell	types	of	the	
distal	airway	were	identifiable	through	differential	gene	expression,	but	each	of	the	
cell	types	within	the	distal	airways	has	very	different	transcriptomes.		By	contrast,	
my	experiments	were	analysing	a	single	cell	type,	and	attempting	to	detect	smaller	
changes	in	a	more	homogeneous	population.		In	order	to	meaningfully	do	this	a	far	
greater	cell	number	would	be	required.		
	
A	significant	limitation	of	this	sc-RNA	seq	analysis	is	that	genes	were	only	included	in	
the	assessment	if	they	were	detectable	in	more	than	10	cells.		By	restricting	the	
analysis	to	this	extent,	the	overall	sensitivity	and	the	ability	to	detect	small	changes	
in	a	heterogeneous	population	is	reduced.		In	one	of	the	analysed	groups	there	were	
only	28	cells,	therefore	if	a	gene	is	discriminatory	for	this	population	(and	only	
expressed	in	these	cells)	it	would	need	to	be	detected	in	almost	a	third	of	cells	to	be	
considered	(and	by	the	nature	of	sc-RNA	seq	the	detection	of	transcripts	in	each	cell	
is	extremely	variable).		Treutlein	et	al	used	80	cells	in	their	analysis	and	considered	
genes	that	were	expressed	in	more	than	2	cells	(214);	this	would	have	allowed	
smaller	changes	and	fluctuations	in	the	cell	populations	to	be	identified.	
	
There	are	alternatives	to	sc-RNA	seq	and,	should	time	have	allowed,	could	have	
been	considered	in	the	analysis	of	the	airway	basal	cell	populations.		Using	qPCR,	as	
demonstrated	by	Watson	et	al	(202)	on	single,	isolated	airway	epithelial	cells	could	
be	an	alternative,	however	this	introduces	bias,	as	the	probes	used	for	the	qPCR	
need	to	be	selected	by	the	investigator	and	there	is	a	limit	to	the	number	of	
reactions	that	can	be	run	on	each	sample.		Watson	et	al	successfully	isolated	single	
epithelial	cells	by	digesting	a	murine	trachea	and	loading	these	onto	a	C1	Fluidigm	
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(202)	for	subsequent	qRT-PCR.		A	selection	of	67	genes	were	chosen	for	analysis	and,	
although	only	17	basal	cells	were	included	in	their	population	(making	it	is	difficult	to	
determine	how	representative	these	few	cells	are	of	the	entire	basal	population),	
clear	differences	in	the	gene	expression	profiles	revealed	that	KRT8	identified	an	
airway	basal	cell	subpopulation.		Jensen	et	al	isolated	single	keratinocytes	and	
amplified	cDNA	to	use	in	microarray	platforms.		In	total,	the	amplified	cDNA	from	12	
cells	was	analysed	(six	cells	from	two	populations	of	interest).			The	differences	in	
expression	levels	were	only	considered	significant	after	a	7-fold	increase	(due	to	the	
sensitivity	of	transcript	detection),	the	data	collection	was	unbiased	and	led	to	the	
identification	of	LRIG1	as	a	discriminator	between	the	stem	cell	and	transit-	
amplifying	populations	of	the	skin	(79).		The	advantages	of	this	technique	have	been	
shown	in	a	more	recent	publication	(225)	where	single	cell	expression	profiling	of	18	
cells	showed	heterogeneity	within	undifferentiated	keratinocytes	and	showed	that	
the	expression	of	delta-like	1	(Dll1)	was	associated	with	genes	associated	for	
endocytosis,	integrin-mediated	adhesion	and	receptor	tyrosine	kinase	signalling.	
	
McConnell	et	al	(208),	have	recently	published	sc-RNA	seq	data	looking	at	
heterogeneity	within	the	murine	airway	club	cell	population	according	to	the	
presence	or	absence	of	p53	expression.		They	identified	4	different	club	cell	
subpopulations,	with	the	four	clusters	containing	various	proportions	of	markers	for	
the	proximal	and	distal	airway	club	cell	subtypes.		The	relative	proportions	of	these	
populations	changed	on	the	loss	of	p53.		These	experiments	are	interesting	as	the	
methods	used	were	very	similar	to	mine,	with	both	designed	to	detect	small	
variations	within	subpopulations	of	the	airway	epithelium	(club	cells	compared	to	
basal	cells).		Both	protocols	required	enzymatic	digestion	to	release	the	epithelial	
cells,	followed	by	FACS	for	an	EpCAM+,	eGFP+	cell	population	and	then	the	use	of	the	
C1	Fluidigm	for	sample	preparation	prior	to	sequencing.		However,	in	contrast	to	my	
results,	McConnell	et	al	were	able	to	detect	distinct	patterns	and	perform	pathway	
analysis,	finding	that	loss	of	p53	influenced	cell	cycle-regulatory	genes.		Therefore	
small	differences	should	be	identifiable	within	my	sc-RNA	seq	samples.				
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In	summary,	the	conclusions	I	can	draw	from	the	sc-RNA	seq	data	are	limited.		I	have	
been	unable	to	successfully	confirm	that	the	cells	used	expressed	eGFP,	Cre	or	
indeed	LRIG1	at	the	anticipated	levels.		Whilst	there	are	potential	explanations,	this	
raised	some	concerns	about	the	validity	of	the	findings.		There	is	an	indication	that	
group	3	(LRIG1-	basal	cells	from	LRIG1-heterozygous	mice)	may	separate	from	groups	
1	(eGFP+,	LRIG1-null	basal	cells)	and	2	(LRIG1+	basal	cells	from	LRIG1-heterozygous	
mice),	but	this	is	not	a	clear,	well-defined	separation	and	this	does	not	occur	based	
on	the	expression	of	a	single	gene,	but	instead	through	small	elevations	in	the	
expression	of	a	number	of	genes.		There	are	no	clearly	differentially	expressed	genes	
between	groups	1	(eGFP+,	LRIG1-null	basal	cells)	and	2	(LRIG1+	basal	cells	from	
LRIG1-heterozygous	mice)		that	are	the	eGFP+	cells	from	LRIG1-null	mice	and	the	
LRIG1+	from	LRIG1	heterozygous	mice.		It	was	intended	that	the	differences	between	
groups	1	(eGFP+,	LRIG1-null	basal	cells)		and	2	(LRIG1+	basal	cells	from	LRIG1-
heterozygous	mice)	would	give	an	understanding	as	to	the	effects	of	loss	of	LRIG1	
and	the	development	of	preinvasive	lung	cancer.		By	looking	at	the	differences	in	the	
gene	expression	profiles	I	was	hoping	to	build	the	rest	of	the	project	on	looking	for	
therapeutic	candidates	that	may	reverse	the	changes	seen	in	preinvasive	disease.	By	
analysing	groups	2	(LRIG1+	basal	cells	from	LRIG1-heterozygous	mice)		and	3	(LRIG1-	
basal	cells	from	LRIG1-heterozygous	mice),	I	was	expecting	to	be	able	to	explain	the	
differences	in	proliferation	and	stem	cell	characteristics	of	LRIG1+	and	LRIG1-	cells	
that	I	have	demonstrated	using	cell	culture	assays.		Unfortunately,	there	are	only	
four	genes	that	appear	to	distinguish	groups	2		(LRIG1+	basal	cells	from	LRIG1-
heterozygous	mice)	and	3	(LRIG1-	basal	cells	from	LRIG1-heterozygous	mice)	and	in	
isolation	it	is	difficult	to	determine	their	biological	significance.			
	
I	have	shown	a	method	for	the	isolation	of	single	tracheal	cells	and	optimised	the	
FACS	process.		I	have	also	shown	that	despite	the	prolonged	experimental	times,	the	
RNA	quality	is	preserved.		Re-analysis	of	this	preliminary	data	set	to	include	genes	
that	are	expressed	in	more	than	two	cells	would	improve	the	sensitivity	of	my	data	
and	should	be	performed.		In	addition,	I	have	demonstrated	that	my	FACS	strategy	
gives	a	clear	epithelial	population,	so	I	could	analyse	the	sorted	cells	using	
alternative	methods	of	gene	expression	analysis.	
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4.5	 Summary	
	
• LRIG1+	basal	cells	are	more	proliferative	than	LRIG1-	basal	cells	(from	LRIG1-
heterozygous	mice).	
• LRIG1+	basal	cells	show	an	increased	spheroid-	and	colony-forming	efficiency	
compared	to	LRIG1-	cells.	
• The	loss	of	LRIG1	in	eGFP+	basal	cells	from	LRIG1-null	mice	does	not	influence	
either	cell	proliferation	or	spheroid-	or	colony-forming	efficiency.	
• sc-RNA	seq	may	not	be	sensitive	enough	to	distinguish	between	the	three	cell	
populations	(at	the	cell	numbers	used)	and	alternative	methods	to	determine	
differential	gene	expression	should	be	explored.	
	
	
	 	
	 150	
5.	 Assessment	of	LRIG1	in	the	
Human	Airway	
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5.	 Assessment	of	LRIG1	in	the	Human	Airway	
	
5.1	 Background	
	
The	loss	of	leucine	rich	repeats	and	immunoglobulin-like	domains	1	(LRIG1)	has	been	
associated	with	the	development	and	the	aggressiveness	of	a	number	of	human	
malignancies.		In	the	airway,	LRIG1	loss	is	seen	in	the	development	of	preinvasive	
squamous	cell	cancers	(104)	and	it	has	a	prognostic	impact	on	the	outcome	of	non-	
small	cell	lung	cancer	(NSCLC)	(105,	226).		Our	understanding	of	the	effects	and	role	
of	LRIG1	have	largely	been	determined	through	the	use	of	Lrig1	knockout	mouse	
models	or	in	vitro	cell	lines	derived	from	tumour	cells.		A	number	of	differences	exist	
between	the	mouse	and	human	airway,	particularly	in	relation	to	the	anatomy	and	
the	extent	of	pseudostratified	epithelium	that	contains	basal	cells-the	putative	cell	
of	origin	of	squamous	cell	carcinoma.		In	the	mouse,	the	basal	cells	are	located	
within	the	trachea,	but	in	humans	they	are	distributed	further	down	the	airway	into	
the	smaller	bronchi	(227).			
	
I	have	shown	that	in	the	mouse,	LRIG1-expressing	basal	cells	have	a	clear	phenotype.		
The	murine	LRIG1-expressing	cells	are	more	proliferative	and	exhibit	an	increase	
spheroid-forming	and	colony-forming	capacity.		By	assessing	whether	the	human	
airway	also	contains	populations	of	LRIG1+	and	LRIG1-	basal	cells	and	whether	these	
populations	have	different	phenotypes,	I	can	determine	if	the	results	I	have	shown	in	
mice	are	relevant	to	humans.			
	
After	examining	the	role	of	LRIG1	in	the	normal	human	airway,	the	effect	of	loss	of	
LRIG1	can	be	determined.		LRIG1	gene	expression	is	downregulated	in	squamous	cell	
lung	cancers	compared	to	that	of	the	normal	epithelium	(30)	and	during	the	
development	of	preinvasive	lung	cancer	lesions,	LRIG1	gene	expression	is	reduced	
(104).	By	using	LRIG1	shRNA	knock	down	in	primary	human	bronchial	epithelial	cells	
(HBECs)	obtained	from	patients,	the	changes	that	occur	when	LRIG1	is	lost	in	the	
airway	can	be	mirrored	in	an	in	vitro	system.			
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Primary	derived	HBECs	can	undergo	only	limited	passages	in	the	traditionally	used	
bronchial	epithelial	cell	growth	medium	(BEGM)	culture	conditions	before	they	
undergo	senescence	(171).		With	increasing	passage,	HBECs	show	a	reduction	in	
their	ability	to	differentiate	into	the	different	cell	types	of	the	respiratory	epithelium.		
The	use	of	3T3	+	Y	culture	conditions	(171,	228,	229),	where	HBECs	are	grown	on	a	
mitotically	inactivated	3T3-J2	feeder	layer	in	the	presence	of	the	RHO-associated	
protein	kinase	inhibitor,	Y-27632,	enables	on-going	passage	and	means	that	they	are	
capable	of	ciliated	differentiation	(171).		The	use	of	Y-27632	has	been	further	shown	
to	facilitate	the	lentiviral	transduction	of	keratinocytes	(230)	and	airway	epithelial	
cells	(231).		Therefore,	by	using	3T3	+	Y	culture	conditions,	knockdown	of	LRIG1	
expression	in	primary	HBECs	can	be	achieved.	
	
5.2	 Aims	
	
• To	assess	where	LRIG1	is	expressed	in	the	human	airway	
• To	assess	whether	LRIG1+	basal	cells	have	a	different	phenotype	to	LRIG1-	
basal	cells	
• To	knockdown	LRIG1	expression	in	primary	human	airway	cells	using	shRNA	
techniques	
• To	examine	how	loss	of	LRIG1	influences	cell	behaviour	
	
5.3	 Results	
5.3.1		 Expression	of	LRIG1	within	the	human	airway	
	
To	confirm	the	presence	of	LRIG1	in	the	human	airway	(104),	sections	of	human	
bronchial	epithelium	were	analysed	by	immunofluorescence	(Figure	5.1.A).		This	
showed	clear	LRIG1	expression	in	the	basal	cells	that	are	adjacent	to	the	basement	
membrane.		Although	appearing	to	be	more	concentrated	within	the	basal	cell	
compartment,	the	expression	of	LRIG1	was	visible	within	the	other	cell	types	of	the	
epithelium.		Of	note,	and	similarly	to	in	the	mouse,	there	were	LRIG1-positive	cells	
	 153	
beneath	the	basement	membrane.		These	were	keratin	5	(KRT5)	negative,	and	likely	
to	be	fibroblasts	(Figure	5.1.A).			
	
To	establish	whether	there	was	an	LRIG1-expressing	and	LRIG1-negative	airway	basal	
cell	population,	as	in	the	mouse,	human	airway	epithelial	cells	were	examined	by	
flow	cytometry.		Human	bronchial	epithelial	cells	were	obtained	at	bronchoscopy	via	
endobronchial	brushings.		In	contrast	to	murine	airway	epithelial	cells,	where	their	
collection	had	proved	challenging	due	to	the	need	for	enzymatic	digestion,	the	
human	endobronchial	brushings	were	simply	placed	into	medium	and	vortexed	to	
release	the	brushed	cells;	this	negated	the	need	for	a	digestion	step.		The	brush	
biopsies	were	taken	from	a	normal	area	of	airway	epithelium	in	patients	undergoing	
bronchoscopy	either	for	the	initial	investigation	of	possible	airway	disease	or	as	part	
of	our	surveillance	programme	for	preinvasive	lesions.		Abnormal	areas	of	possible	
preinvasive	disease	were	excluded	using	autofluorescence	bronchoscopy	and	a	
bronchial	biopsy	was	taken	from	the	same	area.		If	the	associated	bronchial	biopsy	
showed	any	preinvasive	disease,	malignancy	or	other	abnormality,	the	samples	were	
not	included	in	subsequent	analysis.		Once	collected,	the	cells	were	stained	for	flow	
cytometry.		CD45+,	CD31+	cells	and	dead	cells	were	excluded	and	basal	cells	were	
identified	using	the	markers	integrin	α6	and	nerve	growth	factor	receptor	(NGFR)	
(130).		The	basal	cells	were	then	divided	into	LRIG1+	and	LRIG1-	populations	(Figure	
5.1.B).		
	
The	LRIG+	and	LRIG1-	populations	were	less	clearly	defined	than	in	the	mouse,	and	a	
‘shift’	in	the	population	on	LRIG1	staining	was	seen,	rather	than	two	well-defined	
populations.			To	determine	the	LRIG1+	and	LRIG1-	populations	the	flow	cytometry	
gate	was	set	using	the	‘fluorescence	minus	one’	control.		Overall,	the	proportions	of	
LRIG1+	and	LRIG1-	cells	were	similar	(50%)	in	each	donor,	however	a	large	inter-	
patient	variability	was	seen	(Figure	5.1.C).		
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Figure	5.1:		Expression	of	LRIG1	in	human	airway	basal	cells	
	
A)		Immunofluorescence	staining	of	a	fresh	frozen	section	of	human	airway	for	LRIG1	(red)	and	keratin	5	(KRT5;	
green).		Note	increase	in	LRIG1	staining	within	the	basal	cell	compartment	(dual	stained	with	KRT5).		Smaller	images	
show	LRIG1	staining	(red)	and	KRT5	staining	(green).		DAPI	used	as	a	counterstain.		Scale	bar	=	50	μm.		B)		Flow	
cytometry	to	detect	a	population	of	LRIG1+	basal	cells	within	the	human	airway	epithelium.		Red	boxes	show	
population	that	is	taken	forwards.		Initially	there	is	negative	selection	for	CD31+,	CD45+	and	live/dead	cell	
populations.		There	is	then	positive	selection	for	integrin	α6+,	NGFR+	basal	cells.		The	basal	cells	are	next	assessed	
for	LRIG1	expression.	The	final	flow	cytometry	plot	shows	the	population	of	basal	cells	in	the	‘fluorescence	minus	
one’	(FMO)	control	for	PE.		The	FMO	was	used	to	place	the	gate	for	the	LRIG1+	and	LRIG1-	populations.	Antibodies	
were	used	in	the	following	colours:	CD31-	and	CD45-BV421,	Live/dead-DAPI,	integrin	α6+-APC,	NGFR-PE-Cy7,	LRIG1-
PE;	n	=	5.		C)		Proportions	of	LRIG1+	and	LRIG1-	basal	epithelial	cells	obtained	from	brush	biopsies;	n	=	3.					
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5.3.2	 Colony-forming	efficiency	of	LRIG1+	versus	LRIG1-	basal	cells	
	
In	the	murine	airway,	LRIG1	marks	a	more	clonogenic	population	of	basal	cells.		To	
investigate	whether	this	finding	was	similar	in	the	human,	human	basal	cells	were	
sorted	into	LRIG1+	and	LRIG1-	populations.		The	brushes	were	taken	from	areas	of	
normal	epithelium	with	the	patient	characteristics	shown	in	supplementary	table	1.		
Cells	were	sorted	into	96-well	plates,	directly	onto	mitotically	inactivated	3T3-J2	
feeder	cells	and	grown	in	medium	containing	Y-27632.		At	2	weeks,	the	numbers	of	
colonies	that	formed	from	LRIG1+	cells	were	compared	to	those	from	LRIG1-	cells	
(Figure	5.2.A).		For	one	of	the	patient	samples,	there	were	fewer	than	the	96	basal	
cells	required	to	fill	a	plate,	therefore	the	maximum	possible	number	of	cells	was	
sorted	and	equal	numbers	of	LRIG1+	and	LRIG1-	basal	cells	collected.		The	percentage	
of	cells	that	formed	colonies	was	expressed	as	a	percentage	of	the	total	number	of	
cells	plated.		Overall	LRIG1+	basal	cells	were	significantly	more	clonogenic	than	
LRIG1-	(p	=	0.0067)	(Figure	5.2.B).	
	
As	there	was	no	clearly	defined	LRIG1+	and	LRIG1-	cell	populations,	index	sorting	was	
used	to	establish	whether	a	correlation	existed	between	the	degree	of	LRIG1	
expression	and	how	likely	the	cell	was	to	form	a	colony.		The	index	sorting	showed	
no	relationship	between	the	degree	of	LRIG1	expression	and	colony	development	
(Figure	5.2.C),	and	the	cells	that	grew	were	spread	across	the	plot.	
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Figure	5.2:		Colony	formation	in	LRIG1+	and	LRIG1-	epithelial	cells	obtained	at	bronchoscopy	
	
A)		Examples	of	colony	formation	within	a	96-well	plate.		After	2	weeks,	the	cells	are	fixed	and	stained	with	crystal	violet	
and	cells	that	have	formed	colonies	can	be	clearly	seen.		The	number	of	colonies	forming	from	LRIG1+	basal	cells	(upper	
image)	are	then	compared	to	the	number	of	colonies	forming	from	LRIG1-	basal	cells	(lower	image).		Image	
representative	of	n	=	6.		B)		Colony	formation	in	flow	cytometry	sorted	LRIG1+	and	LRIG-	basal	cells.		Dots	indicate	
individual	patients	with	the	positive	and	negative	samples	for	each	patient	joined	by	a	line.		Statistical	analysis	was	
performed	using	a	paired	t-test,	**	indicates	p<0.01.		C)		Index	sorting	shows	the	degree	of	LRIG1	staining	is	not	related	
to	the	likelihood	of	a	cell	forming	a	colony.		i)		Flow	cytometry	plot	for	airway	basal	epithelial	cells,	with	the	upper	gate	
showing	LRIG1-positive	basal	cells	and	the	lower	gate	LRIG1-negative.		ii)	Flow	cytometry	plot	showing	the	levels	of	
expression	of	LRIG1	in	the	LRIG1+	basal	cells	that	grew	into	colonies.		iii)		Flow	cytometry	plot	showing	the	levels	of	
expression	of	LRIG1	in	the	LRIG1-	basal	cells	that	grew	into	colonies.			
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5.3.3	 The	proliferation	of	LRIG1+	versus	LRIG1-	basal	cells	
	
LRIG1-expressing	epithelial	cells	within	the	murine	skin	and	gut	are	more	
proliferative	than	LRIG1-negative	basal	cells	(91,	93)	and	I	have	also	shown	that	
LRIG1+	basal	cells	in	the	murine	airway	are	more	proliferative	than	LRIG1-	basal	cells.		
To	establish	whether	LRIG1+	basal	cells	in	the	human	airway	were	more	proliferative	
than	LRIG1-	basal	cells	Hoescht	33342	was	used.		Cells	were	obtained	from	bronchial	
brushings,	with	patient	characteristics	for	this	experiment	detailed	in	supplementary	
table	1.		Endothelial	and	immune	cells	were	removed	by	excluding	the	CD31+	and	
CD45+	populations	respectively,	and	a	viability	dye	was	used	to	eliminate	dead	cells.		
As	previously,	basal	cells	were	selected	by	their	positive	expression	of	integrin	α6	
and	NGFR.		Due	to	the	limited	number	of	cells	obtained	from	a	brush,	samples	were	
excluded	that	contained	less	than	750	basal	cells.		The	basal	cells	were	then	divided	
into	LRIG1+	and	LRIG1-	populations	and	Hoescht	33342	staining	used	to	establish	the	
proportion	of	proliferative	cells	in	the	G2/M	phase	of	the	cell	cycle	(Figure	5.3.A).	
	
In	total,	samples	were	obtained	from	8	patients.		3	of	these	were	excluded	due	to	
low	basal	cell	numbers	(although	the	proliferation	phenotypes	within	the	LRIG1+	and	
LRIG1-	populations	showed	the	same	behaviour	as	samples	containing	higher	basal	
cell	numbers).		A	further	patient	was	excluded	due	to	the	Hoescht	33342	staining	
being	inadequate	(the	two	peaks	that	corresponded	to	Hoescht	33342	uptake	were	
not	visible).		Collating	the	4	patients	with	adequate	basal	cell	numbers	and	Hoescht	
33342	staining,	it	was	clear	that	LRIG1+	basal	cells	were	more	proliferative	than	
LRIG1-	basal	cells	(Figure	5.3.B).	This	is	statistically	significant	(p	=0.0153)	and	
confirms	the	findings	in	the	murine	airway,	skin	and	gut,	where	LRIG1+	epithelial	cells	
are	more	proliferative	than	LRIG1-.	
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Figure	5.3:		Proliferation	of	LRIG1+	and	LRIG1-	human	basal	cells	obtained	at	bronchoscopy	
	
A)		Flow	cytometry	plots	showing	the	proliferation	of	LRIG1+	and	LRIG1-	basal	cells.		The	first	plot	shows	FSC	
against	SSC,	with	removal	of	the	cell	debris	(bottom	left	corner),	followed	by	the	negative	selection	of	CD31+	and	
CD45+	cells	and	dead	cells.	Single	cells	are	obtained	through	comparing	the	Hoescht	33342-Area	to	Hoescht	
33342-Height.		Next,	basal	cells	are	isolated	through	the	selection	of	integrin	α6+	and	NGFR+.		The	basal	cells	are	
assessed	for	expression	of	LRIG1,	and	LRIG1+	and	LRIG1-	cells	analysed	for	Hoechst	33342	uptake.		Red	gates	
indicate	the	population	of	interest	that	is	analysed	in	the	next	plot.		The	proliferative	cells	in	the	G2/M	phase	of	
the	cell	cycle	are	indicated	on	the	plot.		Antibodies	were	used	in	the	following	colours:		CD31-	and	CD45-	APC,	
live/dead-sytox	red,	integrin	α6+-APC-Cy7,	NGFR-PE-Cy7,	LRIG1-	PE.		Plots	representative	of	n	=	4.		B)		
Proliferation	of	human	LRIG1+	and	LRIG1-	basal	cells.		Statistical	analysis	was	performed	using	a	paired	t-test,	*	
indicates	p<0.05,	mean	±	SEM,	n	=	4.		
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5.3.4	 shRNA	knockdown	of	LRIG1	in	human	epithelial	cells	
	
As	LRIG1	is	lost	in	preinvasive	lung	cancer,	I	wanted	to	determine	the	effect	on	cell	
behaviour	when	LRIG1	is	lost	in	airway	basal	cells.		In	Chapter	4	I	showed	there	was	
no	effect	of	the	absence	of	LRIG1	in	a	constitutively	null	LRIG1	animal,	possibly	due	
to	other	factors	compensating	for	the	loss	or	a	redundancy	of	LRIG1	in	the	airway.		
By	knocking	down	LRIG1	expression	in	human	basal	cells	I	wanted	to	more	closely	
recapitulate	the	LRIG1	loss	that	occurs	in	preinvasive	lung	cancer	and	allow	the	
effect	of	LRIG1	loss	in	airway	epithelial	cells	to	be	examined	in	more	detail.			
	
Primary	HBECs,	isolated	from	patients	at	bronchoscopy,	were	obtained	from	the	
laboratory’s	primary	cell	bank.		The	cell	isolation	strategy	and	culture	conditions	lead	
to	the	culture	of	a	pure	airway	basal	cell	population	(171).		In	total,	samples	from	4	
patients	were	included	in	the	assessment	of	the	effect	of	LRIG1	shRNA	knock	down.		
Their	details	are	included	in	supplementary	table	1.		The	cells	were	grown	on	
mitotically	inactivated	3T3-J2	feeder	layers	in	medium	containing	a	rho-associated	
kinase	inhibitor,	Y-27632	(3T3	+	Y	culture	conditions)	and	all	4	patient	samples	were	
shown	to	express	LRIG1	by	immunoblotting	prior	to	shRNA	knock	down	(Figure	
5.4.C).	Due	to	the	heterogeneous	nature	of	primary	HBECs,	and	that	these	
differences	may	lead	to	variability	in	susceptibility	to	LRIG1	shRNA	knock	down,	
lentivirus	was	made	from	all	three	commercially	available	LRIG1	shRNA	plasmids.		
The	production	of	virus	was	confirmed	by	successfully	transducing	HEK293T	cells	and	
the	addition	of	serial	viral	dilutions	to	plated	HEK293T	cells	allowed	the	viral	titre	to	
be	quantified	(Figure	5.4.A).		
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Figure	5.4:		LRIG1	shRNA	knockdown	in	primary	human	bronchial	epithelial	cells	
(HBECS)	
	
A)		Flow	cytometry	plots	showing	successful	production	of	virus	in	HEK293T	cells.		GFP	indicates	the	
transduced	population.		Amount	of	virus	added	to	each	well	of	a	6-well	plate	indicated	above	the	
plot.		Serial	dilutions	added	to	allow	the	calculation	of	viral	titre.		B)		Successful	transduction	of	
human	epithelial	cells	(PA).		GFP	(green)	indicates	the	successful	transduction.		All	3	plasmids	are	
associated	with	a	successful	transduction.		Parent	control	remains	untransduced.		Scale	bar	=	50	μm.		
Images	representative	of	4	patient	samples.		C)		Immunoblotting	showing	the	successful	knockdown	
of	LRIG1	protein	in	transduced	samples.		LRIG1	is	seen	at	a	weight	of	143	kDa.		Lanes	correspond	
with	samples	1.		PA	p4	plasmid	1	(where	p4	indicates	the	cell	passage	number),	2.	PA	p4	plasmid	2,	
3.	PA	p4	plasmid	3,	4.		PA	p4	non-silencing	(N.S),	5.		PA	p4	parent	cells,	6.		PB	p4	plasmid	1,	7.	PB	p4	
plasmid	2,	8.	PB	p4	plasmid	3	9.	PB	p4	non-silencing	(N.S),	10.	PB	p4	parent	cells.		Blot	
representative	of	two	blots,	one	for	cell	lines	PA	and	PB	and	other	for	cell	lines	PC	and	PD.		
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Once	quantified,	all	three	viruses	were	used	to	transduce	human	epithelial	cells	at	an	
MOI	of	3.		As	the	epithelial	cells	were	transduced	on	a	feeder	layer	of	mitotically	
inactive	3T3-J2	feeder	cells,	the	number	of	feeder	cells	was	included	in	the	
calculation	of	MOI.		A	non-silencing,	scrambled	shRNA	control	was	used	alongside	
the	LRIG1	knockdown	samples	at	the	same	MOI.		All	the	LRIG1	shRNA	plasmids,	as	
well	as	the	non-silencing	control,	contained	a	GFP	reporter.		At	48	hours	post	
transduction	the	cells	became	GFP-positive,	indicating	transduction	success	(Figure	
5.4.B).		After	72	hours	of	puromycin	selection,	the	cells	were	expanded	for	use	in	
subsequent	assays.	
	
Knockdown	of	LRIG1	was	confirmed	by	immunoblotting	for	LRIG1	protein	(Figure	
5.4.C).		As	the	3T3-J2	cells	express	LRIG1	(LRIG1	is	a	negative	inhibitor	of	PDGFRα	
found	in	fibroblasts	(77)),	once	the	transduced	epithelial	cells	were	confluent,	the	
feeder	layers	were	removed	by	differential	trypsinisation.		Trypsin	cleaves	LRIG1,	so	
following	J2-3T3	removal,	the	medium	was	replaced	and	the	epithelial	cells	
incubated	overnight	to	allow	LRIG1	protein	recovery.		The	following	morning	the	
cells	were	lysed	and	protein	samples	collected	for	immunoblotting.		The	effects	of	
the	shRNA	knockdown	by	all	three	LRIG1	shRNA	plasmids	were	compared	to	both	
the	non-silencing	control	and	to	the	parental	non-transduced	cells	(Figure	5.4.C).		
The	transduction	and	assessment	of	LRIG1	protein	knockdown	was	repeated	in	all	
four	patients.		In	each	of	the	four	patient-derived	HBEC	samples,	plasmid	1	showed	
the	greatest	LRIG1	knockdown	and	therefore	the	HBECS	transduced	with	plasmid	1	
were	expanded	and	used	in	subsequent	experiments.	
	
5.3.5	 Effect	of	LRIG1	shRNA	knockdown	on	EGFR	activation	
	
LRIG1	downregulates	epidermal	growth	factor	receptor	(EGFR)	signalling	and,	
following	the	loss	of	LRIG1,	an	upregulation	and	activation	of	EGFR	signalling,	as	well	
as	activation	of	the	downstream	extracellular	signal-regulated	kinase	
(ERK)	pathway,	has	been	detected	in	keratinocytes	(79).		To	confirm	that	loss	of	
LRIG1	in	HBECs	was	exerting	its	effects	through	action	on	the	EGFR	signalling	
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pathway,	cells	were	immunoblotted	for	EGFR,	phospho-EGFR	(Y1068	site),	p44/42	
ERK	and	phospho-p44/42	ERK.	
	
Protein	levels	were	assessed	in	patient	samples	that	had	been	starved	for	16	hours	
prior	to	incubation	with	and	without	10	ng/ml	of	EGF	for	30	minutes	and	then	
lysates	were	collected.		This	dose	and	timing	has	previously	been	shown	to	trigger	
phospho-EGFR	activation	in	human	airway	epithelial	cells	(232).		Following	LRIG1	
shRNA	knockdown	there	was	an	increase	in	both	phospho-EGFR	and	phospho-ERK	
proteins,	confirming	that	loss	of	LRIG1,	a	negative	inhibitor	of	EGFR,	leads	to	both	an	
upregulation	in	EGFR	signalling,	along	with	the	activation	of	downstream	pathways	
(shown	through	increased	phospho-ERK).		This	effect	was	not	seen	in	the	absence	of	
EGF	stimulation	(Figure	5.5).		Two	patient	samples	were	analysed,	with	the	displayed	
blots	representative	of	both	(each	run	in	duplicate).	
	
Of	note,	I	have	seen	through	these	optimisation	experiments	that	the	degree	of	
LRIG1	expression	detectable	by	immunoblotting	is	associated	with	degree	of	cell	
confluence.		When	the	cells	are	not	confluent,	there	is	a	dramatic	reduction	in	LRIG1	
protein.		Cells	were	lysed	at	similar	levels	of	confluence,	although	as	discussed	later,	
the	LRIG1	shRNA	knockdown	cells	proliferate	more	rapidly	than	the	parent	or	the	
LRIG1-expressing	non-silencing	controls.			
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Figure	5.5:		shRNA	knockdown	of	LRIG1	leads	to	increased	EGFR	activation	
	
Immunoblotting	for	LRIG1	(143	kDa),	EGFR	(175	kDa),	phospho-EGFR	(175	kDa),	ERK	(42	and	44	
kDa)	and	phospho-ERK	(42	and	44kDa)	in	lysates	from	parent,	LRIG1	non-silencing	(N.S)	and	LRIG1	
shRNA-transduced	cells.		Samples	were	starved	for	16	hours	and	stimulated	with	or	without	EGF	
at	10	ng/ml	for	30	minutes.		Protein	loading	control	was	α-tubulin,	displayed	beneath	the	blots.		
Blots	representative	of	n	=	2,	with	experiments	performed	twice	in	two	different	patient	cell	lines.		
Blot	shown	for	PB	p7	
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5.3.6	 The	effect	of	LRIG1	shRNA	knockdown	on	colony-forming	ability		
	
LRIG1	siRNA	knockdown	in	skin	keratinocytes,	compared	to	a	non-scrambled	control,	
leads	to	increased	colony	formation	(79).		Colony	forming	assays	measure	a	cell’s	
stem	cell	potential	as	they	measure	the	ability	of	the	cell	to	self-renew	(211).		In	both	
mice	and	humans,	I	have	shown	that	LRIG1+	basal	cells	are	more	clonogenic	than	
LRIG1-	basal	cells.		To	assess	whether	the	knockdown	of	LRIG1	in	an	LRIG1-expressing	
population	of	human	basal	cells	(as	demonstrated	in	Figure	5.4.C)	leads	to	increased	
colony	formation,	the	number	of	colonies	formed	in	LRIG1	shRNA	knockdown	cells	
was	compared	to	that	of	the	LRIG-expressing	non-silencing	shRNA	control.			
	
Cells	were	grown	on	mitotically	inactivated	3T3-J2	feeder	layers	in	6-well	plates.		The	
number	of	colonies	formed	from	1000	seeded	cells	was	counted	at	10	days.		The	
LRIG1	shRNA	knockdown	cells	were	compared	to	the	LRIG1-expressing	non-silencing	
controls	(Figure	5.6.A).		Although	not	significant,	there	was	a	clear	trend	in	the	data,	
with	LRIG1	shRNA	knockdown	in	all	4	of	the	patient	cell	lines	leading	to	an	increase	
in	colony	formation	(Figure	5.6.B).			
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Figure	5.6:		Knockdown	of	LRIG1	leads	to	increased	colony	formation	in	HBECs	
	
A)		Example	of	colony-forming	assay.		1,000	HBECs	were	plated,	in	triplicate,	per	well	of	a	6-well	plate.		These	
were	fixed	and	stained	with	crystal	violet.		Colonies	that	grew	to	greater	than	10	cells	were	included	in	the	
analysis.		B)	The	colony-forming	efficiency	in	HBEC	cells	with	and	without	LRIG1	knockdown.		Samples	
performed	in	triplicate	with	mean	±	SEM	displayed.		Statistical	analysis	was	performed	using	a	paired	t-test,	p	
=	0.1269,	n	=	4.		
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5.3.7	 The	effect	of	LRIG1	shRNA	knockdown	on	cell	proliferation;	optimising	the	
EdU	assay	
	
Lu	et	al	have	shown	that	when	using	cells	from	an	Lrig1-knockout	mouse,	the	loss	of	
LRIG1	prevents	cell-cell	contact	inhibition	and	leads	to	on-going	proliferation	at	cell	
confluence	(104).		If	this	were	to	occur	within	the	human	epithelium	this	may	explain	
the	development	of	preinvasive	lesions	and	how	loss	of	LRIG1	may	lead	to	a	poor	
outcome	from	NSCLC.			
	
To	assess	cell	proliferation	and	the	effects	of	contact	inhibition,	cells	were	incubated	
with	EdU,	a	synthetic	thymidine	analogue,	for	analysis	by	flow	cytometry.		To	
confirm	reported	incubation	and	uptake	times	(171),	EdU	uptake	was	examined	and	
optimised	in	one	patient.		As	the	addition	of	Y-27632	leads	to	increased	cellular	
proliferation	beyond	the	proliferation	rate	seen	in	the	traditionally	used	BEGM	
culture	conditions	(231)	and	with	growth	of	cells	on	3T3-J2	feeder	layers	having	an	
additive	effect	(233),	I	was	concerned	that	3T3	+	Y	culture	conditions	may	cause	an	
artificial	increased	proliferation	phenotype,	and	that	any	subtle	differences	in	
proliferation	resulting	from	the	loss	of	LRIG1	may	be	lost.		To	establish	if	this	may	be	
an	issue,	this	preliminary	experiment	assessed	cells	grown	in	both	3T3	+	Y	and	BEGM	
conditions,	both	at	sub-confluence	and	confluence.	
	
This	trial	showed	no	difference	in	the	EdU	uptake	of	LRIG1	shRNA	knockdown	cells	
or	the	LRIG1-expressing	non-silencing	control	cells	grown	in	3T3	+	Y	conditions,	
either	at	subconfluence	or	confluence	(Figure	5.7.A	and	5.7.B),	possibly	as	a	
consequence	of	the	above	mentioned	factors.		In	fact,	at	confluence,	in	3T3	+	Y	
conditions,	no	EdU+	cells	were	detected	in	either	LRIG1	shRNA	knockdown	cells	or	
the	non-silencing	control	cells,	suggesting	no	proliferation	was	occurring	and	cells	
were	contact	inhibited.		In	BEGM,	EdU	uptake	was	noted	to	be	similar	at	sub-
confluent	conditions	(Figure	5.7.C),	but	the	proliferation	in	the	LRIG1	shRNA	
knockdown	conditions	at	cell	confluence	was	twice	that	of	the	LRIG1-expressing,	
non-silencing	controls	(Figure	5.7.D).			
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Figure	5.7:		Optimisation	of	EdU	proliferation	assay	
	
The	assessment	of	EdU	uptake	in	HBECs	compared	uptake	between	a	non-silencing	control	and	
samples	where	LRIG1	was	knocked	down.		4	conditions	were	compared;	A)		Confluent	cells	grown	in	
3T3	+	Y,		B)		Sub	confluent	cells	grown	in	3T3	+	Y,			C)		Confluent	cells	grown	in	BEGM,		D)	Sub	confluent	
cells	grown	in	BEGM.		
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5.3.8	 The	effect	of	LRIG1	shRNA	knockdown	on	cell	proliferation	at	confluence	
	
As	there	was	an	on-going	proliferation	at	cell	confluence	in	the	BEGM	conditions	(as	
shown	by	Lu	et	al	in	mouse	airway	epithelium	(104)),	the	growth	of	cells	in	BEGM	at	
cell	confluence	was	selected	to	compare	the	difference	in	proliferation	in	cells	from	
multiple	donors.		Despite	the	percentage	of	EdU-positive	cells	being	comparable	at	
sub-confluence	in	my	preliminary	experiments,	it	was	clear	that	the	epithelial	cells	
were	growing	at	different	rates.		The	LRIG1	shRNA	knockdown	cells	reached	
confluence	more	quickly	than	the	LRIG-expressing	non-silencing	controls,	despite	
seeding	at	the	same	cell	density.		I	was	concerned	that	the	higher	cell	number	of	the	
LRIG1	shRNA	knockdown	cells	may	exert	a	greater	inhibitory	effect	on	proliferation.		
Therefore,	the	final	cell	number	in	each	sample	prior	to	flow	cytometry	was	counted	
and	recorded.	
	
The	percentage	of	cells	positive	for	EdU	uptake	in	each	of	the	cell	populations	at	cell	
confluence	was	small	(Figure	5.8.A).		However,	in	each	of	the	patient	samples	
examined,	the	EdU	uptake	in	the	LRIG1	shRNA	knockdown	sample	was	greater	than	
that	of	the	LRIG1-expressing,	non-silencing	control	(Figure	5.8.B).		This	shows	
ongoing	proliferation	in	LRIG1	shRNA	knockdown	cells	despite	cell	confluence.		
When	combining	the	data	from	three	patients,	there	was	a	marked	increase	in	the	
percentage	of	EdU-positive	cells	in	the	LRIG1	shRNA	knockdown	cell	lines	compared	
to	the	LRIG-	expressing,	non-silencing	controls	(Figure	5.8.C).				
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Figure	5.8:		Assessment	of	EdU	uptake	at	cell	confluence	
	
A)		Flow	cytometry	plots	showing	assessment	of	EdU	uptake	in	HBECs	grown	in	BEGM	at	cell	confluence.		Example	
plot	from	patient	PC	p7.		Debris	and	any	remaining	3T3-J2	cells	were	gated	out	using	FSC/SSC	dimensions,	
doublets	excluded	and	then	EdU	(Alexa	647)	uptake	assessed.		B)		Plots	showing	percentage	of	EdU	positive	cells	
at	cell	confluence	in	each	of	the	3	individual	patients.		On	the	right	are	plots	of	total	cell	numbers.		Experiments	
repeated	in	triplicate,	mean	±	SEM.		C)		Combined	data	for	3	individuals,	indicating	that	within	the	shRNA	LRIG1	
knock	down	cells,	the	cells	continue	to	proliferate	at	cell	confluence.		Statistical	analysis	was	performed	using	a	
paired	t-	test,	n=3.		
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Cell	numbers	in	the	LRIG1	shRNA	knockdown	cells	and	the	LRIG1-expressing	non-
silencing	controls	were	similar	in	samples	PC	and	PA.		There	was	a	more	marked	
difference	in	sample	PB,	with	a	much	higher	number	of	LRIG1	shRNA	knockdown	
cells.		Despite	this,	the	LRIG1	shRNA	sample	still	had	a	much	greater	percentage	of	
EdU-positive	cells,	meaning	any	excess	negative	inhibition	caused	by	the	larger	cell	
number	was	out-weighed	by	the	increased	proliferation	at	cell	confluence	of	the	
LRIG1	shRNA	knockdown	cells.		
	
5.3.9	 The	effect	of	LRIG1	shRNA	knockdown	on	rate	of	proliferation	
	
As	noted	above,	the	LRIG1	shRNA	knockdown	cells	grew	faster	than	the	LRIG1-
expressing,	non-silencing	control	cells.		The	use	of	siRNA	in	basal	keratinocytes	has	
shown	that	keratinocyte	proliferation	increases	on	loss	of	LRIG1	(79).		To	assess	this	
in	more	detail,	XTT	assays	were	used	to	compare	the	rates	of	proliferation	in	the	
LRIG1	shRNA	knockdown	and	LRIG1-expressing	non-silencing	control	cell	lines.		
Instead	of	examining	cell	proliferation	at	a	single	time	point,	XTT	assays	allow	the	
assessment	of	cell	number	at	multiple	time	points,	allowing	proliferation	rate	to	be	
assessed.		As	in	the	previous	experiments	the	XTT	assay	was	carried	out	in	BEGM.		
	
Cellular	XTT	metabolism	(and	by	inference	cell	number)	was	detected	by	a	
spectrophotometer.		Readings	were	compared	to	a	baseline	absorbance	
measurement	recorded	at	day	1,	and	the	percentage	change	in	absorbance	values	
determined.		By	days	7	and	10	the	rate	of	growth	in	the	LRIG1	shRNA	knockdown	
cells	was	greater	than	that	of	the	LRIG1-expressing,	non-silencing	control	cells.		This	
occurred	across	all	4	donor	cell	lines,	although	the	difference	was	less	marked	in	PA,	
where	the	rate	of	proliferation	in	both	the	LRIG1	shRNA	knockdown	and	the	LRIG1-
expressing	non-silencing	control	cells	were	similar.			Proliferation	reached	a	peak	at	
day	9	in	3	of	the	4	donor	cell	lines,	and	it	was	at	this	time	point	when	the	greatest	
difference	in	proliferation	rate	between	the	LRIG1	shRNA	knockdown	and	LRIG1-
expressing	non-silencing	control	groups	was	seen	(Figure	5.9.A).		Once	cells	reached	
confluence,	as	assessed	by	eye,	between	days	9	and	11,	the	cell	numbers	decreased,	
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and	the	percentage	difference	in	XTT	uptake	reduced.		This	is	likely	due	to	the	cells	
being	intolerant	of	persistent	levels	of	high	confluence.	The	LRIG1-expressing	non-
silencing	cells	appeared	less	tolerant	of	high	levels	of	cell	confluence	and	did	not	
reach	the	same	cell	numbers	as	the	LRIG1	shRNA	knockdown	cells.		The	difference	in	
decline	between	LRIG1	shRNA	and	LRIG1-expressing	cells	is	likely	due	to	the	LRIG1	
shRNA	knockdown	cells	reaching	a	higher	cell	number	by	day	9	(Figure	5.9.A).		
	
Combining	the	4	patient	samples	gives	a	clearer	indication	of	the	effects	of	LRIG1	
shRNA	knockdown	(Figure	5.9.B).		LRIG1	shRNA	knockdown	increases	the	rate	of	
proliferation	between	days	3	and	4,	and	a	marked	difference	in	proliferation	is	
displayed	between	days	4	and	7.		The	rate	of	increase	reduces	from	day	7–9,	but	is	
still	greater	in	the	LRIG1	shRNA	knockdown	arm	compared	to	the	LRIG1-expressing	
non-silencing	control.		At	day	9,	the	difference	between	the	LRIG1	shRNA	
knockdown	cells	and	the	LRIG1-expressing	non-silencing	control	is	statistically	
significant.		After	this	point	the	number	of	cells	begin	decreases,	the	difference	in	
the	rate	of	decrease	is	significant	at	day	11.		
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Figure	5.9:		Proliferation	rate	of	HBECs	following	LRIG1	shRNA	knockdown	
	
A)		Plots	of	each	of	the	4	patient	samples	including	the	LRIG1	shRNA	knockdown	and	the	LRIG1-expressing	non-
silencing	control	showing	the	percentage	change	in	the	XTT	absorbance	reading	from	values	at	day	1.		Samples	
performed	in	triplicate	and	the	mean	value	plotted.		Measurements	taken	on	days	2,	3,	4,	7,	11	and	14.		B)		Plot	
showing	the	combined	data	for	the	4	patients,	mean	±	SEM.		Statistical	analysis	was	performed	using	a	2-way	
ANOVA	with	Sidak’s	multiple	comparison’s	test,	*	indicates	p	<	0.05.		
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5.3.10	 The	effect	of	LRIG1	shRNA	knockdown	on	invasion	and	differentiation	of	
epithelial	cells	
	
The	loss	of	LRIG1	has	been	shown	to	influence	both	migration	and	invasion	in	human	
cancer	cell	lines	(110,	111).		It	was	seen	that,	on	LRIG1	loss,	genes	associated	with	
epithelial-mesenchymal	transition	(EMT)	were	upregulated	and	the	assessed	cell	
lines	took	on	a	more	migratory	and	invasive	phenotype.		However,	despite	these	
findings,	I	would	hypothesise	that	the	loss	of	LRIG1	from	human	airway	cells	is	
unlikely	to	result	in	invasion	as	LRIG1	loss	is	seen	in	preinvasive	squamous	cell	
carcinomas,	occurring	before	a	detectable	break	in	the	basement	membrane	is	seen.		
If	LRIG1	directly	influenced	invasion,	its	loss	would	only	become	evident	in	samples	
where	the	basement	membrane	has	already	been	breached.		
	
To	assess	whether	LRIG1	has	a	role	in	invasion	and	whether	it	modulates	an	EMT	
phenotype	in	the	human	airway	basal	cells,	invasion	assays	were	performed	using	
the	LRIG1	shRNA	knockdown	cells.		Initially,	cells	suspended	in	serum-reduced	
medium	were	left	to	migrate	through	a	Matrigel-covered	transwell	to	a	serum-
containing	medium	below	the	membrane.		Two	different	cell	concentrations	of	
50,000	and	100,000	cells/well	were	trialled	as	were	2	different	time	points,	72	and	
96	hours.		However,	at	the	experimental	end-point,	the	HBECs	were	seen	to	form	
spheroid-like	structures	within	the	Matrigel	(Figure	5.10.A).	After	removing,	washing	
and	staining	the	membrane	with	crystal	violet,	there	was	no	indication	that	
migration	had	occurred	from	one	side	of	the	membrane	to	the	other	(Figure	5.10.A).		
The	membrane	of	a	control	well,	without	epithelial	cells,	was	identical	to	that	of	a	
transwell	where	cells	were	seeded.		These	preliminary	results	showed	there	was	no	
evidence	of	increased	invasion	of	LRIG1	shRNA	knockdown	cells	through	Matrigel.	
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Figure	5.10:		Effect	of	LRIG1	shRNA	knockdown	on	invasion	of	HBECS	
	
A)		Optimisation	of	invasion	assay	through	a	Matrigel-coated	transwell.		From	left	to	right:	cells	appear	to	
migrate	to	the	centre	of	the	Matrigel	plug	and	form	spheroids;	no	evidence	of	cells	on	the	under	surface	of	the	
transwell,	and	on	right,	no	difference	between	transwells	with	cells	and	control	membranes	(where	no	cells	
were	seeded).		B)		Organotypic	invasion	assays	showing	the	growth	of	epithelial	cells	on	a	collagen/Matrigel	
matrix	with	embedded	fibroblasts.		Picked	examples	of	organotypic	assays	to	show	different	features.		i)	PB	p7	
epithelial	cells	showing	parent,	non-silencing	(NS)	and	shRNA	treated	cells.		i)		PC	p8	parent	and	NS	cells.		ii)		PA	
p8	parent	and	shRNA	cells.		Scale	bar	=	200	μm.	Images	on	right	show	close-up	of	the	larger	image.		Scale	bar	=	
50	μm.		C)		Positive	control	SK-MES-1	cells	that	have	previously	been	shown	to	invade	a	Matrigel	matrix.		Note	
the	presence	of	epithelial	cells	in	layers,	deep	beneath	the	surface	of	the	matrix.		The	close-up	image	shows	
tumour	projections,	reaching	into	the	matrix.		Scale	bars	=	200	μm	(left)	and	50	μm	(right).		
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To	ensure	there	was	no	increase	in	the	invasive	potential	of	LRIG1	shRNA	knockdown	
cells,	organotypic	invasion	assays	were	carried	out.		Organotypic	assays	attempt	to	
replicate	the	tumour/stroma	interface,	and	can	assess	an	epithelial	cell’s	invasive	
potential	(234,	235).		By	growing	epithelial	cells	on	a	Matrigel/collagen	matrix	
embedded	with	fibroblasts	and	then	subsequently	exposing	this	matrix	to	air,	
conditions	are	created	that	more	closely	mirror	an	in	vivo	environment	than	growing	
cells	submerged	on	tissue	culture	plastic.		Basal	cells	grown	using	this	method	are	
capable	of	differentiating	into	all	of	the	airway	epithelial	cell	types	(171).		Therefore,	
the	point	of	the	assay	was	two-fold.		The	first	was	to	assess	invasion	potential,	whilst	
the	second	was	to	ensure	that	lentiviral-transduced	HBECs	were	still	capable	of	
differentiating	into	a	respiratory	epithelium.		If	the	non-silencing	shRNA	control	cells	
were	unable	to	form	a	differentiated	epithelium,	it	may	imply	that	the	lentiviral	
transduction	was	adversely	affecting	HBEC	behaviour.		
	
The	organotypic	assays	were	cultured	for	24	days,	at	which	point	a	layer	of	cells	was	
seen	above	the	matrix.		Following	the	fixing,	embedding	and	sectioning	of	the	matrix	
scaffolds,	transverse	cross-sections	were	stained	with	haematoxylin	and	eosin	to	
assess	both	invasion	and	possible	differentiation	(Figure	5.10.B).		Although	the	
conditions	were	analysed	in	triplicate,	a	wide	variability	existed	from	well	to	well.		In	
some	areas	the	epithelial	lining	was	intact	with	evidence	of	organisation,	whilst	in	
others	the	membrane	was	denuded	(Figure	5.10.B).		The	positive	control,	a	
squamous	cell	lung	cancer	line	SK-MES-1	that	has	shown	invasive	characteristics	in	
reported	invasion	assays	(236),	was	seen	to	clearly	invade	the	matrix	with	the	
presence	of	deep,	finger-like	projections	and	accompanying	tumour	islands	(Figure	
5.10.C).		Amongst	the	4	donor	cell	lines	there	was	no	convincing	evidence	of	
invasion,	and	no	differences	in	the	behaviour	of	LRIG1	shRNA	knockdown	cells	and	
LRIG1-expressing	non-silencing	control	cells.		In	the	majority	of	assays,	the	cells	
appeared	to	sit	in	organised	layers	along	the	surface	of	the	matrix.		In	PC	there	were	
some	areas	of	less	complete	epithelial	coverage	and	a	suggestion	that	a	few	
epithelial	cells	may	have	encroached	into	the	matrix.		This	was	variable	between	the	
triplicate	repeats	and	showed	no	correlation	with	whether	the	cells	were	from	
parent,	LRIG1	shRNA	knockdown	cells	or	LRIG1-expressing	non-silencing	control	
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cells.		The	cells	from	patient	PA	grew	less	well	and	the	epithelial	covering	of	the	
matrix	was	extremely	sparse.		In	areas	that	the	matrix	was	less	well	covered,	
similarly	to	in	PC,	there	were	a	few	cells	that	had	possibly	moved	into	the	matrix.			
	
In	all	4	patients,	there	appeared	to	be	some	evidence	of	differentiation.		This	was	
variable	amongst	the	triplicate	repeats	and	again	showed	no	clear	correlation	with	
whether	LRIG1	was	knocked	down.		To	confirm	these	findings,	immunofluorescence	
was	performed	for	MUC5B	and	ACT	(Figure	5.11).		There	is	a	suggestion	that	the	
basal	cells	were	still	capable	of	secretory	and	ciliated	differentiation,	with	cells	
expressing	these	proteins	seen	in	at	least	one	of	the	triplicate	repeats	in	each	of	the	
conditions	across	the	4	patients.		This	shows	that	lentiviral	transduction	of	epithelial	
cells	does	not	alter	the	differentiation	ability	of	transduced	cells.	
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Figure	5.11:		Differentiation	of	parent,	LRIG1	non-silencing	and	LRIG1	shRNA	knockdown	
cells	in	the	organotypic	assay	
	
Immunofluorescent	staining	of	transverse	sections	of	organotypic	assays,	suggestive	of	early	mucociliary	
differentiation.		MUC5AC	(red;	goblet	cells)	and	ACT	(green;	ciliated	cells)	stained	cells	are	seen	in	sections,	
from	parent,	non-silencing	(NS)	and	LRIG1	shRNA-	transduced	cells.			Labelling	indicates	cells	from	different	
donors	A)	PB	p7,	B)		PC	p8,	C)		PD	p9.		Scale	bar	=	100	μm.		
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5.4		 Discussion	
	
I	have	shown	that	LRIG1	is	expressed	within	the	human	airway	epithelium.		Similarly	
to	the	mouse,	LRIG1	appears	to	be	expressed	across	the	epithelium,	but	there	are	
populations	of	both	LRIG1+	and	LRIG1-	basal	epithelial	cells.		The	proportion	of	
LRIG1-expressing	basal	cells	mirrors	that	of	the	mouse.		When	these	human	airway	
basal	cells	are	isolated	by	flow	cytometry,	the	LRIG1+	cells	are	more	clonogenic	than	
LRIG1-	and	are	more	proliferative.		This	implies	that	either	LRIG1	confers	properties	
to	a	more	stem	cell-like	basal	population	or	marks	those	with	a	more	stem-cell	like	
phenotype.	
	
Using	3T3	+	Y	culture	conditions,	I	have	shown	it	is	possible	to	knock	down	a	gene,	in	
this	case	LRIG1,	in	primary	HBECs.		Analysing	the	effects	of	knockdown	of	LRIG1	
suggests	that	the	protein	confers	properties	to	the	basal	cell	population,	as	its	loss	
produces	a	population	that	is	more	clonogenic,	shows	increased	proliferation	and	is	
less	inhibited	by	cell-cell	contacts.		If	LRIG1	simply	marked	a	basal	cell	population	in	
the	human	airway,	any	knockdown	would	have	no	effect.		Immunoblotting	for	EGFR	
and	downstream	ERK	have	demonstrated	that	the	loss	of	LRIG1,	as	anticipated,	
exerts	an	effect	on	the	EGFR	signalling	pathway,	with	increased	phosphorylation	of	
both	EGFR	and	ERK	in	response	to	EGF	stimulation.		Lentiviral	transduction	of	HBECs	
does	not	affect	the	ability	of	HBECs	to	differentiate,	with	parent,	non-silencing	and	
LRIG1	shRNA	cells	populations	all	showing	evidence	of	mucociliary	differentiation.		
The	isolated	loss	of	LRIG1	does	not	appear	to	influence	invasion.	
	
I	was	concerned	that	the	LRIG1+	and	LRIG1-	cells	obtained	from	the	Lrig1	eGFP-ires-
CreERT2	null	mouse	may	have	given	limited	information	due	to	the	constitutive	
nature	of	Lrig1	loss	(Chapter	3).		By	using	LRIG1	shRNA	knockdown	in	human	airway	
cells,	any	constitutive	compensation	would	not	have	occurred,	and	conditions	would	
be	more	reflective	of	those	in	the	human	airway,	where	LRIG1	expression	is	lost	in	
the	development	of	preinvasive	disease.			
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Whilst	the	mice	used	in	this	project	were	genetically	similar,	used	at	the	same	age	
and	had	similar	environmental	exposures,	the	patients	varied	in	age,	smoking	
history,	gender,	genetic	background	and	other	environmental	factors.		These	factors	
need	to	be	considered	when	analysing	the	data.		Intriguingly,	it	has	been	shown	in	
mice	that	older	animals	have	a	reduced	proportion	of	tracheal	KRT5+p63+	epithelial	
cells,	meaning	the	age	of	the	patient	may	have	a	bearing	on	the	number	of	basal	
cells	collected	from	a	bronchial	brush	(237).		The	smoking	history	is	also	interesting;	
LRIG1	gene	expression	is	downregulated	in	areas	of	‘normal	epithelium’	from	
smokers,	compared	to	ex-smokers	and	these	levels	fall	further	on	the	development	
of	squamous	cell	lung	tumours	(30).		This	may	partly	explain	some	of	the	variability	
in	the	number	of	LRIG1-expressing	cells	seen	by	flow	cytometry.		Many	of	the	
patients	from	whom	samples	were	obtained	had	a	normal	bronchial	tree	(proven	on	
bronchial	biopsy)	whilst	other	samples	were	obtained	during	autofluorescence	
bronchoscopies	from	areas	of	‘normal’	epithelium	in	patients	with	known	
preinvasive	disease	(again	shown	on	bronchial	biopsy).		Increasing	the	patient	
numbers	for	each	of	the	experiments	may	reduce	the	effect	of	these	potentially	
confounding	factors.		Should	time	have	allowed,	it	would	have	been	useful	to	use	a	
greater	number	of	samples	from	patients	with	a	normal	bronchial	tree;	however,	
this	needed	to	be	balanced	with	the	availability	and	suitability	of	patient	samples	
from	either	bronchoscopic	or	surgical	lists.			
	
The	variability	of	both	basal	cell	LRIG1	expression	and	the	number	of	basal	cells	in	
each	sample	may	be	reflective	of	the	quality	of	brush	biopsy	obtained.			Three	of	the	
samples	obtained	for	the	Hoescht	33342	proliferation	experiment	had	to	be	
excluded	due	to	low	basal	cell	numbers	and	in	one	of	the	colony-forming	assays	a	
full	96-well	plate	of	cells	was	not	collected	due	to	low	basal	cell	numbers.		The	basal	
cells	are	firmly	adherent	to	the	basement	membrane	and	it	is	possible	that	the	
LRIG1-expressing	basal	cells	are	those	most	closely	attached	to	the	basement	
membrane	(as	this	corresponds	to	the	brightest	immunofluorescence	staining	for	
LRIG1).		The	effectiveness	of	the	brush	(and	the	technique	of	the	operator)	may	
influence	both	the	number	of	basal	cells	and	the	number	of	LRIG1+	basal	cells	that	go	
into	the	cell	suspension.		Other	methods	of	obtaining	airway	epithelial	cells	were	
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considered,	including	the	use	of	bronchial	biopsies	and	collecting	resected	airway	
samples	from	surgical	procedures.		However,	both	these	methods	require	a	
digestion	step	to	detach	the	basal	cells	and	would	add	1-	2	hours	to	the	preparation	
of	the	samples	for	flow	cytometry.		This	is	likely	to	influence	both	the	viability	of	the	
cells	that	are	ultimately	analysed	(and	the	proportion	of	colonies	that	form),	and	the	
number	of	cells	in	the	G2/M	phase	of	the	cell	cycle	as	seen	through	Hoescht	33342	
uptake.				
	
Whilst	a	shift	in	the	population	of	epithelial	cells	was	seen	on	staining	for	LRIG1,	a	
clearly	defined	LRIG1+	and	LRIG1-	population	was	not	detectable.		There	may	be	a	
gradient	of	LRIG1	expression,	with	the	cells	with	the	‘higher’	LRIG1	expression	being	
more	clonogenic	than	those	with	lower	levels.		However,	(although	using	low	cell	
numbers)	this	was	not	confirmed	by	index	sorting	and	amongst	the	LRIG1-positive	
population	there	appeared	to	be	no	clear	threshold	above	which	the	cells	formed	a	
colony.		This	contrasts	to	the	mouse	data,	where	an	eGFP+	and	eGFP-	cell	population	
was	clearly	distinguishable.					
	
LRIG1	shRNA	knockdown	was	performed	in	cultured	human	basal	cells.		Although	
LRIG1	shRNA	knockdown	cells	formed	increased	numbers	of	colonies	compared	to	
the	non-silencing	controls,	this	failed	to	reach	significance.		The	power	of	the	
experiment	may	be	improved	by	increasing	the	number	of	patient	cell	lines	used	for	
the	LRIG1	shRNA	knockdown,	but	the	failure	to	reach	significance	may	also	be	
explained	by	heterogeneity	within	the	basal	cell	population	and	an	incomplete	LRIG1	
knockdown.		The	population	of	cultured	basal	cells	was	considered	as	a	whole,	
instead	of	being	divided	into	LRIG1+	and	LRIG1-	populations.		Due	to	the	nature	of	
cell	culture,	cultured	basal	cells	are	likely	to	be	more	homogeneous	than	those	
derived	directly	from	a	patient.		It	was	clearly	seen	by	immunoblotting	that	the	
parental	cell	lines	expressed	LRIG1	prior	to	knockdown,	but	whether	LRIG1	
expression	varied	across	the	cultured	basal	cell	population	was	uncertain.		Attempts	
to	assess	differences	in	LRIG1	expression	in	individual	cells	by	flow	cytometry	were	
thwarted	by	the	cleavage	of	LRIG1	by	trypsin	(90),	and	trials	using	a	number	of	
different	digestion	techniques,	including	the	previously	reported	thermolysin,	with	
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the	aim	of	preserving	the	LRIG1	epitope	were	unsuccessful.		To	ensure	complete	
knockdown	of	LRIG1,	CRISPR-Cas9	technology	could	be	employed	(238).		A	good	
shRNA	knockdown	is	considered	as	an	80-90%	reduction	in	protein	expression	(239)	
and,	as	the	LRIG1	shRNA	knockdown	is		incomplete,	may	explain	the	only	marginal	
differences	seen	in	EdU	uptake	at	cell	confluence.		Lu	et	al	showed	a	more	marked	
continued	proliferation	at	cell	confluence	(104)	(using	cells	from	Lrig1	knockout	mice	
where	LRIG1	expression	is	absent),	with	a	greater	proportion	of	Lrig1	knockout	cells	
grown	at	air	liquid	interface	exhibiting	BrdU	uptake	compared	to	wild-type	cells	
(with	9.7%	in	the	knockout	cells	and	0.5%	in	the	wild-type)	but	differences	in	EdU	
uptake	in	these	experiments	were	seen	to	vary	by	only	3-4%.		Enough	residual	LRIG1	
may	be	present	in	the	LRIG1	shRNA	knockdown	cell	lines	to	ameliorate	the	effect	of	
LRIG1	shRNA	knockdown	on	proliferation	at	cell	confluence.		CRISPR-Cas9	
technology	would	entirely	knockout	LRIG1	expression	and	would	give	a	clearer	
indication	of	the	effects	of	LRIG1	loss,	not	only	at	cell	confluence,	but	also	within	the	
other	assays	that	have	been	performed.		Using	CRISPR-Cas9	was	initially	considered,	
but	due	to	time	limitations	was	beyond	the	scope	of	this	thesis.		Should	time	have	
allowed,	and	based	on	the	above	shRNA	data,	this	could	be	revisited.				
	
Using	the	EdU	assay	to	measure	continued	proliferation	at	cell	confluence	may	not	
have	been	the	most	appropriate	assay.		There	was	evidence	of	contact	inhibition	in	
the	3T3	+	Y	culture	conditions,	and	even	the	LRIG1-expressing	non-silencing	control	
cells	continued	to	proliferate	at	cell	confluence	in	BEGM.		This	poses	the	question	as	
to	whether	the	cells	would	ever	be	contact	inhibited	within	BEGM,	but	would	
instead	undergo	apoptosis	before	this	point.		To	more	successfully	address	whether	
the	loss	of	LRIG1	leads	to	a	loss	of	contact	inhibition,	and	would	time	have	allowed	I	
would	repeat	the	assay	performed	by	Lu	et	al	that	assessed	contact	inhibition	at	air-
liquid-interface	(104).				
	
It	is	difficult	to	draw	firm	conclusions	from	the	invasion	assays.		There	was	no	
evidence	of	any	invasion	in	samples	from	PB,	which	had	the	best	growth	of	epithelial	
cells,	but	in	PC	and	PA,	where	the	epithelial	covering	was	less	intact,	there	was	a	
suggestion	of	cell	encroachment	into	the	matrix.		This	was	not	the	expected	reported	
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tumour	bodies	(235),	or	a	tumour	‘front’	as	seen	in	the	positive	control	samples,	but	
a	more	random	encroachment	of	cells.		The	cell	encroachment	may	be	an	artefact	as	
when	the	assays	are	being	prepared	the	cells	are	loaded	onto	submerged	matrices	
and	an	epithelial	covering	is	allowed	to	form	over	72	hours.		At	72	hours,	this	
epithelial	cell-covered	matrix	is	raised	onto	scaffolds.		The	abnormal	appearances	
occur	where	the	epithelial	cells	are	less	confluent,	which	may	reflect	the	exposure	of	
the	matrix	to	air.		Following	exposure	to	air	there	may	be	breakdown	of	the	matrix,	
allowing	epithelial	cell	invasion.		In	retrospect,	this	assay	may	not	have	been	the	
most	appropriate	to	use,	whilst	the	invasive	potential	of	the	positive	control	is	
clearly	visible,	no	changes	in	the	behaviour	of	the	cell	lines	were	seen	on	the	loss	of	
LRIG1.		This	may	be	due	to	the	loss	of	LRIG1	causing	only	a	subtle	increase	in	the	
ability	of	cells	to	invade,	that	is	not	detectable	in	this	assay.		An	alternative	to	
consider	would	be	a	scratch	assay	(240),	where	the	migratory	potential	of	cells	are	
compared	(although	the	increased	rate	of	growth	of	the	LRIG1	shRNA	knockdown	
cells	would	need	to	be	accounted	for).		To	confirm	the	findings	that	lentiviral	
transduction	and	LRIG1	shRNA	knockdown	does	not	affect	differentiation	potential,	
cells	could	be	grown	either	tracheosphere	assays	or	at	air-liquid-interface.	
	
Further	considerations	could	include	how	the	loss	of	LRIG1	leads	to	the	loss	of	cell-
cell	contact	inhibition	and	an	on-going	proliferation	at	cell	confluence	(104).		Lu	et	al	
showed	through	immunoprecipitation	experiments	performed	at	cell	confluence,	in	
LRIG1-expressing	cells,	that	a	ternary	complex	forms	between	LRIG1,	E-cadherin	and	
EGFR	(104).		These	experiments	were	performed	in	A549	cells,	an	adenocarcinoma	
cell	line	that	does	not	express	LRIG1.		The	A549	cells	were	transduced	with	LRIG1	
protein	attached	to	FLAG	(due	to	difficulties	with	antibody	detection	of	LRIG1).		The	
formation	of	the	ternary	complex	may	provide	a	mechanism	by	which	primary	
epithelial	cells	are	growth	inhibited	at	cell	confluence	and	may	explain	how	LRIG1	
loss	leads	to	preinvasive	disease.		It	would	be	of	benefit	to	assess	the	formation	of	a	
ternary	complex	within	the	primary	HBECS,	as	the	system	would	be	more	relevant	
than	using	a	cell	line	transduced	to	over	express	LRIG1.		Since	the	Lu	et	al	paper	
(104)	has	been	published	there	has	been	the	development	of	antibodies	that	are	
more	successful	in	the	detection	of	LRIG1	by	immunoblotting	(as	used	in	my	
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experiments),	making	the	use	of	a	FLAG-tagged	protein	redundant,	and	time	
permitting,	this	is	something	I	would	pursue.	
	
Due	to	the	loss	of	LRIG1	in	preinvasive	lung	cancers	it	would	be	useful	to	obtain	
bronchial	brushings	from	patients	with	preinvasive	lesions.		The	LRIG1	expression	
and	behaviour	of	basal	cells	(with	or	without	LRIG1	expression)	could	then	be	
compared	in	matched	samples	from	areas	of	normal	epithelium	to	those	of	
preinvasion.		To	date,	it	has	not	been	possible	to	grow	preinvasive	squamous	cell	
lung	cancer	cells	in	culture.		Our	group	has	shown	that	growing	cells	from	
preinvasive	epithelial	brushes	or	biopsies	selects	for	cells	with	a	normal	genotype,	
without	the	genetic	mutations	associated	with	preinvasive	disease.		It	has	been	
shown	that	adding	LRIG1	to	the	A549	adenocarcinoma	cell	line	leads	to	a	change	in	
phenotype	(by	inducing	cell-cell	contact	inhibition	at	cell	confluence),	but	A549	cells	
are	derived	from	cancer	in	a	distal	epithelial	cell	that	I	have	shown,	in	mouse,	by	
immunofluorescence	do	not	express	LRIG1.		If	preinvasive	squamous	cells	could	be	
grown	in	culture,	the	effect	of	LRIG1	re-introduction	or	knockout	could	be	
established.		
	
Consideration	of	this	data	as	a	whole	suggests	that	LRIG1	may	act	as	a	possible	
‘brake’	to	regulate	the	airway	epithelial	stem	cell	population.		In	the	mouse	and	
human	airway,	LRIG1	marks	a	population	of	basal	cells	which	are	more	clonogenic	
and	proliferative	than	LRIG1-	basal	cells.		When	LRIG1	undergoes	shRNA	knockdown	
in	an	LRIG1-expressing	basal	cell	population,	the	cells	become	increasingly	
clonogenic	and	proliferative.		This	implies	both	the	loss	of	a	regulator	and	the	
removal	of	a	regulatory	‘brake’.		The	‘brake’	hypothesis	would	explain	how	LRIG1	
loss	may	lead	to	preinvasive	and	lung	cancer	development:	LRIG1+	basal	cells	have	
increased	stem	cell	characteristics,	with	LRIG1	loss	from	these	basal	cells	leading	to	
dysregulation,	compartment	expansion	and	preinvasive	disease.		To	add	support	to	
this	hypothesis,	the	use	of	LRIG1	knockdown	and	overexpression	within	the	same	
parental	cell	lines	would	need	to	be	performed.		This	would	allow	direct	comparison	
of	proliferation	and	clonogenic	capacity	in	an	LRIG1-overexpressing	and	LRIG1-
knockdown	assay.			
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5.5	 Summary	
	
• LRIG1	is	expressed	across	the	human	airway	
• LRIG1+	basal	cells	are	more	proliferative	and	clonogenic	than	LRIG1-	cells	
• shRNA	knockdown	of	LRIG1	in	HBECs	leads	to	increased	EGFR	signalling	
• shRNA	LRIG1	knockdown	leads	to	increased	colony-forming	efficiency,	
continued	cell	proliferation	at	cell	confluence	and	increased	rate	of	
proliferation	of	HBECs	
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6.	 The	effect	of	LRIG1	loss	in	a	murine	
	 squamous	cell	lung	cancer	model	
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6.	 The	effect	of	LRIG1	loss	in	a	murine	squamous	cell	
	 cancer	model	
	
6.1	 Introduction	
	
The	loss	of	LRIG1	predisposes	to	malignancy	across	a	range	of	epithelial	types	(75,	
97,	110,	241)	and	within	the	human	airway	LRIG1	loss	has	been	observed	in	early,	
preinvasive	squamous	cell	lung	cancers	(104).		To	assess	the	effect	of	loss	of	LRIG1	
on	the	development	of	preinvasive	and	squamous	cell	lung	cancers,	a	murine	model	
of	disease	is	required.		By	comparing	disease	in	wild-type	mice	to	LRIG1-null	mice,	
the	role	of	LRIG1	in	the	development	of	preinvasive	lung	cancer	can	be	elucidated.		
	
Despite	progress	with	the	generation	of	murine	models	recapitulating	
adenocarcinoma,	where	disruption	of	a	single	gene	can	cause	disease,	the	creation	
of	a	robust	squamous	cell	carcinoma	model	has	proved	more	challenging	(242).		
Simultaneous	activation	of	KrasG12D	(an	activating	mutation	associated	with	the	
development	of	murine	adenocarcinoma)	with	loss	of	liver	kinase	B1	
(Lkb1)	leads	to	the	development	of	lung	tumours	including	adeno-,	adenosquamous	
and	squamous	cell	lung	carcinomas.		However,	the	loss	of	Lkb1	in	isolation,	although	
lost	in	human	disease,	does	not	lead	to	squamous	lung	tumour	production	in	a	
murine	model	(243).		The	mutation	of	IκB	kinase	(IKKα),	through	an	amino	acid	
replacement	in	the	adenosine	triphosphate	(ATP)	binding	site,	results	in	loss	of	the	
kinase	activity	and	leads	to	the	formation	of	squamous	lung	cancers.		However,	
these	animals	also	develop	skin	and	gut	tumours	that	lead	to	death,	this	often	occurs	
before	lung	tumours	can	be	analysed	and	restricts	their	use	in	a	lung	cancer	model	
(244).	To	keep	the	animals	alive	long	enough	to	be	used	in	a	lung	cancer	model,	the	
authors	expressed	wild-type	IKKα	cDNA	in	the	epidermis,	under	the	control	of	a	
truncated	loricrin	promoter,	which	allowed	the	assessment	of	lung	disease	(244).				
	
Phosphatase	and	tensin	homolog	(PTEN)	is	a	tumour	suppressor	whose	loss	is	
associated	with	the	development	of	human	squamous	cell	carcinomas,	whilst	SOX2	
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overexpression	has	been	shown	in	the	development	of	both	preinvasive	invasive	and	
squamous	cell	carcinomas.		However,	the	loss	of	Pten,	or	Sox2	overexpression	in	
mouse	models	does	not	lead	to	the	development	of	significant	lesions	(227,	245).		
Overexpression	of	Sox2	initiates	adenocarcinomas	that	exhibit	some	squamous	
features,	including	p63	expression	and	although	the	loss	of	Pten	causes	tumour	
development,	only	8%	of	these	lesions	are	squamous	(227,	245).	
	
Combining	the	loss	of	Lkb1	and	Pten	has	been	shown	to	lead	to	development	of	
entirely	squamous	cell	lung	cancers	after	a	40-50	week	latency.		Tumours	initially	
develop	as	small	nodules	at	around	30-40	weeks,	they	then	enlarge	and	progress	to	
lymphovascular	invasion	and	limited	metastatic	spread	(to	the	chest	wall).		However,	
these	tumours	(that	initially	develop	as	nodules)	do	not	progress	through	the	step-
wise	preinvasive	to	squamous	cell	carcinoma	sequence	seen	in	human	disease	(246),	
where	LRIG1	is	thought	to	influence	disease	progression	(104).			
	
More	recently,	the	overexpression	of	Sox2	in	mice	with	a	conditional	loss	of	both	
Pten	and	cyclin-dependent	kinase	inhibitor	2A/B	(Cdkn2ab)	has	been	shown	to	lead	
to	squamous	cell	lung	cancer	development.		Sox2	overexpression	was	targeted	to	
either	keratin	5	(KRT5)-positive	basal	cells,	surfactant	protein	C	(SPC)-positive	cells,	
alveolar	type	2	(AT2)	cells	or	Clara	cell	10	(CC10)-positive	club	cells,	and	in	all	cases	
led	to	squamous	tumours	(247).		Significant	tumour	production	took	over	a	year	to	
develop,	and	again	there	was	no	indication	of	a	preinvasive	disease	phase.			
	
The	use	of	a	chemical	carcinogen	to	induce	murine	squamous	cell	lung	cancers	was	
first	reported	with	the	use	of	benzopyrene,	a	polycyclic	aromatic	hydrocarbon	found	
in	cigarette	smoke.		Unfortunately,	there	is	no	consensus	on	either	the	dosing	
schedule	or	the	application	method	for	benzopyrene,	with	intraperitoneal	injections,	
intranasal	instillation	and	oral	gavage	all	used	with	variable	success	(248,	249).		
Benzopyrene	does	lead	to	both	squamous	and	adenocarcinomas,	with	the	
proportion	of	squamous	lesions	increasing	with	benzopyrene	dosage	(250).		
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In	2004,	Wang	et	al	(251)	reported	that	the	application	of	the	alkylating	agent	N-
Nitrosotris-(2-chloroethyl)urea	(NTCU)	to	the	shaved,	dorsal	skin	of	mice	
recapitulates	both	preinvasive	and	invasive	squamous	cell	lung	tumours.		The	
regimen	consisted	of	8	months	of	twice-weekly	NTCU	treatments	and	the	
investigators	noted	a	large	variability	in	both	the	severity	and	the	number	of	lesions	
that	was	dependent	on	mouse	strain.			More	recently,	a	method	was	reported	that	
treated	animals	with	75	μl	of	0.013	M	NTCU,	this	was	the	same	dose	of	NTCU,	but	
the	drug	was	dissolved	in	a	higher	volume	of	solvent.		This	treatment	regimen	led	to	
both	preinvasive	and	squamous	cell	lung	cancers	developing	after	a	much	shorter,	
18-week	period	(252).		In	contrast	to	the	Wang	method,	which	used	continual	NTCU	
dosing	over	the	8	month	study	period,	the	second	group’s	regimen	involved	only	8	
weeks	of	NTCU	application	followed	by	a	10	week	‘observation’	period	prior	to	
culling.		Both	methods	induce	comparable	levels	of	disease	in	the	cancer-susceptible	
A/J	strain	of	mice.		Wang	et	al,	report	that	following	8	months	of	treatment,	100%	of	
animals	had	developed	hyperplasia,	metaplasia	and	carcinoma-in-situ	and	75%	have	
invasive	tumours	(251),	whilst	following	the	shorter,	8	weeks	of	NTCU	and	10	weeks	
of	follow-up,	animals	were	shown	to	exhibit	comparable	grades	of	preinvasive	
disease	and	71%	had	developed	tumours	(252).		NTCU	is	an	alkylating	agent,	
although	its	mechanism	of	action	is	uncertain	(249).		It	has	been	shown	to	induce	an	
inflammatory	reaction	with	the	plasma	interleukin-6	levels	elevated	in	NTCU	treated	
animals	compared	to	controls	(253).	
	
Due	to	time	constraints,	developing	a	compound	Lrig1-knockout	transgenic	animal	
lacking	both	Lkb1	and	Pten	would	be	prohibitive,	as	would	an	animal	with	Pten	and	
Cdkn2ab	deletion	together	with	Sox2	overexpression.	As	both	models	only	induce	
invasive	squamous	cell	lesions,	they	may	be	best	utilised	in	the	assessment	of	
therapeutics	and	behaviour	of	established	tumours,	rather	than	looking	at	the	
progression	and	evolution	of	preinvasive	disease.		LRIG1	loss	has	been	shown	in	
human	preinvasive	lesions	(104),	so	the	mouse	model	needs	to	recapitulate	the	
human	form	of	disease.		NTCU-treated	animals	develop	the	full	spectrum	of	
preinvasive	disease	whilst	also	developing	invasive	squamous	cell	tumours.		
Therefore,	this	model	more	successfully	recapitulates	the	changes	that	are	occurring	
	 189	
in	the	human	airway	than	any	of	the	previously	discussed	methods	that	involve	
genetically	modified	mice.		By	following	the	shorter,	18	week	treatment	programme	
(252),	there	would	be	an	opportunity	for	optimisation	of	a	dosing	regimen,	specific	
to	the	colony.		A	further	advantage	is	that	the	chemical	can	be	applied	directly	to	the	
Lrig1	EGFP-ires-CreERT2	animals,	without	the	need	for	further	genetic	
manipulations.	
	
To	assess	the	effect	of	LRIG1	loss	in	the	airway,	I	used	the	Lrig1	EGFP-ires-CreERT2	
strain.		As	previously	discussed	(Chapter	3,	Figure	3.1.B),	homozygous	mice	with	two	
copies	of	Lrig1	EGFP-ires-CreERT2	allele	are	equivalent	to	LRIG1-null	animals,	with	no	
LRIG1	protein	produced,	and	LRIG1-heterozygous	mice	have	one	copy	of	the	Lrig1	
EGFP-ires-CreERT2	allele	and	one	wild-type	Lrig1	allele.		
	
6.2	 Aims	
	
• To	set	up	the	NTCU	model	using	the	Lrig1	EGFP-ires-CreERT2	strain	
• To	validate	that	any	subsequent	lesions	are	either	preinvasive	or	invasive	
squamous	cell	carcinomas	
• To	develop	a	strategy	of	lesion	assessment	
• To	compare	lesion	development	in	wild-type,	LRIG1-heterozygous	and	LRIG1-
null	mice	
	
6.3	 Results	
	
6.3.1	 NTCU	treatment	optimisation	and	establishment	of	a	treatment	protocol	
	
The	effects	of	NTCU	on	the	development	of	preinvasive	and	squamous	cell	cancers	
are	strain	specific,	with	studies	identifying	A/J	mice	as	sensitive,	FVB/N	as	
intermediate	and	C57BL/6	as	resistant	to	the	effects	of	the	carcinogen	(251).		In	the	
more	sensitive	A/J	mice,	dysplastic	lesions	are	seen	after	just	2	weeks	of	NTCU	
(followed	by	a	16	week	follow-up)	and	25%	of	these	animals	develop	invasive	
	 190	
disease	(252).		When	the	treatment	period	was	extended	to	4	and	8	weeks	the	
number	and	severity	of	lesions	progressively	increased,	but	a	marked	47%	mortality	
was	seen	following	8	weeks	of	NTCU	treatment	(252).		On	their	arrival	to	the	
laboratory,	the	animals	containing	the	Lrig1	EGFP-ires-CreERT2	allele	were	on	an	
FVB/N	and	C57BL/6	mixed	background.		This	indicates	their	sensitivity	to	NTCU	was	
likely	to	fall	between	that	reported	in	the	FVB/N	and	C57BL/6	mice.		To	increase	the	
animal’s	susceptibility	to	the	development	of	lesions,	the	initial	cross	of	the	Lrig1	
EGFP-ires-CreERT2	was	with	an	FVB/N	animal,	increasing	the	FVB/N	proportion	in	
the	strain.			In	an	effort	to	limit	the	variability	caused	by	their	mixed	background,	all	
animals	were	used	at	the	same	generation.	
	
As	NTCU	had	not	previously	been	used	within	the	group,	I	set	up	three	preliminary	
cohorts	of	mice.		The	first	two	cohorts,	A	and	B,	were	used	to	ensure	that	the	dosing	
regimen	was	appropriate	for	the	mouse	strain,	and	the	third	cohort,	cohort	C,	
examined	the	effect	of	extending	the	observation	period.		My	aim	was	to	determine	
the	dose	where	preinvasive	lesions	developed	(as	I	want	to	investigate	whether	
LRIG1	affects	the	development	of	these	lesions	in	humans),	whilst	balancing	the	risk	
of	any	dose-related	mortality.		All	animals	were	commenced	between	6-8	weeks	of	
age,	and	only	females	used,	due	to	their	increased	predisposition	to	malignancy	
(254,	255).		Cohort	A	(Figure	6.1.A),	received	4	weeks	of	NTCU	followed	by	14	weeks	
of	observation.	The	short	treatment	duration	was	to	ensure	the	mice	could	tolerate	
NTCU	dosing	and	would	not	develop	side	effects	(such	as	skin	irritation).		The	second	
group,	cohort	B,	received	8	weeks	of	NTCU	treatment	followed	by	10	weeks	of	
observation	(Figure	6.1.A).		Both	cohort	A	and	B	contained	a	single	mouse	of	each	
genotype	to	give	both	an	indication	as	to	the	susceptibility	of	the	strain	but	also	as	to	
whether	loss	of	LRIG1	in	the	LRIG1-null	animals	would	lead	to	a	dramatic	increase	in	
lesion	development	and	necessitate	any	dosage	alterations.		Both	groups	included	
an	acetone-only	(vehicle)	control.		All	animals	were	weighed	immediately	prior	to	
each	NTCU	application	and	then	twice	weekly	weights	were	continued	throughout	
the	observation	period.		
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Figure	6.1:		Optimisation	of	NTCU	dosing	strategy	
	
A)	Treatment	cohorts,	showing	NTCU-dosing	period	(blue	bar)	and	observation	period	(open	bar).		B)	
Weights	of	cohort	A	during	assessment	period,	4	animals	were	included,	one	wild-type,	LRIG1-
heterozygous,	LRIG1-null	and	an	LRIG1-heterozygous	control.		Arrows	indicate	the	length	of	treatment	
period.	Haematoxylin	and	eosin	(H&E)	stain	of	end-on	bronchiole	and	transverse	section	from	a	cohort	A	
mouse,	scale	bars	=	100	μm	and	50	μm.		C)	Weights	of	cohort	B	during	assessment	period,	4	animals	were	
included,	one	wild-type,	LRIG1-heterozygous,	LRIG1-null	and	an	LRIG1	heterozygous	control.		End-on	and	
transverse	bronchioles	from	cohort	B	animals	showing	evidence	of	enlarged	hyperplastic	basal	cells,	
indicated	by	arrow	heads,	scale	bars	=	100	μm	and	50	μm.		D)	Weights	of	cohort	C	animals	during	
assessment,	n=2-3	in	each	group.		Bronchiole	from	cohort	C	treated	animal	with	evidence	of	low-grade	
dysplasia,	note	multiple	layers	of	epithelial	cells	and	flattening	of	the	nuclei	at	the	luminal	edge,	scale	bar	=	
50	μm	and	keratin	5	(KRT5;	red)	staining	of	bronchiole	from	a	cohort	C	animal,	BrdU	(green)	stained	cells	
are	seen	adjacent	to	the	basement	membrane,	n	=	3,	scale	bar	=	50	μm.		
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Cohort	A	displayed	no	side	effects,	with	no	skin	irritation	or	weight	loss	and	the	
animals	remained	well	throughout	the	study	period.	On	organ	harvest,	there	were	
no	macroscopic	anomalies	and	histology	revealed	nothing	suggestive	of	preinvasive	
lung	disease	(Figure	6.1.B).	
	
In	the	8-week	treatment	group,	cohort	B,	one	of	the	mice	developed	skin	irritation	
over	the	left	scapula.		This	was	treated	with	manuka	honey	and	resolved	on	
grooming	of	the	nails.		At	the	experimental	end	point,	no	macroscopic	changes	were	
detectable	within	the	lungs,	liver	or	skin	of	the	mice.		Review	of	lung	histology	(with	
pathology	assistance)	identified	that	NTCU	had	induced	basal	cell	hyperplasia.		This	
was	shown	by	basal	cell	enlargement	and	an	increased	nuclear	to	cytoplasmic	ratio	
(Figure	6.1.C).		A	small	difference	in	weight	was	seen	between	the	treated	animals	
and	control,	with	the	control	animal	15%	heavier	than	the	treated	animals	at	the	
experimental	end	point	(Figure	6.1.C).			
	
Cohort	C	(Figure	6.1.D)	consisted	of	8	treatment	mice	(3	LRIG1-null,	3	wild-type	and	
2	LRIG1-heterozygous	animals)	alongside	two	LRIG1-heterozygous	controls	(acetone	
only).		As	the	NTCU	treatments	take	a	number	of	weeks,	this	cohort	had	commenced	
and	finished	the	treatment	phase	prior	to	the	results	from	cohort	B	being	obtained.		
This	meant	the	treatment	period	could	not	be	lengthened,	but	the	observation	
phase	was	extended	from	10	to	14	weeks.		When	the	lungs	from	these	animals	were	
examined,	there	was	evidence	of	more	advanced	preinvasive	disease.		Low-grade	
lesions,	consisting	of	multiple	layers	of	cells	and	flattening	of	the	nuclei	at	the	
luminal	edge,	were	seen	within	the	bronchioles	(Figure	6.1.D).		These	low-grade	
lesions	were	KRT5-positive,	indicating	a	squamous	cell	phenotype	(256).		Cohort	C	
was	the	first	group	to	exhibit	untoward	effects	and	5	animals,	of	varying	genotypes,	
were	lost	(discussed	later).			
	
In	both	cohort	B	and	C,	a	separation	between	the	weights	of	the	treated	and	control	
animals	were	seen	(Figure	6.1.C	and	6.1.D).		During	the	first	8-	10	weeks	the	weights	
remained	similar	but,	after	this	point,	the	weights	of	the	control	mice	increased	
whilst	the	weights	of	the	treated	animals	remained	static.						
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As	low-grade	lesions	were	detectable	in	cohort	C,	NTCU	was	clearly	shown	to	induce	
lesions	in	the	Lrig1	EGFP-ires-CreERT2	colony.		To	assess	for	differences	in	the	
susceptibility	to	develop	preinvasive	and	squamous	cell	cancers,	the	number	of	
lesions	needed	to	be	both	increased	and	be	of	a	greater	severity.		Different	
strategies	were	considered	to	increase	lesion	frequency.		These	included	the	
administration	of	intranasal	lipopolysaccharide	(LPS)	that	has	been	seen	to	increase	
NTCU-induced	tumour	size	by	enhancing	NTCU-induced	inflammation	(181)	and	the	
use	of	naphthalene	that	causes	airway	damage	and	subsequent	epithelial	cell	
proliferation.		Naphthalene	increases	the	number	of	lung	adenocarcinomas	that	
develop	in	a	murine	genetically-induced	KRasG12D	adenocarcinoma	model,	through	
stimulating	the	proliferation	of	bronchioalveolar	stem	cells	(BASCs)	(129),	the	
putative	stem	cell	population	for	the	distal	airway.		The	origin	of	the	NTCU-induced	
preinvasive	lesions	is	uncertain,	but	the	triggering	of	proliferation	in	the	distal	airway	
may	lead	to	increased	disease.		However,	whilst	both	methods	may	increase	lesion	
development,	to	ensure	the	model	remained	reproducible	and	without	adding	
additional	confounders,	the	dosing	period	was	simply	extended	to	12	weeks,	with	a	
12-week	period	of	follow	up.			
	
6.3.2	 An	optimised	treatment	course	for	NTCU	
	
Cohort	D	(Figure	6.1.A)	was	initiated	where	the	NTCU	dosing	period	was	increased	
from	8	to	12	weeks	and	the	period	of	observation	from	10	to	12	weeks.		In	total,	the	
period	of	assessment	was	extended	from	18	weeks	in	cohort	B	to	24	weeks	in	cohort	
D.		Batches	of	animals,	containing	equal	number	of	LRIG1-null,	LRIG1-heterozygous	
and	wild-type	animals	were	set	up	at	3	weekly	intervals,	allowing	closer	monitoring	
of	untoward	effects	and	to	simplify	dosing.		The	follow-up	period	was	curtailed	at	11	
weeks,	giving	a	23	week	total	treatment	period.		This	was	due	to	breathlessness	and	
a	general	deterioration	within	the	colony.		As	the	treatments	were	staggered,	I	
needed	to	ensure	all	animals	could	reach	the	same	end	point	and	would	not	have	to	
be	culled	early.	
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All	of	the	animals	showed	an	initial	weight	gain	and	the	weights	in	the	treatment	and	
control	groups	were	comparable	until	10	weeks	(Figure	6.2.A).		Beyond	10	weeks,	
the	control	mice	continued	to	gain	weight	whilst	the	weight	of	the	treatment	groups	
levelled.		There	was	no	significant	difference	in	the	weights	of	the	wild-type,	LRIG1-
heterozygous	and	LRIG1-null	treatment	arms.		By	23	weeks,	a	difference	of	27%	was	
seen	between	the	weights	of	the	control	and	LRIG1-heterozygous	treated	animals.			
	
Initially,	LRIG1-heterozygous	animals	were	used	as	controls,	as	there	was	a	surplus	of	
LRIG1-heterozygous	mice	(in	accordance	with	the	principles	of	the	‘3	Rs’	(207).		
However,	following	the	finding	by	Powell	et	al,	that	LRIG1-null	mice	develop	gut	
adenomas,	which	spontaneously	progress	to	adenocarcinomas	(94),	LRIG1-null	
controls	were	also	subsequently	included	to	ensure	the	LRIG1-null	animals	did	not	
develop	spontaneous	lung	tumours.		The	weights	of	the	LRIG1-null	control	animals	
mirrored	that	of	the	LRIG1-heterozygous	controls	(Supplementary,	Figure	1).			
	
Histology	from	cohort	D	showed	the	animals	developed	lesions	that	recapitulated	
human	disease.		All	grades	of	lesions	were	seen	across	the	treatment	arms.		Low-
grade	lesions,	with	multiple	layers	of	cells	and	retention	of	organization	from	the	
basal	layer	to	cells	of	a	more	squamous	appearance	along	the	luminal	edge	were	
apparent	(Figure	6.2.Bi),	as	was	flat	atypia	(Figure	6.2.Bii),	defined	through	nuclei	of	
abnormal	morphology	and	increased	basal	cell	size.		These	areas	were	most	clearly	
identified	by	staining	for	KRT5.		In	healthy	mice,	KRT5	is	not	seen	beyond	the	
cartilage-containing	airways	(176),	meaning	any	single	layer	of	KRT5-stained	cells	
beyond	the	cartilage-containing	trachea	and	the	immediate	origin	of	right	and	left	
main	bronchi	is	abnormal.		This	increased	KRT5	expression	is	the	first	indication	of	a	
more	squamous	phenotype	and	is	classified	as	flat	atypia.		
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Figure	6.2:		Cohort	D,	the	final	dosing	regimen	in	the	NTCU	treated	animals	
	
A)	Weights	of	cohort	D,	NTCU-treated	mice	and	controls.		Arrow	indicates	end	of	NTCU	treatment	period.		Error	bars	
signify	S.E.M,	n=	7-10	per	group.		B)	i)	Flat	atypia,	with	enlarged,	flattened	nuclei,	and	increased	nuclear-	cytoplasmic	
ratio,	scale	bar	=	50	μm.		ii)	Low-grade	dysplasia.		Multiple,	ordered	layers	of	epithelial	cells,	with	clear	organisation	
from	the	basement	membrane	to	the	luminal	surface.		Note	flattened	nuclei	adjacent	to	the	lumen,	scale	bar	=	50	μm.	
iii)	High-grade	dysplasia,	with	the	presence	of	disordered	layers	of	epithelial	cells	and	multiple	enlarged	nuclei,	scale	bar	
=	50	μm.	iv)	Invasive	squamous	cell	carcinoma	lesion,	beginning	to	fill	the	alveolar	spaces,	scale	bar	=	50	μm.	v)	Close-up	
image	of	a	keratin	pearl,	a	characteristic	feature	of	squamous	cell	carcinoma,	scale	bar	=	50	μm.	vi)	Bronchiole	showing	
high-grade	dysplasia	and	breakdown	of	the	basement	membrane	(arrowed).	This	signifies	an	early	squamous	cell	
carcinoma.		Note	inflammatory	infiltrate	in	the	top	right	corner,	scale	bar	=	50	μm.		Images	representative	of	lesions	
seen	in	treated	mice	of	all	genotypes.			C)	Caudal	sections	of	the	lung,	stained	with	keratin	5	(KRT5).		The	KRT5	
expression	indicates	localisation	of	changes	to	the	distal	lung,	scale	bar	=	5	mm.		
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High-grade	lesions	were	classified	as	lesions	several	layers	thick,	with	abnormal	
cellular	morphology	and	no	organization	between	the	basal	layer	and	the	luminal	
cells	(Figure	6.2.Biii).		Invasive	cancers	were	seen	to	fill	the	alveolar	spaces	and	they	
exhibited	large	nuclei	with	increased	nuclear-to-cytoplasmic	ratio	(Figure	6.2.Biv).	
Keratin	pearls,	a	classical	feature	of	squamous	aetiology	(251),	were	visible	in	the	
more	advanced	lesions	(Figure	6.2.Bv).		Areas	where	high-grade	dysplasias	were	seen	
to	break	the	epithelial	basement	membrane,	becoming	invasive	cancers,	were	also	
present	(Figure	6.2.Bvi).			
	
Lesions	were	clearly	distributed	in	the	periphery	of	the	lung,	beyond	the	main	
bronchi	(Figure	6.2.C).		These	formed	two	main	patterns:	disease	lining	the	
bronchioles	and	invasive	lesions	clustered	around	the	distal	bronchioles.		Invasive	
disease	was	seen	to	occur	within	the	periphery	of	the	lung,	rather	than	arising	from	
the	main	airway.	
	
No	tumours,	invasive	lesions	or	basal	cell	hyperplasia	was	seen	in	the	control	
animals.		These	included	animals	of	both	the	LRIG1-heterozygous	and	LRIG1-null	
genotypes.		
	
6.3.3	 NTCU	treatment	complications		
	
Animal	losses	occurred	across	all	treatment	groups.		There	was	no	predilection	for	
the	genotype	of	the	mouse	(Figure	6.3.A)	and	no	losses	occurred	in	the	control	
groups.		The	main	cause	of	death	was	bowel	distension.		This	affected	6	of	the	37	
animals	that	were	treated	as	part	of	cohort	D	and	one	of	the	animals	in	cohort	C.		5	
of	the	6	animals	were	culled	due	to	the	animals	reaching	humane	end	points.		The	
cases	all	appeared	during	the	monitoring	phase	of	the	experiment,	after	NTCU	
dosing	was	complete.		A	further	mouse	developed	abdominal	swelling	that	was	
intermittent	and	did	not	progress	over	a	4-week	period.		This	animal	completed	the	
observation	period	and	was	included	in	the	analysis.		The	affected	animals	were	not	
littermates	and	were	from	different	breeding	pairs,	making	a	spontaneous	genetic	
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mutation	unlikely.		Once	the	abdomen	had	begun	to	swell,	other	than	in	the	one	
mouse,	it	progressed	rapidly,	was	associated	with	severe	breathlessness,	lack	of	
movement	and	grimacing,	which	necessitated	immediate	culling.		On	dissection,	the	
abdomen	was	markedly	distended	(Figure	6.3.Bi),	with	the	entire	bowel	swollen	
from	stomach	to	colon.		It	is	known	that	LRIG1-null	mice	develop	spontaneous	bowel	
adenocarcinomas	after	several	months	(94),	but	on	removing	the	bowel,	neither	a	
circumferential	lesion	nor	blockage	was	evident.		Samples	taken	for	histology	
showed	necrosis,	an	inflammatory	infiltrate	and	oedema	(Figure	6.3.Bii	and	6.3.Biii).		
Discussion	with	a	pathologist	confirmed	necrosis,	however,	no	other	anomalies	such	
as	tumour	mucosal	deposits	were	visualised.		It	was	felt	the	necrosis	was	secondary	
to	the	enormous	bowel	distension	and	disrupted	blood	supply,	rather	than	being	the	
initiating	event.		The	cause	of	death	appeared	to	be	a	septic	ileus	with	increased	air	
ingestion.		A	further	discussion	with	Avrum	Spira’s	group,	Boston	University,	USA,	
revealed	similar	complications	within	their	NTCU-treated	animals.		They	attribute	
this	side	effect	to	overwhelming	sepsis	following	an	NTCU-provoked	systemic	
inflammatory	state.	
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Figure	6.3:		Complications	of	NTCU	treatment	
	
A)	The	number	of	animals	lost	from	cohort	D,	according	to	genotype.		B)	i)	Gross	distension	of	the	bowel,	
with	air	insufflation	and	opacity	of	the	walls.		Stomach	indicated	by	*.		ii)	Haemotoxylin	and	eosin	(H&E)	
staining	of	the	bowel	wall,	with	inflammatory	infiltrate,	indicated	by	*	and	haemorrhage,	indicated	by	
arrow,	scale	bars	=	200	μm	and	100	μm.		C)	i)	Genital	swelling,	with	distension	of	soft	tissue	around	the	
vaginal	introitus.		ii)	Compression	on	the	abdomen	increases	the	genital	swelling,	implying	possible	
prolapse.		D)	i)		H&E	staining	of	the	ovary	(*),	fallopian	tube	(^)	and	uterus	(#),	revealing	no	abnormality,	
scale	bar	=	2	mm.		ii)	Close	up	image	of	the	ovary,	with	normal	follicular	appearances,	scale	bar	=	200	
μm.	iii)	Close	up	of	the	endometrium,	showing	no	evidence	of	malignancy,	scale	bar	=	400	μm.		
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Genital	abnormalities	were	a	further	complication	that	had	not	previously	been	
reported	when	using	the	NTCU-model.		These	changes	occurred	after	the	NTCU	
dosing	period	and	affected	both	the	vulva	and	vaginal	introitus	in	cohorts	C	and	D	
(Figure	6.3.C).		The	swelling	was	increased	by	abdominal	compression,	suggesting	
the	pathology	was	secondary	to	a	raised	intra-abdominal	pressure	or	vaginal	
prolapse.		Although	some	mouse	strains	are	susceptible	to	vaginal	and	rectal	
prolapse	(257,	258),	these	complications	had	not	previously	been	seen	within	the	
colony.		Following	discussion	with	the	animal	unit	NACWOs	and	veterinary	surgeon	it	
was	advised	to	cull	the	animals	and	collect	their	reproductive	organs.		Histology	
showed	normal	ovarian	tissue	(Figure	6.3.Dii)	and	a	normal	endometrium	(Figure	
6.3.Diii),	with	no	evidence	of	malignancy.		In	total,	3	animals	from	cohort	C	were	
culled	due	to	the	genital	abnormalities,	none	of	which	developed	weight	loss	or	
features	of	distress.		3	further	animals	in	cohort	D	showed	genital	changes,	these	
were	managed	by	close	observation	and	daily	application	of	aqueous	cream	to	the	
affected	areas.			The	swellings	were	noted	to	be	intermittent	and	all	three	of	the	
cohort	D	animals	reached	the	experimental	end	points.		There	was	no	correlation	of	
the	genital	changes	with	the	genotype	of	the	mouse	(with	the	abnormality	seen	in	all	
genotypes),	the	degree	of	the	disease	seen	in	the	lung	or	whether	the	animals	were	
of	the	same	litter.	
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6.3.4	 Investigation	for	NTCU-associated	disease	in	other	organs	
	
Other	than	skin	ulceration	(253),	NTCU-associated	disease	in	other	organs	has	not	
been	reported.		When	the	animals	were	culled,	they	were	opened	along	the	midline	
and	no	visible	intra-abdominal	pathology	(other	than	in	the	animals	that	failed	to	
reach	the	experimental	end	point)	was	identified.		To	assess	further	for	disease,	both	
the	skin	and	liver	were	removed.			
	
The	animals	were	shaved	for	NTCU	application.		Once	treatment	ceased,	the	fur	
regrew.		Only	one	animal,	from	cohort	B,	developed	a	skin	lesion.		This	appeared	
irritation-related	and	resolved	on	treatment.		When	the	organs	were	harvested,	the	
skin	was	re-shaven	and	palpated	to	detect	any	underlying	lesion.		The	skin	was	
subsequently	removed	and	processed.		No	macroscopic	or	microscopic	anomalies	
were	detected	(Figure	6.4.A).	
	
There	were	no	macroscopic	anomalies	in	the	liver,	however,	microscopically,	4	of	the	
animals	had	lesions.		These	lesions	were	of	a	different	appearance	to	the	normal	
homogeneous	liver	architecture,	with	disorganised	cells	and	visible	red	blood	cells	
(Figure	6.4.B).		There	was	no	association	with	genotype	and	the	animals	had	not	lost	
weight.		The	liver	changes	were	discussed	with	a	liver	pathologist	and	were	felt	to	be	
consistent	with	necrosis.		The	lesions	were	thought	to	have	occurred	pre-mortem,	
with	drug	toxicity	a	probable	cause.		
	
The	upper	part	of	the	trachea,	from	the	midpoint	to	the	larynx	was	taken	for	
assessment.		No	evidence	of	convincing	preinvasive	disease	was	seen	(Figure	6.4.Ci	
and	6.4.Cii).		The	section	of	trachea	from	the	point	of	insufflation	into	the	bronchi	
was	damaged	following	lung	insufflation,	however,	no	preinvasive	disease	was	seen.		
KRT5	staining	confirmed	the	presence	of	a	single	layer	of	KRT5	cells	throughout	this	
section	of	trachea.		This	excluded	the	development	of	any	preinvasive	lesion	other	
than	early	flat	atypia.		
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Figure	6.4:		Assessment	of	NTCU-mediated	disease	outside	the	lung	and	in	the	upper	trachea	
	
A)	Haemotoxylin	and	eosin	(H&E)	staining	showing	normal	structure	of	the	skin.		No	evidence	of	hyperproliferation	
within	the	epidermis	or	hair	follicle	and	no	tumours	visualised,	scale	bar	=	200	μm.		B)	H&E	staining	showing	liver	
abnormalities.		These	are	seen	as	areas	of	different	density	within	the	liver,	indicated	by	arrows.		Close	up	of	these	areas	
shows	necrosis	with	loss	of	the	normal	liver	architecture	and	an	infiltration	of	red	blood	cells.	Scale	bar	=	200	μm.		C)	i)	
H&E	staining	of	the	upper	trachea,	revealing	normal	architecture	with	no	evidence	of	preinvasive	lesions	or	tumours,	
scale	bar=	250	μm.		ii)	Close	up	of	tracheal	epithelium	with	normal	epithelial	cells	seen,	scale	bar	=	50	μm.				
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6.3.5	 Validation	of	NTCU-induced	preinvasive	squamous	cell	lesions	
	
NTCU	is	associated	with	the	development	of	squamous	cell	lung	cancers.		To	confirm	
the	developing	lesions	were	of	a	squamous	phenotype,	the	lungs	were	stained	for	a	
number	of	markers.		Both	KRT5	and	p63	are	markers	of	squamous	cell	lung	cancers	
and	have	been	used	to	validate	NTCU-induced	preinvasive	and	squamous	cell	lesions	
(252,	255,	259,	260).			
	
KRT5	is	not	expressed	beyond	the	trachea	in	the	normal	murine	airway	(other	than	
rare	cells	in	the	distal	lung)	(176)	but	clear	expression	was	seen	in	the	peripheral	
lung	in	the	NTCU	treated	mice.		KRT5	staining	was	seen	across	the	bronchial	tree	and	
marked	early,	preinvasive,	flat	atypia	lesions	(Figure	6.5.A).		KRT5	staining	was	also	
evident	in	both	low-grade	and	high-grade	lesions	(Figure	6.5.Aii)	and	throughout	the	
cells	of	invasive	squamous	cell	lung	tumours	(Figure	6.5.Aiii).			
	
In	the	normal	airway,	p63	marks	basal	epithelial	cells	that	are	adherent	to	the	upper	
airway	basement	membrane.		Interestingly,	p63	staining	is	seen	in	preinvasive	
lesions,	beyond	the	trachea,	but	only	within	the	cells	that	are	in	contact	with	the	
basement	membrane.		As	the	lesions	become	more	advanced	with	a	progressive	
increase	in	the	number	of	layers	of	cells,	the	p63	expression	remains	restricted	to	
the	cells	in	contact	with	the	membrane	(Figure	6.5.B).		When	invasive	lesions	are	
stained	for	p63,	variable	expression	is	seen	within	the	tumour.		The	highest	levels	
appear	to	be	in	those	constrained	by	the	alveolar	membranes	(Figure	6.5.Biii).	
	
EGFR	is	overexpressed	in	preinvasive	and	squamous	cell	lung	cancers	(261).		EGFR	
expression	is	seen	along	the	basolateral	membrane	of	the	epithelium,	throughout	
the	bronchial	tree.		Staining	for	EGFR	confirmed	that	in	both	preinvasive	lung	lesions	
and	lung	tumours,	EGFR	expression	had	increased,	beyond	that	of	basal	levels	
(Figure	6.5.C).	
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Figure	6.5:		Confirmation	that	preinvasive	and	invasive	lesions	have	a	squamous	phenotype	
	
A)	Keratin	(KRT5)	immunofluorescence	staining	(red)	shown	in	i)	flat	atypia,	with	KRT5	expression	seen	only	in	those	cells	
adjacent	to	the	basement	membrane,	in	ii)	low-grade	and	high-grade	dysplasia	where	KRT5	is	expressed	throughout	the	
increased	layers	of	epithelial	cells	and	in	iii)	an	invasive	tumour	where	KRT5	is	seen	distributed	across	all	abnormal	cells.		B)	
p63	immunofluorescence	staining	(green),	demonstrated	in	i)	distal	airway	flat	atypia,	ii)	in	the	cells	adjacent	to	the	basement	
membrane	in	low-grade	atypia	and	in	iii)	invasive	tumours,	where	the	p63	expression	is	not	uniform	but	appears	with	highest	
concentration	in	the	cells	along	a	basement	membrane	and	lining	the	alveolar	surface.		C)	Epidermal	growth	factor	receptor	
(EGFR;	green),	seen	in	i)	low-grade	dysplasia	and	flat	atypia,	ii)	high-grade	lesions	and	iii)	within	invasive	tumours.		D)	Ki67	(red)	
and	BrdU	(green)	immunofluorescence	staining	of	i)	low-grade	lesions	and	ii)	high-	grade	dysplasia	where	the	proliferative	cells	
are	those	seen	along	the	basement	membrane,	and	in	iii)	tumours,	where	the	proliferative	cells	are	distributed	throughout	the	
tumour.		Ki67	labels	a	greater	number	of	cells	than	4	hours	BrdU	labelling.		In	all	cases,	DAPI	used	as	a	counterstain	and	n=	3,	
with	wild-type,	LRIG1-heterozygous	and	LRIG1-null	animals	used	for	comparison.	Scale	bar	=	50	μm.				
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To	assess	proliferation,	sections	were	stained	for	both	BrdU	and	Ki67.		BrdU	was	
administered	4	hours	prior	to	sacrifice,	but	revealed	very	few	proliferative	cells	
within	areas	of	preinvasive	disease	(Figure	6.5.D).		Those	that	were	stained	were	in	
contact	with	the	basement	membrane.		To	obtain	a	clearer	indication	of	
proliferation,	Ki67	staining	was	also	performed.	This	staining	marked	a	greater	
number	of	cells,	and	similarly	to	BrdU,	the	staining	was	detected	in	the	cells	in	
contact	with	the	basement	membrane.		Within	the	lung	tumours	there	was	a	
suggestion	that	the	cells	on	the	tumour	periphery	were	more	proliferative	with	
increased	Ki67	staining	(Figure	6.11.E).		
	
6.3.6	 Assessment	for	markers	of	adenocarcinoma		
	
Surfactant	protein	C	(SPC)	and	thyroid	transcription	factor	1	(TTF1)	are	markers	of	
type	2	cells	within	the	distal	airway	(262).		Both	are	overexpressed	in	lung	
adenocarcinoma	(256,	262).		As	NTCU-induced	lesions	were	anticipated	to	be	SPC-	
negative	and	had	previously	been	reported	to	be	negative	for	TTF1	(253,	259),	dual	
staining	was	performed	with	either	SPC	or	TTF1	in	association	with	KRT5.		The	KRT5	
staining	was	used	to	identify	areas	of	disease.			
	
As	expected,	the	preinvasive	lesions	were	negative	for	SPC,	as	were	the	cells	within	
invasive	lesions	(Figure	6.6.Aiii).		However,	the	TTF1	staining	was	unexpected,	with	
TTF1-positive	cells	detected	across	all	grades	of	preinvasive	and	invasive	lesions	
(Figure	6.6.B).		TTF1-positive	cells	within	the	preinvasive	lesions	were	dual	positive	
for	both	KRT5	and	TTF1.		The	intensity	of	TTF1	staining	was	greatest	in	the	alveolar	
type	2	cells	and	was	slightly	lower	in	those	cells	positive	for	KRT5.		However,	the	co-
staining	of	TTF1	and	KRT5	was	clearly	brighter	than	both	the	negative	control	and	
the	nuclei	in	the	DAPI-stained	stromal	and	alveolar	type	1	cells.		To	further	
characterise	these	lesions,	combined	stains	were	performed	to	examine	airway	
marker	co-expression.	
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Figure	6.6:		Assessment	of	lesions	for	the	adenocarcinoma	associated	markers	TTF1	and	SPC	
	
A)	i)	Immunofluorescence	staining	using	surfactant	protein	C	(SPC;	red)	and	keratin	5	(KRT5;green)	to	identify	abnormal	areas.		
No	SPC	positive	cells	are	visible	in	flat	atypia	lesions,	scale	bar	=	50	μm,	ii)	SPC	(red)	and	KRT5	(green)	staining	of	a	low-grade	
lesion.		Again,	no	SPC-positive	cells	are	seen	within	the	lesion,	scale	bar	=	50	μm,		iii)	SPC	(red)	and	KRT5	(green)	staining	of	
tumour,	showing	no	evidence	of	dual	staining	for	SPC	and	KRT5,	scale	bar	=	50	μm.		B)	i)	Immunofluorescence	staining	for	
thyroid	transcription	factor	1	(TTF1;	green),	with	KRT5	(red)	highlighting	areas	of	abnormal	epithelium.		In	an	area	of	flat	
atypia,	TTF1	staining	is	seen	in	association	with	KRT5.		There	is	a	gradient	of	TTF1	expression	with	highest	intensity	seen	in	the	
nuclei	of	alveolar	type	2	cells	(arrowed),	an	intermediate	level	in	the	dysplastic	epithelium	and	negative	staining	in	the	nuclei	
of	surrounding	stroma	and	alveolar	type	1	cells.		Scale	bar	=	50	μm.		ii)	TTF1	(green)	and	KRT5	(red)	staining	in	a	low-grade	
lesion.		Cells	are	dual	stained	for	both	markers,	scale	bar	=	50	μm.		iii)	TTF1	(green)	and	KRT5	(red)	staining	in	an	invasive	
tumour.		Cells	that	are	dual	stained	for	both	markers	are	clearly	visible,	scale	bar	=	50	μm.		In	all	cases	DAPI	used	as	a	
counterstain	and	n=	3,	with	staining	performed	on	wild-type,	LRIG1-heterozygous	and	LRIG1-null	animals.		
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6.3.7	 Elucidating	the	possible	cell	of	origin	of	preinvasive	and	squamous	cell	lung	
cancers	
	
To	establish	whether	a	TTF1-positive	cell	was	the	origin	of	the	preinvasive	lesion,	and	
whether	it	co-localised	with	a	subpopulation	of	basal	cells,	staining	for	TTF1,	KRT5	
and	p63	was	performed.		p63	marks	an	airway	basal	cell	that	on	airway	injury	can	
develop	into	a	keratin	8	(KRT8)-expressing,	p63-negative	basal	cell,	and	depending	
on	Notch	signalling	then	enters	a	ciliated	or	secretory	lineage	(132).		Therefore,	to	
assess	the	association	of	TTF1	with	the	p63	positive	basal	cells,	triple	staining	was	
performed.		As	anticipated,	all	p63-positive	cells	within	lesions	were	KRT5	positive	
and	all	cells	in	the	preinvasive	areas	appeared	to	be	TTF1-positive.		The	p63-positive	
cells	were	also	TTF1-positive,	but	the	intensity	of	staining	was	not	increased	in	this	
population	(Figure	6.7.A).		TTF1	was	reduced	in	the	preinvasive	lesion	and	tumours	
compared	to	the	surrounding	alveolar	type	2	cells.		Further	co-staining	for	KRT5,	
CC10	and	TTF1	revealed	rare,	triple-stained	cells	(arrowed)	(Figure	6.7.B).		It	has	
been	speculated	that	the	origin	of	NTCU	tumourigenesis	is	a	p63-,	CC10-,	KRT5-
expressing	cell	(260),	however,	staining	for	these	markers	revealed	only	one	
potential	cell	(Figure	6.7.C),	and	further	areas	need	to	examined.			
	
Bronchioalveolar	stem	cells	(BASCs)	are	thought	to	be	a	stem	cell	of	the	distal	
airway.		These	are	identified	through	the	coexpression	of	SPC	and	CC10	(129).		BASCs	
were	detectable	in	the	distal	lung	(Figure	6.7.Di,	arrowed)	and	showed	a	lower	
intensity	of	SPC	staining	compared	to	that	seen	in	surrounding	AT2	cells,	consistent	
with	the	reported	literature	(129).		The	identified	BASCs	were	not	KRT5	stained	(and	
there	was	no	suggestion	of	any	cells	being	triple	stained	for	SPC,	KRT5	and	CC10),	
but	the	BASCs	were	consistently	shown	to	be	adjacent	to	areas	of	preinvasive	
disease	(Figure	6.7.Di).		On	review	of	control	sections,	where	animals	had	not	been	
administered	NTCU,	lower	BASC	numbers	was	seen	compared	with	the	NTCU	treated	
mice	(Figure	6.7.Dii).		
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Figure	6.7:		Co-staining	of	epithelial	markers	within	the	airway	epithelium	
	
A)	i)	Immunofluorescence	staining	of	a	preinvasive	lesion	for	keratin	5	(KRT5;	green),	p63	(white),	and	thyroid	
transcription	factor	1	(TTF1;	red),	indicating	triple	stained	epithelial	cells.		Combined	image	on	left.		Centre	
shows	overlap	of	p63	(white)	and	TTF1	(red)	expression,	whilst	right	image	shows	TTF1	staining	(red)	with	DAPI	
counterstain.		The	expression	of	TTF1	can	be	seen	in	alveolar	type	2	cells	and	also	in	dual	p63+/KRT5+	cells,	but	at	
a	reduced	level.		Scale	bar	=	100	μm.		ii)	Close	up	image	from	i),	demonstrating	clear	triple	expression.		Scale	bar	
=	50	μm.	B)	i)		Immunofluorescence	staining	of	a	preinvasive	lesion	for	KRT5	(green),	Clara	cell	10	(CC10;	white)	
and	TTF1	(red).		DAPI	used	as	counterstain.		Two	KRT5+CC10+TTF1+	cells	are	visible,	indicated	by	arrows.		Scale	
bar	=	100	μm	ii)	Close	up	image	of	the	KRT5+CC10+TTF1+	epithelial	cell,	showing	a	clear	overlap	in	staining.		Scale	
bar	=	50	μm.		C)	Immunofluorescence	staining	of	a	preinvasive	lesion	for	KRT5	(green),	p63	(red)	and	CC10	
(white).		Combined	triple-stained	image	on	left,	centre	image	showing	KRT5	and	p63	staining	and	right	image	
p63	staining.		Arrow	indicating	a	KRT5+p63+CC10+	triple-	stained	cell.		Scale	bar	=	50	μm.		D)	i)	
Immunofluorescence	staining	of	bronchioalveolar	stem	cells	(BASCs),	which	show	positive	staining	for	CC10	
(white)	and	SPC	(red)	(arrowed).		Areas	of	preinvasive	disease	are	indicated	by	staining	for	KRT5	(green).	ii)		
Immunofluorescence	staining	in	control	mice,	not	treated	for	with	NTCU,	showing	BASCs,	indicated	by	arrows.	In	
all	cases	n=	3,	with	staining	undertaken	in	wild-type	animals.		Staining	performed	by	Dr	Sandra	Gomez	Lopez.		
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6.3.8	 Development	of	lung	adenocarcinoma	
	
A	single	mouse	in	cohort	D	lost	weight	rapidly	and	fell	below	the	20%	acceptable	
weight	loss	limits,	necessitating	culling.		In	total	the	mouse	had	received	12	weeks	of	
treatment	followed	by	7	weeks	of	follow	up	and	had	a	wild-type	genotype.		On	
removal	of	the	lungs,	a	large	tumour	was	seen	that	encompassed	the	majority	of	the	
right	upper	lobe	(Figure	6.8.A).		The	histological	appearances	differed	to	the	
previously	seen	KRT5-positive	invasive	lesions.		The	tumour	consisted	of	tightly-
packed	cells,	with	large	nuclei	and	a	glandular	morphology.		A	further	area	was	
present	within	the	leftt	upper	lobe,	which	exhibited	similar	features	and	had	the	
characteristic	glandular	organization	of	a	lung	adenocarcinoma	(Figure	6.8.B).	
	
Both	the	large	right	upper	lobe	tumour	and	left	upper	lobe	tumour	were	KRT5-	
negative,	although	there	were	many	KRT5-positive,	preinvasive	lesions	at	the	lung	
bases	(Figure	6.8.C).		To	confirm	the	tumour	identity,	sections	were	stained	for	the	
adenocarcinoma	markers	TTF1	and	SPC	and	in	addition	to	KRT5,	the	squamous	cell	
markers	p63	and	EGFR.		The	lesions	were	positive	for	SPC	and	TTF1	and	negative	for	
KRT5,	EGFR	and	p63,	confirming	the	tumours	adenocarcinoma	identity	(Figure	
6.8.D).			
	
Ageing	FVB/N	mice	do	develop	spontaneous	lung	adenomas	(180)	and	in	NTCU-	
treated	FVB/N	animals	these	adenomas	have	been	observed	to	progress	to	
adenocarcinomas	(259).		Only	this	mouse	developed	features	of	lung	
adenocarcinoma	and	there	was	no	evidence	of	lesions	in	either	the	control	mice	(in	
either	the	LRIG1-heterozygous	or	LRIG1-null	controls),	or	in	other	treated	animals.		
This	may	have	become	more	problematic	should	the	animals	have	been	treated	for	
longer	periods	of	time.	
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Figure	6.8:		Appearance	of	adenocarcinoma	in	an	NTCU-treated	LRIG1-heterozygous	animal	
	
A)	Large	tumour	situated	within	the	right	upper	lobe.		The	usual	smooth	surface	of	the	lung	seen	on	the	right	is	replaced	by	
nodular	densities.		B)i)	Haematoxylin	and	eosin	(H&E)	staining	of	a	caudal	section	of	lung.		Tumour	has	almost	completely	
replaced	the	normal	architecture	of	the	left	upper	lobe.		A	further	opacity	is	present	in	the	right	upper	zone	(arrow	head).		
Scale	bar	=	0.5	cm.	ii)	Close	up	image	of	left	upper	lobe	tumour,	from	area	marked	with	‘*’	in	‘i’.		Cells	have	a	tightly-	packed	
glandular	appearance	with	an	increased	nuclear	to	cytoplasmic	ratio,	scale	bar	=	200	μm		ii)	Close	up	image	of	right-sided	
lesion,	marked	with	an	arrow	head.		Cells	are	less	tightly	packed	and	the	glandular	structure	is	apparent,	scale	bar	=	100	μm.		
C)	Keratin	5	(KRT5)	staining	of	lung.		Note	both	the	left	upper	lobe	tumour	and	right	sided	lesion	are	negative.		KRT5	staining	
is	seen,	particularly	at	the	left	lung	bases	and	right	upper	zone.		These	areas	show	features	characteristic	of	preinvasive	and	
invasive	squamous	cell	carcinoma,	bar	=	250	mm.		D)i)	Staining	of	tumour	for	the	nuclear	protein	thyroid	transcription	factor	
1	(TTF1;	green),	scale	bar	=	100	μm.		ii)	Staining	of	the	cytoplasm	of	the	tumour	cells	for	the	alveolar	type	2	cell	associated	
protein	surfactant	protein	C	(SPC;	green),	scale	bar	=	100	μm.		iii)	Tumour	negatively	stained	for	epidermal	growth	factor	
receptor	(EGFR)	(red),	bar	=	100	μm.		iv)	Tumour	negatively	stained	for	p63	(red),	bar	=	100	μm.		
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6.3.9	 Association	of	LRIG1	with	preinvasive	and	invasive	squamous	cell	lung	
tumours	
	
As	shown,	LRIG1	is	not	expressed	within	the	distal	lung	parenchyma,	but	is	seen	
within	the	distal	airway	bronchioles	(Chapter	3).		To	confirm	whether	LRIG1	
expression	is	detectable	when	preinvasive	lesions	develop,	slides	were	co-stained	for	
eGFP	(to	identify	the	presence	of	the	eGFP	reporter	protein,	and	hence	LRIG1)	and	
KRT5	(to	identify	areas	of	preinvasive	disease).		eGFP	expression	was	seen	within	
lung	tumours	as	well	as	the	preinvasive	lesions	(Figure	6.9.A);	the	eGFP	expression	
was	also	seen	in	LRIG1-null	animals	(Figure	6.9.B).		As	expected,	this	eGFP	staining	
was	absent	in	wild-type	mice	(Figure	6.9.C).			
	
As	LRIG1	is	clearly	expressed	in	the	distal	lung,	and	the	NTCU-	induced	lesions	are	
developing	in	the	distal	airway	(instead	of	the	trachea),	the	effect	of	the	loss	of	
LRIG1	on	the	development	of	preinvasive	lesions	can	be	assessed	in	this	model.		In	
addition,	the	expression	of	eGFP	in	LRIG1-null	mice	in	the	lesions	indicates	that	the	
Lrig1	promoter	is	active	and	suggests	an	ongoing	biological	need	for	LRIG1.		
	
In	the	LRIG1-heterozygous	animals	there	is	clear	eGFP	expression	(and	hence	LRIG1	
expression)	in	association	with	both	the	preinvasive	lesions	and	tumours.		In	humans	
LRIG1	expression	is	lost	in	preinvasive	lung	cancer	development	(104),	but	in	this	
mouse	model	the	presence	of	eGFP	indicates	that	LRIG1	expression	is	ongoing.	
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Figure	6.9:		Expression	of	LRIG1	in	lesions	of	the	distal	airway	
	
A)	Immunofluorescence	staining	of	a	distal	airway	tumour	in	an	LRIG1-heterozygous	animal.		Keratin	5	(KRT5;	red)	was	
used	to	identify	abnormal	areas,	whilst	eGFP	(green)	was	used	to	assess	areas	of	LRIG1	expression.		Left	image	shows	
combined	stains,	centre	KRT5	staining	and	right	eGFP	(LRIG1)	expression,	scale	bar	=	50	μm.		B)	Immunofluorescence	
staining	for	KRT5	(red)	and	eGFP	(green)	in	an	LRIG1-null	mouse.		Both	preinvasive	and	invasive	cancers	are	seen,	both	
expressing	KRT5	and	eGFP,	scale	bar	=	50	μm.		C)	No	eGFP	expression	in	a	wild-type	mouse.		KRT5	staining	has	marked	
the	abnormal	area.		The	left	image	shows	both	KRT5	and	eGFP	staining,	right	image	shows	eGFP	staining,	indicating	no	
expression	in	wild-type	preinvasive	lesions,	scale	bar	=	50	μm.		n=3	and	staining	performed	on	wild-type,	LRIG1-
heterozygous	and	LRIG1-null	animals.		
	 213	
6.3.10	 Assessment	of	the	effects	of	NTCU	application	
	
Different	methods	of	quantifying	NTCU-induced	lesions	have	been	reported.		These	
range	from	the	use	of	PET-CT	(263),	to	sectioning	lesions	at	intervals	and	counting	
areas	of	disease.		Hudish	et	al	simply	counted	the	number	of	each	type	of	
preinvasive	lesion	across	3	sections,	50	μm	apart,	without	considering	lesion	size	
(255).		Another	group	analysed	the	percentage	of	each	bronchiole	covered	by	each	
type	of	lesion	(low-	grade	dysplasia,	etc.)	and	then	approximated	this	to	the	nearest	
25%	across	three	sections,	100	μm	apart	(253).	
	
It	was	clear	that	the	lesions	that	developed	within	my	colony	were	not	uniform	and	
were	of	varying	sizes.		I	was	concerned	that	if	I	was	to	simply	count	the	number	of	
lesions	I	may	underestimate	the	extent	to	which	the	airways	were	affected.		
Assessing	the	surface	areas	of	lesions	to	the	nearest	25%	also	appeared	insensitive	
due	to	the	subtle	abnormalities	between	each	section,	and	counting	lesions	in	
sections	at	only	50	or	100	μm	apart	seemed	to	be	too	narrow	a	margin.		A	number	of	
tumours	were	greater	than	50	μm	in	diameter,	so	if	sections	were	analysed	at	only	
50	μm	apart,	some	tumours	may	be	counted	twice.		
	
To	obtain	a	clear	representation	of	the	lungs	and	bronchial	tree,	lung	blocks	were	cut	
until	the	trachea	and	main	bronchi	were	reached.		Cutting	until	this	point	ensured	
that	the	greatest	visible	lung	surface	area	and	greatest	proportion	of	the	bronchial	
tree	was	included.		Two	sections	were	analysed	at	200	μm	apart,	with	an	average	
taken	of	the	two.		KRT5	staining	beyond	the	trachea	and	left	and	right	bronchi	is	not	
seen	in	the	mouse	under	normal	conditions	(176),	so	to	assess	the	degree	by	which	
the	individual	animal	had	been	affected	by	NTCU	application,	the	percentage	of	the	
distal	airway	(that	beyond	the	trachea	and	the	origin	of	the	right	and	left	main	
bronchi)	that	expressed	KRT5	out	of	the	total	airway	was	elucidated.		The	
abnormalities	were	then	divided	into	high-grade,	low-grade	and	flat	atypia	and	the	
difference	between	wild-type,	LRIG1-heterozygous	and	LRIG1-null	animals	
compared.		To	assess	invasive	lesions,	the	number	of	tumours	per	section	was	
counted	and	then	both	their	surface	area	and	the	total	lung	surface	area	recorded.		
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Dividing	the	total	surface	area	of	tumour	by	the	total	surface	area	of	lung	allowed	
the	percentage	of	lung	affected	by	tumour	to	be	calculated.			
	
KRT5	staining	in	the	distal	lung	showed	that,	following	NTCU	treatment	the	
proportion	of	wild-type	and	LRIG1-heterozygous	airways	affected	by	abnormal	
epithelium	was	similar.		There	was,	however,	a	significant	reduction	in	the	
proportion	of	the	airway	stained	by	KRT5	in	the	LRIG1-null	mice	(p	<	0.05)	(Figure	
6.10.A).		To	assess	whether	LRIG1-null	animals	developed	lesions	of	a	greater	
severity,	the	type	of	airway	lesion	was	classified	and	the	proportion	of	the	abnormal	
airway	affected	by	each	grade	of	abnormality	was	calculated.		This	demonstrates	
that,	although	there	is	less	abnormal	airway	in	the	LRIG1-null	animals,	the	degree	to	
which	all	genotypes	are	affected	by	each	grade	of	disease	is	similar.		Notably,	there	is	
not	an	increase	in	the	proportion	of	high-grade	disease	in	the	LRIG1-null	mice	(Figure	
6.10.B).		The	grading	and	assessment	of	lesions	was	discussed	and	confirmed	with	a	
histopathologist.		
	
By	assessing	the	number	of	cancerous	lesions	developing	in	each	genotype,	whether	
LRIG1	influences	the	progression	of	areas	of	dysplasia	to	invade	into	the	basement	
membrane	could	be	established.		The	number	of	lesions	across	two	sections	200	μm	
apart	was	counted.		Lesions	were	considered	to	be	part	of	one	larger	lesion	if	the	
distance	between	2	areas	was	smaller	than	200	μm.		The	number	of	invasive	lesions	
that	developed	in	the	LRIG1-heterozygous	and	LRIG1-null	mice	was	similar	(Figure	
6.11.A).		Fewer	lesions	were	seen	in	the	wild-type	group,	however,	the	differences	
between	the	three	groups	were	not	significant.					
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Figure	6.10:		The	development	of	NTCU-induced	preinvasive	lesions	in	LRIG1-wild-
type,	LRIG1-heterozygous	and	LRIG1-null	animals		
	
A)	Quantification	of	the	percentage	of	abnormal	keratin	5	(KRT5)	expression	in	the	distal	airway	in	wild-
type,	LRIG1-heterozygous	and	LRIG1-null	animals.		Statistical	analysis	was	performed	using	a	Kruskal-	
Wallis	test,	with	Dunn’s	post-	test,	following	an	arcsine	transformation;	n=	7-10	mice;	mean	±	SEM;	*	
indicates	p<	0.05.		B)	The	assessment	of	proportion	of	each	type	of	lesion	out	of	the	total	amount	of	
KRT5-	stained	abnormal	airway	in	each	animal,	including	high-grade,	low-grade	and	flat-atypia	lesions;	n	
=	7-	10	mice;	mean	±	SEM.		Statistical	analysis	was	performed	using	a	Kruskal-Wallis	test,	following	
assessment	of	normality	using	the	D'Agostino	&	Pearson	normality	test,	with	Dunn’s	post	test;		n=	7–10	
mice;	mean	±	SEM.				
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In	addition	to	the	cells’	ability	to	invade	surrounding	tissue,	tumour	size	may	be	
affected	by	the	proliferation	of	the	tumour	cells.		To	assess	whether	loss	of	LRIG1	
influences	tumour	size,	the	surface	area	of	each	lesion	was	calculated.		Each	tumour	
size	was	considered	as	an	independent	variable,	with	the	size	of	each	tumour	across	
each	of	two	sections	200	μm	apart	recorded	from	wild-type,	LRIG1-heterozygous	
and	LRIG1-null	mice	(Figure	6.11.B).		This	method	of	analysis	has	been	used	in	the	
determination	of	clonal	sizes	(174).		Tumour	size	was	significantly	increased	in	LRIG1-
null	animals	(Figure	6.11.C),	and	the	sizes	of	tumours	in	mice	of	this	genotype	were	
also	more	widely	distributed	with	a	greater	number	of	LRIG1-null	tumours	recorded	
to	be	over	200,000	μm2.		
	
Finally,	the	proportion	of	the	lung	affected	by	tumours	was	examined	(Figure	
6.11.B).		This	allowed	the	proportion	of	invasive	disease	to	be	normalised	to	the	size	
of	the	lung.		All	mice	were	of	similar	weight	at	the	experimental	end-point,	so	a	
similar	lung	surface	area	was	anticipated.		As	only	three	of	the	wild-type	mice	had	
lung	tumours,	and	many	animals	had	no	lesions,	the	overall	percentage	of	the	lung	
affected	by	disease	was	lower.		In	the	LRIG1-heterozygous	and	LRIG-null	animals,	the	
total	affected	surface	area	was	similar,	a	result	of	the	number	of	tumours	being	
greater	in	the	LRIG1-heterozygous	mice,	but	the	surface	area	of	the	tumours	in	the	
LRIG1-null	animals	being	greater,	leading	to	similar	proportions	of	the	lung	being	
affected.	
	
6.3.11	 Proliferative	index	of	tumours	from	wild-type,	LRIG1-heterozygous	and	
LRIG1-null	animals	
	
The	tumours	that	developed	in	LRIG1-null	animals	were	significantly	larger	than	
those	occurring	in	LRIG1-heterozygous	and	wild-type	mice.		As	Lrig1	loss	appears	to	
increase	the	proliferation	of	human	epithelial	cells	(Chapter	5)	and	cause	ongoing	
murine	epithelial	proliferation	at	cell	confluence	(104),	I	assessed	whether	LRIG1	loss	
was	having	a	proliferative	effect	in	the	development	of	murine	lesions	and	stained	
tumours	from	wild-type,	LRIG1-heterozygous	and	LRIG1-null	animals	for	Ki67	
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expression.		To	ensure	that	any	increase	in	proliferation	was	not	negated	by	tumour	
cell	death,	annexin	V	staining	was	performed	alongside.				
	
Only	rare	cells	were	annexin	V	positive,	with	staining	only	detectable	in	tumours	of	
greater	than	150	cells.		Most	of	the	annexin	V	staining	was	located	around	the	
periphery	of	the	lung	tumour	and	not	as	part	of	the	tumour	mass	(Figure	6.11.E).		
The	staining	of	Ki67	staining	was	greatest	towards	the	edges	of	tumour,	and	
decreased	towards	the	centre.		Comparing	the	LRIG-heterozygous	to	the	LRIG1-null	
mice	showed	that	there	was	no	significant	difference	in	the	percentage	of	Ki67-	
positive	cells	within	the	tumours.	
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Figure	6.11:		The	development	of	invasive	lesions	in	LRIG1-wild-type,	LRIG1-
heterozygous	and	LRIG1-null	animals	
	
A)	Number	of	tumours	found	in	wild-type,	LRIG1-heterozygous	and	LRIG1-null	mice.		Statistical	analysis	
was	performed	using	a	Kruskal-Wallis	test,	with	Dunn’s	post	test;	n	=	7-10	mice;	mean	±	SEM.	B)	
Percentage	of	lung	surface	area	covered	by	tumours	in	wild-type,		LRIG1-heterozygous	and	LRIG1-null	
animals.		Statistical	analysis	was	performed	using	a	Kruskal-Wallis	test,	with	Dunn’s	post	test;	n	=	7-10	
mice;	mean	±	SEM.		C)	Size	of	individual	tumours	from	wild-type,	LRIG1-heterozygous	and	LRIG1-null	
animals.		Statistical	analysis	was	performed	using	a	Kruskal-	Wallis	test,	with	Dunn’s	post	test;	n	=	23-	
166	tumours;	mean	±	SEM.		D)		Histogram	showing	the	distribution	of	tumour	sizes	from	wild-type,	
LRIG1-heterozygous	and	LRIG1-null	mice.		E)	Immunofluorescence	staining	of	a	distal	airway	tumour	
stained	for	Ki67	(red),	annexin	V	(cyan),	keratin	5	(KRT5)	(green)	and	DAPI	(blue).		Note	the	proliferative	
Ki67	cells	are	seen	at	the	tumour	margins,	whilst	the	annexin	V	stained	cells	are	seen	at	the	edges	of	the	
tumour.		F)		Graph	showing	the	percentage	of	Ki67-positive	cell	per	tumour.		Statistical	analysis	was	
performed	using	a	Kruskal-Wallis	test,	following	assessment	of	normality	using	the	D'Agostino	&	Pearson	
normality	test,	with	Dunn’s	post	test,	following	an	arcsine	transformation;	10-46	tumours	analysed	per	
group;	mean	±	SEM.				
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6.4	 Discussion	
	
I	have	shown	that	the	application	of	0.013	M	NTCU	to	the	dorsal	skin	of	the	Lrig1	
EGFP-ires-CreERT2	mouse	strain	leads	to	both	preinvasive	and	invasive	squamous	
cell	lung	cancers.		All	phenotypes	of	human	preinvasive	disease	are	recapitulated	in	
this	model.		Squamous	aetiology	has	been	confirmed	by	the	expression	of	KRT5,	p63	
and	EGFR.	
	
The	preinvasive	and	squamous	cell	carcinomas	arose	in	the	distal	airways	whereas,	
in	humans,	squamous	cell	cancers	are	lesions	of	the	upper	airways	where	the	basal	
cells,	the	putative	squamous	cancer	cell	of	origin,	are	concentrated.		The	distribution	
of	NTCU-induced	disease	may	be	related	to	dilution.		When	0.013	M	of	NTCU	is	
delivered	in	75	μl	of	solvent	(252),	as	used	here,	peripheral	lesions	form.		However,	
when	25	μl	of	0.04	M	NTCU	(equating	to	the	same	dosage)	is	applied,	tracheal	
lesions	develop	(251).		The	higher	volume	of	administration	was	selected	as	lesions	
are	seen	after	18	weeks,	compared	to	the	8-month	treatment	period	when	using	25	
μl	volumes.		The	shorter	treatment	duration	was	selected	to	allow	the	development	
of	lesions	within	the	time	constraints	of	my	PhD.		The	differences	in	lesion	
distribution	may	relate	to	how	the	NTCU	is	absorbed:	NTCU	is	applied	between	the	
shoulder	blades	of	the	mouse	so	when	a	smaller	volume	is	given	the	dose	is	likely	to	
remain	more	localised	and	affect	a	more	discrete	area	of	tissue	(the	trachea),	but	a	
larger	volume	may	spread	and	affect	a	larger	surface	area	of	skin	and	subsequently	
lung,	causing	distal	lesions.		The	cell	density	is	also	reduced	in	the	distal	airway	so	
may	explain	the	appearance	of	lesions	earlier	than	when	they	occur	in	the	trachea,	
with	the	NCTU	needing	to	permeate	through	more	layers	of	tissue	in	the	trachea	
than	more	distally.			
	
Whilst	the	NTCU	experiments	were	underway,	a	further	group	reported	the	
development	of	tracheal	lesions	in	FVB/N	mice	using	25	μl	of	0.02	M	NTCU	(half	the	
dose	as	above)	(259).		Animals	were	treated	twice	weekly	until	the	end-point	(with	
no	observation	phase).		Tracheal	changes	were	first	detected	at	12	weeks,	with	
increased	proliferation	and	a	higher	number	of	KRT5-positive	basal	cells,	followed	by	
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bronchial	dysplasia	at	25	weeks	and	tumours	at	32	weeks	(259).		This	protocol	may	
more	effectively	recapitulate	human	disease	patterns,	and	cause	a	greater	disease	
burden	in	the	upper	airway,	than	the	model	I	have	used.		Although	the	time	course	is	
more	prolonged	(needing	32	weeks	instead	of	23	weeks	for	lesions	to	develop),	I	
would	consider	using	this	dosing	strategy	in	any	further	studies.				
	 	
In	the	model	described	here,	both	the	preinvasive	and	invasive	lesions	express	basal	
cell	markers.		Basal	cells	are	considered	the	origin	of	squamous	cell	carcinoma	and	as	
the	stem	cell	of	the	upper	airway	their	highest	concentration	is	seen	in	the	trachea,	
with	few	basal	cells	seen	in	the	distal	lung.		Therefore,	the	origins	of	the	KRT5-
positive,	p63-positive	NTCU-induced	lesions	in	the	distal	airways	are	of	interest.		The	
use	of	a	murine	acute	respiratory	distress	syndrome	(ARDS)	model,	where	mice	are	
infected	with	the	influenza	virus,	has	shown	the	development	of	p63+KRT5+	‘pods’	in	
the	distal	lung	(142).		During	lung	repair,	these	cells	expand	and	through	lineage	
tracing,	are	seen	to	regenerate	all	alveolar	cell	types.		This	is	consistent	with	previous	
reports	showing	that,	following	the	destruction	of	naphthalene-sensitive	secretory	
CC10-positive	cells,	a	rare	population	of	basal	cells	expands	within	the	bronchiolar	
epithelium	to	repair	the	lung	damage	(264).		More	recently,	extremely	rare	
p63+KRT5+	cells	have	been	identified	in	the	distal	lung.		When	a	human	diphtheria	
toxin	receptor	mechanism	is	used	to	eradicate	these	p63+KRT5+	cells	post	influenza	
virus	infection	the	alveolar	regeneration	is	prevented	and	fibrosis	occurs	(265).	
Consequently,	NTCU	may	either	activate	the	migration	of	basal	cells	from	the	more	
proximal	airways	to	the	sites	of	chemically	induced	injury	or	trigger	the	proliferation	
of	the	rare,	distal	p63+KRT5+	cells.		The	recent	NTCU	paper	where	low	NTCU	doses	
are	utilised	reports	changes	first	in	the	trachea	before	the	distal	lung,	indicating	the	
possibility	of	basal	cells	migrating	outwards	in	response	to	NCTU	application	(259),	
although	I	was	unable	to	see	any	tracheal	effects	in	this	NTCU	model.		Intriguingly,	
an	alternative	possibility	is	raised	by	a	recent	publication	that	targets	shows	SOX2	
overexpression	to	either	KRT5-positive	basal	cells,	or	distal	airway	SPC-	or	CC10-
positive	cells	in	a	conditional	combined	Pten-	and	Cdkn2ab-knockout	mouse.		This	
model	shows	that,	irrespective	of	the	tumour	cell	targeted,	squamous	cell	lung	
tumours	develop	(247).	Whilst	highlighting	the	importance	of	SOX2	overexpression	
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in	squamous	cell	development,	the	results	are	interesting	as	they	are	suggestive	that	
even	an	SPC-	or	CC10-positive	distal	airway	cell,	when	sufficiently	antagonised	and	
on	the	development	of	a	sufficient	number	of	mutations,	is	capable	of	obtaining	a	
squamous	phenotype	and	leading	to	squamous	cell	carcinoma.		SOX2	appears	to	be	
the	key	switch	in	this	change	of	phenotype.		NTCU,	with	its	alkylating	effects,	may	
create	an	environment	where	multiple	mutations	occur	within	the	distal	airway	
epithelium,	meaning	the	preinvasive	lesion’s	cell	of	origin	is	a	distal	epithelial	cell	
that	has	acquired	sufficient	mutations	to	develop	a	squamous	phenotype,	rather	
than	a	basal	cell	that	has	travelled	distally.		
	
A	further	consideration	in	regards	to	the	origin	of	the	distal	KRT5+	lesions	is	the	dual	
expression	of	TTF1	and	KRT5	in	preinvasive	and	invasive	squamous	cell	lesions.		This	
contrasts	to	previous	reports	where	NTCU-induced	lesions	were	TTF1-negative	(253,	
255).		There	appears	to	be	a	gradient	in	the	level	of	TTF1	expression,	with	alveolar	
type	2	cells	brightly	stained	and	a	lower	intensity	of	TTF1	expression	in	cells	co-
expressing	KRT5.		Dual	positive	KRT5	and	TTF1	positive	cells	are	not	normally	present	
in	the	lung,	other	than	during	lung	development	where	TTF1	plays	a	role	in	lung	
morphogenesis.		In	the	adult	lung,	it	is	localised	to	the	distal	airway	(266).		As	TTF1	is	
expressed	in	all	grades	of	lesion	it	is	suggestive	that	the	lesions	possibly	arise	from	a	
TTF1-expressing	cell.		However,	notably,	there	does	not	appear	to	be	a	reduction	in	
the	number	of	TTF1+	KRT5+	stained	cells	in	either	the	high-grade	lesions	or	invasive	
tumours	that	may	suggest	the	lesion	has	originated	from	a	TTF1-positive	cell	that	is	
subsequently	developing	a	squamous	phenotype.			If	the	origin	were	a	TTF1-positive	
epithelial	cell	that	had	become	squamous	the	TTF1-	positive	cells	would	be	expected	
to	decrease	as	the	lesions	became	more	advanced	with	fewer	cells	seen	in	more	
advanced	preinvasive	lesions	and	tumours.			
	
A	triple-positive	CC10+p63+KRT5+	cell	has	been	identified	in	the	distal	lung	(260),	
these	triple-positive	stained	cells	also	expressed	CD44,	a	potential	cancer	stem-cell	
marker,	suggesting	that	the	origin	of	an	NTCU-induced	lesion	could	be	a	CC10-
positive	cell.		A	number	of	sections	were	stained	for	these	markers	but	only	one	
potential	triple	stained	cell	was	identified.		This	section	was	unusual,	as	in	contrast	to	
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all	other	sections	investigated,	the	p63	positive	cell	was	not	adjacent	to	the	
basement	membrane.		This	is	either	an	artefact,	or	indicative	of	rare	p63	positivity	in	
association	with	CC10	and	KRT5	markers	and	expressed	in	cells	where	squamous	
lesions	subsequently	develop.		
	
Assessment	of	the	epithelium	for	BASCs	in	the	NTCU-treated	airways	has	shown	the	
location	of	BASCs	adjacent	to	areas	of	preinvasive	disease.		Their	number	appears	to	
be	increased	compared	to	untreated	controls,	where	BASCs	are	rare.			The	BASCs	sit	
at	a	stem	cell	niche	within	the	distal	airway,	and	the	increase	in	BASC	numbers	
suggests	that	either	the	development	of	preinvasive	disease	may	arise	from	the	
BASC	population	(although	unlikely	as	no	triple-stained	KRT5+SPC+CC10+	lesions	were	
visible)	or	that	the	BASCs	facilitate	and	support	the	development	of	preinvasive	
disease.		To	investigate	this	further,	the	use	of	naphthalene	could	be	revisited.		
Naphthalene	causes	hyperplasia	of	the	BASC	population	(following	the	death	of	
CC10+	cells)	and	increases	the	development	of	adenocarcinomas	in	an	
adenocarcinoma	model,	so	the	effects	of	naphthalene	exposure	on	NTCU-induced	
lesions	would	be	valuable	to	determine.		If	BASCs	were	the	squamous	cell	of	origin	or	
supportive	of	preinvasive	lesion	development,	then	naphthalene	in	combination	
with	NTCU	treatment	would	be	expected	to	increase	the	number	and	severity	of	
NTCU-induced	lesions	in	addition	to	causing	BASC	hyperplasia.	
	
To	analyse	the	cell	of	origin	of	squamous	cell	carcinoma	in	more	detail	further,	
methodical	sectioning	of	the	airway	epithelium	is	required.		This	would	assess	
whether	triple-positive	CC10+p63+KRT5+	cells	exist	in	high	numbers	and	the	
association	of	BASCs	with	preinvasive	disease.		The	use	of	cell	counting	and	
mathematical	modelling	may	be	of	additional	benefit	in	determining	the	cell	of	origin	
of	these	lesions,	this	could	be	combined	with	lineage	tracing	models.		Lineage	tracing	
in	TTF1-,	SPC-,	CC10-	and	KRT5-	reporter	animals	following	NTCU	administration	
would	assist	in	the	elucidation	of	which	cell	type	is	the	origin	of	squamous	disease.			
	
LRIG1	is	expressed	within	the	bronchioles	of	the	distal	airways	of	mice	(Chapter	3),	
and	in	the	NTCU	model	both	preinvasive	and	invasive	lesions	show	evidence	of	LRIG1	
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expression.		It	is	possible	that,	lesions	do	develop	from	an	LRIG1-	expressing	cell	as	
when	the	lesions	develop,	the	p63+/KRT5+	cells	may	constitutively	express	LRIG1	(if	
they	have	migrated	from	the	upper	airways	or	developed	from	the	rare	distal	
p63+/KRT5+	cells,	whose	LRIG1	expression	is	unknown),	or	if	their	origin	is	from	the	
transformation	of	a	distal	cell	type	(such	as	an	LRIG1-positive,	TTF1-positive	cell)	the	
expression	of	LRIG1	is	maintained	with	the	change	in	phenotype.		Lineage	tracing	
could	be	used	to	answer	this	question,	with	the	activation	of	a	reporter	in	LRIG1-
expressing	KRT5-positive	cells	together	with	the	administration	of	NTCU.			
	
It	is	notable	that	the	expression	of	LRIG1	is	not	lost	in	the	development	of	
preinvasive	lesions	in	LRIG1-heterozygous	mice,	as	has	been	seen	in	the	human	
airway	(104).		To	confirm	the	relevance	of	the	model	to	human	disease,	genomic	
sequencing	of	the	tumours	could	be	performed.		This	would	necessitate	the	laser	
capture	of	both	preinvasive	lesions	and	tumours	(267),	and	give	an	insight	into	not	
only	the	natural	history	of	mutations	in	the	NTCU	model	but	how	closely	the	NTCU-
induced	mutations	are	aligned	to	those	seen	in	human	squamous	cell	lung	cancer,	
and	whether	the	driver	mutations	are	shared.		It	would	particularly	interesting	to	
assess	whether	SOX2	is	overexpressed,	as	this	genetic	abnormality	appears	to	be	the	
key	‘switch’	in	the	development	of	squamous	lesions	when	targeted	to	the	varying	
epithelial	cell	types	of	the	distal	lung	one	(247).			
	
Contrary	to	the	initial	hypothesis,	where	loss	of	LRIG1	predisposes	to	preinvasive	
disease,	LRIG1-null	animals	do	not	develop	any	more	preinvasive	lesions	than	the	
LRIG1-heterozygous	or	wild-type	animals.		It	is	intriguing	that	the	LRIG1-null	animals	
actually	show	less	distal	airway	KRT5	staining,	the	marker	of	the	presence	of	an	
abnormal	epithelium	after	NTCU	treatment	than	either	the	LRIG1-heterozygous	or	
wild-type	mice.		When	lesion	type	is	taken	into	consideration,	the	proportion	of	
abnormal	airway	that	is	affected	by	high-grade,	low-grade	dysplasia	or	flat	atypia	is	
similar	across	the	three	groups.		The	similar	behaviour	of	the	wild-type	and	LRIG1-
heterozygous	animals	mirrors	my	findings	of	there	being	no	difference	in	the	
proliferation	of	the	epithelium	between	LRIG1-heterozygous	and	wild-type	animals	
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(Chapter	3).		This	finding	also	corresponds	to	previous	research	where	
haploinsufficiency	of	Lrig1	has	no	phenotypic	effect	(104).	
	
The	downregulation	of	LRIG1	is	associated	with	the	increased	epithelial-to-
mesenchymal	(EMT)	transition	of	breast	and	nasopharyngeal	epithelial	cells	(110,	
111)	and	its	loss	within	the	ocular	epithelium	precipitates	progression	of	surface	
neoplasia	to	invasive	disease	(103).		This	implies	the	protein	influences	the	onset	of	
EMT	and	triggers	the	invasion	of	abnormal	cells	through	the	basement	membrane.		
Across	all	three	genotypes	there	is	a	similar	proportion	of	abnormal	airway	that	is	
affected	by	high-grade	dysplasia,	but	although	there	are	more	tumours	in	the	LRIG1-
heterozygous	mice,	this	is	not	significantly	higher	than	the	LRIG1-null	animals.		If	loss	
of	LRIG1	contributed	to	EMT	it	may	be	expected	that	the	number	of	invasive	lesions	
in	the	LRIG1-null	group	would	be	higher	than	that	of	the	LRIG1-heterozygous	or	wild-
type	animals.		This	is	not	seen,	and	indicates	that	in	this	model	LRIG1	does	not	
influence	the	invasion	of	abnormal	epithelial	cells	and	the	number	of	cancers	
produced.			
	
The	loss	of	LRIG1	does	lead	to	the	development	of	significantly	larger	tumours	than	
in	LRIG1-heterozygous	or	wild-type	mice.		There	is	also	a	greater	distribution	in	the	
number	of	tumours	formed	in	the	LRIG1-null	animals.		It	is	known	that	loss	of	LRIG1	
causes	a	loss	of	contact	inhibition	between	epithelial	cells	(104),	so	it	is	possible	that,	
when	tumours	lack	LRIG1,	they	are	not	inhibited	by	cell-cell	contact	or	the	airway	
walls	and	continue	to	proliferate	beyond	the	size	of	that	generated	by	LRIG1-
expressing	tumours.		
	
To	establish	whether	the	larger	tumour	size	in	the	LRIG1-null	mice	was	a	result	of	
increased	proliferation,	tumours	were	stained	for	both	Ki67	and	annexin	V	
expression.		However,	no	differences	in	the	proliferation	of	tumours	from	LRIG1-
heterozygous	and	LRIG1-null	mice	were	detectable,	despite	the	findings	in	Chapter	5	
showing	that	loss	of	LRIG1	through	shRNA	knockdown	in	human	airway	epithelial	
cells	leads	to	increased	cell	proliferation.		The	similar	proliferation	may	be	explained	
by	the	tumour	size	and	the	location	of	the	proliferative	cells.		It	is	clear	from	the	Ki67	
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staining	that	the	proliferating	cells	are	at	the	tumour	margins.		In	a	small	tumour,	the	
cells	around	the	margin	of	the	tumour	are	still	proliferating.		There	are	very	few	
tumour	cells	in	the	centre	that	are	not	dividing,	so	the	percentage	of	proliferating	
cells	for	the	size	of	the	tumour	is	high.		In	a	much	larger	tumour,	the	cells	that	are	
proliferating	are	still	around	the	periphery,	but	the	number	of	tumour	cells	in	the	
centre	that	are	not	dividing	is	increased.		Therefore	the	percentage	of	proliferating	
cells	in	larger	tumours	is	reduced	compared	to	tumours	of	a	smaller	size.		The	
presence	of	large	tumours	in	the	LRIG1-null	mice	may	lead	to	a	reduction	in	the	
overall	number	of	cells	proliferating,	and	mean	the	results	are	comparable	in	the	
LRIG1-heterozygous	and	LRIG1-null	animals.		To	understand	how	larger	tumours	
develop	in	the	LRIG1-null	mice,	measurements	of	tumour	size	need	to	take	place	at	
several	time	points	in	the	same	animal,	giving	an	indication	of	tumour	growth	
dynamics.		This	may	be	possible	through	imaging	techniques	such	as	micro-CT	(268)	
or	PET	scanning	(263).			
	
Some	subtleties	within	the	data	may	have	been	missed	due	to	an	under-powering	of	
the	experiment.		During	experimental	design,	the	number	of	animals	needed	in	each	
group	to	show	a	significant	difference	was	calculated	at	9.		However,	there	were	
very	few	studies	on	which	to	base	the	anticipated	likelihood	of	lesion	development.		
When	animal	losses	occurred,	further	experimental	cages	were	set	up	to	account	for	
these.		However,	due	to	the	length	of	the	experiments	these,	were	staggered	at	
several	weeks	apart.		Animals	were	lost	in	one	of	the	final	cages	due	to	husbandry	
issues	(so	that	they	could	not	be	replaced	because	of	time	restrictions),	meaning	
only	7	animals	were	ultimately	included	in	the	LRIG1-null	arm.		The	NTCU	when	
made	up	in	solvent	is	also	extremely	volatile,	meaning	the	dosing	of	animals	was	
difficult	before	the	chemical	evaporated.		Each	cage	contained	an	animal	of	each	
genotype,	so	the	animals	sequentially	rotated	for	the	first,	second	and	third	dose.		
Small	dosing	inaccuracies	may	have	led	to	a	different	dose	being	administered	to	
each	mouse.		By	increasing	the	power	of	the	experiment,	the	effect	of	these	
variables	may	be	reduced.	
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Further	bearings	on	the	results	may	be	that	the	animals	have	a	constitutive	loss	of	
LRIG1,	and	do	not	lose	the	protein,	as	occurs	in	the	development	of	preinvasive	lung	
cancer.		As	shown	in	the	experiments	that	assessed	the	characteristics	of	basal	cells	
(Chapter	4),	no	differences	were	seen	between	basal	cells	from	LRIG1-heterozygous	
and	LRIG1-null	animals.		This	raises	the	possibility	that	loss	of	LRIG1	from	gestation	
leads	to	compensatory	mechanisms	and	that	any	effect	of	LRIG1	on	the	
development	of	malignancy	may	not	be	best	assessed	in	this	model.		The	
observation	that	eGFP	is	expressed	(following	activation	on	the	Lrig1	promoter)	in	
LRIG1-null	mice	implies	LRIG1	may	still	have	a	biological	function	and	that	the	
animals	are	suitable	for	modelling	the	effects	of	LRIG1	loss	following	NTCU	
treatment.		Using	NTCU	to	initiate	tumour	development	in	an	Lrig1-conditional	
knockout	would	answer	this	question	more	succinctly,	and	clarify	the	role	of	loss	
LRIG1	in	lesion	development.		
	
A	final	caveat	is	that	the	mice	are	on	an	FVB/N	and	C57BL/6	mixed	background,	
which	may	have	led	to	a	variable	proportion	of	each	genotype	within	the	
experimental	groups.		Whilst	animal	backcrossing	was	considered,	the	time	
necessary	to	produce	a	pure	strain	and	then	to	optimise	the	NTCU	regimen	would	
not	have	been	available	within	the	constraints	of	a	PhD.		The	loss	of	LRIG1	on	a	pure	
FVB/N	background	has	also	been	shown	to	lead	to	perinatal	death	at	p10,	and	would	
prevent	their	use	in	these	NTCU	experiments	(93).		To	account	for	the	potential	
effects	of	the	mixed	background,	animals	were	pooled	from	the	same	generation	
and	littermates	included	where	possible.		FVB/N	animals	are	a	more	sensitive	strain	
than	C57BL/6	(251),	so	if	the	final	proportion	of	FVB/N	was	greater	within	an	
individual	mouse,	it	may	be	more	susceptible	to	the	development	of	malignancy	and	
influence	the	final	result.		Increasing	the	power	of	the	experiment	would	reduce	the	
effect	of	this	potential	confounder.	
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6.5	 Summary	
	
• Application	of	NTCU	induces	the	development	of	both	preinvasive	and	
invasive	squamous	cell	lung	cancers	which	closely	models	the	progression	of	
human	disease	
• The	cell	of	origin	of	the	squamous	cell	changes	induced	by	NTCU	has	yet	to	
be	determined.	
• There	is	no	effect	of	the	loss	of	LRIG1	on	the	development	of	preinvasive	
disease.	
• Loss	of	LRIG1	leads	to	the	development	of	larger	squamous	cell	carcinomas.			
	 	
	 229	
7.	 Summary	and	Future	Directions	 	
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7.	 Summary/	Future	Directions	
	
7.1	 Summary	
	
LRIG1	is	lost	in	human	preinvasive	lung	cancer	lesions	(104)	and	its	loss	is	associated	
with	a	worsening	prognosis	of	non-small	cell	lung	cancer	(NSCLC)	(105).		In	fact,	it	is	
also	one	of	4	key	genes	whose	loss	is	associated	with	a	worsening	of	outcomes	
across	epithelial	cancer	subtypes,	including	lung	cancer	(98).		The	aim	of	this	work	
was	to	elucidate	the	role	of	LRIG1	in	the	airway	and	how	its	loss	may	lead	to	
preinvasive	lung	cancer.	
	
I	have	shown	that	LRIG1	is	expressed	in	the	murine	airway	epithelium.		Instead	of	
marking	a	subpopulation	of	airway	epithelial	cells,	or	being	found	to	mark	the	airway	
stem	cell	population,	as	it	is	in	other	organs,	LRIG1	expression	is	seen	across	the	
ciliated,	secretory	and	basal	cells.		By	isolating	the	airway	basal	cells,	l	have	shown	
that	only	50%	of	basal	cells	are	LRIG1-positive.		These	LRIG1-expressing	basal	cells	
exhibit	increased	stem	cell	features	with	an	increased	colony-	and	spheroid-forming	
capacity.		LRIG1-expressing	basal	cells	are	also	more	proliferative	than	LRIG1-
negative	basal	cells.		These	features	are	in	line	with	recent	research	suggesting	that	
the	airway	basal	cell	population	is	more	heterogeneous	than	first	appreciated.		
Interestingly,	basal	cells	isolated	from	LRIG1-null	mice	do	not	show	a	change	in	
proliferation,	colony-	or	spheroid-forming	capacity	compared	to	the	LRIG1-
expressing	basal	cells	from	LRIG1-heterozygous	mice.		This	implies	that	either	LRIG1	
is	only	the	marker	of	a	more	proliferative	and	stem-cell	like	population	of	basal	cells,	
or	that	in	LRIG1	constitutively-null	animals,	there	is	a	compensation	for	absence	of	
LRIG1.	
	
By	isolating	human	airway	epithelial	cells	obtained	at	bronchoscopy,	I	have	
confirmed	there	is	an	LRIG1-expressing	basal	cell	population	in	the	human	airway	
and	that	the	characteristics	seen	in	mouse	airway	basal	cells	are	conserved	in	the	
human.		The	human	LRIG1-expressing	basal	cells	show	an	increased	colony-forming	
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capacity	and	are	more	proliferative	than	LRIG1-negative	basal	cells.		By	using	shRNA	
knock	down	of	LRIG1	in	cultures	of	primary	human	epithelial	cells,	I	have	shown	that	
LRIG1	does	not	simply	mark	a	basal	cell	population	but	that	loss	of	the	protein	
affects	cell	phenotype.		Lrig1	shRNA	knocked-down	basal	cells	exhibit	an	increased	
proliferation,	colony-forming	ability	and	a	reduction	in	cell-cell	contact	inhibition	at	
cell	confluence.	
	
To	assess	the	effects	of	LRIG1	loss	in	an	in	vivo	animal	model,	I	have	optimised	the	N-
Nitrosotris-(2-chloroethyl)urea	(NTCU)	model	for	the	development	of	murine	
squamous	cell	lung	cancers	in	LRIG1-null,	LRIG1-heterozygous	and	wild-type	mice.		I	
have	demonstrated	that	these	mice	not	only	develop	lung	tumours	but	also	that	the	
developing	lesions	recapitulate	all	stages	of	human	preinvasive	disease.		Whilst	the	
absence	of	LRIG1	does	not	influence	the	development	of	preinvasive	lung	cancers,	
significantly	larger	tumours	were	detected	in	LRIG1-null	mice.		However,	in	this	
NTCU	model,	LRIG1	was	not	lost	in	the	development	of	preinvasive	lesions	or	lung	
tumours.		It	is	possible	that	in	humans,	the	loss	of	LRIG1	is	not	essential	or	the	key	
event	in	the	development	of	preinvasive	disease.	
	
I	have	shown	that	LRIG1,	similarly	to	in	the	skin	and	the	gut,	regulates	a	stem	cell	
population	within	the	airway.		LRIG1-expressing	basal	cells	exhibit	a	more	stem	cell-
like	phenotype,	with	LRIG1	shRNA	knockdown	leading	to	the	dysregulation	of	these	
characteristics.		Loss	of	the	inhibitory	regulation	of	LRIG1	in	the	airway	stem	cell	
compartment	may	lead	to	both	the	development	of	preinvasive	lesions	and	lung	
tumours.		An	LRIG1-expressing	airway	basal	cell,	that	exhibits	stem	cell	
characteristics,	on	the	loss	of	LRIG1	may	become	dysregulated	and	develop	the	
features	of	a	cancer	stem	cell.		This	basal	cell	may	then	act	as	the	cell	of	origin	for,	
initially	preinvasive,	and	later	invasive,	squamous	cell	lung	tumours.		The	reduction	
of	cell-cell	contact	inhibition,	seen	here	and	in	the	work	of	Lu	et	al,	may	explain	the	
formation	of	larger	tumours	in	LRIG1-null	mice	and	the	worsening	of	NSCLC	
prognosis	on	LRIG1	loss.	
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7.2	 Future	directions	
	
The	main	aim	of	this	project	was	to	increase	our	understanding	of	LRIG1	initially	in	
airway	homeostasis,	but	then	to	assess	the	effects	of	its	loss	in	preinvasive	lung	
cancer,	with	a	view	to	developing	therapeutic	candidates.			
	
The	comparison	of	the	mouse	and	human	airway	suggests	that	there	is	
compensation	in	the	LRIG1-null	mouse,	but	as	there	are	differences	between	the	
wild-type	and	LRIG1-null	mice	in	the	NTCU	experiment,	this	indicates	compensation	
may	not	be	present.		To	clarify	the	findings,	I	could	use	an	Lrig1-conditional	knockout	
mouse	model	which	would	more	closely	recapitulate	the	loss	of	LRIG1	that	occurs	in	
the	human	airway.		To	confirm	the	effect	of	loss	of	LRIG1	in	the	human	airway	seen	
by	shRNA	knockdown	I	would	also	perform	CRISPR-Cas9	to	gene	edit	and	completely	
remove	the	effects	of	LRIG1	expression.			
	
Due	to	difficulties	with	the	single	cell-RNA	sequencing	data,	I	was	unable	to	use	this	
data	to	gain	an	insight	into	the	gene	expression	changes	that	occur	on	loss	of	LRIG1	
and	therefore	how	this	loss	might	lead	to	preinvasive	disease.		Re-exploring	gene	
expression	analysis	may	be	of	benefit	in	the	identification	of	pathways	downstream	
of	LRIG1	activation	that	may	be	targeted	for	a	therapeutic	intervention.		The	use	of	
the	above-mentioned	Lrig1-conditional	knockout	mouse	would	be	advantageous	for	
any	further	gene	expression	analysis.	
	
However,	LRIG1	has	been	identified	as	a	tumour	suppressor	in	the	gut	and	I	have	
shown	that	the	loss	of	LRIG1	leads	to	larger	lung	tumours	in	LRIG1-null	mice,	
therefore	the	replacement/administration	of	LRIG1	may	provide	a	potential	therapy	
to	established	disease	and	would	provide	a	natural	progression	of	the	project.		It	is	
interesting	that	administration	of	EGFR	receptor	antagonists	to	patients	with	
squamous	cell	lung	cancers	leads	to	small	improvements	in	cancer	survival	(26,27),	
so	reducing	EGFR	signalling	in	lung	cancer	would	be	a	logical	therapeutic	target.		To	
date,	full-length	LRIG1	has	been	administered	to	bladder	tumour	xenografts	in	mice	
by	the	direct	injection	of	LRIG1-producing	adenoviruses	into	an	established	tumour	
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bulk	(269).		This	leads	to	a	reduction	in	tumour	mass.		The	soluble	LRIG1	(s-LRIG1)	
extracellular	domain	has	been	explored	as	a	potential	therapy	and	has	been	
delivered	to	murine	glioblastoma	models,	by	using	s-LRIG1-producing	cells	contained	
within	alginate	beads	(86).		Again,	this	model	has	been	shown	to	reduce	both	the	
size	of	established	tumours	and	to	reduce	tumour	development	when	the	s-LRIG1-
producing	beads	are	implanted	simultaneously	with	the	glioblastoma	cells.	
	
The	optimised	NTCU	squamous	cell	lung	cancer	model	could	be	used	to	assess	
LRIG1’s	potential	as	a	therapeutic	agent.		LRIG1	could	be	potentially	administered	to	
established	squamous	cell	lung	tumours	to	assess	whether	tumour	growth	and	
development	could	be	reduced.		LRIG1	administration	may	prove	challenging	in	the	
lung.		Initially,	the	identification	of	the	lesion	would	necessitate	imaging	and	
injecting	the	LRIG1-producing	cells	into	a	tumour	mass	is	would	be	challenging	
without	direct	vision.		The	use	of	mesenchymal	stem	cells	to	successfully	deliver	the	
cancer	targeting	agent	tumour	related	apoptosis	inducing	ligand	(TRAIL)	to	the	lung	
in	a	mesothelioma	model	has	been	reported	by	our	research	group	(270),	and	will	
soon	move	into	a	clinical	trial	setting.			This	strategy	may	provide	a	modality	by	
which	LRIG1	could	be	delivered	directly	to	the	site	of	the	tumour.	
	
A	therapy	for	patients	with	preinvasive	lesions	would	be	advantageous	but	would	
need	to	be	patient-acceptable	with	minimal	side	effects	(as	lesions	may	never	
progress	to	cancer).		The	NTCU	model	failed	to	show	an	effect	of	LRIG1	loss	on	the	
development	of	preinvasive	lesions,	although	the	model	could	be	optimised	further	
with	larger	sample	numbers	and	the	use	of	a	conditional	Lrig1	knockout	targeted	to	
the	keratin	5	basal	cell	population.		Confirming	the	link	of	LRIG1	to	preinvasive	
disease	may	provide	the	option	for	prophylactic	treatment	in	patients	with	known	
lesions.		An	inhaled	therapy	would	be	ideal	in	targeting	the	upper	airways	where	the	
preinvasive	lesions	are	situated,	and	an	inhaled	therapy	is	likely	to	lead	to	fewer	side	
effects	than	systemic	medications.		However,	LRIG1	expression	is	seen	in	association	
with	that	of	EGFR	and	is	localised	to	the	basolateral	cell	membrane	(61),	so	a	
significant	challenge	would	be	to	get	LRIG1	to	the	site	of	action.			
	
	 234	
8.	 Supplementary	
	 235	
8.	 Supplementary	
	
	
	
	
	
	
	
	
	
	 	
0 5 10 15 20 25
15
20
25
30
35
Weeks
W
ei
gh
t (
gr
am
s)
LRIG1-het
LRIG1-null
Supplementary	Figure	1.	Weights	of	LRIG-heterozygous	and	LRIG1-null	animals.	
	
The	LRIG1-null	animals	initially	weigh	less	than	the	LRIG1-heterozygous	mice,	but	over	
the	course	of	the	experiment	the	weights	of	the	two	groups	equilibrates.	Error	bars	
signify	the	S.E.M,	n=3	in	each	group	
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Supplementary	table	1	
	
1	pack	year	of	smoking	equivalent	to	20	cigarettes	a	day	for	a	year	
	
	
	
	
	 Gender	 Age	 History	 Smoking,	pack	
years	
Site	 Histology	 Experiment	
A	 M	 65	 Left	upper	lobectomy	January	
2014.	CIS	at	stump,	regressed,	
now	clear	
25,	ex	smoker	 	 Normal	
epithelium	
Cell	culture	
B	 M	 54	 Foreign	body	RLL	 30,	current	 Right	
upper	
Normal	
epithelium	
Cell	culture	
C	 F	 77	 Surveillance	 Ex	smoker	 	 Normal	
epithelium	
Cell	culture	
D	 M	 64	 Interventional	due	to	
obstructing	sarcoma,	normal	
area	sampled	
	 	 Normal	
epithelium	
Cell	culture	
E	 F	
	
58	 surveillance	RLL	CIS	 55	 Main	
carina	
Normal	
epithelium	
LRIG1	assess	
F	 M	
	
75	 surveillance	 40	 Main	
carina	
Normal	
epithelium	
LRIG1	assess	
G	 SF	
25/1	
57	 Surveillance,	previous	
carcinoid	tumour	
	 Main	
carina	
Normal	
epithelium	
Granulatio
n	tissue	
elsewhere	
LRIG1	assess	
H	 M		 54	 Foreign	body	RLL	 30,	current	 Right	
upper	
Normal	
epithelium	
Colony	
	
I	 M	
	
58	 Haemoptysis	 63,	ex	smoker	 Main	
carina	
Normal	
epithelium	
Colony	
	
J	 F		 76	 Surveillance	for	RMB	dysplasis	 30,	ex	smoker	 Left	upper		 Normal	
epithelium	
Colony	
	
K	 M		 84	 Surveillance	
Previous	lung	cancer	x	2	
50,	ex	smoker	 Main	
carina	
Metaplasia	 Colony	
	
L	 M	 70	 Haemoptysis	 45,	current	 Main	
carina	
Normal	
epithelium	
Colony	
	
M	 F	 55	 Surveillance	RLL	CIS	 55	 Main	
carina	
Normal	
epithelium	
Colony	
	
N	 M	
	
54	 Lingula	hamartoma	 50,	ex	smoker	
2002	
Main	
carina	
Normal	
epithelium	
Proliferation	
O	 M	 76	 Previous	squamous	cell	
cancer,	CIS	at	resection	
margin	
current	 Left	upper	 Normal	
epithelium	
dysplasia	
elsewhere	
Proliferation	
P	 M	 63	 CIS	surveillance	 60,	ex	smoker	
2011	
Right	
upper	
lobe	
Normal	
epithelium	
Proliferation	
Q	 F	 58	 CIS	surveillance	 50,	ex	smoker	
2000	
Right	main	
bronchus	
Normal	
epithelium	
Proliferation	
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